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1 INTRODUCTION 
When Michel Peyrone (Figure 1) reported on the compound named 
cis-diammine dichlorido platinum(II) in 1844,4 he could have never 
envisioned what an important substance he had created for the very first 
time. It was not until the 1960s, through a serendipitous finding of Barnett 
Rosenberg (Figure 2), that the potential of this complex gradually become 
apparent.57 Since then, the story of the discovery of the first platinum-based 
chemotherapeutic has been told numerous times and thousands of 
researchers worldwide have dedicated their research to elucidating the 
chemistry, biochemistry and medicinal properties of the compound which is 
now widely known as Cisplatin. It has reached such popularity in research 
and clinical application that it has even been termed penicillin of cancer 
drugs,8 being applied in ca. 50 % of all cancer medications with activity 
against a wide variety of cancers.9,10 
Cisplatin is not only one of the most simple square-planar complexes 
known, bearing just two types of small donor groups  chloride and 
ammonia, being bound in cis position to a Pt(II) center (Chart 1).i It moreover 
exhibits a very sophisticated solution chemistry which 
complexity is greatly enhanced when a biological milieu 
adds to the conditions it is placed in: platinum-
biomolecule interactions in general, platinum-nucleic acid 
as well as platinum-protein interactions in particular, have received considerable 
interest over the last 50 years.  
  
                                                          
i The differences in cis and trans isomers of PtCl2(NH3)2, amongst other metal-ammine complexes, have been 
investigated by Alfred Werner in great detail. He was awarded the 1913 Nobel Prize in Chemistry in 
recognition of his work on the linkage of atoms in molecules by which he has thrown new light on earlier 
investigations and opened up new fields of research especially in inorganic chemistry.11 
 
Figure 1 Michele Peyrone 
(1813-1883). Graphic 
reproduced from ref. 1 as 
originally taken from ref.
2. 
 
Figure 2 Barnett 
Rosenberg (1924-2009). 
Graphic from ref. 3.  
Chart 1 Cisplatin, 
cis-diammine 
dichlorido 
platinum(II). 
2 
 
1 Introduction 
 
 
 
Bernhard Lippert recently concluded:12  
The impact Cisplatin had on cancer chemotherapy is probably exceeded by the influence 
its discovery had on fundamental science regarding metal-nucleic acid interactions and 
on the then (1960s and later) emerging field termed Bioinorganic Chemistry in general. 
There can be no doubt that Rosenbergs discovery of Cisplatin provided a major boost to 
this new topic, and it is probably no exaggeration to state that without the interest in 
understanding Pt-nucleobase chemistry on the molecular level, our present knowledge 
on metal-DNA and metal-RNA chemistry would be considerably less advanced. 
 
With this thesis, an attempt is made to contribute to the wide field of research on platinum(II) based 
chemotherapeutics by designing new drug candidates with a common ligand structural motif. In 
particular, the antiproliferative properties of the likely drug candidates will be determined and their 
interactions with proteins and nucleobases will be tested.  
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1.1 Cisplatin and analogs: Current clinical status and research focus 
To date, the panel of platinum-based drugs is comprised of three compounds being approved 
worldwide for clinical application (Cisplatin/PlatinolTM, Carboplatin/ParaplatinTM and 
Oxaliplatin/EloxatinTM, Chart 2 top panel),1315 accompanied by some compounds being mainly 
approved in Asia. These are (Chart 2, middle panel):16 Nedaplatin (AquplaTM), approved in Japan for 
the treatment of several tumorsii (NSCLC, SCLC, oesophageal cancer and head and neck cancers)13 
and is currently undergoing further clinical trials in China and Japan;17,18 Lobaplatin, approved in 
China for different cancers (e.g. the treatment of SCLC, chronic myelogenous leukaemia, and 
inoperable metastatic breast cancer);13,19 and Heptaplatin, approved for the treatment of gastric 
cancers in South Korea, and recently reported to undergo further clinical trials for head and neck 
cancers.20,21  
 
Chart 2 Platinum drugs that are approved worldwide (top panel), locally (middle panel) and such that have recently been 
evaluated in advanced clinical trials (bottom panel). 
                                                          
ii Abbreviations used in this paragraph: NSCLC  non-small cell lung cancer; SCLC  small cell lung cancer. 
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Satraplatin, the first Pt(IV) complex to enter clinical trials, reached phase III clinical studies.22 It was, 
however, not approved23 because its performance was not superior enough compared to the 
established drugs and has not yet re-entered clinical trials.24 Other Pt(IV) compounds that entered 
clinical evaluation are Tetraplatin (Ormaplatin) and Iproplatin, none of which has reached approval to 
date.25 Furthermore, Picoplatin, another Pt(II) drug candidate, has been investigated in phase III 
clinical trials but failed.26 Surprisingly, its approval status is currently unknown.27 Additionally, the 
multinuclear trans-Pt(II) complex BBR 3464 has been investigated in clinical phase II trials, but is not 
approved.28,29 All described compounds are comprehensively shown in Chart 2 (bottom panel). Some 
other Pt(II) compounds have entered clinical phase I studies but never reached advanced stages.30 
Two more compounds should be mentioned for attempts to bring platinum-based compounds into 
the clinic: LipoplatinTM and ProLindacTM. Both are polymeric formulations of either Cisplatin 
(Lipoplatin; a liposomal formulation)31,32 or Carboplatin (ProLindac, incorporated into a polymer 
based on hydroxypropylmethacrylamide)33,34 and show promising properties in clinical development.  
It is surprising that although numerous platinum-derived potential anticancer therapeutics were 
reported in literature,25,3547 the approval rate of platinum-based chemotherapeutics has somewhat 
experienced a stand-still in recent years. Unfortunately, the transfer of research drugs into clinical 
trials and eventually to approval is very difficult: the preclinical and clinical testing is exceptionally 
expensive, and the requirements a drug candidate has to meet have grown more and more over the 
last years, making it very hard for new compounds to fulfill all criteria.12,48 It is particularly important 
to reduce toxic side-effects that come along with most platinum chemotherapeutics, the most severe 
ones being of nephro- and neurotoxic nature. Furthermore, the selectivity of novel compounds for 
cancer tissue over normal, healthy, tissue marks an important parameter in drug evaluation.49  
These demanding criteria make research on Pt(II) compounds even more motivating:50 On the one 
hand, a thorough understanding of the biological mode of action of metal-based chemotherapeutics 
is necessary to enable rational drug design. On the other hand, novel, unconventional approaches 
towards the classical motif of Pt(II) being bound to two am(m)ines (A) and suitable leaving groups (X) 
are necessary to circumvent some of the problems associated with platinum treatment, such as 
severe side effects or the occurrence of acquired or intrinsic resistance towards the drugs.5052 
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Up-to-date developments of metal-based chemotherapeutics include 
1. the exploration of alternative amine ligands or leaving groups,  
2. changing the geometry from a cis-[PtII(A)2(X)2] to a trans-isomer,  
3. oxidizing Pt(II) to Pt(IV) to make use of the activation by reduction principle,  
4. attaching targeting units,  
5. or exchanging the metal by others, such as ruthenium, gallium, titanium or gold 
and were reviewed in numerous peer-reviewed journals within the last 10 years.25,3547,5358  
1.2 Chemistry, biological mode of action of Cisplatin and analogs 
In general, the mode of action of Cisplatin can be subdivided into three steps: accumulation, 
activation and cellular processing,30 with multi-faceted reaction cascades occurring during each of 
the three steps. 
1.2.1 Accumulation 
Cisplatin is administered through intravenous injection from saline or dextrose solutions,59 so that it 
immediately enters the bloodstream.60 From there, it rapidly diffuses into tissues and can enter cells 
(Figure 3). 
It is still not entirely clarified whether Cisplatin enters cells through active transport mechanisms or 
by passive diffusion; most probably both processes contribute to its uptake into the (cancer) cell.61,62 
For active transport, the copper transporter protein Ctr1 has been identified as one of the most 
probable candidates that is able to enhance Cisplatin uptake into cells.6366 Other proteins, such as 
organic cation transporters, OCTs, or proteins involved in copper homeostasis have been identified 
to play a significant role in platinum-drug uptake.67,68  
Contrary, recent studies on Cisplatin-serum protein interactions suggested that passive transport, 
meaning diffusion through the phospholipid bilayer, mainly contributes to the drugs' uptake into 
cytoplasm. Furthermore it was proposed that binding to serum proteins results in a drug reservoir for 
gradual release of the drug inside the cells.69  
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Figure 3 Schematic uptake of Cisplatin into the cell and subsequent cellular processing possibilities. In serum, Cisplatin is 
already prone to reactions with biomolecules. The drug enters the cell mainly undissociated, either by active uptake 
through e.g. Cu transport proteins or by passive diffusion through the phospholipid bilayer of the cell membrane. Due to a 
drop in cellular chloride ion concentration, aquation and subsequent biomolecule binding is facilitated. Genomic DNA is 
considered the main therapeutic target, but binding to proteins and other biomolecules inside the cell also takes place to a 
large extent. Both result in manifold cellular responses.  
A passive diffusion into the cell, however, will only be possible for neutral, rather nonpolar 
compounds as opposed to highly polar or ionic species. Due to the comparably high chloride ion 
concentration in the blood (approx. 100-120 mM), most of the administered Cisplatin can remain 
unchanged and will thus be able to diffuse into the cell.70 
1.2.2 Activation and biomolecule binding 
Once inside the cell, a decrease of chloride concentration from high levels in blood and extracellular 
areas to ca. 4 mM in the cytosol71 leads to several hydrolysis products to give cationic, aquated 
species, ǁhiĐh aƌe ŵoƌe oƌ less ͞tƌapped͟ iŶside the Đell (Figure 3).70 Once they reach the nucleus, 
these aquated species are then capable of DNA platination. As specific binding sites at nuclear DNA, 
several units have been established, with the N7 atom of guanines being considered the primary 
donor atom to bind the Pt(II) center.72,73 This binding then results in 1,2 or 1,3-intrastrand links as 
well as interstrand links between nearby guanines (Figure 4). Furthermore, adenine and cytosine can 
bind platinum through their N7 and N3 atoms, respectively – such adducts are however far less 
frequently observed.74–77  
INTRODUCTION 
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Figure 4 Typical platinum-DNA adduct structures. Duplex DNA containing (A) cisplatin 1,2-d(GpG) (B) 1,3-d(GpTpG) 
intrastrand, and (C) interstrand cross-links at different representative DNA double strand sequences. Reproduced from ref. 
67. 
In principle, metal centers could also bind towards other N atoms of the purine (A/G) and pyrimidine 
(C/T) bases. Some of those are, however, sterically protected or require deprotonation before metal 
binding (Figure 5).78 
Apart from DNA as the desired target, other biomolecules are available in the cellular environment 
which contain preferable binding sites for Cisplatin and analogs. Biomolecules containing sulfur sites 
have been ascribed to present a central structural target in this context.79 As an example, SCys donors 
in metallothionein (MT)80 and glutathione (GSH)81 have been recognized as very probable targets, 
and adduct formation with these two compounds is regarded as a main cellular protective response. 
Acquired resistance to Cisplatin treatment has been closely associated with elevated GSH and MT 
levels in long-term treated cells.82 Contrary, NMR-based studies with whole-cell extracts have not 
been able to identify platinum-GSH adducts and recently, doubt has been shed on this general 
hypothesis of a principal preferable platinum-GSH binding.83  
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Figure 5 Possible binding sites for heavy metals in a representative tetramer of nucleotides. Stabilization of guanine-N7 
binding through H-bonding in contrast to binding at adenine-N7 is demonstrated. Adapted from refs. 78,84. 
In addition to the two aforementioned sulfur-containing target molecules, MT and GSH, various 
proteins have been found to bind Cisplatin or analogs in recent times (cf. chapter 7). Growing 
evidence is built towards alternate targets for Cisplatin in the cell which do not necessarily lead to 
the inactivation of the complexes pharmacophore.85  
One example of important metal-biomolecule interactions in chemotherapy are the effects platinum 
compounds have on serum proteins. Platinum-protein binding can either lead to a simple 
inactivation of the initial drug or results in toxic effects, e.g. through disturbance of crucial protein 
functions or through transport to healthy tissue which shouldnt be affected by the metal drug. In 
addition to such unwanted consequences of metal-biomolecule binding, it may well be possible that 
metal-protein adducts themselves contribute to the desired cytotoxic effects. Furthermore, the 
protein can serve as a chaperone or drug reservoir to transport the drug into the (right) cells to be 
killed.69,79,86 The overall picture of the consequences that transition metal-protein binding has on 
cellular processes is by far not yet completely assembled, and multiple research groups strive to 
contribute to the images manifold facets.  
The question why Cisplatin and analogs are still able to bind DNA despite the vast number of 
alternate binding sites has been mainly attributed to a thermodynamic stability of platinum-
INTRODUCTION 
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nucleobase adducts, whereas Cisplatin-protein adducts are rather kinetically stabilized. Thus, 
eventually a transfer from the kinetically to the thermodynamically preferred biomolecule adduct is 
feasible.84,86–88  
1.2.3 Cellular Processing  
As a consequence of DNA platination, the β-helical structure of DNA is distorted, leading to inhibition 
of replication and transcription through several cellular pathways.89,90  
Platinum-DNA adducts can be recognized by different cellular proteins, such as enzymes relevant for 
DNA repair, histones, high mobility group box (HMGB)-domains, or transcription factors.51,77 DNA 
repair occurs mainly through nucleotide excision repair (NER) mechanisms,91 a process highly 
dependent on the nature of the adducts and many other factors. Within this repair mechanism, it has 
been found that e.g. HMGB domains can specifically bind 1,2-intrastrand DNA adducts92 and shield 
the adduct from being recognized by NER mechanisms.93,94 The cellular response to Cisplatin-DNA 
damage is furthermore tightly associated with the activity of the p53 tumor suppressor gene. It can 
control processing of DNA adducts by activation of various, complex, downstream pathways.95  
In any case, platinum-DNA binding leads to the onset of multiple direct cellular responses, and the 
final outcome – cell death through apoptosis or necrosis or cell survival depends on many different 
factors which have to date not been fully understood (Figure 6).67,96  
 
 
Figure 6 Direct cellular responses to Cisplatin-DNA binding. Adapted from ref. 67. 

  
 
 
 
2 MOTIVATION, AIM OF THIS WORK 
Cisplatin and its clinically approved analogs are very powerful drugs, able to cure several types of 
cancer and being applied in many combination therapy schemes. Their major drawback is the large 
panel of side-effects that are mainly associated with biomolecule binding at the wrong sites or 
unselective accumulation in both cancerous and healthy tissue.  
In order to reduce side-effects associated with an unselective binding of the drug towards any 
available biomolecule, the concepts of hard and soft acids and bases (HSAB) and of the trans effect 
were brought into consideration for this work.  
The HSAB concept is a general way of classifying compounds based on their ratio of charge to size, 
therefore allowing for an assessment of the hardness (high charge, low mass/radius) or softness 
(low charge, high mass/radius) of functional groups. It is assumed that chemical bonds between a 
Lewis acid (here the metal center) and a Lewis base (the ligand) are in principle more stable if the 
two binding partners are equally hard or soft.97  
According to the concept of the trans effect, the two ligands in trans position of square-planar Pt(II) 
complexes are in competition for the !-electron density contributed by the ligands and the metal 
center. The ligands therefore have a significant influence on the kinetic lability or inertness of the 
trans-positioned bonds. Pearson precisely stated this circumstance in 1973:98 Two soft ligands in 
mutual trans position will have a destabilizing effect on each other when attached to class b metal 
atoms. iii 
Cisplatin, possessing a soft Pt(II) center, has two types of ligands that contribute to the coordination 
environment: ammonia and chloride. Both ligands can be classified as hard Lewis bases.99 In this 
particular case, this binding situation leads to a preferential substitution of chlorido ligands by soft 
donors, such as biomolecular sulfur atoms, as described above.  
                                                          
iii A class b metal atom is a soft metal center according to HSAB. 
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On the contrary, a sulfur atom is a rather soft donor, allowing for a stable binding towards the Pt(II) 
center ǁith suďstaŶtial deloĐalizatioŶ of π eleĐtƌoŶs. The soft sulfur donor then induces a 
preferential binding of ͞haƌd͟ ligaŶds iŶ trans position. Therefore, using a soft donor atom set as 
non-leaving group can reduce a platinum(II) ĐoŵpouŶds’ affiŶitǇ toǁaƌds ďiologiĐal sulfuƌ doŶoƌ 
targets.  
These considerations represent the basis for the structural rationale that lead to the preparation of 
the compounds presented in this thesis (Figure 7). The ligands designed as non-leaving groups for 
Pt(II) complexes are based on the structural motif of β-hydroxydithiocinnamic esters, a compound 
class which is well-established in the Weigand group and has been gaining growing attention also by 
others in recent years (cf. chapter 3). By forming very stable Pt(II) complexes with this (O,S) bidentate 
ligand, the ƌesultiŶg ĐoŵpouŶds’ ƌeaĐtiǀitǇ toǁaƌds ďiologiĐal taƌgets should ďe diƌeĐted toǁaƌds a 
selective interaction pattern rather than a ͞ǁild͟ ƌeaĐtiǀitǇ toǁaƌds too ŵaŶǇ uŶseleĐtiǀe taƌgets. 
The monodentate ligands designed as leaving groups, chloride and dimethylsulfoxide (DMSO), are 
conveniently situated in their favored positions relative to O and S of the bidentate unit: The hard 
chlorido ligand binds platinum trans to the soft S donor; and trans to the harder O donor, DMSO 
binds platinum through its sulfur atom. This coordination environment is assumed to afford a specific 
activity against cancer cell lines, but at the same time to express a more defined interaction pattern 
with biological targets.  
 
 
Figure 7 Rationale for the structural motif of Pt(II) complexes used within this thesis. Soft sulfur donors (blue) coordinate in 
trans position to hard O and Cl- donors (pink). 
All these issues, antiproliferative activity and reactivity towards biomolecules, are addressed within 
this thesis: The design, synthesis and characterization of a panel of Pt(II) compounds based on the 
aforementioned structural criteria is reported (chapter 3), alongside with a primary elucidation of the 
ĐoŵpouŶds’ ďehaǀioƌ iŶ solutioŶ (chapter 4) and their activity against selected cell lines (chapter 5). 
In addition, the interaction of selected model compounds with potential biological targets, namely 
proteins and DNA, is investigated in detail by applying ESI mass spectrometry as primary 
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investigational method and UV-visible spectroscopy to corroborate the obtained data (part B, 
chapters 7 and 8). Furthermore, first steps towards enhanced cellular targeting are made by 
exploring synthetic methods towards bio-conjugation of the (O,S)Pt(II) unit with peptides (part C, 
chapters 11 and 12). 

  
 
PART A 
(O,S) CHELATE COMPOUNDS: SYNTHESIS, 
STRUCTURAL CHARACTERIZATION AND BIOLOGICAL 
EVALUATION 
 
Partial results of the chapters within this part have been published in the manuscripts listed below: 
Novel Platinum(II) Compounds with O,S Bidentate Ligands: Synthesis, Characterization, 
Antiproliferative Properties and Biomolecular Interactions, Dalton Transactions 2014, 43 (8), 3072-
3086, 
 Parts appear in chapter 3 
and Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, 
Antiproliferative Activity and Crystallographic Evidence of Protein Binding, Inorganic Chemistry 2015, 
accepted manuscript,  
 Parts appear in chapters 3, 4, and 5. 
 
Syntheses of compounds 29, 30, 32, 33, 34, and 36 and their corresponding ligands have for the first 
time been executed within the diploma project.100 In the course of investigations executed for the PhD 
project, these compounds have been re-synthesized and their analytical data independently re-
evaluated.  
Compound 50 was prepared by Matthias Hartlieb (FSU Jena) during an advanced practical course, 
which he conducted under my instruction and supervision of Prof. Dr. Wolfgang Weigand.  
 

  
 
 
3 COMPOUNDS BASED ON -HYDROXYDITHIOCINNAMIC 
ESTER DERIVATIVES 
3.1 -Hydroxydithiocinnamic esters 
3.1.1 Known synthetic approaches 
-Hydroxydithiocinnamic ester derivatives have been used in various synthetic applications for 
several years.101 Their syntheses have been described by a number of groups (Scheme 1, Scheme 2). 
The first reported compound, -hydroxydithiocinnamic methyl ester, was described in 1967 by 
Gompper and Schaeffer (Scheme 1a).102 Later on, Larson and Lawesson reported a two-step-
synthesis of various esters via isolation of the respective -hydroxydithiocinnamic acid (Scheme 
1b).103 A one-pot synthesis leading to -hydroxydithiocinnamic esters with variable alkyl groups was 
finally described by Saumweber et al. in 1998 (Scheme 1c).104 Since then, the procedure has been 
refined and well-established in the Weigand group.105108 The method conveniently circumvents the 
isolation of the respective dithiocinnamic acid, which is often associated with purification difficulties. 
It thus presents the preferred synthesis route applied in this work. 
Alternate pathways for the synthesis of methyl esters starting from acetophenone derivatives have 
been developed (Scheme 1d);109 optimized110 and varied (Scheme 1e).111 Furthermore, methyl esters 
could also be obtained from the respective ketene mercaptals using different approaches (Scheme 1f 
and g).112,113 
 
18 
 
3 Compounds Based on -Hydroxydithiocinnamic Ester Derivatives 
 
 
 
 
Scheme 1 Synthetic pathways towards -hydroxydithiocinnamic ester derivatives. a, One-pot synthesis affording 
-hydroxydithiocinnamic methyl ester. b, Two-step synthesis via the -hydroxydithiocinnamic acid. c, One-pot synthesis 
mainly used in this work. d and e, Syntheses utilizing methyl trithiocarbonate derivatives to give methyl esters. f and g, 
Dealkylation of ketene mercaptals.  
Additional reports exist on the synthesis of -oxo dithioesters with various substituents, e.g. alkyl 
groups in   position. Early reports by Thuillier and Vialle made use of CS2 to give dithioacid sodium 
salts, which were then alkylated (Scheme 2h).114116 In another report, lithium diisopropyl amide was 
used for the conversion of dithioesters with aldehydes to give -hydroxydithioesters, which were 
subsequently oxidized (Scheme 2i).117  
3.1.2 Synthesis and characterization of -hydroxydithiocinnamic ester derivatives 
7-28 
Aliphatic esters of -hydroxydithiocinnamic ester derivatives were obtained by applying established 
synthetic procedures (Scheme 3).118,119 First, the hydroxyl groups of acetophenones 1 and 2 required 
protection by a tert-butyl dimethylsilyl (TBDMS) group, aided by imidazole, to give 3 and 4.120 This 
protection was necessary because such an acidic OH group could easily be activated through the 
conditions of the following step, namely deprotonation of the CH-active methyl group to enable 
attack of CS2.  
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Scheme 2 Further synthetic pathways towards -oxo dithioesters. Substituents in  position result in -oxo forms of the 
dithiocinnamic esters. h, method employing CS2. i, derivatization of dithioesters with aldehydes and aubsequent oxidation.  
Acetophenone derivatives 3, 4 as well as 5 and 6, could then be subjected to the previously described 
one-pot synthesis to afford -hydroxydithiocinnamic esters 7-22, bearing H, p-Br or m-/p-O-TBDMS 
as substituent X. Alkyl chains R of increasing chain length were introduced by proper choice of the 
alkylating agent. All compounds were obtained in moderate yields which mainly depended on the 
alkyl group R being introduced.  
Notably, yields were generally best for ethyl rests. Obviously, the reactivity of ethyl iodide proved to 
be both high enough for a high degree of conversion alongside with sufficient inhibition towards the 
formation of the frequently observed ketene mercaptals. Yields of methyl esters were generally 
lowered by the preferential double alkylation and reaction towards ketene mercaptals, and butyl 
iodide resp. hexyl bromide were significantly less reactive, as seen by incomplete conversion in some 
of the conducted syntheses. 
In order to obtain ligands 23-28 with hydroxy groups in meta or para position of the aromatic unit, 
O-TBDMS protected compounds 15-22 were subjected to fluoride-based silyl ether cleavage by using 
tetrabutyl ammonium fluoride (TBAF) as cleavage reagents, followed by acidic work-up to obtain the 
protonated phenyl-OH group.105 The conversion usually proceeded smoothly and the desired 
compounds 23-28 could be isolated in moderate to high yields (Scheme 3).  
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X \ acetophenone 
m-OH 1 
p-OH 2 
m-O-TBDMS 3 
p-O-TBDMS 4 
H 5 
p-Br 6 
 
X \ R Me Et Bu Hex 
H 7 8 9 10 
p-Br 11 12 13 14 
m-O-TBDMS 15 16 17 18 
p-O-TBDMS 19 20 21 22 
m-OH 23 24  25 
p-OH 26 27  28 
 
Scheme 3 Synthetic procedures towards derivatives of -hydroxydithiocinnamic esters, being varied at the aromatic and 
dithioester subsite. Reactions with a dashed arrow were only performed for hydroxy-derived compounds.  
The compounds were investigated by standard analytical methods (1H and 13C NMR spectroscopy, IR 
spectroscopy, mass spectrometry, elemental analysis). A detailed discussion of spectral data can be 
found in the respective manuscripts118,119 and earlier work of the Weigand group.104107  
The most characteristic signals observed in NMR spectra of -hydroxydithiocinnamic ester 
derivatives 7-28, recorded in CDCl3, include those of the  -methine group, being observed at 6.8-6.9 
and 107-108 ppm in 1H and 13C NMR spectra, respectively. 13C NMR signals belonging to the 
quarternary CS2 group are generally observed at 215-217 ppm, those of the -C-OH group in a 
range of 168-170 ppm. Furthermore, the -OH group is commonly observed as a sharp singlet in the 
range of 15.0-15.3 ppm in 1H NMR spectra, indicative for the postulated cis-enolic structure of the 
compounds.  
The combined NMR data suggest that an intramolecular hydrogen bonding is an important stabilizing 
factor for the ligands 7-28, as has been confirmed by X-ray crystallographic studies by Schubert et al. 
earlier on compound 26105 as well as by Mancilla-González et al. on compounds 7, 11 and other 
derivatives.121 Other groups have postulated -oxo dithioester122,123 or thio-enol structures124 as 
possible tautomers, but structural findings for all ligands presented here point towards the 
postulated -hydroxydithiolato structure. 
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Further relevant structural data are given through presence or absence of the silyl-based protection 
group. In compounds 15-22 with an O-TBDMS group, characteristic NMR signals are observed at 0.2 
and 1 ppm (in 1H) as well as at ca. -4 and 26 ppm (in 13C) for the methyl and tert-butyl groups, 
respectively. The quarternary C(Me)3 carbon exhibits a signal at ca. 18 ppm in 13C NMR spectra. These 
signals are diminished upon cleavage of the O-Si bond. NMR spectra of the ligands were typically 
recorded in CDCl3, so that the formed phenyl-OH group was generally not witnessed in 1H NMR 
spectra of compounds 23-28. 
Mass spectra (EI) of the isolated compounds usually afforded the [M]+ or [M+H]+ molecular ion and 
further characteristic peaks, such as the signal after loss of the S-R group.  
3.2 Platinum(II) complexes 
3.2.1 Reported metal complexes with ligands based on derivatives of 
-hydroxydithiocinnamic esters 
Metal complexes based on the described ligand system have been reported by several groups, 
mostly affording bis-functional complexes with divalent transition metal centers.104,105,108,125,126 In 
principle, coordination of -hydroxydithiocinnamic esters towards a metal(II) center readily proceeds 
upon deprotonation of the ligands hydroxy group, and MII(O,S)2 bischelate complexes are obtained, 
which form a stable, six-membered chelate unit for each ligand (Chart 3a). As has been reported and 
demonstrated by X-ray crystallographic methods, transition metal complexes are selectively obtained 
showing the ligand in cis configuration respective to the O and S donor molecules.104,106,107,125,126  
Furthermore, monocationic complexes have been prepared based on pyridine-derived ligands in 
combination with a neutral trans-(1R,2R)-diaminocyclohexane (DACH) co-ligand, thus only having 
one (O,S) binding unit (Chart 3b).127 Also their incorporation into half-sandwich titanium complexes 
has been reported (Chart 3d).121 
Very recently, a report on a selective tuning of the coordination mode from the typical (O,S) to a (S,S) 
chelate environment was reported with mercury(II) by altering the aromatic substituent of the 
-hydroxydithiocinnamic esters: When using pyridine as aromatic substituent (as opposed to p-OMe 
or p-Br substituted phenyls, Chart 3e), intermolecular interactions forced the Hg(II) center into a 
(S,S)HgII(CPh)(NPy) coordination environment (Chart 3f).128 Such a coordination mode is usually 
observed for transition metal complexes of the free -hydroxydithiocinnamic acids (Chart 3c).106,107  
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Chart 3 Literature-reported metal complexes based on -hydroxydithiocinnamic ester derivatives. 
3.2.2 Syntheses of the (O,S) bidentate Pt(II) complexes 
The synthesis of Pt(II) complexes with one (O,S) unit and two monodentate ligands, namely dimethyl 
sulfoxide (DMSO) as neutral ligand binding via its S atom and a chlorido anionic ligand, was reported 
for the first time in the publication which appeared in Dalton transactions 2014.118  
To obtain Pt-DMSO species, several approaches have been reported in literature.129133 Once 
activated by DMSO coordination, further derivatizations of the coordination environment can be 
performed, and DMSO can either be substituted by more stable ligands134 or retained within the 
coordination sphere.135137 For the method described here, a Pt-DMSO species was generated in situ 
and immediately converted with the respective (O,S) ligand, which binds to the Pt(II) center to give 
the desired (O,S)Pt(DMSO)(Cl) structural motif. This approach avoids tedious and substance-
consuming work-up procedures and is thus very efficient from an economical point of view. 
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X \ R Me Et Bu Hex 
H 29 30 31 32 
p-Br 33 34 35 36 
m-O-TBDMS 37 38 39 40 
p-O-TBDMS 41 42 43 44 
m-OH 45 46   
p-OH 47 48   
 
 
Scheme 4 Synthetic procedure towards Pt(II) complexes with an (O,S) bidentate ligand based on -hydroxydithiocinnamic 
esters, as well as DMSO and chloride as monodentate ligands 
For preparation of complexes 29-48, compounds 7-28 were subjected to the following generalized 
conditions (Scheme 4): Potassium tetrachloro platinate(II), K2PtCl4, was activated with a slight excess 
of dimethyl sulfoxide (DMSO) and the ligand, deprotonated through an appropriate base, was added 
in slightly submolar quantities to suppress the formation of strongly preferred bischelates. The 
desired compounds 29-48 were obtained in varying yields.118,119,138  
For compounds with X = O-TBDMS or OH and R = butyl or hexyl group (Scheme 4), the preparation of 
the desired complexes was only partially successful; not all compounds could be obtained or purified 
to the desired degree. Interestingly, compounds 43 and 44, with the substituent in para position, 
were more difficult to obtain than the respective meta substituted counterparts (39/40). Both 
species could not be isolated sufficiently. For compounds with a free phenyl-OH group, the synthesis 
of complexes based on ligands 25 and 28, bearing hexyl groups, was not successful at all and 
afforded solely unidentified decomposition products. The alternate approach to obtain the 
compounds via cleavage of the O-TBDMS unit after complexation, i.e. from compounds 37-44, was 
generally not successful. Again, NMR spectroscopy did not show any sign of the desired complex. 
Further efforts to obtain these compounds (respectively the butyl compounds) were not undertaken 
since the main goal of the synthesis of these complexes was to enhance aqueous solubility. The 
formation of complexes with longer alkylic chains was only of synthetic interest rather than of 
functional rationale.  
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3.2.3 Influence of the base 
To elucidate whether the nature of the base used to deprotonate the -hydroxydithiocinnamic ester 
has an influence on the yield of the respective Pt(II) complex and to better be able to adapt the base 
to the ligands needs, different bases were used to prepare the p-Br/Et substituted model complex 
34. The standard base used in all early experiments was sodium hydride (NaH), which required the 
deprotonation to be carried out under inert conditions.118,119 The great advantage of this approach is 
that evolving H2 gas can be used to monitor the completion of the reaction and that all acidic protons 
are removed from the system, thus giving the (O,S) compound as a sodium salt. Alternatively, KOtBu 
was explored as candidate since it was successfully applied for the ligand synthesis and was therefore 
expected not to induce unwanted side reactions. Third, sodium acetate (NaOAc) was explored as 
potential base, together with the change from inert to non-inert conditions, thus facilitating the 
handling of the compounds.  
All three approaches lead to the desired complex 34, but unexpectedly the deprotonation approach 
with sodium acetate gave the highest yield (66%) of the target compound.iv KOtBu proved to be the 
least effective base (25 % yield) and use of NaH lead to 33 % yield. Therefore, where possible, NaOAc 
was used as the preferential base in later experiments unless functional groups required otherwise.  
3.2.4 Bischelates 
Typical side products formed during the described procedure are the respective bischelates with two 
(O,S) bidentate units being bound in cis configuration. This can be prevented to a large degree by 
adding the deprotonated ligands to the Pt-DMSO adduct slowly and in sufficient dilution. In some 
early experiments, still a substantial amount of bischelate was formed during complexation and thus 
isolated from the mixtures. One representative, compound 49 with H/Me substitution pattern, was 
chosen as occasional reference for further studies (Scheme 5).  
                                                          
iv When the synthetic procedure was developed, various approaches had been tested. The compounds could 
for the first time be obtained when using NaH as base under inert conditions. Attempts to work under air failed 
in the first experiments, probably due to other parameters that had not been optimized at that point. Later on, 
it was found that the crucial step for a successful synthesis is the sufficient pre-activation of K2PtCl4 by DMSO 
rather than the deprotonation of the base. Moreover, the synthesis could even proceed without base in special 
cases, vide infra. 
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Scheme 5 Representative bischelate complexes obtaineed during the synthesis of compounds 30 and 38. 
Another representative, compound 50 (Scheme 5), was obtained in crystals suitable for X-ray 
structure determination. Cis-coordination of the two (O,S) units to give a square-planar coordination 
environment is clearly demonstrated. The entire molecule, as depicted in Figure 8, is more or less flat 
and interestingly, the phenyl ring is rotated in such a fashion that the O-TBDMS groups point towards 
the center of the molecule. This leads to a slight tilting of the phenyl rings to position the silyl units 
above and below the molecular plane. 
 
 
  
Figure 8 Molecular structure of bischelate 50 (Space group: P21/c). Left: view onto the molecular plane; right, view along 
the molecular plane. Thermal ellipsoids are given at 50 % propability level.  
3.2.5 Characterization of the complexes 
All described compounds were characterized by standard analytical methods as described in detail in 
the respective manuscripts.118,119 Compounds 32 and 33 were furthermore analyzed by X-ray 
crystallographic studies as discussed elsewhere.118 
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The most characteristic spectral changes respective to the corresponding ligands are observed in the 
compounds NMR spectra, typically recorded in CDCl3 (for 29-44), acetone-d6 or THF-d8 (for 45-48). 
The loss of the high-frequency -OH proton signal is generally accompanied by a shift of the binding 
-C-OPt carbon signal to higher frequencies by ca. +5 ppm (found at 173-176 ppm in 13C NMR 
spectra). Furthermore, the signals belonging to the methine group experience characteristic shifts, 
i.e. by ca. +0.3 ppm to 7.0-7.2 ppm and by ca. +4 ppm to 111-112 ppm in the 1H and 13C NMR spectra, 
respectively. In addition, the dithiocarbonyl-carbon atom experiences a massive shift to lower 
frequencies by ca. 35 ppm and can be found at 180-182 ppm when coordinated to the Pt(II) center. A 
broad singlet belonging to the phenyl-OH group may be witnessed at ca. 8-9 ppm in 1H NMR spectra 
of 45-48 when recorded in acetone-d6 or THF-d8, but not in NMR spectra recorded in CDCl3.  
These typical signal sets can be observed in both, the desired monofunctional compounds 29-48, but 
very similarly also in the bis-functional side products such as 49 or 50. An unambiguous proof of the 
formation of (O,S) bidentate compounds with DMSO and chloride being bound towards platinum 
presents the combination of mass spectrometric data (typically obtained through ESI), which 
frequently gave signals of the molecular ions or Na+ adducts, and the observation of Pt-coordinated 
DMSO in NMR spectra. In 1H NMR spectra, a singlet at ca. 3.6-3.7 ppm with Pt-satellites and a 3JPt-H 
coupling constant of 23-24 Hz can be assigned to Pt-coordinated DMSO with a shift of ca. +1 ppm 
compared to free DMSO.139 In 13C NMR spectra, Pt-bound DMSO is observed at 46-47 ppm, thus 
shifted by ca. 6 ppm compared to free DMSO.139 Under some circumstances (high compound 
concentration and low magnetic field, typically 200 MHz), even Pt-C coupling could be observed with 
1JPt-C  59 Hz. In cases where THF-d8 presented the most suitable deuterated solvent for NMR 
analyses (as was the case for compounds 45-48), the proton signal of coordinated DMSO was 
obscured by intrinsic solvent signals but could typically be detected from cross-peaks in HSQC 
experiments.  
Overall, the spectral data for complexes 29-48 markedly demonstrate that it is possible to alter the 
structure of the (O,S) bindentate ligand in a wide range without significantly affecting the 
pharmacophores electronic structure, thus enabling further variations for functional optimization. 
  
 
 
4 SOLUTION CHEMISTRY OF THE (O,S) CHELATE 
COMPOUNDS 
4.1 Solubility in aqueous medium  determination of LogPo/w values 
It is generally a desirable aim to prepare compounds with a defined aqueous solubility which makes 
the uptake of drug candidates via oral administration (for highly water soluble compounds) or the 
blood stream possible. Highly lipophilic compounds may also be administered by other means, such 
as oil immersions or emulsions, but some degree of hydrophilicity is in general needed for the 
application of new drug candidates.140 A well-defined polarity of a compound can lead to an 
appreciable degree of aqueous solubility; if aided by H-bonds, this can be significantly enhanced.141 
The solubility of organic compounds in aqueous or organic medium is frequently quantified by their 
water/n-octanol partition coefficient, given as LogPo/w value, which is usually determined through the 
shake-flask method.142,143 In recent times, this quantification method has also been introduced in 
medicinal inorganic research scopes for determining the polarity of metal compounds.144147 It 
appears indeed to be a straight-forward idea since the method is simple and versatile at the same 
time: essentially, a defined stock solution of the compound in water or n-octanol is mixed with the 
respective complimentary solvent, followed by determination of its concentration in both phases by 
appropriate quantification methods). Computer programs are nowadays even available which try to 
predict these values by using different increment methods.147149 In addition, alternate methods have 
been developed, such as HPLC-based regression methods, where the compounds LogPo/w value is 
extrapolated from its retention time in a water-methanol gradient.150153 
However, the shake-flask method will not give reliable results when using metal complexes that are 
prone to hydrolysis reactions in aqueous medium. As an alternative method to determine the 
polarity of the compounds discussed here, the HPLC method was tested. However, the compounds 
under investigation underwent fast solvolysis at conditions appropriate for this approach, thus 
rendering this method inapplicable for the compounds under investigation.  
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It is indeed not useful to determine the polarity of the complexes in a water/n-octanol mixture. If the 
experiment is planned in a time-frame shorter than needed for full hydrolysis, the system will not be 
in equilibrium state due to ongoing aquation reactions (even if slowed down by the addition of 
appropriate salts). If the experiment is performed at true equilibrium state, as required for a correct 
determination of LogPo/w, there will be two (or more) different components in the mixture.154 For 
example, the LogPo/w value of Cisplatin is reported in literature as ranging from -1.7147 to -2.5144 and 
therefore spans almost one order of magnitude of Po/w (Po/w ! 2·10-2 and 3·10-3, respectively). These 
deviating values may originate from differences in the determination method, but foremost these 
differences can be ascribed to hydrolysis processes going on during the experiment. Notably, similar 
variations were observed with the herein described complexes 29-48, rendering this method 
unsuitable for determining meaningful data. 
To circumvent this predicament, LogPo/w values were determined for the pre-ligands 7-28 presented 
here and not for their Pt(II) complexes. The decision was based on a simple rationale: the final 
pharmacophore of the complexes is identical in all cases, only variations of the (O,S) bidentate ligand 
contribute to changes in the complexes polarity. It is therefore possible to attribute the complexes 
relative polarity from their ligands LogPo/w values. Although the obtained results cannot give exact 
results for the complexes, they allow for a comparison of the polarity development within this series.  
The compounds were subjected to the shake-flask method as described in detail in the experimental 
section. The relative concentration in both phases was determined by UV-visible spectrophotometry. 
LogPo/w values were then calculated from the average absorbance in the range of 300 and 500 nm 
using formula (1). The results are summarized in Figure 9.  
 Log !/" = #$ %&!'()*!+&")(,- . = #$ 01!'()*!+2334533*61")(,-2334533*67  (1) 
The LogPo/w values range from 1.71 to 2.72 and hence span one order of magnitude for Po/w. The 
lowest values were obtained for the meta-hydroxy substituted compounds 23-28, the highest for the 
O-silyl protected compounds 15-22. Unsubstituted or Br-derived compounds 7-14 gave intermediate 
LogPo/w values.  
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Figure 9 LogPo/w values of β-Hydroxyditioncinnamic acid esters as obtained from the shake-flask method. 
The graph in Figure 9 deŵoŶstƌates that the stƌoŶgest iŶflueŶĐe oŶ the ĐoŵpouŶds’ polaƌitǇ 
originates from the substitution pattern at the aromatic unit rather than from the length of the 
alkylic chain at the sulfur moiety. Nevertheless, an overall rising LogPo/w was observed when the 
thioester chain length was increased. The most significant observation is made within the series of 
hydroxy-substituted compounds 23-27: whilst m-OH compounds 23/24 exhibit the lowest LogPo/w 
values, those bearing p-OH groups 26/27 are higher and come into the range of unsubstituted and 
Br-substituted compounds 7-14. Obviously, the position of the polar group has a significant impact 
on the final polarity of the compound.  
Some technical note should be given on the experimental setup. UV-vis spectroscopy provides a 
useful tool to deteƌŵiŶe a ĐoŵpouŶds’ ĐoŶĐeŶtƌatioŶ in solution, given a well-defined absorption 
spectrum and a proper concentration range. The compounds discussed here, both 
β-hydroxydithiocinnamic esters and their corresponding Pt(II) complexes, give a characteristic 
absorption spectrum in the visible range of the spectrum. In the aqueous phase however, the signal 
intensity is very low and noise dominates the spectrum. Several approaches have been employed to 
circumvent this issue, including the application of smoothing functions or choosing certain singular 
wavelengths for the determination of the logPo/w value. Furthermore, it was attempted to calculate 
the absolute concentration of the compounds in each phase through their extinction coefficients ɸ 
(for a detailed description, cf. the experimental part), but siŶĐe the ĐoŵpouŶds’ soluďilitǇ iŶ ǁateƌ 
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without the use of solubility-mediating additives (such as DMSO) is low, no extinction coefficient for 
the aqueous phase could be calculated, so that this approach also did not lead to reliable results.  
Based on these considerations, it was decided to use the average absorbance in the wavelength 
range of 300-500 nm, as mentioned earlier, for calculating the relative concentration in the aqueous 
vs. n-octanol phase. This range was chosen on the rationale that below 300 nm, absorptions of the 
solvents could obscure the spectrum even after baseline correction. Above 500 nm, no specific 
absorptions of any investigated compound were observed. Choosing a 200 nm range furthermore 
middled out noise in the water-phase spectra to a large degree. Representative spectra are given in 
Figure 10. 
 
Figure 10 Some representative UV-vis absorption spectra of methyl-dithioesters 7, 11, 23 and 26 as used for calculation of 
LogPo/w in the relevant wavelength range 300-500 nm. The three well-defined signals (reds/yellows) originate from the 
n-octanol phase, the spectra close to the baseline (blues) were recorded in water.  
IŶ pƌiŶĐiple, also otheƌ ŵethods to deteƌŵiŶe the ĐoŵpouŶds’ ƋuaŶtitǇ iŶ eaĐh phase aƌe thiŶkaďle. 
For experiments that were conducted with the complexes, quantification of Pt content by ICP-OES 
was attempted;v yet the sample preparation failed since it was not possible to mineralize the large 
quantity of octanol present in the respective phase.  
  
                                                          
v These experiments were carried out by Tiziano Marzo (Firenze, private communication). 
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4.2 Behavior in solution  UV-visible spectroscopic experiments 
The investigational compounds behavior in aqueous solution was also monitored by UV-visible 
spectroscopic experiments. In-depth discussion of procedures and results can be found in the 
respective manuscripts.118,119 Some further details of these investigations are presented in this 
section. 
All metal complex spectra share a very similar chromophore expressed as three absorption bands, 
centered at about 270-280 nm, 350-370 nm, and at 410-430 nm. The exact position and shape of the 
spectrum differs with the varying substituents at the (O,S) bidentate ligand. Overall, these bands well 
represent the yellow color of the solid compounds and solutions. A definite assignment of the three 
transition bands is purposely not made due to the complexity of influences contributing to the 
compounds electronic structure.vi Nevertheless, based on spectra obtained from pure ligands (as 
shown e.g. in Figure 10) and the experiments described below, it becomes clear that the electronic 
transitions must originate from the (O,S) bidentate ligand bound to the Pt(II) center and that the 
positions of the bands are strongly influenced by the ligands in trans position.  
In general, it was found that the compounds stay dissolved in 100 µM buffered solutions over 24 h 
when a suitable amount of DMSO (10-25 %) is added to aid dissolution. Some evidence of partial 
hydrolysis is found from minor spectral changes in the long-wave band at ca. 420-430 nm.  
For H and Br compounds, a noticeable dependence of solubility and alkyl chain length was found (i.e., 
increasing aqueous solubility by shortening the alkyl chain, as would be expected), alongside with an 
enhanced aqueous solubility for unsubstituted compounds in comparison with their p-bromo 
counterparts.118 These observations correlate well with the found LogPo/w values, even though the 
mere observation of UV-visible spectra suggest much stronger changes in P than the determined 
logPo/w values show. This might, however, be an issue of perception.  
Similar UV-visible spectra were recorded from buffered solutions of the OH substituted compounds 
45-48 and are discussed in detail in the corresponding manuscript.119 Overall, these compounds 
present an appreciable solubility in buffered solutions containing 25 % v/v DMSO. Some indications 
of hydrolysis were found, as expected, and no significant influence of the alkyl group at the 
dithioester moiety was observed  an expectable result, given the fact that only methyl and ethyl 
groups were incorporated into the structural motif. Interestingly, the position of the OH group 
                                                          
vi Initial attempts to simulate the most probable electronic transitions of these UV-vis spectra by DFT methods 
gave no reliable data due to the presence of Pt as heavy atom. (Pablo Rivera Fuentes / ETH Zürich, private 
communication) 
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proved to be relevant for the relative intensity of the long-wave band at ca. 410 nm. It is, in contrast 
to all other compounds, in p-OH complexes 47 and 48 more intensive than the middle band around 
350 nm. In addition, a shoulder at about 470 nm could be observed in spectra with 50 % DMSO v/v. 
This observation is indicative of some mesomeric effects induced by the para-position of the hydroxy 
group. 
When kept in pure DMSO, no spectral changes are observed over the course of 96 h for a 1 mM 
solution of compound 34, indicating that DMSO stabilizes the compound (Figure 11). Even when kept 
in mixtures with 50 vol-% water or phosphate buffer (PB, 10 mM) at 1 mM, most of the compound 
stays dissolved over 96 h. At lower DMSO concentrations, e.g. 10 vol-% DMSO, significant 
precipitation is observed immediately, thus demonstrating the expected low aqueous solubility. 
Comparable results were obtained when using water instead of PB (data not shown). The spectra 
depicted here were recorded in pure DMSO to enable direct ĐoŵpaƌisoŶ of the ďaŶds’ iŶteŶsitǇ. 
These conditions, however, will not allow for an assessment of possible hydrolysis processes going on 
in the aqueous mixtures: Obviously, DMSO is a favorable ligand that may well bind to platinum itself 
and thus alter the ĐoŵpouŶd’s Đhƌoŵophoƌe. 
 
Figure 11 Long-term UV-visible spectra of 34. 1 mM solutions in the respective solvent combination were kept at r.t. over 
the period of time. Aliquots were taken periodically and diluted to 100 µM in DMSO for measurement.  
To ŵoŶitoƌ the ĐoŵpouŶd’s ďehaǀioƌ diƌeĐtlǇ iŶ the ƌespeĐtiǀe solǀeŶt, UV-visible spectra were 
recorded over the course of 24 h as depicted in Figure 12. Interestingly, some minor spectral changes 
are observed here even at 100 vol-% DMSO, but to a very low degree. When keeping the solutions in 
buffered solutions, in addition to effects of precipitation, some variation in the relative band 
intensity of the bands at ca. 365 and 420-430 nm are observed. Apparently, hydrolysis occurs over 
time. First spectral evidence for this process is found after ca. 1 h in the spectra recorded from 
10 vol-% DMSO solutions in form of a loss of the long-ǁaǀe ďaŶds’ iŶteŶsitǇ. This is aĐĐoŵpaŶied ďǇ a 
slight, gradual blue-shift of the ďaŶds’ ŵaǆiŵuŵ fƌoŵ ϰϭϯ nm to 409 nm.  
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Figure 12 UV-visible spectral development of 34, dissolved in the indicated solvents, at 100 µM over 24 h. The compound 
was kept at 100 µM in the respective solvent combination and UV-visible spectra recorded periodically. 
It is further interesting to see that the band maximum of the long-wave band at t = 0 is solvent-
dependent whilst the other two bands are not: in pure DMSO, the band maximum lies at 430 nm; in 
10/90 % v/v DMSO/PB, this maximum is blue-shifted to 413 nm. The other two bands remain fairly 
stable throughout all experiments. Representative peak data can be found in Table 1. 
When the chlorido ligand of compound 34 was abstracted by an excess of silver nitrate, the long-
wave band at initially 430 nm experienced a blue-shift of 20 nm towards 410 nm in spectra recorded 
in pure DMSO (Figure 13). In the spectra recorded in DMSO/H2O 50/50 % v/v,vii the long-wave band 
shifts from 418 nm to 410 nm. These results strongly indicate that an exchange of the chlorido ligand 
results in a shift of the long-wave band, which can be used as an indicator for further UV-vis 
spectroscopy-based investigations.  
 
Figure 13 UV-visible spectra of 34 before (black) and after (red) abstraction of the chlorido ligand by AgNO3. Precipitation 
was performed with a 100-fold excess of AgNO3 (1 M in DMSO) at 1 mM drug concentration, followed by dilution to 100 µM 
in the respective solvent for spectra recording. 
  
                                                          
vii In this case, the use of PB was impractical due to the formation of Ag3PO4. 
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Table 1 Representative UV-visible peak data for compound 34 under different conditions. Wavelengths are given from peak 
maxima with an accuracy of ± 1 nm. 
Solvent time / additive   !"#  (nm ± 1)  !"$  (nm ± 1)  !"%  (nm ± 1) 
DMSO  
100 % 
0 h 279 361 430 
24 h 273 360 425 
0 h + AgNO3 n.o.a 360 410 
DMSO/PB 
50/50 % v/v 
0 h 273 363 421 
1 h 274 362 415 
24 h 278 361 414 
0 h + AgNO3 n.o.a 360 410 
DMSO/PB 
10/90 % v/v 
0 h 275 364 413 
1 h 274 366 408 
24 h 274 366 409 
a n.o.  not observed due to overlay with AgNO3-induced signals at short wavelentghs 
 
 
  
 
 
5 BIOLOGICAL ASSAYS 
In order to gain insight into the compounds biological activity, a panel of suitable candidates was 
selected (Chart 4) and subjected to the resazurin-based PrestoBlue® assay. The prepared compounds 
were tested against a panel of representative cell lines, i.e. HeLa (cervical cancer), HT29 (colon 
carcinoma), MCF7 (female breast cancer), and HEK 293T (kidney) cell lines. The cell lines were 
incubated with a concentration series of the investigational compounds for 72 h and then their IC50 
values determined from logarithmic regression of the sigmoidal dose-response curves obtained from 
PrestoBlue® assay (vide infra for more detailed information).  
 
 
 
 
X \ R Me Et Bu Hex  Ligand (L) 
H 29 30 31 32  7 R = Me 
p-Br 33 34 35 36  11 R = Me 
m-OH 45 46    23 R = Et 
p-OH 47 48    26 R = Et 
Chart 4 Overview of compounds under investigation for biological assays. 
5.1 Results of antiproliferative assays 
The results of the PrestoBlue® assays, executed after 72 h incubation with the platinum compounds, 
are shown in Table 2 and Figure 14. It can be seen that the determined IC50 values of the newly 
synthesized compounds are generally higher than the corresponding reference, Cisplatin (here 
abbreviated with CDDP). Some further interesting trends can be seen from these studies. 
For the unsubstituted compounds 29-32, a substantial difference in activity is observed for 
compounds bearing a short alkyl chain (i.e., Me or Et groups), and those bearing longer alkyl chains. 
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With elongation of the alkyl substituent, the activity against cells is markedly reduced and IC50 values 
above 100 µM are obtained.  
Curiously, when a p-Br substituent is introduced into the same structural motif, compound 36 with 
R = Hex seems to be the most active compound in this series against all cell lines.  
This difference in structure vs. activity ŵaǇ ďe eǆplaiŶed tƌough the ĐoŵpouŶds’ diffeƌeŶĐes iŶ 
lipophilicity, but possibly also by differences in their metabolism. Compounds with less lipophilic 
character, i.e. H/Me or H/Et compounds, may be metabolized more rapidly or easily than the more 
lipophilic ones, but very lipophilic compounds might preferentially be taken up into the cells by a 
different pathway, e.g. by passive diffusion through the lipophilic cell membrane.  
In general, the differences in activity of the single unsubstituted or Br-substituted compounds against 
the individual cell lines is rather low and no general trend can be deduced from this data, given the 
high standard deviations of the IC50 values. 
On the contrary, when an OH group is incorporated into the aromatic ring in meta or para position, 
marked differences in activity of the resulting complexes are observed. The substances present an 
antiproliferative activity against HeLa and MCF7 cells, but very low activity against HT29 or 293T HEK 
cells.viii  
 
Figure 14 IC50 values of the Pt(II) compounds and representative ligands against the model cell lines HeLa (blue), HT29 (red), 
MCF7(green) and 293T HEK (purple). Compounds with values above 100 µM (dotted line) are considered inactive. Bars 
crossing the 250 µM scale (dashed line) continue above but are not defined. Error bars are given as biological standard 
deviation (SD) out of at least two independent experiments. 
                                                          
viii The activity of the OH substituted compounds against 293T HEK cells was only assayed once and shall 
therefore not be discussed in detail. 
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Table 2 IC50 values of the compounds under investigation as determined by PrestoBlue® assay. IC50 values are given as mean 
out of individual regressions ± biological standard deviation.  
Compound HeLa  HT29  MCF7  293T HEK 
Nr. X R IC50 [µM]  IC50 [µM]  IC50 [µM]  IC50 [µM] 
29 H Me 18.8 ± 11.0  39.5 ± 4.0  31.9 ± 3.8  16.7 ± 4.8 
30 H Et 21.9 ± 4.5  69.1 ± 38.6  37.3 ± 18.8  21.3 ± 4.4 
31 H Bu 127.2 ± 65.5  95.4 ± 118.1  131.5 ± 48.2  118.8 ± 49.7 
32 H Hex 113.2 ± 74.4  147.6 ± 48.7  127.0 ± 39.6  106.3 ± 50.8 
7 (L) H Me 85.9 ± 78.8  188.2 ± 98.0  >250  150.2 ± 84.9 
33 p-Br Me 57.4 ± 48.7  164.3 ± 65.2  180.3 ± 86.7  122.9 ± 25.3 
34 p-Br Et 127.1 ± 55.6  194.9 ± 82.4  133.2 ± 57.9  144.2 ± 44.0 
35 p-Br Bu 72.9 ± 26.8  157.4 ± 127.4  152.7 ± 76.8  97.1 ± 42.5 
36 p-Br Hex 41.3 ± 5.3  73.3 ± 33.4  76.5 ± 39.0  45.8 ± 22.8 
11 (L) p-Br Me 135.6 ± 20.4  >250  138.6 ± 23.9  28.3 ± 16.4 
45 m-OH  Me 24.3 ± 5.1  162.6 ± 31.1  32.6 ± 0.3  111.2a 
46 m-OH  Et 20.3 ± 3.3  158.2 ± 59.7  27.4 ± 3.3  109.3a 
47 p-OH  Me 36.7 ± 0.7  238.3 ± 9.3  105.7 ± 55.0  95.2a 
48 p-OH  Et 35.3 ± 2.1  227.2 ± 2.2  88.5 ± 68.6  156.2a 
24 (L) m-OH  Et 100.7a  >250  >250  n.d.b 
27 (L) p-OH  Et 121.1a  >250  >250  n.d.b 
CDDP   9.0 ± 2.7  25.4 ± 8.3  11.6 ± 4.0  12.0 ± 3.1 a only one reliable value obtained, therefore no biological standard deviation available; b n.d.  not determined 
Notably, the meta-hydroxy complexes 45 and 46 are significantly more active than their para-
hydroxy counterparts 47 and 48 up to a degree that the p-OH compounds can also be considered 
inactive against MCF7 cells, when taking an IC50 value of max. 100 µM as a reference. Obviously, 
introducing an OH group brings forth increased selectivity towards certain cell lines with a marked 
difference between the two substitution patterns.  
To test the activity of the ligands alone, selected reference compounds, i.e. the methyl esters of 
unsubstituted and p-Br derived -hydroxyditiocinnamic acid (7 resp. 11) and the ethyl esters of the 
two OH-derived hydroxyditiocinnamic acids (24, 27) were screened for antiproliferative activity as 
well. They did show some minor activity, but IC50 values were generally determined to be above 
100 µM and thus no in-depth investigations were conducted on these compounds.  
Furthermore, the activity of one bischelate, i.e. of 49, and of the O-TBDMS derived complexes 37, 38, 
41, and 42 was also screened. However, the solubility of these compounds in the biological cell 
culture medium was too low to reliably determine IC50 values when keeping any influence from an 
organic solvent at below 2% (data not shown).  
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5.2 Use of DMSO as solvent 
It has to be noted that for all the compounds except Cisplatin, DMSO was used as solvent for 
manufacturing stock solutions.  
For compounds that are not well soluble in aqueous medium, it is common practice to use DMSO as 
initial solvent for stock solutions.140,155 Still, some drawbacks exist when using this solvent, e.g. the 
occurrence of unwanted side reactions such as ligand exchange156 or an intrinsic cytotoxic effect of 
DMSO itself.157 In the case of the here discussed compounds, the presence of DMSO in stock 
solutions may even be favorable, because it can actually slow down the solvation process. 
Nevertheless, stock solutions were always prepared freshly from powder for each assay and the 
amount of DMSO used was kept at a minimum level. This was achieved by preparing the stock 
solutions at the highest possible concentrations (min. 10 mM, typically 50 mM) that allowed for the 
dilution series prepared with the biological cell culture medium to be made without precipitation. 
More precisely, the amount of DMSO present in all dilutions was max. 1 vol-%, typically lower 
(0.2 vol-%) at 100 µM drug concentration. In separate experiments using only DMSO as additive, 
cellular activity was found to be only marginally affected by the highest amounts of DMSO present, 
and thus generally neglected. 
In principle, keeping the amount of DMSO constant in every single dilution within an assay is a 
different approach to equalize the solvents effect towards the cells at all concentrations. This, 
however, results in unnecessarily high DMSO concentrations in all samples and might also influence 
the compounds hydrolysis behavior. In order to use optimized conditions for all compounds, this 
approach was therefore evited. 
Cisplatin, as reference, was dissolved in phosphate-buffered saline (PBS) to better represent its 
therapeutic application scheme. The use of DMSO as a solvent for Cisplatin might furthermore lead 
to various side reactions that could eventually lead to inactivation of the initial drug.158,159  
5.3 Infuence of incubation time on antiproliferative activity 
In initial experiments on the unsubstituted and p-bromo substituted compounds,118 substantial 
activity of the (O,S) chelate compounds was observed against A549 cell lines upon a short incubation 
time of 24 h. In an attempt to deeper investigate the compounds activity against a greater panel of 
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cell lines and at different time points, further investigations were conducted using the panel of cell 
lines presented here. 
(O,S)Pt compounds 33-36, bearing a bromo substituent at the aromatic moiety, were chosen for a 
representative time-dependent experiment. Cells were incubated with these drug candidates for 24, 
48, and 72 h, and subsequently subjected to the PrestoBlue® assay. Results are summarized in Table 
3 and Figure 15. The IC50 values and standard deviations obtained from these experiments are 
comparably high (many IC50 values are calculated above 100 µM), so that a precise value comparison 
is not feasible. However, the cellular response towards the compounds shows an unusual trend: In 
HeLa and HT29 cells, the compounds seem to be most active after 48 h. After 72 h, the ĐoŵpouŶds’ 
activity is reduced in HT29 and MCF7 cells (and to some degree in HeLa cells). 293T HEK cells give a 
cellular response almost as expected, i.e. a slightly increased activity with elongated incubation time.  
  
  
Figure 15 IC50 values of Br-substituted compounds and Cisplatin (CDDP) as determined by PrestoBlue® assay after 24 (blue), 
48 (red) and 72 h (green bars). Compounds with values above 100 µM (dotted line) are considered inactive. Bars crossing 
the 250 µM scale (dashed line) continue above but are not defined. Error bars are given as biological standard deviation 
(SD) out of at least two independent experiments.  
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Table 3 IC50 values of the activity of Br substituted compounds against the investigated cell lines. IC50 values are given as the 
mean value of at least two experiments ± biological standard deviation out of the individual determinations.  
cpd time HeLa  HT29  MCF7  293T HEK 
X/R  IC50 [µM]  IC50 [µM]  IC50 [µM]  IC50 [µM] 
33 
Br/Me 
24h 61.8 ± 5.9  162.5 ± 45.8  57.8 ± 33.0  171.3 ± 122.8 
48h 46.2 ± 14.8  100.3 ± 0.6  63.5 ± 18.7  132.9 ± 62.6 
72h 57.4 ± 48.7  164.3 ± 65.2  180.3 ± 86.7  122.9 ± 25.3 
34 
Br/Et 
24h 114.1 ± 31.0  204.3 ± 13.6  86.3 ± 28.1  249.3 ± 156.9 
48h 63.4 ± 10.1  123.4 ± 84.7  65.3 ± 5.5  130.3 ± 108.5 
72h 127.1 ± 55.6  194.9 ± 82.4  133.2 ± 57.9  144.2 ± 44.0 
35 
Br/Bu 
24h 106.7 ± 22.2  193.6 ± 12.6  75.9 ± 28.7  130.4 ± 110.7 
48h 83.7 ± 32.4  125.3 ± 36.3  75.3 ± 15.4  149.1 ± 57.6 
72h 72.9 ± 26.8  157.4 ± 127.4  152.7 ± 76.8  97.1 ± 42.5 
36 
Br/Hex 
24h 42.6 ± 10.1  94.2 ± 4.5  34.4 ± 12.0  56.8 ± 26.1 
48h 35.4 ± 13.4  60.2 ± 23.1  37.6 ± 7.9  43.3 ± 12.5 
72h 41.3 ± 5.3  73.3 ± 33.4  76.5 ± 39.0  45.8 ± 22.8 
11 (L) 
Br/Me 
24h 211.4 ± 14.6  >250  205.5 ± 105.4  178.3 ± 131.7 
48h 68.0 ± 26.7  166.3 ± 175.4  75.6 ± 19.7  42.7a 
72h 135.6 ± 20.4  >250  138.6 ± 23.9  28.3 ± 16.4 
CDDP 
24h 56.7 ± 63.9  >250  >250  83.9 ± 53.2 
48h 5.0 ± 2.5  23.6 ± 5.0  12.1 ± 6.1  8.6 ± 2.2 
72h 9.0 ± 2.7  25.4 ± 8.3  11.6 ± 4.0  12.0 ± 3.1 
a only one reliable value obtained, therefore no biological standard deviation available. 
In comparison, Cisplatin is least active after 24 h, excerts its highest activity after 48 h and keeps this 
activity up to 72 h incubation. Remarkably, the IC50 values after 48 and 72 h are reduced by at least a 
factor of 10 when compared to their 24 h counterpart in all investigated cell lines. The data obtained 
for Cisplatin can be well explained by the kinetics of the different hydrolysis and biomolecule binding 
processes and has been investigated by many researchers.160 
In general, the compounds cytotoxic activities are rather comparable over the time scale - albeit 
generally lower than Cisplatin under the given conditions: As obvious in Figure 15, the order of 
magnitude of the determined IC50 values does not change as strongly as for Cisplatin.  
For the investigated compounds 33-36 and the ligand 11, this time-dependent behavior might result 
from different cellular response processes going on under the influence of these drug candidates. 
One (unfavorable) effect might be the onset of repair mechanisms, which effectively reduces the 
compounds antiproliferative activity.   
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5.4 Fluorescence microscopy 
A possibility to visualize the cellular response towards the drug candidates is given by fluorescence 
microscopy after staining with appropriate fluorescent dyes. For a representative experiment, the m-
OH/Et compound 46 was chosen and allowed to react with HeLa and MCF7 cells, followed by staining 
with 4′,6-Diamidin-2-phenylindol (DAPI) and propidium iodide (PI). Their emission was examined 
using fluorescence microscopy.  
DAPI/PI ĐouŶteƌstaiŶiŶg is a useful ŵethod to easilǇ eǆaŵiŶe the Đells’ ǀiability based on 
morphological features. Both dyes can bind to DNA and produce fluorescence signals at specific 
wavelengths, which can be excited and detected separately. DAPI is in principle able to penetrate 
intact cell membranes. It stains virtually all nuclei, living and early apoptotic as well as dead cells. 161–
163 PI, on the contrary, stains DNA inside the cell only after loss of membrane integrity. It is therefore 
only permanent to late apoptotic, necrotic, or dead cells.164 By selective excitation and detection of 
both stains and overlaying the resulting micrographs, one is able to distinguish between living/early 
apoptotic and late apoptotic/necrotic cells.165–167 The shape of the fluorescent spots can indicate 
morphologies for the stained cells typical after apoptosis (found as small, round bodies leaving the 
dish’s suƌfaĐeͿ oƌ ŶeĐƌosis ;seeŶ as sĐatteƌed fƌagŵeŶts, sǁiŵŵiŶg Đell paƌts, and indicated by fields 
of distributed fluorescence through undefined distribution of cellular material in the medium).  
 
Figure 16 Fluorescence micrographs of HeLa (left) and MCF7 cells (right) exposed to 46 in concentrations below, at, and 
above the determined IC50 value. Bottom, PI staining; middle, DAPI staining; top, overlay. All pictures were recorded at 200-
fold magnification. 
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Figure 17 Fluorescence micrographs of HeLa (left) and MCF7 cells (right) at 50 µM. Bright field (bf), DAPI and PI channels are 
overlaid to demonstrate the aggregates of apoptotic bodies in HeLa cells which may appear as undefined PI staining in 
fluorescence micrographs. All micrographs were recorded at 200-fold magnification.  
HeLa and MCF7 cells were exposed to 46 in concentrations below, at, and above the respective IC50 
value for 72 h and then stained with both dyes. Inspection of the cells by fluorescence microscopy 
resulted in fluorescence micrographs depicted in Figure 16 and Figure 17.  
Both cell lines respond to drug treatment, as can be seen from the formation of condensed nuclei in 
DAPI-stained pictures in the micrographs of cells below and at the respective IC50 value. Extensive 
drug treatment leads to cell death, as visualized by the large number of PI-stained cells at high drug 
concentration. The earlier mentioned possibility of necrosis was excluded by comparison of the 
fluorescence images with their bright field (bf) counterpart (Figure 17). The appaƌeŶtlǇ ͞sŵeaƌed͟ 
labeled DNA in this figure merely originates from the formation of aggregated apoptotic bodies, 
which cannot be displayed sharply in the short field depth of the microscopic setting needed to 
visualize staining properly. 
It is therefore reasonable to assume that this compound induces substantial cellular reactions in the 
investigated cell lines, rather inducing apoptosis than necrosis. A further strong indicator for 
apoptosis induction is provided by activation of the caspase cascade, observed by caspase 3/7 assay, 
as described in detail elsewhere.118 
5.5 Comparison of assay methods 
For the biological assays discussed here, the resazurin-based PrestoBlue® assay was used. It is a 
reliable assay, which monitors the cellular redox potential as a function of viability.168 Viable cells 
maintain a reducing environment within their cytosol and lose this environment upon death. Viable 
cells are therefore able to reduce resazurin to resurofin, whereas dead cells cannot produce 
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resurofin (Figure 18). The amount of formed resurofin can be monitored quantitatively by 
absorbance or, more effectively, fluorescence intensity measurements – as was used in this study.  
An alternate, well-established assay protocol used in many laboratories investigating metal-based 
chemotherapeutic agents is the MTT assay. It is based on a colorimetric monitoring of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction into formazan, which 
is also only produced in viable cells and accumulates in crystals at the bottom of the assay wells.169 
The factors that determine this reducing environment are manifold and have in the last years been 
studied and not completely been understood.170,171  
Generally speaking, both methods reliably produce similar data on cellular viability on various model 
systems.172–174 However, the assay protocol used for both assays is substantially different.175 For the 
PrestoBlue® assay, the protocol used for this work has been established by the supplier, life 
technologiesTM.176 On the other hand, the MTT assay protocol, being employed since decades in 
different laboratories worldwide, has numerous variations and is by far not uniform.ix In order to see 
the effects that these differences may have on the activity data obtained, a one-time representative 
experiment was carried out by incubating HeLa cells with Cisplatin under the conditions used for 
PrestoBlue® and MTT (internal protocol of Metzler-Nolte and Hahn groups).  
 
 
Figure 18 Principle of the resazurin-based PrestoBlue® assay. A typical plate protocol of the applied assay is shown with 
drug concentrations from high (200 µM, top rows) to low (1 µM, bottom rows). 
                                                          
ix A comparison of internal MTT protocols used by e.g. the Keppler group (Wien), and the Metzler-Nolte and 
Hahn groups (Bochum) already surfaces differences in important parameters such as drug incubation volume 
and incubation time after adding MTT reagent. (Verena Pichler, Wien / Sandra Bobersky, Bochum, private 
communications) 
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Different concentrations of Cisplatin in the range of 0.5 to 50 µM were added to HeLa cells and 
incubated for 48 h; positive and negative controls included. A first substantial difference is the 
incubation volume: For the PrestoBlue® assay, 90 µL drug-containing medium are used, for MTT 
assay, the final volume is 200 µL at the same concentrations. After 46 h, PrestoBlue® reagent was 
added to the respective wells and after 48 h total incubation time, the cellular viability was read 
through fluorescence measurement. After these 48 h, MTT reagent solution was also added to the 
respective wells, the samples incubated for 2 h upon which the medium was removed, the formazan 
crystals formed by viable cells extracted using DMSO and the absorbance read for the respective 
wells.  
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Figure 19 Results of the MTT (blue) and PrestoBlue® (red) assays on %viability scale. The regression graphs are for 
visualization purposes only; regression has been performed from individual values as described in the experimental section. 
Data analysis of the obtained results gives some indication on the different outcome that can be 
obtained just by following different protocols. First, it is obvious that the IC50 value obtained differs 
significantly; it is ca. 12 µM for MTT and ca. 26 µM for PrestoBlue® assay. This rough doubling of IC50 
values may well be explained by the different volumes of drug-containing medium used in each assay 
– 200 µL and 90 µL for MTT and PrestoBlue®, respectively, resulting in a more than doubled molar 
amount of substance affecting HeLa cells in the MTT assay protocol. Furthermore, the standard 
deviation of measurements of each single concentration is substantially higher in MTT assays than it 
is for PrestoBlue®. This may originate from the fact that after incubation with MTT, the medium is 
decanted from the formazan crystals that have accumulated at the bottom of each well and 
subsequently the crystals have to be dissolved in DMSO in order to read out the absorbance. Various 
sources of error are apparent during this process, e.g. accidental removal of formazan from the wells 
or inhomogeneous dissolving of the formazan crystals in DMSO. The process is furthermore more 
PART A 
5 Biological Assays 45 
 
 
time-consuming and requires more consumables (solvent, pipette tips, etc) than the PrestoBlue® 
method  which is albeit more expensive in the initial purchase.x 
The aim of this short study was not to deeply investigate the effectiveness of either method, 
determine precise IC50 values, or judge the methods applicability. The intention was rather to 
demonstrate that the experimental conditions strongly affect the outcome of biological assays, even 
if performed on the same compound, cell line and microwell plate. Both methods have their 
advantages and disadvantages and can well be used for the assessment of the cytotoxic potential of 
drug candidates. It has, however, to be strongly emphasized that data obtained from different 
laboratories or different methods cannot be directly compared  it is rather necessary to make use of 
a standard reference compound towards which a comparison may be conducted and can then enable 
comparisons of results amongst different experimental settings. The here presented studies use 
Cisplatin as a reference; a compound which has evolved as the state of the art reference compound 
in many research scopes investigating metal-based drug candidates.  
5.6 Possible sources of error 
The biological data obtained exhibits quite strong standard deviations, which might necessitate some 
rationalization. 
It is generally accepted amongst scientists that biological assays exhibit large variations due to 
several factors, such as biological, technical and chemical influences that alter the results of each 
individual assay.  
Biological factors may, amongst others, be aging effects of the cells during prolonged passaging, 
leading to alterations in cellular metabolism and growth. By using cells only up to a certain passage, 
these effects may be kept low, but can never be evited. Attachment of the cells onto the respective 
culture or multiwell plate may vary from plate to plate, leading to differences in cellular metabolism. 
Contamination with bacteria, such as mycoplasma, can significantly alter cellular activity and is a 
common problem in cell culture labs. To circumvent this, antibiotics are generally used as 
supplement to the cell culture medium (here: Penicillin/Streptomycin), and cells frequently analyzed 
                                                          
x 100 mL PrestoBlue® assay solution (suitable for the assay of 10 000 wells in a 96-well plate format) cost ca. 
330 , giving a price of ca. 3.3 ct/well. 1 g MTT powder costs ca. 72  and is suitable for 8 000 wells. When also 
calculating the price of PBS (ca. 16 /500 mL) and DMSO (ca. 63 /1 L), the cost for an MTT assay is at ca. 
2.4 ct/well, not considered the need of extra consumables (tips, pipettes) for medium removal and DMSO 
addition in comparison to the PrestoBlue® assay. 
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by PCR (polymerase chain reaction) analysis,177 but contamination can still remain undetected for a 
certain period of time. Edge growth effects (i.e., different cellular growth on the multiwell plate 
depending on the wells position on the plate) can influence the assays outcome. Here, these effects 
have been widely avoided by choosing a multiwell plate layout that preferentially places blanks or 
controls and very high drug concentrations at the plates outermost positions. The mere choice of 
supplier and type of all consumables used for cell culture plays another important role in the cellular 
growth.xi Therefore, the consumables (plates, pipettes, containers, etc.) used for the here described 
assays were kept constant all the time. Such, and other biological factors, contribute most 
significantly to differences between otherwise identical assays and are the main reason why they are 
usually repeated in biological triplicate. 
Technical errors may be those produced by pipetting inaccuracies, producing e.g. inhomogeneous 
cell distribution over the entity of the multiwell plate, or leading to deviations in the volume of drug-
medium or assay solution being applied. Such errors can be circumvented in most cases by thorough 
and concentrated working procedures, but may always contribute to the final results. Such errors 
would often lead to outliers within the replicates produced for each drug concentration and can 
often be eliminated by outlier detection. Other technical errors, such as variations in the stock 
solutions concentrations (and thus all following dilutions), can be caused by weighing or pipetting 
errors caused by either the analyst or the used devices. Such variations could lead to systematical 
deviations not necessarily detectable in the experiments outcome. In order to circumvent such 
errors, again a most careful working procedure was conducted. Inaccuracies can still not be excluded 
from any of the experiments, especially since the stock solutions were prepared freshly from powder 
for each individual assay to prevent long-term storage effects (a possible chemical source of error). 
The method applied for IC50 value determination also affects the results. Many different approaches 
are possible and have been reported in literature, but shall not be discussed in detail here. For 
regression and IC50 value determination in the actual work, the procedure is described in detail in the 
experimental section (chapter 18) and was kept constant throughout all experiments. It should be 
noted, however, that every IC50 value determined through regression of the semi-logarithmic growth 
curves contains a technical standard deviation itself. For the calculation of the biological standard 
deviation, this SD was generally neglected.  
                                                          
xi As an example, the IC50 value of Cisplatin was recently determined on several cell lines, using two different 
96-well plates, i.e. ThermoScientific nunc and Eppendorf plates. The determined IC50 value depended strongly 
on the used plate. For example, results for MCF7 and HeLa cell lines obtained after 72 h incubation differed in a 
factor of 2 (MCF7: 1.65 ± 0.72 µM (nunc) / 3.12 ± 0.81 µM (Eppendorf); HeLa: 4.49 ± 0.89 µM (nunc) / 2.57 
± 0.61 µM (Eppendorf)). (Sandra Bobersky, RU Bochum, private communication) 
PART A 
5 Biological Assays 47 
 
 
Overall, manifold sources of error contribute to the final determinations of IC50 values and their 
biological standard deviation. All values given in this section have been obtained by thorough 
working procedures to best knowledge and belief and are not manipulated other than as described in 
the experimental section.  

  
 
PART B 
INTERACTION WITH BIOMOLECULES 
 
Partial results of the chapters within this part have been published in the manuscripts listed below: 
Novel Platinum(II) Compounds with O,S Bidentate Ligands: Synthesis, Characterization, 
Antiproliferative Properties and Biomolecular Interactions, Dalton Transactions 2014, 43 (8), 3072-
3086, 
 Parts appear in chapter 7 
Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative 
Activity and Crystallographic Evidence of Protein Binding, Inorganic Chemistry 2015, accepted 
manuscript,  
 Parts appear in chapter 7 
Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA using various 
model systems and analytical techniques, manuscript in preparation 
 Chapter 8 is part of this manuscript.  
 
Incubation with model proteins has been performed by myself, with the exception of mass 
spectrometry samples 37-48 in combination with cytochrome c. These particular samples were 
prepared together with Jana Hildebrandt (FSU Jena) during her time as a master student, when she 
performed a research internship in the laboratory of Prof. Dr. Luigi Messori (Florence) under my 
instruction and supervision of Prof. Dr. Luigi Messori and Prof. Dr. Wolfgang Weigand. All obatined 
results have been individually evaluated by myself.  
Preparation of all DNA-model adducts and data interpretation has been performed by myself.  
Data acquisition of the ESI mass spectra discussed within these chapters has generally been executed 
by the mass spectrometers operator, Elena Michelucci (CISM Florence).  
X-Ray crystallographic studies on adducts of 46 and 48 with HEWL have been performed by Dr. 
Antonello Merlino and co-workers (Naples). 
Oligonucleotide sequences were synthesized by Dr. Domenica Musumeci in the laboratory of Prof. Dr. 
Daniela Montesarchio (Naples). 

  
 
 
6 STUDYING BIOMOLECULE INTERACTIONS WITH ESI 
MASS SPECTROMETRY 
In the last decades, the investigation of drug-biomolecule interaction has attracted growing 
attention. Metallomics, the analysis of metal-biomolecule interactions in particular, has grown to 
be one of the most useful tools in investigations concerning the mode of action of new metal-drug 
candidates.178,179 Such studies can e.g. give information on cytotoxic metal compounds mode of 
action, since metal-biomolecule interactions are considered a key factor in both, favorable 
antiproliverative activities, and also unwanted side effects. At the molecular level, especially mass 
spectrometry proves to be a versatile and frequently used method to gain valuable insight into such 
interactions. With the proper experimental setup and in connection with suitable additional 
techniques to corroborate the data, such as UV-visible (UV-vis) or circular dichroism (CD) 
spectroscopy, information on metal-biomolecule adducts and also binding sites can be gathered. 
Mass spectrometry has found widespread application in the investigation of metal-protein as well as 
metal-nucleic acid interactions by several researchers,179183 as described in detail in the following 
sections.  
Electrospray ionization mass spectrometry (ESI MS), coupled to suitable detectors, presents itself as 
an ideal tool to investigate biomolecules and metals that bind to them. Since it is a soft ionization 
method, protein-coordinated metal fragments can be conserved and obtained as multiply charged 
ions. In contrast to MALDI-ionization mode (matrix-assisted laser desorption ionization), no matrix is 
needed and thus a direct detection of the adduct ions under investigation may be afforded.184 To 
understand why this is possible, a short introduction into the method is given in the following 
section.  
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6.1 Electrospray ionization mass spectrometry 
6.1.1 ESI technique  
The electrospray ionization (ESI) technique is one of the most frequently applied ionization 
techniques when it comes to large molecules, such as biomolecules. Its basic principles in application 
for mass spectrometry have been developed in the late 1960s by Dole and co-workers,185 but only 
the pioneering works by John Fenn and his co-workers, published in the 1980s, made the technique 
popular and well-accepted in the scientific community.186,187 For his contributions to the 
development of methods for identification and structure analyses of biological macromolecules, John 
B. Fenn was awarded the 2002 Nobel Prize in Chemistry.188xii  
 
Figure 20 Principle of electrospray ionization. The solubilized analyte is introduced into the injection needle (1) which is 
maintained at a potential (2) relative to the spray chamber wall (3) and counter electrode (4). Due to the resulting electric 
double layer at the needle tip, a meniscus (5) forms, resulting in a liquid jet (6). Due to surface tension and viscosity, the 
liquid forms varicose waves (7/8), which eventually cause it to separate into small droplets (9). Due to solvent 
evaporation and growing coulomb repulsion, these break up further and result in a conical electrospray (10). Inset: 
evolving quasi-molecular ions through the electrospray process. Graph derived from literature 187,189. 
The techniques principles, as shown in Figure 20, are based on the production of highly charged 
droplets from solutions of (non-volatile) analytes in volatile solvents due to coulomb repulsion, 
known as the Raleigh instability.190 First reported by Rayleigh in 1882,191 this term describes the 
                                                          
xii Fenn shared the prize (¼) with Koichi Tanaka (¼), who was rewarded for his development of soft laser 
desorption (SLD), which later lead to MALDI MS techniques, and with Kurt Wüthrich (½), who received the prize 
for his development of nuclear magnetic resonance spectroscopy for determining the three-dimensional 
structure of biological macromolecules in solution.  
1 injection needle
2 power supply
3 spray chamber wall
4 counter electrode
5 conical meniscus (Taylor cone)
6 liquid jet
7/8 emerging varicose waves, 
gradually breaking up
9 charged droplet
10 conical electospray of charged
droplets
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processes happening during the evaporation of solvent from a droplet with an electric net charge  
induced by the electric field applied to the system. As the droplet becomes smaller, the coulomb 
repulsion within the droplet increases until it reaches a critical limit, the Rayleigh limit, and the 
repulsion overcomes surface tension. This results in a breaking of the droplet into smaller droplets.190 
This process may be repeated through continuous solvent evaporation until each droplet could 
contain only one gas-phase molecule which retains some of the droplets charge and can then be 
detected by a suitable mass analyzer.189,192 The droplet can either be loaded with excess positive or 
negative charge, depending on the polarization of the electrodes, making the method well- suitable 
for various applications. 
 
 
Figure 21 One of the first reported multicharge ESI mass spectra of a whole protein was that of cytochrome c.187 The 
deconvolution technique has been successfully applied for the first time to this milestone spectrum.  
This principle was fostered by several technical improvements,189 so that since the first recognized 
report of mass spectrometry on whole proteins,187 a vast number of researchers have utilized this 
technique for various biomolecular research scopes. One major aspect of the technique is the 
formation of multiply charged ions (cations or anions), which can be transformed (deconvoluted) to 
give averaged signals of the analytes relative molecular mass, i.e. the m/z value of a (theoretical) 
single ion with one massless charge (Figure 21).187 This bears the great advantage that the mass 
analyzer only needs to be able to measure m/z values in a reasonable range, e.g. up to 2 000, and still 
can obtain mass spectra of large biomolecules. 
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6.1.2 The LTQ-Orbitrap device 
Given the opportunities to analyze large, multiply charged molecules through the proper ionization 
method, the analysis method must be able to resolve the complex peak pattern generated by the 
ions. Nowadays, high-resolution mass spectrometers are available, utilizing different detection 
techniques. One very recent and powerful mass analyzer is the Orbitrap, allowing for a very high 
resolution of multicharged mass spectra and a good mass accuracy.193 The device used for the here 
presented studies was a Thermo Finnigan LTQ Orbitrap mass spectrometer of the type similar to the 
one depicted in Figure 22.194 
 
Figure 22 Schematical drawing of an LTQ Orbitrap hybrid FT mass spectrometer from Thermo Scientific. The drawing was 
modified to meet the used devices specifications. 194 
The device is basically composed of an ESI source, which introduces the generated ions into a linear 
ion trap (linear trap quadrupole, LTQ), where they can be subjected to collision-induced ionization 
(CID) if needed, or directly transferred into the C-trap. The C-trap is a curved radio-frequency only 
quadrupole ion trap, working as a connection between the ion trap and Orbitrap, where the ions 
could, in principle, be fragmented further. In the C-trap, the ions are stored and collisionally cooled 
(through residual nitrogen gas), before they are introduced into the Orbitrap mass analyzer. The 
detailed working mode of Orbitrap mass analyzers is very complex and has been described in detail 
by the developers.195197 In short, the ions are captured through a rapid increase of the electric field. 
By introducing ion packets in a slight offset relative to the traps equator, they gradually spread into 
thin rings, oscillating along the inner electrode.195,197 When all ions have entered the trap, the image 
current from coherent ion packets is detected once the voltage of the inner electrode has been 
stabilized. The image current is detected at the two halves of the outer electrodes. Signals are 
amplified and a frequency spectrum is generated through Fourier transformation which is related to 
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the axial oscillations of the ions along the Orbitrap (equation 2). This frequency spectrum is then 
converted back into a mass spectrum. Through this method, peak resolutions of up to 100 000 (full-
width-half height) are achieved.196  
axial oscillation frequency  =  ! "#/$   oscillation frequency (2)  k  instrumental constant  m/z mass-to-charge ratio 

  
 
 
7 STUDYING METAL-PROTEIN INTERACTIONS 
The interactions of various metal-based anticancer agents with proteins have been studied by mass 
spectrometric techniques in the past, amongst them compounds containing platinum,198202 
ruthenium,203,204 or gold.205209 Frequently used model proteins for such studies include e.g. 
cytochrome c, lysozyme, albumin, or ubiquitin.210,211  
To characterize the reactivity of the here discussed platinum compounds with protein targets, their 
reactions with the model proteins horse heart cytochrome c (cyt c), hen egg white lysozyme (HEWL), 
and bovine pancreas ribonuclease A (RNase A) were analyzed through ESI MS analysis according to 
established procedures.212 Spectral analysis allows determining the nature of the protein-bound 
metallic species and to define the stoichiometry of the formed adducts. Furthermore, the reactivity 
of selected compounds towards bovine serum albumin was monitored through inductively coupled 
plasma optical emission spectrometry (ICP-OES) analysis.  
These model proteins were chosen on the basis of several rationales as described below. All proteins 
have been well-investigated in view of their interaction with platinum-based drugs and some very 
interesting results have been reported (cf. the following sections). 
7.1 The model proteins 
7.1.1 Cytochrome c 
Cytochrome c (cyt c, Figure 23) is an electron-carrier protein primarily located in the mitochondria. It 
is comprised of 104 amino acids in one singular chain. Most of the sequence is identical throughout 
various vertebrates,213 which makes it an overall highly conserved protein. Cyt c is furthermore 
found in various plants and microorganisms, such as yeast.214  
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Figure 23 Molecular structure of horse heart cytochrome c, PDB ID: 1HRC.215 Left, ribbon/band representation with the 
heme group bound via C14 and C17. Right, potential metal binding sites H18, H26, H33, M65 and M80 in the cartoon 
representation. Graphs were generated with the RCSB PDB protein workshop tool.216 
The protein carries a heme group which is covalently bound to Cys14 and Cys17. This heme group 
can interchange between the ferrous (FeII) and ferric (FeIII) state217,xiii within the cellular environment 
and thus enables its function as universal catalyst in cellular respiration: It allows for electron 
transport between oxygen and respirable substrates such as cytochrome c reductase or cytochrome 
oxidase.220  
Moreover, it has been recognized as an important mediator in apoptotic pathways:221,222 Under 
proapoptotic conditions, release of cyt c from the intermembrane space of mitochondria into the 
cytosol can be triggered by proteins of the Bcl-2 family.xiv Released cyt c, in course, can then bind to 
calcium channels (the IP3 receptorxv) on the outer membrane of the endoplasmatic reticulum (ER), 
resulting in release of Ca2+ into the cytoplasm and in last consequence, to apoptosis. It furthermore 
participates in the caspase cascade by association with the apoptotic protease activating factor 
(Apaf), leading to the formation of the apoptosome complex.xvi This leads to downstream activation 
of caspase 9, which in turn leads to activation of caspases 3 and 7, both hallmark proteases in the 
apoptotic process.226,227 The aforementioned release of Ca2+ from the ER also facilitates activation of 
caspases 3 and 9, since both processes are Ca-dependent.228  
                                                          
xiii Unlike other heme proteins like cytochrome P450 or cytochrome c oxidase, which can adapt FeIV and FeV 
oxidation states,218,219 cyt c only occurs with its heme-iron in oxidation state +II/+III.217 
xiv Bcl-2 proteins play important regulatory roles in cellular apoptosis processes.223 
xv Inositol 1,4,5-trisphosphate (IP3) is a second messenger that induces the release of Ca2+ from the 
endoplasmic reticulum (ER).224 
xvi Apaf-1 oligomerizes in the presence of cytochrome c and dATP to form the very large (700–1400 kDa) 
apoptosome complex. The apoptosome recruits and processes caspase-9, which in turn recruits and activates 
the effector caspases.225 
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Due to its ubiquitous abundance and compact size, cyt c is a well-recognized model protein for 
metal-binding experiments; easily these can be carried out by ESI MS. Preferential binding sites have 
previously been assigned for Cisplatin and other metallodrugs (Figure 23, right): two methionine 
sites, Met65 and Met80 as well as three histidine sites, His18, His26 and His33 (Figure 23).229,230 In 
earlier studies, Met65, followed by His26 and His33 have been determined to be the most prominent 
binding sites for Pt drugs since His18 and Met80 are not readily accessible on the protein 
surface.199,201,212,231 Recently, the predominant role of Met65 as binding site was also shown in the X-
ray structure of a Cisplatin-ĐǇt Đ adduĐt; heƌe togetheƌ ǁith aŶ ͞assistiŶg͟ ƌole of Glu ƌesidues.230  
7.1.2 Lysozyme 
Lysozymes are a class of proteins with glucosaminidase activity, i.e. the proteins generally hydrolyze 
1,4-β-glycosidic bonds of N-actylmuramic acid and N-acetyl-D-glucoseamine residues in 
peptidoglycans or between N-acetyl-D-glucoseamine residues in chitodextrins.232,233 It is generally 
able to degrade bacterial cell walls (through hydrolysis of peptidoglycans) and has been found in 
various organisms, including birds, humans (in tissues and secretions), various other vertebrates and 
also invertebrates.234,235  
Hen egg white lysozyme (HEWL, Figure 24), the protein used for the here presented studies 
specifically, is a small protein, consisting of a single chain with 129 amino acids and bridged by four 
SCys-SCys disulfide bridges. Its crystal structure was one of the first whole-peptide structures solved.236 
It is known to crystallize in a number of forms, mainly dependent on the pH and nature of the 
precipitation salt.237 This makes lysozyme a well-suitable model protein e.g. for crystallography 
studies. 
 
 
 
Figure 24 Molecular structure of HEWL, PDB ID: 4J1A.238 Left, ribbon/band representation with surface structure. Right, 
potential metal binding sites M12, H15 and M105 in the cartoon representation. Graphs were generated with the RCSB PDB 
protein workshop tool.216 
M105
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Moreover, it is well-suitable for ESI MS analytic investigation, since ionization occurs well due to the 
presence of several positively charged groups at its surface. It has, in principle, three possible metal 
binding sites (Figure 24 right): His15 is the only potential metal-binding site which is located at the 
surface of the protein. Furthermore, two methionine sites, Met12 and Met105, are theoretically 
available for metal binding, but difficult to access.239–241 Thus, a straight-forward interaction pattern 
is expected in ESI MS spectra of drug-incubated proteins. 
Interestingly, in a recent study in the group of Merlino on competitive binding of Cisplatin and 
Oxaliplatin to HEWL using X-ray crystallography, ESI MS and other methods, two distinct binding 
positions were found for each metal: Cisplatin was expectedly found at His15, whilst Oxaliplatin was 
bound to Asp119.242 Contrary, in a study comparing Cisplatin and Carboplatin, Tanley et al. found 
fragments of both drugs bound to His15.243 
7.1.3 Ribonuclease A 
Ribonucleases are a class of nucleases that generally degrade RNA. They can be subdivided into exo- 
and endonucleases,xvii with ribonuclease A (RNase A, Figure 25) being the most prominent 
representative of the latter type: It is considered as one of the best-investigated proteins of the 20th 
century, with four Nobel prizes being associated with studies on this protein.244–246 RNase A is found 
primarily in ruminant pancreas, but RNases in general are abundant also in humans and other 
mammals and vertebrates in general.247  
 
 
 
Figure 25 Molecular structure of bovine pancreatic ribonuclease A, PDB ID: 4OT4.248 Left, ribbon/band representation with 
surface. Right, potential metal binding methionines and histidines in the cartoon representation. Amino acids that have 
actually been found involved in metal binding are given in boldface. Graphs were generated with the RCSB PDB protein 
workshop tool.216 
                                                          
xvii Exoribonucleases remove terminal nucleotides of RNA, endoribonucleases cleave RNA at internal sites. 
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RNase A catalyzes the cleavage of the phosphodiester bond between the 5-ribose of a nucleotide 
and the phosphate group attached to the 3-ribose of an adjacent pyrimidine (C or U) nucleotide. This 
cleavage forms a 2,3-cyclic phosphate, which is then hydrolyzed to the corresponding 3-nucleoside 
phosphate.249 It consists of 124 amino acids and is stabilized by 4 disulfide bridges,250 making it a 
suitable model protein for MS-based or crystallographic investigations of metal-protein adducts.  
Recent crystallographic studies of RNase A  metal adducts revealed a high diversity of binding sites 
depending on the studied compound (Figure 25, right). In some cases, such as a trans-amine Pt(II) 
dichloride,240 a Au(III)251 and a Ru(III) compound,252 metal binding to several histidine side chains (i.e. 
His12, His48, His105, and/or His119) was observed, with His119 being part of the protein active site. 
Interestingly, the data obtained from crystals of Cisplatin with RNase A revealed selective binding of 
Cisplatin towards Met29,248 thus demonstrating its high preference for sulfur donors, even if Cisplatin 
has been found to preferentially bind histidine side chains in other model proteins, such as cyt c or 
lysozymes (vide supra).  
7.2 Execution, technical considerations 
In order to investigate metal-protein interactions, the compounds were generally incubated with the 
respective model protein in a 3:1 molecular ratio at 37 °C, using a buffered system (tetramethyl 
ammonium acetate, TMAA, pH 7.4). After the desired incubation time, the samples were introduced 
into the ESI source and possible adduct formation monitored from the evolution of peaks assignable 
to free protein or protein with a metal unit.  
After deconvolution, i.e. data processing to extract the ion masses from the multicharged spectra,253  
a) an assignment of the composition/stoichiometry of formed adducts is possible from the peak 
position and  
b) an estimation of the amount of Pt being bound towards the protein can be made from 
comparison of relative peak intensities.  
Even though mass spectrometry is not a quantitative method per se due to compound-dependent 
tendencies to ionize, it is still possible to semi-quantitatively characterize metal-protein adducts: In 
studies where ICP-OES was used for the quantification of platinum-protein adducts, a remarkable 
correlation was found between peak intensity and adduct quantity.212,231,239 This may be made 
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possible by the overall dominant role the biomolecule plays in ionization, which equalizes the 
ionizability of all compounds to detect in the mixture.  
7.3 Interaction of selected (O,S)Pt complexes with cytochrome c 
Selected Pt(II) compounds were incubated with cyt c for a typical incubation time of 72 h. 
Representative adduct spectra of S-ethyl compounds 30, 34, 41 and 48 are shown in Figure 26, 
details of the cyt c adducts with 46 are given in Figure 27. All other spectra can be found in 
supplement B (Figures marked with an S) and supplementary information of the respective 
manuscript.118  
 
  
  
Figure 26 Deconvoluted LTQ-Orbitrap ESI mass spectra of platinum compounds 30 (top left), 34 (bottom left), 41 (top right) 
and 48 (bottom right) dissolved in 25 mM TMAA buffer, pH 7.4 after 72 h of incubation with cyt c. Protein concentration is 
100 µM with a metallodrug-protein molar ratio of 3:1 in all cases. 
In all spectra, several adduct peaks are witnessed which can be assigned to 1, 2 or 3 (O,S)Pt units 
bound to the protein. Here, (O,S)Pt refers to the Pt(II) center with the chelating ligand still bound to 
the metal center. In principle, the adduct stoichiometry is comparable for all depicted compounds, 
but compound 46, bearing a meta-hydroxy group, seems to bind to protein sites to a larger degree 
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than the other investigated compounds as seen from the relative peak intensities of free vs. 
platinated cyt c (Figure 27). In addition, compounds 46 and 48 of the hydroxyl-substituted series 
show adducts with a DMSO ligand still bound to the (O,S)Pt unit, an observation not made with the 
H or Br series. For the latter, a good correlation between chain length and adduct formation 
tendency was found, the S-Me derivative 29 giving the most intense cyt c interaction pattern (up to 
five (O,S)Pt fragments were found at cyt c) and the S-Hex compounds 32 and 36 giving the lowest 
intensity of adduct peaks (Figure S 1).118 
When the precursor complexes 37, 38, 40 and 41, bearing a O-TBDMS moiety at the aromatic ring, 
were reacted with cyt c as model protein, the adduct spectra proved protein binding of the 
complexes, however in all cases the initially applied protecting group was lost and thus confirmed 
fast hydrolysis of the TBDMS group under physiological conditions (Figure 26, top right, and Figure S 
2). These compounds were thus excluded from further testing.  
These results indicate that in general, the (O,S) moiety is retained with the Pt(II) center, whilst the 
chlorido ligand is always lost. The fate of the DMSO ligand seems to depend on the substitution 
pattern of the ligand and the protein binding site.  
 
 
 
Figure 27 Left, deconvoluted ESI mass spectra of compound 46 after 72 h (top) or 24 h (bottom) hours of incubation with 
cyt c. Right, comparison of experimental vs. theoretical isotopic pattern of the cyt c-46 monoadduct at charge state +7.  
Some conclusions might be drawn from these observations: Binding of the investigational 
compounds to the primary binding site leads to adducts of the (O,S)Pt unit without DMSO in all cases. 
When two and three Pt units are bound to the protein, two different scenarios emerge for the two 
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compound series: For the H or Br complexes, all subsequently binding (O,S)Pt centers can bind to 
the protein under release of the chlorido and DMSO ligands. For the OH series, the second adduct 
binding to cyt c still contains DMSO whilst the third one seems to resemble another adduct of the 
(O,S)Pt unit bound after DMSO release, as observed from the fact that only one DMSO molecule is 
found within the detected adduct. Binding of the (O,S)Pt unit could in principle take place in a 
bidentate fashion, under assistance of nearby donor atoms such as oxygen or nitrogen of amino acid 
side chains or the backbone, but the lack of a fourth ligand is not uncommon in Pt(II)-protein 
adducts.254,255  
In principle, three amino acid side chains have been identified as most probable Pt(II) binding sites, 
namely Met65, followed by His26 and His33 (vide supra). On the basis of chemical similarity of the 
binding sites and the resulting coordination environment around Pt(II), one might hypothesize that 
these findings are an indicator that the two readily available NHis donors in His26 and His33 represent 
the first and third binding site, whilst binding to SMet in Met65 is not always accompanied by DMSO 
loss. Most certainly, also contributions of the other possible Pt(II) binding sites, i.e. His18 or Met80, 
are thinkable: In an earlier study concerning the binding of cis-bisphosphane platinum(II) dichlorides 
to cyt c, the histidines H18, H26, H33 were identified as the three primary binding sites.255 An exact 
binding mode at defined amino acids can, however, in this case not be determined with certainty by 
mass spectrometric methods: MSn techniques would unequivocally lead to a break of the Pt-DMSO 
bond, as has been observed in mass spectra with the free compounds. Digestion experiments could 
also result in fragmentation of the metal adducts bound in monodentate (and thus less stable) 
fashion.  
Experiments with the compounds 45-48 containing a Ph-OH group were also carried out at shorter 
incubation times, namely 24 h, to elucidate whether this affects the stoichiometry of adduct 
formation (Figure 27 left, Figure S 3). Almost no difference in the spectral composition in the 24 h vs. 
72 h spectra is witnessed; not even when comparing the peak intensities of (cyt c + x(O,S)Pt) vs. (cyt c 
+ x(O,S)Pt(DMSO)) peaks. This indicates that the maximum possible conversion of the metal core 
with the model protein has occurred within the first 24 hours of incubation and further supports the 
hypothesis of a defined manner of binding of either (O,S)Pt or (O,S)Pt(DMSO) units towards distinct 
amino acids.  
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7.5 Interaction of selected (O,S)Pt complexes with lysozyme 
Also, incubating the samples with HEWL proved the reactivity of the (O,S)Pt center towards this 
model protein. Defined adduct formation with one (O,S)Pt unit bound to the intact protein is 
demonstrated for all compounds, only a very small peak corresponds to a (O,S)Pt-HEWL bisadduct 
(Figure 28, Figure S 4, Figure S 5). No noteworthy abundance of a (O,S)Pt(DMSO) adduct peak is 
observed. An apparently less pronounced metalation with respect to cyt c can be well-explained by 
the fact that in HEWL; less binding sites are available. His15, Met12 and Met105 are in principle able 
to serve as donors, His15 has been identified as the highly preferred binding site for Cisplatin and 
analogs earlier, but also a contribution of Asp119 to Oxaliplatin binding has been discussed (vide 
supra).239243 
Overall, the reactivity of all investigated complexes towards HEWL is comparable and structural 
differences lead to almost negligible changes in the intensity of adduct peaks. Furthermore, as 
demonstrated from 24 and 72 h incubation spectra of compound 46, elongation of the reaction time 
to 72 h did not significantly alter the degree of adduct formation (Figure 29). 
 
  
  
Figure 28 Deconvoluted LTQ-Orbitrap ESI mass spectra of platinum compounds 30 (top left), 34 (bottom left) after 72 h, and 
of compounds 46 (top right) and 48 (bottom right) after 24 h of incubation with lysozyme. Incubation was performed in 
25 mM TMAA buffer, pH 7.4, at a protein concentration of 100 µM with a metallodrug-protein molar ratio of 3:1. 
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Figure 29 Left, deconvoluted ESI mass spectra of compound 46 after 72 (top) or 24 (bottom) hours of incubation with 
HEWL. Right, comparison of experimental vs. theoretical isotopic pattern of the HEWL-46 monoadduct at charge state +8. 
In addition to these experiments, crystallization experiments of HEWL with compounds 45 and 46 
were performed by Antonello Merlino and co-workers. As a result, molecular structures of HEWL-Pt 
monoadducts could be solved.119 The structures obtained unambiguously show the binding of the 
(O,S)Pt unit under retention of DMSO towards the expected binding site, to ND1 in the side chain of 
His15. This binding is stabilized by several hydrogen bonds towards the Ph-OH and DMSO units. A 
detailed discussion on the structural data is given in the respective manuscript. 
 
 
 
Figure 30 Left, ribbon-and band representation of HEWL with compound 46 bound to His15 (side chain of His15 and 
(O,S)Pt(DMSO) unit given in wireframe). Right, 2F0-fc electron density map of the binding site in the HEWL-46 structure with 
contours given at 0.6σ after model building and refinement. Stabilizing hydrogen bonds are depicted through dashed lines.  
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7.6 Interaction of selected (O,S)Pt complexes with ribonuclease A  
Adducts of the OH compounds 45-48 with bovine pancreatic RNase A further prove the defined 
interaction of these complexes with model proteins (Figure 31 and Figure S 6, Figure S 7 for 
simulation). Adducts of RNase A, containing one and two (O,S)Pt units, are witnessed. The reactivity 
towards RNase A appears to be slightly higher for the meta-substituted compounds 45 and 46 than 
for the para-OH compounds 47 and 48.  
Unlike in the case of cyt c or HEWL, a slight increase in the relative signal intensity of adducts formed 
after 72 h vs. 24 h is witnessed. These findings suggest a slower but progressive binding of one or two 
(O,S)Pt units towards the model protein. All adduct peaks witnessed originate from metal fragments 
after loss of both possible leaving groups Cl- and DMSO. No higher stoichiometries than bisadducts 
are observed. These findings again suggest a distinctive selectivity of these compounds for available 
binding sites. As discussed above, RNase A bears various amino acid side chains which may in 
principle be available for metal binding. For the here presented compounds, binding to His side 
chains might be the most reasonable assumption which remains to be clarified in future experiments.  
  
Figure 31 Deconvoluted LTQ-Orbitrap ESI mass spectra of platinum compounds 46 (left) and 48 (right) dissolved in 25 mM 
TMAA buffer, pH 7.4 after 24 h (bottom) and 72 h (top) of incubation with RNase A. Protein concentration is 10-4M with a 
metallodrug-protein molar ratio of 3:1. Presence of sulfate in the RNase A spectra is intrinsic to the protein and has been 
observed in other, independent experiments. It does not originate from the actual incubation experiment and was thus 
neglected. 
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Figure 32 UV-visible time-course spectra of the reaction of compound 46 with the three model proteins over 72 h. Spectra 
were recorded at a Pt:protein ratio of 3:1; c(protein) = 10 µM in TMAA.  
7.7 UV-visible spectroscopic data 
For all described model proteins, analogous binding experiments have been carried out using UV-
visible spectroscopy. Representative spectra obtained with compound 46 are given in Figure 32. The 
so obtained data generally support the observations made by ESI MS experiments through 
ĐhaƌaĐteƌistiĐ tƌaŶsfoƌŵatioŶs of the Đoŵpleǆes’ iŶitial speĐtƌal pƌofile. Oǀeƌall, a siŵilaƌ tƌeŶd is 
observed: Bands which are characteristic for the intact (O,S)PtCl(DMSO) chromophore gradually lose 
iŶteŶsitǇ uŶtil theǇ ƌeaĐh a ͞statiĐ͟ state. When comparing these spectral changes with those 
observed for the compounds in absence of any biomolecule (cf. chapter 4.2), these changes can be 
attributed to gradual hydrolysis of the chloride ligand and eventually by the DMSO ligand, followed 
by binding of the respective protein.  
The time development of these spectra seems to be in good accordance with the amount and speed 
of witnessed adduct formation in the ESI data: the conversion seems to be complete after 
approximately 12 h for the cyt c adduct, after 24 h for HEWL and after about 48 h in the case of the 
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RNase A adducts. This corroborates the findings of no spectral changes in mass spectra of cyt c or 
HEWL adducts recorded after 24 h vs. 72 h, and the adduct peak increase for spectra with RNase A. 
Through metal binding, the proteins intrinsic chromophores do not seem to be affected by metal 
binding. This is an indicator that their overall structure, respective their active center (which gives the 
predominant signal in the cyt c spectra), is not altered to a large degree and is therefore in good 
agreement with the ESI measurements, where intact proteins are witnessed rather than protein 
fragmentation. 
7.8 Interaction of selected (O,S)Pt complexes with albumin 
Furthermore, experiments with H- and p-Br substituted compounds were carried out using bovine 
serum albumin (BSA) as model protein. The binding of numerous drugs towards serum proteins, 
especially albumin, is well documented.85 As a consequence of metal-albumin binding, either the 
concentration of free, available drug which was initially introduced into the blood stream may simply 
be reduced. Alternately, the protein could serve as a chaperone256,257 to actually aid transportation 
of the metal-drug towards its final target. Various Cisplatin binding sites towards albumins have been 
reported.200,258260 It is however a rather large protein (of ca. 66 kDa) which is not ideally suited for 
high-resolution ESI MS of the whole protein. Therefore, experiments with BSA were carried out using 
ICP-OES as analysis method which gave quantitative feedback on metal-BSA binding. These 
experiments are in detail discussed in the respective manuscript.118 
When incubating selected compounds bearing either no or a p-Br substituent at the aromatic site 
with 1 eq. BSA over 96 h, practically complete binding of all added Pt(II) to the protein was found, 
less than 1 % of unbound Pt was determined.  
In addition, detachment experiments, using glutatione (GSH) as competitive ligand, gave no evidence 
of a release of BSA-bound Pt from the protein. This finding might be considered as a hint that binding 
of this kind of platinum complexes is not reversible, other than has been discussed for Cisplatin and 
analogs.199,211,261 
 

  
 
 
8 STUDYING METAL-DNA INTERACTIONS 
It is generally accepted that nuclear DNA is the main therapeutic cellular target of Cisplatin and its 
analogs. Even though it is today considered that only a small percentage of initially applied Cisplatin 
reaches this final target and that the level of accumulation is tissue-dependent,262 the consequences 
of this biomolecular interaction are crucial for the compounds success as anticancer therapeutic (cf. 
chapter 1.2).  
In order to establish the DNA-binding potential of the compounds presented within this thesis, three 
representative compounds with an S-ethyl group and H or OH substituents, 30, 46, and 48 (Chart 5), 
were selected for an in-depth investigation of their reactivity towards DNA. Two DNA model systems, 
suitable for investigations through different analytical techniques, were chosen: 9-methylguanine 
(9-mg), and oligonucleotides (ODNs). Metallodrug-biomolecule interactions were analyzed through 
UV-vis and CD spectroscopy, as well as ESI MS methods as described in detail in the respective 
manuscript.138 In this chapter, the focus shall be set mainly on the ESI MS based experiments on DNA 
interaction.  
 
 
Chart 5 (O,S) bidentate Pt(II) complexes used for DNA interaction studies. 
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8.1 Studies on metal-oligonucleotide adducts: recent developments and 
practical considerations 
Several reports exist on MS-based studies of metal-oligonucleotide adducts. Often Na+ adducts263 or 
other alkali/ alkaline earth metals264,265 are investigated, e.g. aiming at the elucidation of charge 
distribution or phosphate backbone binding. Few studies deal with cytotoxic compounds, such as 
platinum complexes, with the intention to find potential nucleobase binding sites.266276 In these 
studies, different mass spectrometric methods have been applied to obtain information on the 
metal-ODN composition. Usually, negative ESI in various modifications is usedxviii (e.g. by coupling of 
the ESI source to LC methods,267 detecting the signals by FTICR269271 or TOF274,275 detectors or 
applying different MS2 ionization methods,277 including IRMPD276), but sometimes also FAB 
methods,266 MALDI,268 or positive ESI274,278,279 are applied to investigate oligonucleotide adducts.  
Especially the use of positive ESI seems quite contradictory since on the one hand, the DNA-binding 
fragments of Cisplatin and other Pt compounds are expected to bear an intrinsic positive charge. On 
the other hand, the phosphodiester backbone of DNA is strongly negatively charged. For the 
biomolecule to become a cation, all phosphodiester groups will need to be protonated up to a 
neutral state and additional protons will have to bind, eventually, at the nucleobases.280 In 
combination with unfavorable effects of the overall charge in the droplets to be ionized, negative ESI 
methods are suggested to be the superior choice for studying metal-oligonucleotide adducts.279 
8.2 Interaction of compounds 30, 46 and 48 with 9-methylguanine  
As a small model for the possible target DNA, 9-methylguanine (9-mg) was chosen. It resembles the 
smallest-possible nucleobase model that still has the binding site which is understood as Cisplatins 
preferential binding position at its final target, DNA.84,86,281 Binding to 9-mg was monitored with ESI 
mass spectrometry and with UV-visible spectroscopy. By both methods, the binding of the metal 
complexes to 9-mg could be shown.  
  
                                                          
xviii Abbreviations in this section: LC  liquid chromatography; FTICR MS  fourier transform ion cyclotron 
resonance mass spectrometry; IRMPD MS  infrared-multiphoton dissociation mass spectrometry; FAB  fast 
atom bombardment; MALDI  matrix-assisted laser desorption ionization 
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8.2.1 ESI mass spectrometric data 
ESI mass spectra were recorded in positive mode after an incubation period of 24 h or 90 h at 37 °C 
in a 3:1 metal:nucleobase ratio. The obtained spectra showed that upon platination of 9-mg, several 
adducts can be formed. Apart from the signal of free 9-mg at m/z = 166.07 as dominant peak, two 
main adduct peaks are observed: those of the (O,S)Pt(DMSO) and the (O,S)Pt units bound to one 
9-mg molecule (Figure 33 and Table 4, Figure S 8 for a spectrum of free 9-mg). In principle, this can 
be interpreted as monodentate binding of (O,S)Pt(DMSO) towards N7 of 9-mg in the first case, and 
the formation of a chelate structure between the (O,S)Pt unit and the (N7,O6) unit of 9-mg in the 
second case. Yet, it cannot be ruled out that the latter signals simply originate from the ionization 
process and not from gradual chelate formation: Fraska recently discussed ESI mass spectra of Pt(II) 
adducts with DMSO and guanine and found defined DMSO dissociation upon increase of the cone 
voltage during the ionization process.282 In combination with the results obtained with 
oligonucleotides, as discussed below, it is however unlikely that dissociation of DMSO due to the 
ionization process is the only reason for the appearance of these signals. 
In lower abundance, also adduct peaks of the (O,S)Pt unit and two 9-mg molecules could be detected 
in adduct spectra of 30 and 46. These findings suggest that the here discussed compounds could, 
under certain circumstances, bind DNA in a comparable manner as Cisplatin and analogs would; 
namely in a bis-functional manner to give 1,2- or 1,3- intrastrand or interstrand links.  
A principal change of spectral composition over time (24 h vs. 90 h) is not observed (Figure 33, left). 
This is in good accordance with data obtained from UV-vis spectra, which indicate that the reaction 
reaches equilibrium within the first hour (vide infra).  
Table 4 Typical ESI MS adduct peaks for the reaction of 30, 46 and 48 with 9-mg. 
Fragmenta 30 46 48 46 / 48 m/z valueb calcd. massc m/z valueb m/z valueb calcd. massc 
[(O,S)Pt(DMSO)Cl+H]+ n.o. 532.98 n.o. n.o. 547.98 
[(O,S)Pt(9-mg)]+ 583.05 583.05 599.05 599.05 599.05 
[(O,S)Pt(DMSO)(9-mg)]+ 661.07 661.07 677.06 677.06 677.06 
[(O,S)Pt(9-mg)2]+ 748.12 748.12 764.11 n.o. 764.11 
[9-mg+H]+ 166.07 166.07 166.07 166.07 166.07 
a (O,S)Pt - Pt(II) with the complete (O,S) bidentate ligand bound; b n.o.  not observed; c calculated monoisotopic mass 
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Figure 33 Left, Comparative positive ESI MS spectra of adducts formed between 9-mg and 30 after incubation for 24 h (top) 
and 90 h (bottom). Right, spectra of adducts formed between 9-mg and 46 (top), and 48 (bottom). All spectra were 
recorded in LC-MS grade water at a 3:1 metal:9-mg ratio.  
A short note should be given on the incubation conditions. The experiment discussed here was 
performed in LC-H2O instead of in buffered solutions, as would usually be the case. Indeed, 
experiments were initially performed in ammonium acetate buffer (pH 6.8) in order to represent a 
more physiological-like environment. In the resulting ESI mass spectra, the same adduct peaks could 
be found; however the signal intensity was by far decreased under these conditions. Therefore, in 
order to get a more detailed structural information (i.e. on the molecular composition of the 
adducts), conditions were chosen that allowed to directly obtain signals in an optimal data 
acquisition setting. 
8.2.2 UV-visible spectroscopic results 
The reaction of the model compounds was also monitored by UV-visible spectrophotometry. 
Compounds 30 or 46 and 9-mg were combined in a 1:1 metal:nucleobase ratio in water and the 
spectral profile recorded at different time points (Figure 34 and Figure S 9). In initial experiments, a 
screening over 72 h was performed with measurement intervals of 10 min during the first hour. It 
was found that substantial spectral changes occurred already during the first 10 minutes of the 
experiment, so that these happenings should be monitored more closely. After shortening the 
measurement intervals to 30 seconds, two isosbestic points became apparent, indicative of a 
binuclear reaction such as the substitution of one leaving ligand by 9-mg. In parallel, the band set at 
low wavelengths decreases in intensity, which is indicative of a reduction of the amount of free 9-mg. 
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Figure 34 UV-vis spectra of the adduct formation between 30 and 9-mg (c = 50 µM, LC-MS H2O), recorded without 9-mg 
(black line), and after different time intervals up to 72 h (left spectra) and over 30 min in short intervals (right). 
It is quite obvious to see that the spectral profiles after 30 min are very similar in both cases of 30 
and 46, as is their time-dependent behavior. For 46, the band at 403 nm reaches maximum height 
after ca. 6 min (Figure S 9); for 30 the changes are slightly slower and a maximum height of the 
404 nm band seems to be reached after ca. 12 min (Figure 34).  
Over the course of the full 72 h, some further spectral changes seem to occur which are less 
pronounced and overlap with some precipitation of the formed compounds. Wavelengths of the 
respective absorption maxima are given in Table 5.  
The speĐtƌal deǀelopŵeŶt ǁas also ŵoŶitoƌed iŶ puƌe ǁateƌ to Đoŵpaƌe the ĐoŵpouŶds’ ďehaǀior in 
presence and absence of 9-mg (Figure 35). It can be clearly seen that without any additives, 
immediate hydrolysis of the compounds seems to take place, leading to substantial reduction of 
signal intensity of the long-wave absorption band. 
Table 5 Band maxima of the UV-visible spectra of 30 and 46 during the reaction with 1 eq. 9-mg 
Cpd Time (min) ����૚ (nm) ����૛  (nm)a ����૜  (nm) ����૝  (nm) 
9-mg  252 275 s - - 
+ 30 0 / complex - - 362 412 
 0,5 250 275 s 360 410 
 30 254 280 s 356 404 
 shiftb  +2 +5 -6 -8 
+ 46 0 / complex - - 363 420 
 0,5 250 275 s 361 414 
 30 254 278 s 357 403 
 shiftb  +2 +3 -6 -17 
a s = shoulder; b shift reported compared to free 9-mg (λ௠�௫ଵ/ଶ ) resp. 30 or 46 (λ௠�௫ଷ/ସ ) 
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Figure 35 Behavior of 30 (left) and 46 (right) in pure water (light-colored lines) and in presence of 9-mg (intensive-colored 
lines). Spectra at t = 0, 0.5 min and 30 min are given.  
This fast hydrolysis is clearly promoted by the absence of any buffer or other salts, also resulting in a 
low pH,xix which could slow down aquation reactions of the compounds. In contrast, in presence of 9-
mg this band shifts to lower wavelengths and has similar or higher intensity than in the initial 
spectrum. Together, these data give a good indication that the Pt(II) complexes can react with 9-mg 
quickly upon ligand exchange. Both major bands observed in the initial UV-vis spectra are ascribed to 
the (O,S) ligand chromophore bound to Pt(II). As was demonstrated in chapter 4.2, the electronic 
structure of the (O,S) chelating unit and the adjoining moieties are strongly influenced by the nature 
of the monodentate ligands trans to S and O. This is again clearly shown by the here presented data. 
On the contrary, the free ligand would give a completely different spectral profile (Figure 10) – thus 
the loss of the bidentate donor molecule can again be ruled out in these investigations.  
8.3 Selection and preparation of the DNA model systems - 
Oligonucleotides 
The reactivity of compounds 30, 46 and 48 towards three selected model oligonucleotide sequences 
was investigated in detail using different spectroscopic (CD, UV-vis) and spectrometric techniques 
(ESI MS). Results of CD and UV-vis experiments are discussed in detail by Daniela Montesarchio and 
Domenica Musumenci (University of Naples Federico II).138,283 The results obtained from of mass 
spectrometric investigations of the interaction with model oligonucleotides are subject of the 
following chapter.  
The choice of oligonucleotide sequences was based on the initial assumption that the DNA binding 
properties of compounds 30, 46 and 48 could in principle be similar to those of Cisplatin, which is 
                                                          
xix The pH of the used LC-MS grade water was determined to be 3.98. 
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able to form stable covalent adducts with contiguous guanines in a DNA strand.281,284288 Therefore, 
the following DNA model systems with presence or absence of adjacent guanines (GG boxes) have 
chosen for the present study (Table 6): a single strand 12-mer oligonucleotide ODN1, containing one 
unit of adjacent guanines in the middle of the sequence; a 12-mer ODN2, containing two GG sites at 
either end of the sequence; and a single strand 24-mer ODN3 not containing guanines in the 
sequence. All ODN sequences were synthesized by Domenica Musumeci in solid phase using an 
automatic DNA synthesizer with the standard phosphoramidite method.289 For ESI MS studies, 
representative samples were desalted by dialysis vs. H2O and lyophilized. 
Table 6 Overview of oligonucleotides (ODNs) used in this study. GG boxes are given in boldface. 
ODN sequence sum formula Mav (g/mol)a Mmono (g/mol)b 
1 d(5CCTCTGGTCTCC3) C114H149N36O74P11 3548.353 3546.607 
2 d(5GGAGACCAGAGG3) C118H145N56O66P11 3744.505 3742.678 
3 d(5TCACACACACACACACACACACTT3) C229H292N89O135P23 7163.761 7160.260 
a Mav  molar mass - average mass, b Mmono  monoisotopic mass  
8.4 ESI MS studies of free oligonucleotides 
First, to establish the measurement conditions for all following experiments, negative ESI mass 
spectra of the free oligonucleotides were recorded (Figure 36). As medium, LC-MS grade water was 
chosen in order to reduce oligonucleotide-cation adduct peaks. Such, especially in the presence of 
sodium, would lead to numerous [M+xNa+]z- adducts and thus strongly reduce the signal-to-noise 
ratio in the resulting ESI mass spectra. This was the case e.g. in spectra of ODN3, where dialysis could 
not give a completely desalted product (Figure 36, bottom right). Nevertheless, an appreciable signal-
to-noise ratio was achieved and experiments on ODN3-Pt adduct formation with the model 
complexes were carried out.  
A comparison of theoretical vs. experimental isotopic patterns of the most abundant multicharged 
peak sets are given in Figure 36, top right, for ODN1 and Figure S 10 for ODN2 and 3. Expected and 
found masses for the respective oligonucleotide sequences are given in Table 7. 
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Figure 36 Multicharged negative ESI mass spectra of free ODN1 (top left) and comparison of theoretical vs. experimental 
multicharge isotopic patterns at charge state -6 (top right). Bottom, multicharged negative ESI mass spectra of free ODN2 
(left), and ODN3 (right).  
The multicharged spectra of the 12-mers ODN1 and 2 exhibit signals of the intact ODNs at charge 
states z = -4 to -8, with the signal at charge state -6 being the most abundant. Spectra of ODN3, 
owing to the longer sequence, give signals at higher charge states; those at z = -5 to -10 are resolved 
well enough for charge assignment. For ODN1 and 2, only a marginal abundance of sodium adducts 
was found. In the case of the 24-mer ODN3, up to 6 Na+ ions were found bound to the single strand 
(Table 7). 
8.4.1 Optimization of measurement conditions 
Various reports exist describing the use of positive ionization278,279,274 and also the use of additives 
such as organic solvents that might facilitate the ionization of the desired molecules. Especially the 
use of ammonium acetate (NH4OAc) buffer was reported in several cases.267,272,271,274,276 
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Table 7 Calculated and observed multicharged peaks of the free oligonucleotides. For ODN3, only values of the peak with 
highest intensity are listed per charge state  multiple signal sets corresponding to different Na+ adducts are in fact found 
(signals with maximum intensity given for experimental data).  
ODN m/z -4 -5 -6 -7 -8 -9 -10 
1 calcd
a 886,14699 708,51562 590,26180 505,79479 442,44453 - - foundb 886,14698 708,51537 590,26141 505,79452 442,44438 
2 calcd
a 935,16460 747,72973 622,94023 533,80487 466,95336 - - foundb 935,16393 747,72961 622,94001 533,80459 466,95321 
3 calcd
a 
- 
1457,82581 1211,02331 1031,73875 899,77243 797,24336 719,71675 
foundb 1457,82312 1211,02308 1031,73749 899,77138 797,24268 719,71616 
 x Na 6Na 5Na 3Na 2Na 1Na 2Na 
 
It is discussed that the ammonium ion should substitute all possibly phosphate-bound Na+ and K+ 
cations and then dissociate in the ESI source to release NH3 and keep the proton residing at the 
phosphate backbone, thus leading to cleaner spectra.272 In initial experiments to find the optimal 
experimental setup, oligonucleotide mass spectra were also recorded in ammonium acetate buffer. 
Albeit the data could be acquired in ammonium acetate, the signal-to noise ratio was found to be 
greatly increased when pure water was used (cf. Figure S 11 for comparative spectra). The positive 
effect of slightly reduced Na+ adduct abundance in spectra of ODN3 could not compensate the 
overall low signal-to-noise ratio under these conditions. However, ionization had to be enhanced by 
adding 50 vol-% MeOH to solutions of ODN3 directly prior to measurement to acquire a suitable 
spectrum (Figure 36, bottom). For all experiments except for this singular spectrum, water without 
any additives was used and the same sample preparation and measurement conditions throughout 
the experiments were applied.  
8.5 ESI MS of ODN-platinum adducts 
After these initial experiments, conversion with the Pt(II) compounds was pursued. The 
oligonucleotide sequences were incubated with Pt(II) complexes in a 1:1 and a 3:1 
metal:oligonucleotide ratio in water for 24 h and also in a 3:1 ratio for 72 h. Adduct formation was 
investigated with negative ESI mass spectrometry. Representative results can be seen in Figure 37 
and Figure 38, isotopic patterns and detailed peak data can be found in Supplement C. 
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8.5.1 General observations 
After 24 h of incubation, Pt-ODN adduct peaks can be observed that correspond to monoadducts 
with ODN1, alongside with free ODN1 (Figure 37 left). An increased metal:protein ratio also favors 
the presence of bis- and triple adducts being formed, but unplatinated ODN1 still is a dominant 
species (Figure 37 right).  
 
  
  
  
 
Figure 37. Multicharged negative ESI mass spectra of 1 after incubation with 1 (left) and 3 (right) equivalents of compound 
30 (top), 46 (middle) and 48 (bottom) for 24 h at 37 °C. Z values are generally negative. 
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Figure 38 Multicharged negative ESI mass spectra of ODN2 (left) and ODN3 (right) after incubation with 3 equivalents of 30 
for 24 h at 37 °C. Z values are generally negative. 
For the base-complimentary strand ODN2, ďeaƌiŶg tǁo ͞GG͟ ďoǆes aŶd thus a gƌeateƌ Ŷuŵďeƌ of G 
and GG binding sites, also a significant abundance of higher adduct stoichiometries can be found 
(Figure 38 left and Figure S 12).  
For ODN3, having no guanine residues and thus no favorable binding site, platinum adducts are 
found as well (Figure 38 right and Figure S 12). This indicates that also different binding sites than G 
are possible for this type of Pt(II) compounds. Binding of the compounds towards ODN3 has also 
been witnessed in CD and UV experiments.138 Overall, ODN3 still proved to be the least reactive 
towards the three model Pt(II) compounds discussed here. As expected, the absence of the 
conceivably favored binding site G considerably reduces adduct formation. Adenine (A) most 
probably serves as alternative binding site, in analogy to findings for Cisplatin or other drug 
candidates – but cytosine (C) and after deprotonation of NH even thymine (T) may as well allow Pt 
binding (cf. Figure 5).290  
As a general observation, signals assigned to platinated ODNs mostly display their peaks with highest 
intensity at lower charges than those observed for the free ODNs. This is in good accordance with the 
theory that the (O,S)Pt fragment, after loss of Cl- and DMSO, is a monocharged cation which 
ĐoŶtƌiďutes to aŶ oǀeƌall ƌeduĐtioŶ of the oďseƌǀed adduĐt ioŶs’ Ŷet Đhaƌge.  
8.5.2 Comparison of the compounds’ reactivity  
In accordance with results from CD and UV-vis data,138 the reactivity of the unsubstituted compound 
30 towards the ODNs appears to be generally higher than that of 46 or 48 with a hydroxy group. 
Compound 30 is even able to coordinate five (O,S)Pt units towards ODN2, which is the highest 
observed stoichiometry in these experiments. Compounds 46 and 48 seem to have a similar 
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reactivity towards this sequence with a low abundance of four (O,S)Pt units bound (Table S 12). On 
the contrary, 48 seems to be the most reactive complex towards the 24-mer ODN3 – up to 4 (O,S)Pt 
units were detected in ODN3-48 adduct spectra, the same samples with compounds 30 and 46 
exhibited a maximum of triple adducts (Table S 13 - Table S 15).  
8.5.3 Influence of incubation time 
When ODN1 was allowed to react with the metal salts 30 and 46 for a longer time, i.e. 72 h, also 
multiple adducts are found (Figure 39) and unplatinated ODNs are not observed anymore. This again 
indicates that alternative binding modes, e.g. on the phosphate backbone or at C and T bases are in 
general thinkable. It is however unlikely that these serve as primary binding sites. In that case, a less 
defined interaction pattern would be observed in adducts with ODN1 at lower incubation ratio and 
time.  
 
  
  
 
Figure 39 Top, multicharged spectrua of ODN1 incubated with 30 (left) and 46 (right) in a 3:1 metal:ODN ratio for 72 h. Z 
values are generally negative. Below, comparison of the theoretical vs. experimental multicharge peaks of the ODN1-30 
triple adduct (left) and ODN1-46 bisadduct (right), both at charge state -5.  
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Rather could gradual C binding be envisioned with cytosine-N3 as another potential platinum binding 
site. It generally has to be kept in mind that the experimental setup provides the oligonucleotide 
target with a stoichiometric excess (3 eq.) of metallodrug over ODN1, which is necessary for the 
measurement conditions of this proof-of principle experiment. In an actual cellular environment, the 
ratio of platinum over nucleobase is expected to be much lower: In a recent study by Groessl and co-
workers, the concentration of metallated DNA of A2780 cells after treatment with Cisplatin at IC50 for 
24 h was determined to be about 2 nmol/mg DNA.291 
8.6 MS2 Experiments of ODN1-platinum adducts 
For a more precise insight into the binding position of the metal fragments, MS2 experiments were 
performed on selected adducts formed with ODN1.  
8.6.1 Typical fragmentation pathways  fragmentation of unplatinated ODN1  
First, MS2 experiments were conducted on free ODN1 to build a reference library of fragment peaks. 
The most abundant multicharge peak set was selected for collision-induced dissociation (CID) 
experiments, i.e. the z = -6 signal at m/z = 590 (Figure 41, top). Signal assignment was performed by 
comparison with theoretical fragmentation data using the web-based Mongo Oligo Mass 
calculator.292 Theoretical and identified fragment signals are summarized in Table S 16.  
CID ionization of the full strand of ODN1 at charge state -6 yielded all typical types of fragmentation 
known for nucleotide strands, i.e. an-Bn, wn and yn fragments293 of nearly all positions n (Figure 41).xx 
Their origin is schematically depicted in Figure 40. [an-Bn]x- ions derive from elimination of the 
respective nucleobase Bn, followed by strand breaking at the corresponding 3 Cribose-Ophosphate site an. 
This in turn results in a further elimination reaction which finally results in a furan ring at the 3-
terminal ribose n.294 They thus give fragments of the intact 5 end of the oligonucleotide under 
investigation. [wn]x- ions give information on the intact 3 end of the sequence. They are considered 
as the complimentary fragments to an-Bn fragments since it is discussed that base elimination is the 
initial step of CID-induced oligonucleotide fragmentation. Thus, often both types of fragments are 
observed that originate from strand breaks at the same position.295,296 At low m/z ratios (which have 
                                                          
xx Negative charges of all discussed peaks originate from the loss of a defined number of H+ ions, typically from 
Phosphate groups, in the respective fragments. For the sake of better readability, these proton abstractions are 
not explicitly noted in the discussion of such peaks and will only be given in detailed calculations or where 
needed for better understanding of the signals. 
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not been considered here), also ions of the eliminated bases can usually be detected as [B-H]-. 
Further typical fragmentation pathways lead to yn-type fragments which occur after strand breaks 
fƌoŵ the iŶtaĐt ϯ’ eŶd of the oligoŵeƌ at the P-O ďoŶd Ŷeǆt to the ϱ’eŶd of ƌiďose.297 Interestingly, 
corresponding cn fragments are not observed. Less frequently, internal fragments are described (i.e. 
of breaks at two an/wn sites afteƌ ďase loss at the ϯ’-end), but were not observed in these spectra.  
 
 
Figure 40 Schematical drawing and nomenclature of the most abundant fragmentation patterns after CID ionization of 
oligonucleotides according to McLuckey et al.293–295 fragments marked in red are the most typical observed fragments.  
8.6.2 Fragmentation of adduct peaks – general observations 
MS2 data was then collected from selected adduct peaks in ODN1-46 and ODN1-30 spectra and 
compared to fragmentation data of unplatinated ODN1, as has been reported by others earlier.271,274 
The most abundant peak set of the monoadduct of the m-OH substituted compound 46 as well as of 
mono-and bisadduct peak sets of 30 were subjected to CID ionization. Results are depicted in Figure 
41 and listed in Table 8 and Table 9. For more detailed data, cf. supplement C. 
It is quite obvious to see that in the Pt-adduct MS2 spectra, only an-Bn signals up to a7-B7 and wn 
fragments up to w6 can be assigned in reasonable abundance. In the MS2 data of free ODN1, the 
whole range of possible fragments is found – including the typical complementary an-Bn/wn pairs. 
This indicates that the initial ODN1 seƋueŶĐe is uŶĐhaŶged fƌoŵ the ϱ’ eŶd up to positioŶ ϱ ;i.e. 
ϱ’OH-CCTCT-Ϳ aŶd fƌoŵ the ϯ’ eŶd up to positioŶ ϴ ;i.e. –TCTCC-OHϯ’). These findings give a first 
indication that the primary platinum binding site may be, as expected, at positions 6 and 7, where 
guanine residues are located.  
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Figure 41 Comparative assignment of MS2 signals of free ODN1 (top) and the ODN1-46 (middle) and ODN1-30 
monoadducts (bottom). Green, signals found in all spectra; blue, signals found only in free ODN1; orange, signals found only 
in adduct spectra; red, diagnostic adduct peaks with detected (O,S)Pt unit; grey, pseudo-signals (noise) due to overall low 
signal intensity. For the sake of clarity, only one line is used for very close signals. m/z values given are those of the signal 
with highest intensity, not necessarily the monoisotopic peak. (O,S)Pt* in ODN1-30 adduct: (O,S)Pt unit after loss of the S-
ethyl fragment. 
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It should be noted that in general, the signal intensity in these adduct spectra was rather low due to 
very small sample amounts and a low relative intensity of the mother peaks subjected to CID 
ionization. As a result, some of the found signals that occurred in all spectra could not be attributed 
to any of the usually discussed fragmentation pathways; not even to the less common bn/cn/dn, xn/zn 
type or internal fragments. Some of these signals also appeared in MS spectra, even in those of 
ODN2 and its adducts. They therefore seem to present non-diagnostic peaks, maybe source 
impurities, which will not be considered in more detail. Such signals appear at e.g. m/z = 481, 531, 
534, 681, 934, 944 or 1192 and are indicated by grey lines in Figure 41. 
8.6.3 Fragmentation of the monoadduct between ODN1 and compound 46 
In the case of the ODN1-46 monoadduct, it was possible to identify the Pt(II)-containing [(a7-
B7)+(O,S)Pt]2- ion at m/z = 1166.64 (Figure 42, for all relevant adducts cf. Figure 41 middle and Table 
8). This locates the (O,S)Pt moiety at base G6. Together with the observation that also unplatinated 
[a7-B7]2-/3- ions are found at m/z =  950.15 and 633.10, Pt could additionally be located at base G7.xxi  
This thesis is further underlined by the identification of a [G+(O,S)Pt]- adduct ion at m/z = 583.02 
(Figure 43, right), which could originate from a preferred base loss of the platinated base in advance 
of the typical an strand break. This possibility has been discussed in great detail by Nyakas et al., 
together with several possible platination-specific fragmentation pathways.273 
 
  
Figure 42 Comparison of the experimental and theoretical isotopic patterns belonging to ODN 1 fragments a6-B6 (left) and 
a7-B7 (right) with one (O,S)Pt unit bound at charge state -2.  
                                                          
xxi It cannot be ruled out that fragments such as [a7-B7] originate from adducts of (O,S)Pt being bound at e.g. G6 
in an initial fragment [(a7-B7)+(O,S)Pt] and that the Pt unit is cleaved during CID. All additional spectrometric 
evidence however fortifies the stated hypothesis and makes the occurrence of such a cleavage unlikely. 
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Table 8 Relevant fragment peaks of the ODN1-46 monoplatinated adduct in the MS2 experiment. identified (O,S)Pt adducts 
and unplatinated but diagnostic fragment peaks are listed. For found signals, one characteristic peak is listed  typically the 
first of the pattern. For calculated signals, the corresponding multicharge peak is listed. 
found 
(m/z) z 
calcd 
(m/z) 
error 
(ppm) sum formula fragment 
582,01421 -1 582,01701 4,81 C16H14N5O3PtS2 [G- + (O,S)Pt+  H+]- 
772,90004 -5 772,90225 2,86 C121H151N33O75P11PtS2 [ODN1  C + (O,S)Pt+ -6H+]5- 
785,62387 -2 785,62671 3,61 C52H66N13O34P5 [a6-B6  2H+]2- 
847,87952 -4 847,88328 4,43 C109H142N31O73P11 [ODN1  G  4H+]4- 
950,14898 -2 950,15297 4,20 C62H78N18O40P6 [(a7-B7)  2H+]2- 
1002,11136 -2 1002,11538 4,01 C63H77N13O36P5PtS2 [(a6-B6) + (O,S)Pt+  3H+]2- 
1166,63925 -2 1166,64164 2,05 C73H88N18O42P6PtS2 [(a7-B7) + (O,S)Pt+  3H+]2- 
 
Generally, all complimentary ions of a mother fragment should be detectable in oligonucleotide MS2 
experiments.294 Thus, this fragment could comprise the platinated G7 ion leading to the occurrence of 
the unplatinated (a7-B7) fragment which is also detected as z = -2 and -3 ions (vide supra). In good 
correlation with the observation of unplatinated [a6-B6]2-, it could as well originate from the G6 ion, as 
already suggested in combination with the [(a7-B7)+(O,S)Pt] fragment.  
Furthermore the [ODN1-G]4- ion was identified (Figure S 13). This is another good indicator that 
ribose-bound G, upon platination, is destabilized and thus released from ribose easier than 
unplatinated G: No such fragment can be found in free ODN1. The stability of the newly formed 
(O,S)Pt-G adduct is nicely demonstrated by these findings. 
One other diagnostic Pt-containing fragment was identified from the signal at m/z = 1002.61 as the 
[(a6-B6)+(O,S)Pt+-3H+]2- ion (Figure S 13). In this segment of ODN1, no G is available. Therefore 
another binding site for Pt must exist in this sequence. A plausible explanation would be C4 as a 
secondary binding site: Even though no fragments that give direct evidence for a bisfunctional 
binding of the (O,S)Pt unit towards one G and one C were found, the presence of a [a4-B4]- ion at 
m/z = 979.16 together with (low abundance) w8 fragments at m/z = 612.83 (z = -4) and 817.45 (z = -3) 
indicate a preferential fragmentation position at the 3 side of ribose 4 and possible release of 
(platinated) C4. One might envision a bisfunctional binding of the (O,S)Pt unit to C4 and G6, which 
could explain most of the found fragments. This can, however, not be proven solely with the 
methods provided here. Further, detailed investigations using additional complementary methods 
might lead to a definite binding site assignment. 
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Figure 43 Experimental and theoretical isotopic pattern of the (O,S)Pt-G adducts formed with 30 (left) and 46 (right) 
8.6.4 Fragmentation of the mono-and bisadducts between ODN1 and compound 30 
When evaluating the data obtained from CID ionization of the monoadduct formed between ODN1 
and compound 30, a similar fragmentation pattern is observed (Figure 41, Table 9, Supplement C). 
The most important signals are those of [G+(O,S)Pt]- at m/z = 566.02 (Figure 43, left) and of 
[(a6-B6)+(O,S)Pt+-3H+]2- and [(a7-B7)+(O,S)Pt]2- at m/z = 994.62 and 1158.64, respectively, which 
indicate a similar binding mode of the two compounds 30 and 46 (Figure S 14). 
Due to the rather high intensity of the mother peak of intact ODN1+(O,S)Pt at m/z = 792.71, less 
diagnostic fragments are observed in this MS2 spectrum. Increasing the collision energy to enforce 
more fragmentation, however, would have lead to complete destruction of adduct signals, thus 
making a definite assignment of adduct sites impossible. This fact is tellingly shown by the signal at 
m/z = 779.50, z = -5, which is attributed to platinated whole ODN1 after release of [S-Et] from the 
bidentate ligand (Figure S 14).  
Table 9 Relevant fragment peaks of the A-1 monoplatinated adduct in the MS2 experiment. . identified (O,S)Pt adducts and 
unplatinated but diagnostic fragment peaks are listed. 
found 
(m/z) z 
calcd 
(m/z) 
error 
(ppm) sum formula fragment 
566,01989 -1 566,02209 3,89 C16H14N5O2PtS2 [G- + (O,S)Pt+  H+]- 
769,50044 -5 769,50291 3,21 C121H150N33O75P11PtS2 [1  48 + (O,S)Pt+  6H+]5- 
779,50487 -5 779,50932 5,71 C123H150N36O75P11PtS [1 + {(O,S)Pt-SEt}+  6H+]5- 
847,87996 -4 847,88328 3,92 C109H142N31O73P11 [1  G  4H+]4- 
994,11421 -2 994,11792 3,73 C63H76N13O36P5PtS2 [(a6-B6) + (O,S)Pt+ 3H+]2- 
1158,64034 -2 1158,64419 3,32 C73H88N18O42P6PtS2 [(a7-B7) + (O,S)Pt+ 3H+]2- 
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In an attempt to identify the second binding site in the observed bisadducts of ODN1 with 30, the 
signal belonging to ODN1+2(O,S)Pt at m/z = 875.51, z = -5, was also subjected to CID ionization 
(Figure S 15). In this case, only few fragment peaks could be assigned, no platinum-containing adduct 
peaks could be determined due to the low signal intensity. Again, it is striking to see that the most 
abundant assignable signals belong to w5, w6, a4-B4 and a6-B6, thus drawing a similar picture as the 
monoadduct did. In addition, the appearance of a signal belonging to unplatinated ODN1 at 
m/z = 886.70 demonstrates the obvious instability of the bisadduct towards CID ionization. No 
structural conclusion will therefore be drawn from this data. 
 

  
 
 
9 DISCUSSION TO BIOMOLECULE INTERACTION DATA 
9.1 Interactions of platinum(II) complexes with model proteins 
It could be shown through ESI MS and UV-vis spectroscopy that the compound class presented within 
this thesis is capable of forming adducts with proteins. Detailed studies of the adduct mass spectra 
reveals that the interaction pattern is distinctive, and that the compounds occupy defined amino acid 
binding sites within each protein which well correlate with the number of principally available 
binding sites in each particular sequence. The compounds seem to have a preference for binding N 
atoms of His side chains as opposed to e.g. S atoms at Cys or Met sites, but may possibly also bind 
these amino acid side chains.  
X-ray crystallographic data on the HEWL-46 and HEWL-48 adducts tellingly demonstrate the adduct 
formation between the (O,S)Pt unit and ND1 of a His side chain. Interestingly, DMSO is retained 
within the coordination sphere and stabilized by hydrogen bonds. In the corresponding ESI mass 
spectra however, no evidence of DMSO being retained is found. Obviously, the different 
experimental conditions make the retention in one case and the release of DMSO in the other case 
possible.  
For the hydroxy-substituted complexes 45-48, adducts formed with cyt c also reveal partial retention 
of the DMSO ligand within the coordination sphere of the Pt(II) center, a feature that is not observed 
for the compounds of the unsubstituted or p-Bromo substituted series 29-36. Apart from this 
difference between the compound subgroups, they generally exhibit a similar adduct formation 
behavior; with slight differences in adduct quantity depending on the substituent and the length of 
the alkyl chain. Compounds with a short alkyl chain usually form more adducts than their 
homologues with longer chains. This behavior can most probably be explained by a better solubility 
in the buffer medium and by the smaller size of the S-methyl esters, making them easier available 
and allow them to better access binding sites.  
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Compound 46, with a m-OH group, generally seems to bind the proteins to the largest extent when 
comparing all S-ethyl esters. This is deduced from the overall higher intensity of adduct peaks 
compared to the other compounds.  
When comparing the reactivity of the compounds towards the different proteins, UV-vis spectra give 
a good indication that the reactions with the proteins occur on slightly different time scales. Taking 
as a measure the time needed for the spectrum to equalize (i.e. to show no further significant band 
shifts), the speed of adduct formation by the Pt(II) compounds can be put in the order cyt c > HEWL > 
RNase A; a finding that is also corroborated by ESI MS spectra recorded after 24 vs. 72 h of 
incubation.  
In summary, it can be concluded that a defined interaction pattern of the (O,S)PtCl(DMSO) 
compounds with the model proteins is witnessed, with slight differences arising from the substitution 
pattern at the (O,S) bidentate ligand and the protein used. In all cases, the chlorido ligand is released 
as a prerequisite for biomolecule binding. Whether DMSO is substituted or retained within the Pt(II) 
coordination sphere mainly depends on the experimental setup und to some extent on the 
compound. These findings show, in any case, that DMSO is a ligand that forms a stable and partially 
inert bond between its sulfur donor atom and the Pt(II) center. This might, in consequence, slow 
down the general reactivity of the compound class towards biomolecules and might therefore 
contribute to the goal of this thesis to achieve compounds that do not interact with all biomolecules 
available in an uncontrolled manner.  
9.2 Interactions of platinum(II) complexes 30, 46 and 48 with 
9-methylguanine and single-stranded ODNs 
ESI MS analyses carried out in negative ion mode show that compounds 30, 46 and 48 are able to 
form adducts with the single strand DNA models ODN1-3. The resulting metallodrug-DNA adducts 
contain only (O,S)Pt fragments, implying that the loss of both monodentate ligands is a crucial step in 
the DNA binding mechanism.  
The presence of more than one (O,S)Pt fragment linked to the model sequences suggests that the 
selected platinum complexes have an affinity also for sequences different from the GG-boxes or, in 
alternative, form adducts within the same nucleobase involving the participation of e.g. the guanine 
O6 atom (N7,O6) chelates,298 thus leaving the N7 of the neighboring guanine available for coordination 
with another metal center. 
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MS2 experiments on adducts of ODN1 with 30 and 46 further confirm that guanine is the primary 
DNA binding site for these compounds. Direct evidence is given from the detection of [G + (O,S)Pt] 
fragments in both MS2 fragmentation spectra, indirect evidence emerges from the combined 
appearance of characteristic platinated and unplatinated fragments. It was furthermore shown that 
binding of the (O,S)Pt unit to other nucleobases, perhaps C, is also possible as described above.  
As an alternative to nucleobase binding, one might envision the binding of Pt(II) towards the 
phosphate backbone. This is highly unlikely for several reasons: First, no direct evidence in form of 
typical small-molecule adducts was found. Secondly, it is generally discussed that transition metals 
preferentially bind DNA nucleobases while alkali and alkali earth metals generally prefer backbone 
pohosphodiester groups.264 Thirdly, altered fragmentation pathways have been identified for 
oligonucleotides with Na+ bound to the phosphate backbone, none of which are observed here.264,265 
Therefore, phosphate binding can be ruled out.xxii 
When taking into account the data obtained from experiments with 9-mg, the following picture 
emerges: Binding of the investigated Pt(II) compounds occurs fast under the given conditions, 9-mg 
replaces the chlorido ligand of the intact Pt(II) compounds and can, to some extent, also substitute 
the DMSO molecule, possibly leading to the formation of a bischelate structure with platinum 
coordinated to the (O,S) ligand and to 9-mg in a (N7,O6) bidentate manner. Given the fact that not all 
platinum is bound in that way, it can be concluded that the O6 atom of 9-mg is not very efficient in 
binding the (O,S)Pt unit. This is in good accordance with the initially stated thesis that trans to a hard 
donor atom in Pt(II) complexes  here the -hydroxy oxygen -, a soft ligand is preferably bound, thus 
explaining the retention of DMSO in parts of the adducts (cf. the HSAB concept in chapter 2).  
These results with 9-mg give further indication that such a monofunctional binding may also be 
possible within a single strand oligonucleotide. However, when two guanines are spatially adjacent in 
an ODN sequence, two N-donors (the N7 positions of the two guanines) can efficiently replace 
chloride, DMSO or water to give cross-links, as is indicated by the complete absence of 
(O,S)Pt(DMSO) units in the adduct spectra with ODNs. In the presence of excess of platinum, 
alternate binding sites can then be occupied by the (O,S)Pt units, such as the aforementioned (N7,O6) 
bidentate site or alternate nucleobase donor atoms.  
                                                          
xxii At this point it should be mentioned that attempts to investigate the compounds reactivity towards 5-
guanosine monophosphate (5-GMP) as a nucleotide model have also been pursued. However, ESI mass 
spectrometric studies gave no reliable peak data. Efforts to study the behavior in solution by NMR methods 
were also inconclusive due to solubility issues and overlay of solvent signals with essential signals of the 
compounds. 
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9.3 General conclusions 
Taken together all the findings of biomolecule binding experiments, it is noteworthy that the extent 
of reactivity observed for the three compounds is somewhat different when reacting with proteins or 
ODNs: towards ODNs on the one hand, the unsubstituted complex 30 was found to be most reactive 
and compounds 46 and 48 behaved more or less similar in ESI MS experiments. In experiments 
conducted by CD and UV-vis spectroscopy,138,283 an order of reactivity 30, 46 > 48 (>> CDDP) was 
elucidated. On the other hand, ESI MS data of adducts formed with proteins manifested a reactivity 
order to be set as 46 > 30, 48. Thus, it can be concluded that the nature and position of the aromatic 
substituent plays a role when it comes to a defined biomolecule binding and target preferences. 
Together with the data on antiproliferative assays described in chapter 5, it becomes clear that 
structure-activity relationships of this series of compounds cannot be broken down to a singular trait 
or reaction pattern. It is rather the sum of all consequences that derivatizations bring forth with 
them that contribute to a final biological activity. Nevertheless, compounds 29/30 and 45/46 can be 
considered to represent the most potential drug candidates within this series.xxiii 
                                                          
xxiii Even though in depth-experiments were only carried out with the S-ethyl compounds 30 and 46 for practical 
reasons, their S-methyl homologues should be considered as similarly potential compounds as deduced from 
the overall data. 
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Parts of the here described syntheses on alkynyl group-bearing compounds 51-67 have been carried 
out by Nora Nowak (FSU Jena) during her bachelors thesis and advanced practical course, which she 
conducted under my direct instruction and supervision of Prof. Dr. Wolfgang Weigand. All relevant 
analytical data has been independently re-evaluated and syntheses repeated when necessary. 
 

  
 
 
10 BACKGROUND 
-hydroxyditiocinnamic esters bear several moieties which can, in principle, easily be modified to 
fine-tune their properties. Incorporation of functional groups that allow for the formation of metal 
complexes as bioconjugates is therefore a desirable aim. Such bioconjugates could improve e.g. the 
compounds selectivity towards certain biological targets through specific receptor targeting. They 
could also lead to chimeric compounds that bear several biologically relevant functionalities for 
complex and directed pharmacological applications.299,300 
10.1 Metal-peptide bioconjugates 
The field of bioconjugates is huge, and a plethora of methods and techniques are being applied in the 
field of forming bioconjugates.301,302 Metal-complex bioconjugates resemble a small portion of this 
research, but are nowadays explored for different biological/medical applications.303,304 Especially 
metal-peptide bioconjugates have emerged as promising research focus in recent years, several 
reviews have dealt with this subject.305307 As one of the first representatives, ferrocene-derived 
peptides have been prepared by solid-phase peptide synthesis.308,309 Other early approaches include 
those of the group of G. Jaouen, who used e.g. Mo and Co alkyne organometallic compounds to 
prepare peptide conjugates.310  
The concept of metal-peptide bioconjugate formation has been widely extended, especially by the 
Metzler-Nolte group, to give bioconjugates of various metals and based on very different structural 
approaches. Some are named here as representatives for the large number of metal-peptide 
bioconjugates that have been described in the literature by many researchers.  
Iron(II), in form of ferrocene carboxylic acids, has been explored in detail and reported frequently as 
basis for metal-peptide bioconjugates. It is usually bound to model peptides via an amide bond 
(Chart 6a),311314 in one case the use of an alkyne spacer was reported (Chart 6b).315  
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Chart 6 Some coordination environments of transition metal bioconugates from the Metzler-Nolte group. Green peptide 
box: various peptides; red peptide box: enkephalin derivatives. Blue peptide box: short sequences. Cf. the text for detailed 
description.  
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Other metals have been explored for their applicability in metal-peptide bioconjgates, e.g. gold(I), 
bound to Cys5-Enkephalin through SCys (Chart 6c).316 Cobalt, bound to peptides as Co-carbonyl via 
terminal propiolic acid (Chart 6d),317 or as cobaltocenium carboxylic acid (Chart 6e),318,319 have been 
reported. In the latter case, enhanced cellular uptake and delivery to the nuclei was observed by 
making use of nuclear localization signal (NLS) peptide sequences. Furthermore, molybdenum has 
been attached to enkephalin via nitrogen donors (Chart 6f and g),320,321 and also ReI(CO)3, PtIVMe3, 
and (5-Cp)RuII units have been bound to this model peptide by making use of the monoanionic 
tris(pyrazolyl)borate ligand (Chart 6h).322,323  
Binding of a (5-Cp*)RhII unit was made possible by forming a sandwich complex with Tyrosine, thus 
giving a (5-Cp*)RhII(6-PhTyr) structural motif, incorporated into several peptide sequences (Chart 
6i).324 The binding of the enkephalin derivative of this series towards opiod receptors has been 
studied in detail by 2D NMR spectroscopy and modeling techniques.325 Titanocene326 and Ru-arene 
units327 (Chart 6j and k, respectively) have been attached to model peptides through copper(I)-
catalyzed alkyne-azide cycloaddition (CuAAC).  
The first report on Pt(II)-petide bioconjugates appeared in the year 2000 by members of Jan Reedijks 
group:328,329 Fully working under solid phase conditions, a tripeptide, tethered to ethylenediamine, 
was prepared and coordinated towards a PtIICl2 unit (Chart 7l). Further derivatives have subsequently 
been described, all bearing a common (en)PtCl2 pharmacophore (en = ethylenediamine).330,331 In DNA 
binding studies, it was shown that these compounds produce DNA adducts structurally similar to 
those Cisplatin or free (en)PtCl2 would.332 Taking advantage of the newly developed method, the 
group also prepared a dinuclear Pt(II) complex with two trans-(NH3)2PtCl moieties being bound in 
monodentate fashion to a short peptide (Chart 7m). 333 
Furthermore, Pt(II) conjugates with octreotide derivatives have been obtained from a solid-phase 
approach (Chart 7n), and binding of this conjugate towards a short oligonucleotide sequence was 
demonstrated.334 An organometallic variant of a Pt-peptide bioconjugate was prepared by using a 
(N,C,N)-binding pincer ligand which was readily attached to different peptide sequences (Chart 
7o).335 In two independent reports, Pt(II) peptide bioconjugates were described utilizing a malonate-
based ligand and a long linker to connect the coordination site with a peptide (Chart 7p and q).336,337 
In addition, the variability of the axial position in Pt(IV) complexes was exploited by several research 
groups (Chart 7r and s).322,338340 
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Chart 7 Literature-reported peptide bioconjgates based on Pt(II) and Pt(IV) scaffolds. Green peptide box: various peptides; 
Blue peptide box: short sequences (3 amino acids); pink box: linker unit. Cf. the text for detailed description. 
It should be noted that efforts have also been made in attaching Pt(II) or Pt(IV) scaffolds to polymeric 
nanoparticles or nano-metal organic frameworks.55,341 Lipoplatin31 and ProLindacTM34 are examples of 
such compounds that have actually reached clinical trials (cf. chapter 1.1), the latter being a 
carboplatin analog which is in fact connected to a polymer backbone via short peptide linkers. 
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In several of these mentioned reports on metal-peptide bioconjugates, enhanced uptake into 
cells314,318,336 and/or activity against selected cancer cell lines was reported as compared to their non-
conjugated subunits.317,327,337340  
These results strikingly demonstrate the effects that conjugation of active metal centers with defined 
peptide sequences can have and show the great structural versatility of artificial metal-biomocelule 
conjugates. It is thus only a logical consequence to use the structural motif available from the 
previous studies and strive to combine (O,S) chelating Pt(II) complexes with peptides.  
10.2 The model peptide 
As a model for the here described studies, the pentapeptide Leu5-Enkephalin (Leu5-Enk) was chosen. 
Enkephalins are known neurotransmitters and ligands for opioate receptors,325,342,343 and naturally 
occur in two forms (Chart 8): Met5-Enk, with methionine being bound in position 5, and Leu5-Enk 
with leucine as amino acid in position 5. Enkephalins originate from precursor proteins of the 
preproenkephalin group and of -Lipotrophin344 by protolytic processes. They were first isolated and 
characterized from porcine brains in 1975,345,346 where they are produced in neuronal cells. 
Molecular structures of both forms were solved,347349 but in solution a very flexible secondary 
structure is assumed350352 which allows for the peptides to potentially adapt to several receptor 
binding sites. Opioid-receptors occur in the brain,353 but also in the spinal region354 and colon,355 and 
have been found to be overexpressed in small-cell lung carcinoma, neuroblastome and breast cancer 
cell types.356  
 
 
Chart 8 The Enkephalins. 
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Due to their high potency to bind to opioid receptors and thus induction of analgesic effects, they 
were initially considered as potential analgetic drug candidates. However, a short life-time in several 
test systems and evidence for addictive properties have lead to a need for structural modifications of 
the naturally occurring peptide sequence.353 Among these, e.g. the substitution of amino acids by 
non-natural derivatives or the introduction of metal centers, may increase the compounds lifetime 
and could lead to more favourable properties in such a quest. 
Overall, the pentapeptides can be considered suitable model peptides for bioconjugate preparation. 
Leu5-Enk, from here on referred to as Enk, was chosen for the first attempts to form (O,S)Pt derived 
bioconjugates on the basis of several considerations: Firstly, Leu5-Enk is a readily available model 
peptide. It is short (5 amino acids) and bears one functional group which requires the application of 
protective groups, i.e. a tert-butyl (tBu) group for the Tyr1-OH,357 still making various structural 
alterations possible. Secondly, is this a well-established model peptide which is known to be a good 
representative for subsequent experiments with further, larger, peptides  as was demonstrated in 
the previous section. 
10.3 Considerations on different conjugation methods 
The versatile possibilities of forming metal bioconjugates have just recently been reviewed in great 
detail300 and some examples been outlined in the previous chapter. Here, the two methods applied 
for this project are described briefly. 
10.3.1 Copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) 
The use of click chemistry as versatile and bioorthogonal approach has attracted growing attention 
in the last years. The prototype of classical click chemistry as established by Kolb, Finn and 
Sharpless,358,359 is the linking of two separate building blocks via Huisgen-type 1-3 dipolar azide-
alkyne cycloaddition360,361 and has become increasingly applied in its Cu(I) mediated application 
scheme, as independently reported by the groups of Sharpless362,363 and Meldal364 and wiedely 
applied over the last decade.365369  
Azides do not occur in nature,370 alkynes are very sparse;371 both do have some biological activity.372 
Nevertheless, terminal alkynes and azides bear a number of structural features which render them 
important in many synthetic approaches. They are both stable towards nuleophiles, electrophiles 
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and a variety of standard reaction conditions. Importantly, both are nearly unreactive towards most 
biological molecules since they are small, relatively unpolar, and do not form hydrogen bonds to a 
significant degree.373 These characteristics renders them perfect candidates for bioorthogonal 
synthetic approaches, also because they are considered to not significantly change the properties of 
the biomolecules they are attached to.370 The resulting 1,2,3-triazoles have found wide-spread 
applications, e.g. as pharmacophores374 or simply as linking function of building blocks.367 
One aim of this study was thus to explore synthetic approaches towards the incorporation of both 
functional groups, azides and alkynes, into the main structural unit of (O,S)Pt complexes to finally 
enable bioconjugation with peptides as model compounds. In the here described studies, first the 
introduction of terminal alkynyl groups at either the aromatic or dithiocarbonyl subsite was explored. 
Secondly, preparation of an azide-functionalized structure was pursued. In parallel, derivatization of 
Enk with the respective complementary functional group should be explored.  
10.3.2 Amide bond formation 
Another approach which has frequently found application is the binding of suitable metal units via 
amide bonds. Usually, the metal unit should bear a carboxylic group which can then be coupled 
N-terminally to the desired peptide unit. In this context, both the coupling on solid phase - during 
peptide synthesis -, or in solution - after synthesis of the whole peptide -, are thinkable and have 
been utilized earlier (vide supra for various examples). Coupling in solid phase or in solution can in 
principle occur by the same methods,375377 and usually typical amino acid coupling methods are 
applied to the desired system. It is generally considered that coupling in solid phase is more efficient 
and leads to less unwanted side reactions.378 However, deprotection and cleavage from resin usually 
require harsh conditions (e.g. high concentrations of TFA) which some target compounds, especially 
metal complexes with highly functionalized ligands, might not survive. Therefore, it is favorable if the 
(metal-bound or free) ligand can survive deprotection/cleavage conditions without decomposition 
(when coupling in solid phase), and is not reactive towards other functionalities present in the 
peptide (if coupled after deprotection and/or cleavage from resin).  
These considerations in mind, a second approach towards metal-peptide bioconjugates was the 
introduction of a carboxylic group into the overall structure of the -hydroxy ditiocinnamic ester to 
enable its coupling towards the model peptide Enk via amide bonds.  

  
 
 
11 BIOCONJUGATES VIA COPPER(I)-CATALYZED ALKYNE-
AZIDE CYCLOADDITION (CuAAC) 
11.1 Introducing alkyne functionalities into -hydroxydithiocinnamic 
esters 
11.1.1 Introducing the alkynyl group at the aromatic subsite 
For the formation of compounds that bear a phenyl-ether with a terminal CC triple bond, it is 
possible to directly introduce the alkynyl group into hydroxy acetophenones and then attempt ligand 
synthesis. It may as well be possible to first protect the hydroxy group, e.g. by the already discussed 
silyl-based ethers, commence with building up the (O,S) main structure and subsequently deprotect 
the OH group to then etherificate the resulting phenolate-bearing ligand. This procedure is by far 
more laborious and since the yields of the first three steps are known to be only moderate (cf. chaper 
3.1), the first-described pathway was chosen as primary route; knowing that an alternate route 
would be available. 
From an economic standpoint, propargyl bromide, a C3 building block, is the cheapestxxiv and most 
readily available aliphatic alkynyl halide and therefore presented the substrate of choice in initial 
experiments. Subsequently, also C4 and C5 units were used.  
 
  
                                                          
xxiv e.g. Costs of propargyl bromide, 80 % solution in toluene: ca. 35 eur/50 mL vs. butynyl bromide or pentynyl 
chloride: 5 g ca. 65 eur when retrieved from SigmaAldrich 
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11.1.1.1 Derivatzation of 4-hydroxy acetophenone 
Compound 51 was prepared in good yields (81 %) by a literature-reported Williamson-ether 
synthesis, using 4-hydroxy acetophenone and propargyl bromide as starting materials and potassium 
carbonate as base (Scheme 6).379 In subsequent steps, the propargylic group proved to be prone to 
rearrangement reactions, mostly due to the acidity of both terminal CH380 and internal CH2 groups 
(vide infra). Therefore the elongation of the distance between the two functional groups was 
pursued. First, one CH2 group should be added to obtain compound 52. 
 
 
Scheme 6 Introduction of a terminal alkyne at the p-O-Ph site of acetophenone. 
To introduce a butynyl group at the aromatic subsite, 4-hydroxy acetophenone was convereted with 
butynyl bromide according to the same procedure, but no conversion was achieved after 24 h or 
even 7 days of stirring. As an alternative base with better solubility in organic solvents, caesium 
carbonate (Cs2CO3) was applied. Still, merely 4-hydroxyacetophenone was recovered, even after 
heating at reflux, long-time stirring or addition of KI as activator.381  
It seems that a Williamson-ether type synthesis of p-butynyl-oxy-acetophenone 52 is not possible 
from butynyl bromide. This might be due to an E2-type elimination which may be favoured in butynyl 
halogenides (Figure 44): the -CH2 group respective to the halogenide is CH-acidic due to 
neighbourhood to the alkynyl group,382 thus enabling the abstraction of a proton in  position, 
followed by elimination of the halogenide. This would explain why in most cases, the reagent 
4-hydroxyacetophenone was recovered quantitavely. Such a reaction would neither be possible in 
propargyl halogenides, where no -CH is available, nor in pentynyl halogenides, where the -CH is 
not activated enough for proton abstraction.  
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Figure 44 Possible E2-type elimination of the terminal halogenide due to CH-activation of the -CH2 in butynyl halogenides. 
The acidity and activity of the functional groups is schematically depicted.  
Based on these considerations, the expected favourable properties of the pentynyl group (i.e. no 
superimposed C-H activating effects due to the increased distance by one CH2 group) lead to the 
usage of pentynyl chloride as substrate. Phenol has been described to react with the reactant by 
usage of Cs2CO3 and KI.381 with this procedure, the desired product 53 was obtained in excellent yield 
of 92 % (Scheme 6).  
11.1.1.2 Preparation of -hydroxydithiocinnamic esters from acetophenones 51 and 53 
The alkynyl-functionalized acetophenone derivatives were then converted into -hydroxy 
dithiocinnamic esters. In principle, it is possible to prepare this substance class in two steps,103 or by 
using a one-pot approach.104,105 The latter is faster and in many cases more efficient, but sometimes 
reactive intermediates caused by functional groups might require the isolation of the respective 
dithiocinnamic acid. 
 
Scheme 7 -Hydroxydithiocinnamic esters based on acetophenones 51 and 53. 
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Following the one-step approach, compound 51 was converted with CS2 and methyl iodide (Scheme 
7) and gave the desired compound 54 in a low yield (14 %). As a side reaction in this setup, 
deprotonation of the propargylic group through potassium tert-butoxide (KOtBu) could compete 
against deprotonation of the acetophenone-methyl group. In a second and third attempt to improve 
the yield, more equivalents of KOtBu, i.e. 2.5 and 3 eq., were therefore used, giving almost no 
improvement of the reactions outcome in the first (yield 16 %) and a more than doubled yield of 55 
(36 %) in the second case. It appears as if the presence of the alkynyl group requires one additional 
equivalent of base for complete deprotonation of the terminal alkyne-carbon atom prior to 
activation of the methyl group in !-position to the carbonyl group. 
The acetophenone derivative 53 was also successfully converted to the respective 
-hydroxydithiocinnamic ester 55 in 42 % yield, using 2.5 eq. of KOtBu and ethyl iodide as alkylating 
agent. Not only the favourable pentynyl group, but also the use of an ethyl- instead of a methyl 
group contributed to the markedly increased yield. It has been found in earlier experiments that the 
use of methyl iodide as alkylating agent lead to an enhanced formation of the respective ketene 
mercaptal, thus lowering the overall yield.118 In some cases, the use of substoichiometric amounts 
(0.9 eq.) of alkylating agent could improve the overall yield by suppressing this unfavourable side 
reaction.104,105 
11.1.2 Introducing the alkynyl group at the dithiocarbonyl site 
11.1.2.1 Introducing a propargyl group 
The synthesis of compound 57 in a two-step reaction reported in literature (Scheme 8)383 . Following 
this procedure, first the free -hydroxydithiocinnamic acid 56 was isolated in 56 % yield by 
recrystallizaion from n-hexane/ethyl acetate. In the second step, the propargylic group was 
introduced via a two-phase reaction in chloroform/water with tetrabutyl ammonium hydroxide 
(nBu4NOH) as base and phase-transfer salt. After recrystallization from ethanol and isopropanol, pure 
57 was obtained in 43 % yield (overall yield 24 % in two steps). 
In an attempt to optimize the preparation of 57, the well-established one-pot method was explored 
as an alternative approach (Scheme 8). However, it was not possible to isolate the desired 
compound: A yellow solid was recovered which could not be identified as the target molecule. 
Analysis with NMR, mass spectrometry and IR spectroscopy lead to the assumption that a 
rearrangement process must have occurred during the reaction. 
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Scheme 8 Two possible pathways towards compound 57. 
The isolated compound has the identical sum formula as 57, established from EI-MS data: [M]+ and 
[M+2]+ singals at m/z = 312/314, characteristic for a Br-containing compound were found, but not 
the typical fragment after release of S-alkyl (here: S-Propargyl), as was found as dominant fragment 
peak in the EI mass spectrum of 57. NMR spectroscopic analyses point towards a cyclization reaction, 
leading to a compound 58 with a seven-membered heterocycle as outlined in Scheme 9. It is 
noteworthy that several signals appear to be doubled in both 1H and 13C NMR spectra of 58, 
indicative of two isomers being present in the CDCl3 solution (Figure S 17). These could originate 
from different ring-bent formations of this heterocycle which may be stabilized through lone pair 
electrons of S and O, leading to diverse electronic effects onto the conformer structures. This 
rearranged compound may be formed from an allene-propargyl tautomeric  intermediate as 
suggested in Scheme 9.  
  
 
Scheme 9 Possible rearrangement of compound 57 during conditions of the one-pot reaction to give 58. The cyclization may 
occur via an allene tautomeric intermediate. 
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Such a cyclization towards a seven-membered ring has not previously been discussed in literature. 
Larsson and Lawesson reported on a thio-claisen rearrangement of the homologous ketene 
mercaptal towards a thiapyran structure (Chart 9a),383 furthermore a cyclization leading to a 
5-membered ring and an exocyclic double bond was reported from cyclization of compounds bearing 
propargyl thioamide structure (Chart 9b).384,385 Similar reactions might in principle be thinkable also 
in this present case, however spectroscopic data point against these structural motifs, e.g. by 
absence of a band of (C=O) in the IR spectrum of 58. 
 
 
Chart 9 Products of rearrangement processes originating from propargyl-substituted -oxo thioesters. 
In this first one-pot reaction, an instantaneous dark-brown discoloration upon addition of propargyl 
bromide at room temperature indicated an immediate, probably unwanted, reaction. No such color 
change was observed in the successful two-step synthesis. Therefore the reaction was repeated and 
maintained at -78 °C until addition of propargyl bromide and closely monitored by TLC. As soon as 
the mixture was allowed to warm up to room temperature, the discoloration appeared again but did 
not manifest itself in a significant change in the TLC pattern. Since column chromatography might 
present one other source of side reactions, the mixture was subjected to crystallization from 
isopropanol; however without success. The isolated red-brown oil did include the desired product (as 
established from NMR and MS data), but a purification was not possible.  
11.1.2.2 Introducing a butynyl group 
In contrast to the encountered problems with the synthesis of propargyl-derived compound 57, it 
was possible to convert 4-bromo acetophenone 6 into the S-butynyl derived -hydroxy 
dithiocinnamic ester 59 via the one-pot synthetic procedure in 22 % yield. No rearrangement or 
other significant side reactions were observed; even after workup via column chromatography 
(Scheme 10). 
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Scheme 10 Synthesis of -hydroxydithiocinnamic ester 59 with a S-butynyl group. 
11.2 Complexation reactions of alkyne-derived -hydroxydithiocinnamic 
esters 
The obtained alkyne-functionalized compounds were subsequently used to prepare the respective 
(O,S) chelate complexes. Since a variety of bases can be used to deprotonate the -hydroxy group, 
sodium acetate (NaOAc) was chosen as the preferable base. It is not as acidic as the typically used 
NaH which is expected to probably also deprotonate the terminal alkynes, thus leading to unwanted 
side reactions. Table 10 lists pKa and pKb values for representative C-H acidities and relevant bases. 
Table 10 pKa and pKb values of acid/base combinations relevant for this study. 
compound pKa ref.  compound pKb ref. 
CH4 48 380  NaH ca. -26 386 
H2C=CH2 44 380  KOtBu ca. -18 387 
HCCH 24 380  NaOAc 9.24 386 
 
11.2.1 Complexation reactions of Ph-O-propargyl compound 54 
Compound 54 was converted with K2PtCl4 according to the standard procedure, using NaOAc as base. 
A yellow solid was recovered from recrystallization; purification via column chromatography was not 
attempted due to the previously observed rearrangements under such conditions. Based on MS and 
NMR data, the isolated compound did neither contain platinum nor did it show the main structural 
features of compound 54. Even the use of KOtBu as a base, both under inert and non-inert 
conditions, did not lead to the desired compound 60 (Scheme 11). 
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Scheme 11 Attempts to coordinate -hydrxydithiocinnamic ester 54, bearing a O-propargyl group, towards a Pt(II) center. 
It is generally known that due to the strong delocalization of electron density in the chelate ring, 
bischelates are very stable and preferably formed.107 To assess whether the ligand would in principle 
be capable of forming (O,S) bidentate Pt(II) complexes, the synthesis of the respective bischelate 61 
was attempted. It was possible to isolate the desired compound, however in low yield (10 %) and not 
to an appreciable degree of purity. This is mostly due to decomposition during the reaction and 
work-up processes.  
11.2.2 Complexation reactions of Ph-O-pentynyl compound 55 
To establish whether the pentynyl-functionalized substance 55 would in principle be capable of 
forming Pt(II) complexes, the synthesis of the corresponding bischelate was attempted (Scheme 12). 
Deprotonation was achieved using sodium acetate, followed by conversion with an aqueous solution 
of potassium tetrachloroplatinate. After work-up by filtration through silica, the red, pure bischelate 
was obtained in 28 % yield. Analytical data proved the formation of the desired compound 62.  
After the successful conversion of 55 into 62, synthesis of the respective monochelate was 
attempted. NMR spectra gave characteristic signals indicating the formation of an (O,S) chelate with 
DMSO as co-ligand, however the pentynyl group was not retained (Scheme 12).  
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Scheme 12 Conversion of pentynyl-derived -hydrxydithiocinnamic ethyl ester 55 to mono- and bisfunctional Pt(II) 
complexes. 
Instead, the triple bond had been hydrated and a methyl ketone was formed, as indicated by the 
analytical data of 63: 1H and 13C NMR spectroscopy (Table 11) showed the loss of signals belonging to 
the alkynyl group, whilst the newly formed COCH3 unit gave characteristic signals for the methyl 
group at 2.2 ppm and 29.8 ppm in 1H and 13C NMR spectra, respectively, as well as at high frequency 
for the carbonyl-C at 208.9 ppm in 13C NMR spectra. Mass spectrometry gave the [M+Na]+ peak with 
matching isotopic pattern at m/z = 653. In the IR spectrum, C!C stretching vibrations were lost and a 
new band at 1705 cm-1 was assigned to a C=O stretching vibration. Finally, elemental analysis proved 
the composition of the formed compound.  
Table 11 NMR spectroscopic data of 55 and the resulting Pt(II) complexes 62 and 63. All spectra were recorded in CDCl3. 
 1H NMR data [ppm]   13C NMR data [ppm] 
 55 62 63   55 62 63 
CH 1.98 1.99 2.18 (CO-CH3)  CH 69.2 69.2 29.85 (CO-CH3) 
     C- 83.3 83.4 208.9 (C=O) 
CH2  2.42 2.43 --  CH2  14.9 14.9 39.6 
CH2   2.03 2.04 2.06  CH2   27.8 28.3 20.8 
CH2 ! 4.14 4.15 4.01  CH2 ! 66.4 66.4 67.1 
C-OH 15.23 -- --  C-OX 170.7 174.6 174.8 
=CH- 6.88 7.08 7.09  =CH- 107.7 112.6 111.3 
     CS2 215.88 175.9 178.6 
DMSO -- -- 3.65 3JPtH = 23.4 Hz 
 DMSO   46.7 
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Platinum-catalyzed alkyne hydration has been known since the early 1960s388 but not investigated 
until the 1990s, when the hydration of terminal and internal C!C triple bonds through Zeises dimer 
was first described.389 This concept was quickly expanded to other Pt(II) salts.390,391 Today, a great 
variety of alkyne-hydrating catalysts from platinum or other metals is known that efficiently and 
regioselectively hydrate terminal and internal alkynes.392  
With this information in mind, the conversion of two equivalents 55 with K2PtCl4 was repeated, also 
in presence and absence of DMSO to rule out any influence from that additive. NMR data of the 
crude material gave no evidence for a hydration of the alkyne functionality. Obviously, the fast and 
stable formation of the bischelate structure prevents the Pt(II) center from attacking an alkyne 
functionality in that case. When preparing monochelate complexes, usually a slight stoichiometric 
excess of aqueous potassium tetrachloroplatinate (1.1 eq.) is used to prevent the formation of 
bischelates. Therefore some unchelated K2PtCl4 might remain in solution which could act as catalyst. 
In addition, in monochelate complexes, two binding sites are available that can easily bind and 
substitute available donor atoms. It is unlikely that Pt(II) exerts its catalytic properties on alkynes that 
are directly (O,S) chelate-bound to the same metal center: The ligands steric features do not allow 
for the pentynyl group to bind to the same Pt(II) center. Instead, an intermolecular pathway may be 
envisioned where the alkyne group of a (O,S) ligand bound to a different Pt(II) center or of unbound 
ligands is attacked.  
Detailed clarification of the possible reaction mechanism has not been pursued since catalysis of 
triple bond reactions is not within the scope of these studies. Future investigations might elucidate if 
it is possible to prevent this side-reaction by substituting water as solvent for the pre-activation of 
K2PtCl4, working completely water-free and at the same time avoiding an excess of K2PtCl4. For the 
further development of this research scope, using alkyne functionalities at the Pt(II) unit was proven 
to be not favourable and alternative lead structures should be found. 
11.2.3 Complexation reactions of S-propargyl compound 57 
Despite the aforementioned difficulties, the prepared S-Alkynyl functionalized ligands 57 and 59 
should be converted into the respective complexes to see whether this altered position of the alkyne 
function might lead to a different outcome (Scheme 13).  
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Scheme 13 Attempts to coordinate compound 57 to a Pt(II) center. 
Compound 57, with the propargyl group at the sulfur site, was converted with K2PtCl4 under various 
conditions. Neither the use of NaOAc nor of KOtBu as base lead to the desired product 64, even 
though analytical data hint towards the formation of the same product mixture in both cases. 
Isolated solids did, however, neither contain platinum (established from the missing characteristic 
isotopic pattern in MS spectra) nor the main structural features of the ligands in NMR data.  
It was not even possible to isolate the respective bischelate 65 under the conditions which proved to 
be successful in attempts with the other ligands. Strikingly, structural features of the rearranged 
compound 58 from ligand synthesis were observed in MS and NMR spectra, thus indicating that the 
same reaction that was induced earlier had now also occurred under the complexation conditions.  
11.2.4 Complexation reactions with the S-butynyl derived compound 59 
The butynyl-derived ligand 59 was successfully converted to give the bischelate 66 upon 
deprotonation with sodium acetate as red solid (Scheme 14). Although mass spectra did not give 
signals of the whole molecule, NMR (Table 12) and IR spectroscopic data as well as elemental 
analysis proved the formation of compound 66. 
After the confirmation that this ligand is able to form Pt(II) bischelate complexes, preparation of the 
monochelate 67 was attempted. Similar to 63, spectroscopic data gives evidence for the formation of 
a monochelated (O,S) bidentate complex with assisting coordination of DMSO, however again 
hydration of the triple bond occurred, as observed in NMR spectroscopic data (Table 12).  
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Scheme 14 Conversion of S-butynyl-derived -hydrxydithiocinnamic ester 59 to mono- and bisfunctional Pt(II) complexes. 
Table 12 NMR spectroscopic data of 59 and the resulting Pt(II) complexes 66 and 67. All spectra were recorded in CDCl3. 
 1H NMR data [ppm]   13C NMR data [ppm] 
 59 66 67   59 66 67 
CH 2.07 2.11 2.20 (CO-CH3)  CH 70.06 70.56 29.53 (CO-CH3) 
     C- 81.97 81.67 206.36 (C=O) 
CH2  2.65 2.74 3.00  CH2  17.91 18.64 42.12 
S-CH2! 3.46 3.40 3.45  S-CH2! 32.01 32.70 27.56 
C-OH 14.10    C-OX 169.49 174.07 174.17 
=CH- 6.88 7.05 7.02  =CH- 108.18 113.22 111.8 
CS2     CS2 216.57 177.01 180.88 
DMSO -- -- 3.66  DMSO -- -- 46.81 
 
11.3 Introducing an azide group into -hydroxydithiocinnamic esters 
In parallel to the above-mentioned efforts, the preparation of a -hydroxydithiocinnamic ester with 
an azide group at the aromatic subsite was attempted. Introducing a N3 group in arylic or benzylic 
positions is a widely applied methodology and well documented. Phenyl azides could be introduced 
from amino acetophenones,393,394 azidomethyl groups could be formed from methyl 
acetophenones.395,396  
In this work, the azidomethyl group was chosen as preferential lead structure. The azide group itself 
can be considered as a pseudo-halogenide, inducing (-I) and (+M) effects onto an aromatic ring quite 
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similar to a bromo substituent.372 In the final clicked products, delocalization of -electrons in the 
triazol ring might also lead to  at this point unwanted  additional electronic influences to the 
chelating system (e.g. by mesomeric effects), thus adding more variables to the coordination 
environment than wanted for these first proof-of-principle experiments.  
11.3.1 Synthesis of benzylazide-derived compound 71 
The preparation of 4-(azidomethyl) acetophenone 70 in two steps was achieved in good yields from 
4-methyl acetophenone 68 via 4-(bromomethyl) acetophenone 69 by modified literature 
procedures.395,396 It was then used to prepare  -hydroxydithiocinnamic ester derivative 71 in 
moderate yield (33 %) through the one-pot synthetic approach. By IR spectroscopy, the presence of 
the intact azido group could be proven by a strong band at  = 2098 cm-1 which represents the 
asymmetric stretching bond of the azide group and has since decades been used as a reliable 
identifier for the presence of such groups.397 The symmetric stretching bond, generally more variable 
in position (ca. 1250-1300 cm-1), is overlaid by a strong, broad band of the C=S stretching vibration at 
1228 cm-1.  
In contrast to experiences with alkynyl-derived compounds, this synthetic route proved to yield the 
target compounds without rearrangement processes or major impeding side-products.  
 
 
Scheme 15 Sequential synthesis of Compound 71 with a benzyl-azide functionality. 
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11.3.2 Reactions of compound 71 with K2PtCl4 
Preparation of the corresponding Pt(II) complexes was successful for both mono-and bis-functional 
complex types (Scheme 16).  
 
 
Scheme 16 Coordination reactions of of compound 71 towards platinum. 
The monochelate 72 was initially isolated with a crude yield of 53 %, but decomposition was 
witnessed during final purification processes (i.e. crystallization from DCM/n-hexane and further 
column chromatographic work-up) so that the final yield was significantly lowered (33 %). In a second 
attempt, by slightly altering the work-up procedure, an appreciably increased yield (82 %) of the 
product as orange needles was achieved. The molecular structure of 72 was be confirmed by single-
crystal X-ray analysis (Figure 45, left). Single crystals, despite having an appreciable appearance at 
macroscopic scale, showed substantial twinning. In several crystallization attempts, this could not be 
circumvented  therefore no bond lengths or angles are discussed in detail. Still, all desired 
functional groups, especially the intact benzyl-azide unit and the monodentate chlorido and DMSO 
ligands, the latter binding via its sulfur atom, were found and the typical square-planar coordination 
environment clearly demonstrated. 
It was unfortunately not possible to obtain MS data that corresponds to the compound or to 
characteristic fragments. The presence of the N3 group might account for this problem, or the 
complexes generally low tendency to ionize under the applied conditions. 
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Figure 45 Molecular structures of Pt(II) complexes 72 (space group P21/n, left) and 73 (space group P-1, right) obtained on 
the basis of benzylazide-based ligand 71. Structural motifs are given by ball and stick models.  
Furthermore, it was possible to isolate the respective bischelate 73 from the conversion of two 
equivalents 71 with K2PtCl4. Crystals suitable for X-ray structure analysis were obtained from 
crystallization in DCM/n-hexane (Figure 45, right). Again due to twinning effects and the flexibility of 
the azido unit, no detailed discussion of bond lengths and –angles is possible. The square-planar 
coordination environment with the (O,S) units in cis position and the intact benzyl-azide units are still 
unambiguously shown within the structural motif.  
During the course of various syntheses of this compound 73, it was noted that addition of DMSO, as 
is usually done for the synthesis of monochelates, leads to strongly raised yields also of the 
bischelate (O,S)Pt(II) complexes: Low yields of ca. 12 % were obtained without DMSO, and ca. 70 % of 
73 could be isolated when K2PtCl4 was pre-activated with 2 eq. of DMSO. Even though the formation 
of bis-functional (O,S)2Pt(II) complexes is strongly favored (which can be seen e.g. by the fact that 
bischelates are frequently formed as a side product in monochelate syntheses), incomplete 
conversion alongside with decomposition have been a problem in purposeful bischelate syntheses. 
DMSO obviously accelerates PtCl42- solvolysis and thus leads to neater conversion with subsequently 
offered donors. 
11.3.3 Stability at HPLC conditions 
Both products, 72 and 73, were thoroughly characterized by analytical methods and their stability 
towards typical rp-HPLC conditions tested. This presents a key prerequisite for subsequent 
bioconjugation and purification of such compounds.  
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When 72 and 73 were eluted in a typical water-acetonitrile buffer gradient (i.e. 100/0 to 0/100 % v/v 
water/acetonitrile) on a C8 rp column, it became apparent from their retention time that these 
compounds are significantly more soluble in the organic phase than in water (both eluted at 95-
100 % acetonitrile). Furthermore it was found that the monofunctional complex is prone to ligand 
substitution under the given conditions: additional peaks occurred in the HPLC chromatogram of 72 
at earlier retention times, i.e. more polar solvent conditions. By ESI MS analysis, these were assigned 
to species where one and two monodentate ligands had been exchanged by acetonitrile. Since it is 
assumed that this solvolysis takes place gradually during the complexes contact with acetonitrile in 
the buffer mixture, it cannot be excluded that the newly formed species peaks tailed into the peak 
of the initial complex; thus no baseline separated peaks could be obtained in the HPLC 
chromatograms and HPLC stability of monodentate (O,S) compounds can generally not be 
established.  
11.4 Preparation and derivatization of Leu5-Enkephalin 
In addition to the (O,S) units, the model peptide Enk required suitable derivatization prior to CuAAC 
reactions. The peptide was prepared by Fmoc-based solid phase peptide synthesis (SPPS) on Rink 
amide resin,317,320,322 using an automated peptide synthesizer (Scheme 17). As activator, the 
TBTU/HOBt/DiPEA method was applied.xxv Before deprotection of the Tyr1-OH group and cleavage 
from the resin, 74 was further derivatized using either pentynoic acid or azido-acetic acid to 
introduce a terminal alkyne or azide, respectively (Scheme 17). Both acids were coupled manually to 
H-Enk-Rink 74 on solid phase using the same standard coupling procedures, upon which the 
functionalized peptide was deprotected and cleaved from the resin to give C-terminal amides. The 
functionalized peptides were obtained in good yields (59 % and 84 % for 76 and 77, respectively) and 
were used for further reactions without HPLC purification since analytical HPLC proved the purity of 
the compounds to be greater than 85 %, a sufficiently high level for further reactions.  
The identity of the functionalized peptides was established from their ESI MS data, in all cases 
yielding the [M+H]+ signal. Furthermore, signals in 1H and 13C NMR spectra could, assisted by HSQC 
and HMBC experiments, unambiguously be identified.  
                                                          
xxv Abbreviations in this paragraph: TBTU: N,N,N,N-tetramethyl-O-(benzotriazol-1-yl)uronium 
tetrafluoroborate, HOBt: 1-hydroxybenzotriazol, DiPEA: diisopropylethylamine 
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Scheme 17 Solid-phase peptide syntheses of Leu5-Enk derivatives 75-77. 
Upon binding of either azidoacetic or pentynoic acid, some significant shifts are induced onto signals 
belonging to adjoining units (see Figure 46 for comparative 1H NMR data). The N-terminal NH2 of 75 
is converted to an amide-NH (a in Figure 46) and results in a slight shift to higher frequencies in both 
76 and 77 (by ca. +0.25 and +0.08 ppm, respectively). The NH of Gly2 (g in Figure 46) experiences a 
substantial shift to lower frequencies by -0.34 and -0.51 ppm in 76 and 77, respectively. The Phe1-OH 
(f in Figure 46), giving a sharp signal at 9.32 ppm in 75, is broadened and shifted by ca. -0.20 ppm 
when a termial acid is conjugated. The H of Phe1 (b in Figure 46) also experiences a substantial shift 
to higher frequencies by ca. +0.5 and by +0.43 ppm in 76 and 77, respectively. Signals of conjugated 
azido acetic acid and pentynoic acid could be witnessed and are assigned as indicated in Figure 46 (u, 
v, w). It should be noted that signal assignment of N-H and H signals deviates from data found for 
Leu5-Enk in literature.322 The here presented assignment is however strongly fortified by HSQC and 
HMBC experiments; in the latter a defined 2JCH coupling of the C(=O)-NH- groups was witnessed, 
alongside with other strongly indicative cross-peaks of H/C couplings.  
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In 13C NMR spectra of the two Enk-derivatives 76 and 77, only negligible signal shift differences are 
observed. All carbon atoms belonging to conjugated azidoacetic and pentynoic acid were identified. 
 
 
Figure 46 1H NMR spectra (400 MHz, DMSO-d6) of azido-functionalized 77 (top), unfunctionalized Enk-amide 75 (middle) 
and alkyne-functionalized 76 (bottom). Significant signal shifts in 76/77 relative to 75 are marked by grey lines. * represents 
solvent residual signals. 1H NMR spectra were recorded from peptides not subjected to HPLC purification. 
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11.5 Formation of bioconjugates via CuAAC 
11.5.1 Bischelates 
In initial experiments to form enkephalin bioconjugates via CuAAC, the (O,S)2Pt bischelate 
compounds 66 and 73 were used to establish wether a Cu(I)-catalyzed formation of triazol rings 
would in principle be possible in the presence of the essential functional groups of the (O,S) unit.  
 
Scheme 18 Combination of compounds 72 and 76 by CuAAC to give bioconjugate 78. 
First, compounds 73 and 76 were linked under Cu(I) catalysis (Scheme 18), using the combination of 
copper(II) sulfate (CuSO4) and sodium ascorbate to generate the Cu(I) species in situ, as was 
introduced by Sharpless and coworkers.362 The course of the reaction was monitored by analytical 
HPLC; the degree of conversion was indicated by reducing signal intensity of the starting material 
Enk-alkyne 76 and increasing intensity of the product peak. Conversion was complete after two days 
of stirring at room temperature. Work-up included removal of all water-soluble byproducts and 
precipitation, the pre-purified adduct was then subjected to preparative HPLC to give pure 78 in 31 % 
yield. When copper(I) iodide was used as catalyst for the reaction, the yield was lower and more side 
products were formed (based on rp-HPLC of the crude material), so that the CuSO4/ascorbate 
combination was used in subsequent experiments.  
Furthermore, compounds 66 and 79 were successfully combined under similar conditions to give 79 
(Scheme 19). The conversion was, however, markedly lower and more side products were formed, as 
was established from analytical HPLC of the crude material. This combination was, not only because 
of the lower yields but also due to the above-described difficulties with alkyne-derived (O,S) 
compounds, not used in following experiments. 
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Scheme 19 Combination of compounds 66 and 77 by CuAAC to give bioconjugate 79. 
11.5.2 Monochelates 
Subsequently, the bioconjugation of the monofunctional Pt(II) complex 81 was attempted. Two 
pathways are in principle thinkable for this endeavour (Scheme 20):  
a) linking of a monofunctional Pt(II) complex towards the Enk derivative, and  
b) linking of the respective ligand by CuAAC, followed by coordination towards the Pt(II) center.  
The first-mentioned option was found to be less promising, since Cu(I/II) could partially stand in 
concurrence to Pt(II) coordination. Furthermore could the HPLC-chromatographic work-up lead to 
ligand substitution of the monodentate ligands, leading to various solvolysis products. The second 
option, on the contrary, was expected to also lead to possible copper complexes, which might albeit 
be cleavable by addition of proper copper chelators. Subsequent Pt(II) coordination could lead to 
monofunctional Pt(II) complexes with a defined set of monodentate ligands which could either be 
conserved by circumventing HPLC workup through alternative work-up techniques or could 
selectively be exchanged by HPLC-stable ligands. 
Indeed, when the monofunctional Pt(II) complex 72 was combinded with 76 under influence of 
CuSO4 and ascorbate, it was not possible to isolate a pure compound. A plethora of signals was 
observed in HPLC chromatograms of the reaction mixture, and the main peaks that were isolated 
could not be identified as Pt(II) containing bioconjugates. In fact, the isotopic pattern which was 
observed in ESI mass spectra of several peaks rather pointed to copper-containing adducts than 
towards the presence of Pt(II) in these samples. It was not possible to clearly identify the formed 
products, but obviously this approach was not going to lead to the desired bioconjugates.  
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Scheme 20 Pathways towards bioconjugate 81 via CuAAC. 
When following the second approach, i.e. linking of 76 with the azide-derived ligand 71 through 
CuAAC, it was necessary to use more than 1 mol-eq. of CuSO4 for a successful conversion of the 
reactants  the usage of the typical 0.2 eq. (or less) of CuSO4 did not lead to sufficient conversion of 
the starting materials. Obviously, one eq. of copper was indeed consumed through coordination 
towards the (O,S) chelating unit. The starting materials were consumed after two days, and the 
addition of excess Na2EDTA (disodium ethylendiamine tetraacetate) lead to reversal of Cu-(O,S) 
chelation. The water-soluble Cu-EDTA complex was conveniently removed from the mixture through 
liquid-liquid extraction. Purification by rp-HPLC lead to pure bioconjugated -hydroxydithiocinnamic 
ester 80 in appreciable yields (42 %).  
Purified 80 was then used to prepare 81 by conversion with K2PtCl4 and DMSO by adapting the 
established protocol for small-molecule complex formation. After a reaction time of one day, crude 
81 was obtained and purified by repeated extraction and precipitation steps. According to ESI MS 
analysis, the presence of DMSO and chloride as monodentate ligands was confirmed.  
1H NMR spectra of 80 and 81 were recorded in DMSO-d6 and are shown comparatively in Figure 47 
with the starting material 76 as reference. Signal assignment was confirmed through HSQC and 
HMBC experiments. Upon formation of the triazole by CuAAC, the signals belonging to pentynoic acid 
in 76 are shifted in 80, its -CH2 group appearing at 2.76 ppm, thus shifted by ca. +0.5 ppm to higher 
fields. The newly formed methine group of the triazol linker (w in Figure 47) appears at 7.79 ppm. 
The OH proton of the free -hydroxydithiocinnamic unit is clearly observable at high field 
(15.15 ppm). Upon coordination towards the Pt(II) unit, this signal is lost and a typical shift of the 
methine proton belonging to the (O,S) unit (4 in Figure 47) by ca. +0.05 ppm is witnessed so that it 
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appears together with aromatic signals of Phe4. Even though ESI mass spectral data proved the sum 
formula to include DMSO and chloride, the signal of Pt-coordinated DMSO is not detected in the 
1H NMR spectrum of 81 due to gradual exchange with its deuterated equivalent.xxvi  
 
 
Figure 47 1H NMR spectra (400 MHz, DMSO-d6) of Pt(II) complex 81 (top), the ligand with triazole linker 80 (middle) and the 
starting material, alkyne-derived Leu5-Enk 76 (bottom). The signal of Pt-coordinated DMSO is not witnessed in the spectrum 
of 81 due to a gradual exchange by DMSO-d6.  
                                                          
xxvi Data recording in an alternate solvent, such as THF-d8, would have been favourable. Unfortunately, 
compounds 76 and 80 were not soluble in THF-d8 enough for appreciable signal intensity. For the sake of better 
comparability, spectra of 81 were therefore also recorded in DMSO-d6. 
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12 BIOCONJUGATES VIA AMIDE BOND FORMATION 
12.1 Ligand and complex synthesis 
As described above, incorporation of a carboxy group into subunits of the chelating ligand might 
enable bioconjugation through formation of amide bonds.  
 
 
Scheme 21 Preparation of compounds 82 and 83 with a carboxylic group at the dithioester unit. 
For that reason, 4-bromo acetophenone was converted with CS2 and bromoacetic acid to form the 
-carboxyethane derived -hydroxy dithiocinnamic ester 82 in good yields via the one-pot approach 
(Scheme 21). The successful synthesis of this compound was proven by standard analytical methods 
as well as by X-ray crystallographic data.  
In crystals of 82, the molecules are arranged in a catamer-type398 array through intermolecular 
hydrogen bonds of the molecules carboxy groups (d(O···O) =2.675 Å), leading to band-like secondary 
structures in the unit cell. The molecule is flat, with only the carboxy function protruding from the 
molecular plane. The stabilization of the cis-conformation in the (O,S) unit through intramolecular 
hydrogen bonding is clearly demonstrated by the structural data. Furthermore, the -hydroxy / 
dithiolato structural motif is undoubtedly shown from the bond lengths of the O3-C5=C4-C3=S2 unit, 
which are typical for O-Csp2 and Csp2-Csp2 single bonds (d(O3-C5) = 1.323(3) Å; d(C4-C3) = 1.431(3) Å) 
and Csp2=S and Csp2=Csp2 double bonds (d(C3-S2) = 1.671(2) Å; d(C5-C4) = 1.375(3) Å) in the expected 
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positions. This structural feature is furthermore confirmed by the sharp singlet signal at 15.02 ppm in 
the ĐoŵpouŶd’s 1H NMR spectrum which can be attributed to the β-OH proton being involved in 
intramolecular hydrogen bonding.105,399  
 
 
 
Figure 48. Molecular structure (left) and catamer-type arrangement (right) in single crystals of carboxy-derived compound 
82. The Structure is depicted in thermal ellipsoids at 50 % propability level. Space group: P212121. 
Also the respective monofunctional (O,S) complex 83 (Scheme 21) was successfully prepared by 
slightly modifying the coordination protocol: no base was used for deprotonation of the β-hydroxy 
group, since this was expected to preferentially deprotonate the β’-carboxy group, thus enabling 
unforeseeable side reactions. Analytical data of the isolated product proved the selective 
coordination of the ligand via the (O,S) unit and not through atoms of the newly introduced carboxy 
function. NMR spectroscopic and mass spectrometric data showed the chloride and DMSO ligands to 
be bound according to the established binding mode. 
12.2 Formation of amide bonds 
Subsequently, the formation of amide bonds was attempted for both 82 and the respective complex 
83 by coupling in solution (Scheme 22). A slight excess (1.1 eq.) of the carboxy-functionalized 
monomer was used. TBTU400 and DiPEA were used as coupling reagents, no HOBt was applied – as 
would usually be the case in solid phase coupling: Compound 82 does not contain a stereo center 
and thus does not require the racemization-supressing additive HOBt.401 Amide bonds were 
successfully formed within 2 h of coupling.   
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Scheme 22 Synthetic approaches towards (O,S)Pt bioconjugates through amide bond formation. When subjecting 83 to 
standard coupling contiotions, 85 could not be not isolated. Instead, 86 is formed with a mixture of monodentate ligands 
X/Y; amongst them HOBt which is formed from TBTU under coupling conditions (vide infra). 
By this method, compound 84 was isolated in good yields (38 %) and purity (>95 %) after preparative 
rp-HPLC. Its identity, purity and structure could be established through ESI MS and 1H NMR analysis 
(vide infra).  
Coupling of the complex 83 by the same method was successful in retaining the Pt(II) center within 
the coordination sphere (86, Scheme 22). The monodentate ligands DMSO and chloride, however, 
were partially substituted by HOBt, a side product which is released from the coupling reagent TBTU 
during the coupling reaction (Scheme 23).375377 A mixture of different substitution products was 
obtained as crude material, HPLC-based analysis of 86 revealed several fractions of complexes 
containing DMSO, HOBt or CH3CN (from HPLC) as monodentate ligands (Scheme 24).  
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Scheme 23 Mechanism of activation of carboxylic acids through TBTU for the formation of amide bonds. Upon amide bond 
formation, HOBt is liberated.  
 
Scheme 24 Possible formation of HOBt complexes by the applied coupling procedure. 
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In an alternate approach to isolate the desired Enk-derived (O,S) bidentate Pt(II) complex with DMSO 
and chlorido ligands, 84 was converted with K2PtCl4/DMSO under the same conditions as used for the 
clicked bioconjugate system (Scheme 22). By precipitation from water and applying repeated steps 
of washing with water and diethyl ether, the desired complex 85 was successfully isolated. 
Coupling in solid phase was not attempted after these positive findings, since the necessary cleavage 
step, involving the use of TFA, was expected to lead to decomposition of the chelating unit resp. the 
resulting complexes. Indications for such an outcome had been observed in an initial NMR-based 
study on the stability of a model compound in presence of 50 vol-% TFA: the half-life of the 
complexes was found to be about 2 h, with first indications of decomposition appearing already after 
40 min (cf. experimental section).  
12.2.1 HOBt coordination 
HOBt has been found to coordinate transition metals in various models, however these usually 
involved Ni(II), Cu(II) and other early transition metals.402404 There is only one Pt-HOBt complex 
reported in literature to date.405 In these reports, it was demonstrated from X-ray crystallographic 
studies that both O- and N- coordination can occur at the same time.  
To check if a ligand exchange of chloride and/or DMSO by HOBt would take place also under non-
coupling conditions, simply through the presence of HOBt, a model reaction was performed (Scheme 
25). Compound 34, the homologous monochelate to 83 without the carboxy functionality, was 
stirred in DMF in presence of two equivalents of HOBt. Subsequent column chromatographic work-
up and analysis by ESI mass spectrometry and 1H NMR spectroscopy (Figure 49) showed that both 
monodentate ligands had been replaced by HOBt in 87.  
 
 
Scheme 25 Substitution of the monodentate chlorido and DMSO ligands by HOBt to give a (O,S)Pt(HOBt)2 compound with a 
proposed coordination environment as given for 87. 
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Figure 49 Left, selected regions of the 1H NMR spectra of 87 (in CD3OD, 200 MHz) in comparison with the starting 
compound 34 (in CDCl3, 400 MHz). Loss of DMSO is clearly demonstrated; detailed analysis of the aromatic region is not 
possiďle due to the ĐoŵpleǆitǇ of the ĐoŵpouŶd’s stƌuĐtuƌal featuƌes. * ŵaƌk solǀeŶt ƌesidual sigŶals. Right, ĐoŵpaƌisoŶ of 
the experimental vs. theoretical ESI MS signal of the [M+H]+ signal of (O,S)Pt(HOBt)2 compound 87. 
Signals in 1H NMR spectra were, however, not clearly assignable since in the aromatic region multiple 
signals overlay. It is on the contrary obvious that DMSO has been released from the system. Even 
though no crystals suitable for X-ray crystallography were obtained, it can be assumed that HOBt 
coordinates towards Pt(II) in two different modes when presupposing the formation of an overall 
neutral complex: Since the (O,S) unit is negatively charged, one excess positive charge has to be 
neutralized by the newly introduced ligands. HOBt itself bears three possible donor sites, namely two 
N and one OH group. It is thus reasonable to assume that one HOBt is coordinated through oxygen 
after deprotonation of the same, and the other HOBt molecule should bind via a nitrogen atom; most 
probably N3. This versatile coordination behavior certainly contributes to the complex signal pattern 
in 1H NMR spectra.  
A short note should be given on the used deuterated NMR solvent: the isolated compound was 
readily soluble in ethanol but only moderately soluble in methanol-d4. Even though it should be well-
soluble in acetonitrile or DMSO, use of these solvents was avoided due to the known coordinating 
properties of both towards the Pt(II) center in this peculiar system. Therefore signal intensity in the 
NMR spectra of 87 is low and intrinsic impurities of the solvent obscure the signals.  
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12.3 Analysis of the amide-linked bioconjugates 
Compounds 84 and 85 were analyzed by ESI MS analysis and NMR spectroscopy. The resulting data 
can be found in Figure 50 and Figure 51. 
ESI MS analysis provided evidence for the sum formulae of both compounds, the isotopic patterns 
matched the calculated ones well: For 84, the [M+H]+ ion was found at m/z = 868.8, and for 85, the 
[M+K]+ ion was detected at m/z = 1214.9 (Figure 50).xxvii 
 
  
Figure 50 Comparison of ESI+ MS spectral profiles of 84 (left) and 85 (right). Top, experimental data, bottom, simulated 
pattern.  
Furthermore, 1H NMR spectra of 84 and 85 were recorded in THF-d8 and gave all expected signals of 
Leu5-Enk. Comparative NMR spectra are given in Figure 51. 
A 1H NMR spectrum of Enk 75 was also recorded in THF-d8 to enable a direct comparison between 
the compounds in the same solvent. Solubility of unfunctionalized Enk is, however, very low in 
THF-d8 so that only signals in the aromatic region can be clearly seen in this experimental setup; 
signals in the aliphatic region are in part obscured by solvent signals. When comparing the 1H NMR 
spectrum of 75 in THF-d8 towards the one recorded in DMSO-d6 (vide supra) or other 
solvents,351,320,317,322 it becomes apparent that the solvents influence on chemical shifts and visiblitiy 
of acidic protons is substantial.  
  
                                                          
xxvii The peak positions of the MS signals discussed in this chapter generally deviate from the theoretical values 
since the used ESI MS device is not laid out for high-resolution ESI MS data collection. Still, the isotopic profiles 
are clearly indicative of the proposed sum formulae. 
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Figure 51 Comparison of 1H NMR spectra of Leu5-Enk 75 (top/violet), ligand 84 (second, petrol), complex 85 (third, green) 
and complex 83 (bottom, red). Spectral range of 3-9 ppm given, the full spectral range can be found in Figure S 16. All 
spectra were recorded in THF-d8. Asterisks mark residual signals. Below: representative signal assignment, demonstrated on 
compound 85. 
Massive shifts of the amide protons are observed by the change of solvents, and a definite 
assignment of all NH protons was not feasible for the 1H NMR spectrum of free Enk 75 in THF-d8.  
Amide bond formation of the initially terminal NH2 group was still demonstrated by appearance of a 
sharp doublet assignable to the Leu5-NH signal at 8.20 ppm in spectra of 84 (a in Figure 51), together 
with massive shifts of all other NH protons compared to those in 75. Furthermore, all characteristic 
signals for the β-hydroxydithiocinnamic unit were found, alongside with a splitting of the S-CH2 signal 
at 4.11 ppm into a doublet of doublets (4 in Figure 51), indicative of  
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a) the formation of an amide bond in close proximity to this CH2 group, and  
b) of a significant sterical crowding around this group, inhibiting rotation and therefore 
creating diastereotopic effects.  
Upon binding of 84 towards the Pt(II) center to give 85, the signal belonging to the methine proton 
experiences the typical shift to higher frequencies (+0.17 ppm from 7.17 in 84 to 7.34 ppm in 85, 3 in 
Figure 51). From HSQC experiments, the presence of Pt-bound DMSO could also be proven from the 
characteristic 1JCH cross-peak at 3.63/46.4 ppm. This signal was not directly witnessed in the 1H NMR 
spectrum due to an overlay with the intrinsic THF-d8 signal.  
Recording of 13C NMR spectra was not possible due to the low quantities available, but indirect 
measurement through HSQC experiments gave the signal positions of the most important 
characteristic peaks. 
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13 BIOACTIVITY OF THE PLATINUM-PEPTIDE 
BIOCONJUGATES 
13.1 Triazol-linked compounds 
The pƌepaƌed ͞ĐliĐk͟ ĐoŵpouŶds ǁeƌe eǆaŵiŶed foƌ theiƌ ďiologiĐal aĐtiǀitǇ toǁaƌds seleĐted ĐaŶĐeƌ 
cell lines. A first screening of the compounds in this series showed that IC50 values of bioconjugates 
and precursor molecules were in most cases too high to be considered bioactive; only the 
monochelate 72 aŶd the ĐoƌƌespoŶdiŶg ͞sŵall-ŵoleĐule͟ ligaŶd 71 showed antiproliferative activity 
with some IC50 values determined below 100 µM (Figure 52). For this reason, the cell tests on these 
compounds were only carried out once; the depicted values merely embody an orientation and do 
not represent statistically verified IC50 values. 
 
 
Figure 52 Preliminary IC50 values of the bioconjugates obtained from CuAAC and their precursor compounds. Bars are cut 
off above a determineable IC50 of 250 µM. A biological standard deviation is not available. 
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The apparent lack of biological activity of these compounds could be explained by the choice of 
peptide vs. the investigated cell lines: Enk 75, being a ligand for opioid receptors, may be selectively 
taken up by cells expressing those receptors, and might be excluded from other cells. The cell lines 
that were available for the here described studies, however, are not known to express this receptor.  
Since the aim of this study was to establish the possibility of bioconjugation of Pt(II) compounds with 
ligands based on β-hydroxydithiocinnamic esters in principle, these data do not necessarily represent 
a draw-back. They merely demonstrate that for these cell lines, the proper chaperone is not 
Enkephalin.  
13.2 Amide-linked compounds 
The amide-linked compounds were also screened once for their potential cytotoxic properties (Figure 
53). The obtained preliminary IC50 values of 84 and 85, albeit lower than those of the triazol-linked 
compounds, are still too high to consider them cytotxic.  
 
 
Figure 53 Preliminary IC50 values of the bioconjugates 84 and 85 obtained through amide bond formation and their 
precursor compounds 82 and 83. Bars are cut off above a determineable IC50 of 250 µM. A biological standard deviation is 
not available. 
Interestingly, very low concentrations of 82 were found to be effective against the tested cell lines. 
This might in part be associated with the enhanced hydrophilicity of this compound – the logPo/w 
value of its ligand 82, determined alongside with the earlier discussed compounds 7-28, was found to 
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be the lowest in the series (logPo/w = 1.11). Compound 82 produced the strongest cellular response, 
irrespective of the used cell line, with preliminary IC50 values of 1-6 µM. This interesting finding 
indicates that the structure of this purely organic unit might represent a potent substrate for a vital 
cellular target and might be investigated in more detail in future experiments. 
 

  
 
 
14 DISCUSSION 
It was shown that the formation of bioconjugates through CuAAC is in principle possible by utilization 
of both azide/alkyne combinations by the successful preparation of peptide-conjugated (O,S)2Pt(II) 
bischelates 78 and 79. One approach should however be preferred: When introducing the azide 
group into the (O,S) unit (73) and deriving the peptide with pentynoic acid to give a terminal alkyne 
(76), far less synthetic obstacles were encountered along the way to compound 78 as opposed to the 
complimentary combination to give 79: Alkyne-derived -hydroxydithiocinnamic esters 54, 55, 57, 
and 59 could be isolated but coordination towards platinum resulted in a variety of side reactions 
such as hydrogenation of the CC triple bond or uncontrolled rearrangements. Only bischelates of 
compounds 54, 55 and 59 were obtained, no monochelate complex was isolated that still contained 
the alkynyl group. On the contrary, the synthesis of the benzylazide-derived series 71, 72 and 73 was 
straight-forward and yields were generally higher than for the alkyne series. CuAAC of the two units 
73 and 76 furthermore lead to a cleaner reaction (less side products were formed) and a higher yield 
of purified bioconjugate 78 than the opposite combination (i.e. 66+75 to give 79). It is therefore the 
preferred set-up for further experiments. 
In efforts to obtain the respective monochelate 81, first CuAAC was performed with the ligand 71 
and Enk derivative 76 using the classical CuSO4/ascorbate catalyst combination, followed by 
quantitative removal of copper through addition of EDTA. Subsequently, the Pt(II) unit could be 
introduced into the system by an adaption of the complexation procedure frequently used for small-
molecule complexations. Since the resulting product is not stable to classical rp-HPLC conditions, it 
was purified by repeated precipitation. NMR- and ESI MS analysis could however prove the identity 
of the compound and also showed that the compound was sufficiently pure. 
Furthermore, it was found that a direct conjugation of the (O,S) chelating unit through an amide 
bond is possible. Carboxy-derived precursor molecules were prepared and both the ligand 82 and the 
(O,S)Pt monochelate 83 were coupled to Leu5-Enk in solution. Since coupling of 83 under standard 
TBTU-based coupling conditions resulted in a ligand exchange of chloride and DMSO by 
intermediately formed HOBt in 86, the desired Pt(II) complex was prepared by introduction of the Pt 
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center after bioconjugation. Also in this case, NMR and ESI mass spectroscopic methods proved the 
formation of the desired compound.  
Preliminary results of the compounds cytotoxic potential were obtained from the resazurin-based 
PrestoBlue® assay. It was found that the bioconjugates are not active towards the selected cancer 
cell lines in a measure to consider them cytotoxic. The small units proved to be more active than the 
bioconjugated structures, with the purely organic 82 being the most cytotoxic compound measured 
under these experimental conditions. This overall finding is not considered a negative result per se, 
since none of the used cell lines overexpress a receptor for Enk: The rationale for the use of this 
model peptide laid in its function as a well-established and understood model peptide rather than 
in its potential targeting abilities. 
  
 
EXPERIMENTAL PART 
 
 
 
Experimental work presented in this thesis has been carried out in different laboratories in Jena (D), 
Bochum (D) and Florence (IT): 
Syntheses of small-molecule -hydroxydithiocinnamic esters and their corresponding (O,S)Pt 
complexes were carried out at Friedrich-Schiller Universität Jena, IAAC (Institut für Anorganische und 
Analytische Chemie), under supervision of Prof. Dr. W. Weigand. 
Syntheses of peptides and bioconjugates, including selected precursors, were executed at Ruhr-
Universität Bochum, LS AC1 (Lehrstuhl für Anorganische Chemie I - Bioanorganische Chemie), under 
supervision of Prof. Dr. N. Metzler-Nolte. 
Biological assays were carried out at FSU Jena, IZKF (Interdisziplinäres Zentrum für Klinische 
Forschung), under supervision of Dr. J. Clement (2009-2013) and at RU Bochum, LS AC1, under 
supervision of Prof. Dr. N. Metzler-Nolte (2014-2015). 
Biomolecule interactions were investigated at Università degli Studi di Firenze, Laboratory of metals 
in medicine, under supervision of Prof. Dr. L. Messori. 
 

  
 
 
15 SYNTHESES: GENERAL REMARKS 
15.1 Syntheses of compounds based on the -hydroxydithiocinnamic 
ester structural motif 
Syntheses were carried out under argon or nitrogen atmosphere using conventional Schlenk 
techniques when stated in the general procedures, otherwise standard air-exposed methods were 
used.  
Most starting materials and solvents were purchased from common suppliers (ABCR, Acros, Aldrich, 
Fluka, Merck, SigmaAldrich, and TCI). Starting materials were usually obtained in the highest 
available purity grade (analytical or ACS grade). Solvents were of technical grade or higher and were 
dried according to known procedures406 and distilled prior to use when required. For air-exposed 
syntheses, they were used as received. For column chromatography, Silica gel of the type VWR 
Kieselgel 60 was used. 
15.2 Peptide syntheses 
All chemicals and solvents used for peptide syntheses were of analytical reagent grade or better and 
purchased from Novabiochem (Bad Soden, Germany), Iris Biotech (Marktredwitz, Germany). 
Dimethyl formamide (DMF) was purchased from Biosolve (Valkenswaard, NL) or Fisher scientific 
(Schwerte, D) and of peptide synthesis grade. HPLC-grade acetonitrile was purchadsed from VWR or 
Fisher Scientific. Water was purified by a milliQ purification system. 
A Fmoc-Rink-Amid AM resin407 (Iris Biotech Br-1330.0025, in 100-200mesh) was used with loadings of 
0.59 or 0.71 mmol/g.  
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All solid phase syntheses were carried out according to standard solid phase peptide synthesis 
procedures (SPPS, GP12) using the Fmoc- protection approach with HOBt/TBTU as coupling 
reagents.400,401,408,409 Leu5-Enk was synthesized using an automated peptide synthesizer (CEM Liberty 
microwave assisted peptide synthesizer) in a 250 µmol scale. Further derivatization was performed 
manually using plastic syringes with a filter disc made of polypropylene as reaction vessels following 
GP12. 
NMR signal assignment of peptide data was based on HSQC and HMBC experiments. In some cases, 
direct measuring of 13C NMR data was not possible due to low available sample quantity, but 
13C NMR data could be deduced from cross-peaks of HSQC and HMBC experiments. 
15.3 Literature-reported syntheses 
Acetophenone derivatives 1, 2, 5 and 6 were obtained from commercial suppliers. Derivatives 3 and 
4 were prepared according to literature procedures.105,106  
-Hydroxydithiocinnamic esters 7,103 11,102 14,107 15,106 19,105 23,106 26105 have been reported in 
literature. Syntheses and characterizations of compounds 8, 10, and 12, have for the first time been 
executed during the diploma project and are reported in the corresponding publication.118 For this 
research project, all syntheses of previously reported -hydroxydithiocinnamic esters were repeated 
following GP3.  
The preparation of Pt(II) complexes 29, 30, 32-34, 36, and 49 has been performed for the first time 
during the diploma project. Details are reported in the corresponding publication.118 Syntheses have 
been repeated for this project by following GP5 or GP7. 
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4-(Prop-2-inyloxy)acetophenone 51 was prepared according to literature procedures379 following 
GP1. 
Azidoacetic acid was kindly provided by Martin Strack (Bochum) and has been prepared according to 
literature procedures.410 
15.4 Analytical methods and devices 
Melting points were determined on a Stuart melting point SMP3 or using a polarization microscope 
Axiolab (Zeiss Jena GmbH) equipped with a heating plate THMS 600 and control devices LNP and CI 
93 (Linkam). All values are uncorrected.  
Elemental analyses (C, H, N, S) were carried out on a LECO CHNS-931 instrument (Jena) or a 
Elementar Hanau vario EL device (Bochum). Obtaining proper elemental analyses of (O,S)Pt 
complexes proved to be difficult since the simultaneous presence of the elements Pt, S (and Si in 
some cases) lead to the formation of various undetectable or false-detected combustion products. 
Results are represented in the form: 
 Sum formula (molar weight in g/mol): element, percentage (in %). 
 
NMR-Spectra (1H-, 13C{1H}-, 31P{1H}-, H,H-COSY, HSQC, HMBC) were recorded on different devices and 
operating at different frequencies as listed below. 
 Spectrometer 1H 13C 
Jena Bruker AVANCE 200 200.13 MHz 50.33 MHz 
 Bruker AVANCE 400 400.00 MHz 100.63 MHz 
 Brukere ultrashield+ AVANCE 600 600.13 MHz 150.94 MHz 
Bochum Bruker DPX200 200.13 MHz 50.32 MHz 
 Bruker DPX250 250.13 MHz 62.9 MHz 
 Bruker DRX400 400.13 MHz 100.61 MHz 
 
Chemical shifts  are given in ppm relative to TMS. The undeuterated residues of the deuterated 
solvent served as an internal standard in 1H and 13C{1H} NMR spectra.   
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In some cases, signals are obscured by solvent residual signals (SRS). Signal assignment was 
confirmed by H,H COSY, HMBC and HSQC experiments. Signals are given in the following form: 
1H NMR spectra: chemical shift  in ppm (multiplicity, coupling constant, number of hydrogen 
atoms, assignment). 
13C{1H} NMR spectra: chemical shift  in ppm (multiplicity, coupling constant, assignment). 
 
Mass spectra were recorded on different instruments listed below.  
 device ionization source notes 
Jena Finnigan MAT SSQ 710  FAB / DEI  
 Finnigan MAT95XL ESI high-res 
Bochum Bruker Esquire 6000 ESI  
 
Peaks are given in the form:  
 fragment m/z [assignment]. 
 
FT-IR spectra were measured on different devices listed below 
 device  form 
Jena Perkin-Elmer 2000  pressed discs (KBr) 
 Bruker Equinox 55 FRA 106/5 Specac Golden ATR unit ATR 
Bochum Bruker Tensor 27 Pike MIRacle micro ATR unit ATR 
 
Signals are given in the form:  
 Wave number  in cm-1 (intensity). 
15.5 X-ray data collection and structure solution refinement 
Crystals of 50 were obtained by Matthias Hartlieb by evaporation of the solvents used for column 
chromatography, dichloromethane and hexane. 
Crystals of 72, 73 and 82 were grown by slow diffusion of hexane into solutions of the compounds 
dissolved in chloroform or dichloromethane.  
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Crystal structure collection and data refinement of compound 50 was executed by Helmar Görls 
(University Jena); for 72, 73 and 82 samples were processed by Ulf-Peter Apfel (University Bochum). 
Detailled crystallographic data is given in Supplement A. 
Data collection and refinement of compound 50 
The intensity data were collected on a Nonius KappaCCD diffractometer using graphite-
monochromated Mo-Ka radiation. Data were corrected for Lorentz effects, polarization effects and 
for absorption effects.411413 The structure was solved by direct methods (SHELXS)414 and refined by 
full-matrix least squares techniques against Fo2 (SHELXL-97).414 All hydrogen atoms were included at 
calculated positions with fixed thermal parameters. All non-disordered, non-hydrogen atoms were 
refined anisotropically.414  
Data collection and refinement of compounds 72, 73 and 82 
Single crystals suitable for X-ray analysis were coated with Paratone-N oil, mounted on a fiber loop, 
and placed in a cold, gaseous N2 stream on a Rigaku XtlabMini diffractometer performing   and ! 
scans at 170(2) K. Diffraction intensities were measured using graphite-monochromatic Mo K" 
radiation (# = 0.71073 Å). Data collection, indexing, initial cell refinements, frame integration, final 
cell refinements, and absorption corrections were accomplished with the program CrystalClear.415 
Space groups were assigned by analysis of the metric symmetry and systematic absences 
(determined by XPREP) and were further checked by PLATON416,417 for additional symmetry. 
Structures were solved by direct methods and refined against all data in the reported 2$ ranges by 
full-matrix least squares on F2 with the SHELXL program suite414 using the OLEX2 interface.418  
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15.6 General synthetic procedures 
General procedure 1 (GP1):  
Williamson ether synthesis of alkinyl-derived acetophenones  
4-Hydroxyacetophenone (1 eq., typically 2 g) and potassium carbonate (K2CO3, 1.5 eq.) or caesium 
carbonate (Cs2CO3, 1.5 eq.) are suspended in 10 mL anhydrous DMF and stirred at r.t. for 10 minutes. 
Subsequently, the alkinyl halide (1.2 eq.) is added and the mixture stirred at room temperature for at 
least 24 h. The suspension is treated with 5-10 mL ice-cold water and the white precipitate washed 
with ice-water. Purification is achieved by crystallization from methanol.  
General procedure 2 (GP2):  
Williamson ether synthesis of alkinyl-derived acetophenones 
4-Hydroxy acetophenone (1 eq., typically 1 g), Cs2CO3 (1.5 eq.), potassium iodide (KI; 0.1 eq.) and 
butinyl bromide (1.1 eq.) are suspended in 30 mL acetonitrile and stirred at reflux for 20 h. After 
cooling to room temperature, 10 mL water and 10 mL ethyl acetate are added. The phases are 
separated, extracted with ethyl acetate (3 x 5 mL) and the combined organic phases washed with 
water (2 x 5 mL). The organic solvents are dried over sodium sulfate and then evaporated.  
General procedure 3 (GP3):  
Synthesis of -hydroxydithiocinnamic acid esters  
The synthesis requires inert working conditions. The desired acetophenone derivative (ca. 2 g, 1 eq.) 
is dissolved in dry diethyl ether (40 mL) and transferred into a precooled suspension of potassium-
tert-butoxylate (KOtBu, 2 eq.) in dry diethyl ether (40 mL) at -78 °C. Carbon disulfide (CS2, 1.4 eq.) is 
added dropwise to the solution under vigorous stirring, the mixture maintained at -78 °C for 3 hours 
and allowed to warm up to room temperature. After adding the alkyl halide (0.9-1 eq.), the mixture is 
stirred protected from light at room temperature for further 15 hours.  
Subsequently, the suspension is acidified with sulfuric acid (50 mL 2 M aqueous solution), leadig to a 
two-pased system of an organic and aqueous phase which are then separated. The aqueous phase is 
extracted with dichloromethane (3 ´ 5 mL), the combined organic solutions washed with water (3 ´ 
5 mL), and dried with sodium sulfate.  
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After filtration, the crude product is obtained which is usually purified by column chromatography on 
silica gel (eluent: dichloromethane/n-hexane in varying ratios). 
General procedure 4 (GP4):  
Cleavage of the O-TBDMS group 
The reaction is performed under inert conditions. The O-TBDMS protected compound (1 eq, 3 mmol) 
is brought to reaction with tetrabutyl ammonium fluoride (TBAF, 2 eq., 1 M in THF) in THF (ca. 50 mL) 
and stirred for several days until TLC control shows consumption of the starting material (usually 5 to 
6 days). Then, the mixture is acidified using H2SO4 (2 M aqueous solution) and stirred for 3 h. The 
evolving two-phased system is separated, the aqueous phase extracted with chloroform (3 ´ 10 mL), 
the combined organic phases washed with water (3 ´ 10 mL) and dried with sodium sulfate. The 
crude material is further purified as described separately for each compound. 
General procedure 5 (GP5):  
Monofunctional complexes using NaOAc as base 
The -hydroxydithiocinnamic acid ester (1 eq., dissolved in 30-50 mL THF), is stirred for 30 min with 
sodium acetate (1 eq. in ca. 9 mL THF/water (7:2)). Potassium tetrachloro platinate (K2PtCl4; 1.1 eq., 
typically 200 mg) is dissolved in 2 mL water and dimethyl sulfoxide (DMSO; 2 eq.) is added. Within 
30 minutes, a white precipitate is formed. The solution of the deprotonated -hydroxydithiocinnamic 
acid ester is slowly added and the mixture and stirred at room temperature overnight. The resulting 
red-orange solution is concentrated and extracted with DCM (3 ´ 4 mL). The combined organic 
phases are washed with water (2 ´ 3 mL) and dried over sodium sulfate. Purification is typically 
performed via column chromatography on silica gel as described individually for each compound. 
General procedure 6 (GP6):  
Monofunctional complexes using KOtBu as base 
The synthesis is conducted in analogy to GP5 under usage of potassium tert-butoxide (KOtBu) as 
base. The reaction was either carried out under normal atmosphere, using standard solvents or 
under nitrogen atmosphere and usage of dry/degassed THF as well as degassed water as stated 
individually. 
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General procedure 7 (GP7):  
Monofunctional complexes using NaH as base 
Working in analogy to GP5, the synthesis is carried out under argon or nitrogen atmosphere. NaH 
(60 % susp. In mineral oil, 1 eq) is used as a base. Deprotonation takes place in dry THF, degassed 
water is used to dissolve K2PtCl4.  
General procedure 8 (GP8):  
Synthesis of bischelate complexes 
-Hydroxydithiocinnamic acid ester (2 eq., in 30 mL THF), is deprotonated by addition of NaOAc 
(1 eq. in 7 mL THF and 2 mL water). After 30 min of stirring at room temperature, K2PtCl4 (1 eq., 
typically 100 mg dissolved in 2 mL water) is added and the mixture stirred overnight. The crude 
product is obtained by evaporation of the solvent in vacuo, followed by extraction with DCM (3 ´ 
4 mL), washing with water (3 ´ 3 mL) and drying with sodium sulfate. 
General procedure 9 (GP9):  
Copper-catalyzed 1,3-dipolar azide-alkyne cycloaddition (CuAAC) of (O,S)Pt(II) 
complexes and Enk derivatives 
The complimentary compounds, one containing the alkyne and one containing the azide group (1:1 
ratio of functional groups, 1 eq. = 1 functional group pair; FGP), are dissolved in a THF / water 
mixture (ca. 7 mL 5:2 ratio) and degassed for at least 30 min by an Ar-stream. Sodium ascorbate 
(0.4 eq./FGP, 0.1 or 1 M aqueous solution) and CuSO4·5 H2O (0.2 eq./FGP, 0.1 M aqueous solution) 
are added to initiate the reaction. The mixture is stirred at r.t. until no further conversion of the 
starting materials was observed according to HPLC analysis. Work-up is performed individually for 
each compound and includes precipitation from diethyl ether and / or preparative HPLC.  
General procedure 10 (GP10):  
Copper-catalyzed 1,3-dipolar azide-alkyne cycloaddition (CuAAC) of -
hydroxydithiocinnamic esters and Enk derivatives 
The complimentary compounds, one containing the alkyne and one containing the azide group (1:1 
ratio of functional groups, 1 eq. = 1 FGP), are dissolved in a THF / water mixture (ca. 7 mL 5:2 ratio) 
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and degassed for at least 30 min by an Ar-stream. Sodium ascorbate (2.4 eq./FGP, 1 M aqueous 
solution) and CuSO4·5 H2O (1.2 eq./FGP, 0.5 M aqueous solution) are added to initiate the reaction. 
The mixture is stirred at r.t. until HPLC control shows consumption of the starting materials. To 
remove the copper salts, sodium ethylenediamine tetraacetate (Na2EDTA, 2.5 eq./FGP, 0.1 M 
aqueous solution) is added and the mixture stirred overnight. Work-up is performed individually for 
each compound and includes removal of Cu(EDTA), precipitation from diethyl ether and / or 
preparative HPLC.  
General procedure 11 (GP11):  
Complexation of bioconjugates  
In a microreaction tube, K2PtCl4 (2eq. 0.1 M aqueous solution) is activated by addition of an excess of 
DMSO (50 µL). In parallel, the Enk-conjugated -hydroxydithiocinnamic ester (1 eq., dissolved in 
600 µL THF) is deprotonated by NaOAc (10 eq., 0.1 M aqueous solution) and added to the Pt-mixture 
in portions of 50 µL; 100 µL water are added to facilitate mixing of the solvents. After over-night 
shaking on a laboratory shaker, water and THF are removed in vacuo. By addition of 500 µL water the 
compound is precipitated, then centrifugated and the solvents decanted. The solid residue is washed 
repeatedly with water and Et2O and dried under vacuum to give the desired complex.    
General procedure 12 (GP12):  
Solid Phase Peptide Synthesis (SPPS)  
In general, peptide synthesis consists of the following steps irrespective of manual or microwave-
assisted coupling (µW): 
Swelling: Before synthesis, the resin is swollen in DMF or DCM for at least 30 min.  
Deprotection: N-terminal Fmoc protection groups are removed by a solution of 20 % piperidine in 
DMF (µW: (i) P = 30 W, t = 35 s, T = 38 °C; (ii) P = 50 W, t = 180 s, T = 77 °C). 
Washing: After each deprotection and each coupling step, the resin is washed excessively with DMF 
to remove any residual activation or deprotection reagents. 
Coupling: Fmoc protected amino acids (4 eq., 0.2 mmol/mL in DMF) resp. functionalized acids (4 eq., 
0.1 mmol/mL in DMF) are mixed with 1-Hydroxybenzotriazol (HOBt, 4 eq. 0.5 M in DMF) and 
N,N,N ,N -Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU, 3.8 eq. 0.5 M in DMF). 
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Coupling is initiated by addition of diisopropylethylamine (DiPEA, 8 eq. 2 M in DMF). Conditions for 
manual coupling reactions: shaking at r.t. on a laboratory shaker (350 rpm); for µW-assisted coupling: 
P = 24 W, t = 300 s, T = 78 °C. 
Ninhydrin test: For manual coupling reactions, a ninhydrin test is performed to ensure complete 
conversion of all terminal amines. For that, few resin beads are soaked with a solution of ninhydrin 
(2 mg/mL) in 2-butanol/H2O/acetic acid (95:4.5:0.5 v/v) and heated to 100 °C for 5 min. A purple 
color would indicate the presence of amines and thus incomplete conversion; no color change 
indicates complete conversion of all terminal amines. 
Workup after automated synthesis: After deprotection of the last amino acid, the peptide-loaded 
resin is transferred into a filter syringe, washed with DMF and DCM (3 ´ 5 mL, 1-2 min each) and 
dried in vacuo. When needed, the dried resin is split into smaller portions at this point and manual 
coupling performed equally as described above. 
Cleavage: After coupling of all (amino) acids, the peptidyl resin is treated with a mixture of 
TFA/H2O/TES (trifluoroacetic acid/water/triethylsilane) (95:2.5:2.5 v/v; 1200 µL / 100 µM peptide on 
resin) and shaken on a laboratory shaker at r.t. for approx. 2 h.  
Purification: The cleaved peptide is precipitated by introduction into ca. 80 mL of a 1:1 mixture of 
n-hexane and diethyl ether at -80 °C and the resin washed with a minimum amount of cleavage 
mixture. The precipitate is centrifuged (8000 rpm, 10 min, r.t.), decanted and washed with diethyl 
ether (2-3 ´ 5-10 mL). When needed, the peptide is purified by HPLC as described for the individual 
compounds. Purified peptides are lyophilized from H2O/CH3CN solutions and obtained as amorphous 
solids. 
General procedure 13 (GP13):  
Coupling in solution liquid phase peptide synthesis (LPPS) 
In a microreaction tube, the free carboxylic acid (1.1 eq.) and peptide (Enk, 1 eq.) are mixed with 
TBTU (1.1 eq.) in DMF (600 µL). Coupling is initiated by addition of DiPEA (2.3 eq.) which can be seen 
through a dark discoloration of the reaction mixture. The mixture is vigorously shaken for 30 sec, 
centrifuged to collect all solvents and then continuously shaken on a laboratory shaker (350 rpm) at 
r.t. for 2 h. Workup is performed individually for the respective compounds. 
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15.7 HPLC analysis and purification 
High Performance Liquid Chromatography (HPLC) was performed by using reversed phase (rp) 
columns of the type Knauer EurospherII 100-5 C18A (5 µm, 250 ´ 4 mm), or Dr. Maisch ReproSil-Pur 
120 C8 (5 µm, 250 ´ 4.6 mm) for analytical and Dr. Maisch ReproSil-Pur C18-AQ (5 µm, 250 ´ 10 mm) 
for preparative runs. Millipore Water (mQ-H2O) and HPLC-grade acetonitrile (CH3CN), both 
containing 0.1 vol-% trifluoroacetic acid (TFA), were used as eluents. All analytical measurements 
were performed at a flow rate of 1 mL/min, semi-preparative HPLC was performed at a flow rate of 
5 mL/min using different gradient setups:  
Buffer A: mQ-H2O / 0.1 %TFA 
Buffer B: CH3CN / 0.1 % TFA  
 
Gradient 1 used for analytical (1 mL/min) and semi-preparative (5 mL/min) applications: 
time A [%] B [%]  
 
0 100 0  
5 100 0  
25 0 100  
30 0 100  
35 100 0  
40 100 0  
 
Gradient 2 used for semi-preparative (5 mL/min) applications: 
time A [%] B [%]  
 
0 60 40  
5 60 40  
20 0 100  
30 0 100  
35 60 40  
40 60 40  
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Gradient 3 used for semi-preparative (5 mL/min) applications: 
time A [%] B [%]  
 
0 100 0  
5 100 0  
45 0 100  
50 0 100  
55 100 0  
60 100 0  
 
Gradient 4 used for semi-preparative (5 mL/min) applications: 
time A [%] B [%]  
 
0 70 30  
5 70 30  
45 0 100  
50 0 100  
55 70 30  
60 70 30  
 
  
 
 
16 COMPOUND SYNTHESES AND ANALYSES 
16.1 -Hydroxydithiocinnamic esters  
-Hydroxydithiocinnamic acid butyl ester (9) 
Using acetophenone 5 (2 g, 20 mmol), KOtBu (4.5 g, 40 mmol), CS2 
(1.7 mL, 28 mmol), and butyl iodide (2.3 mL, 20 mmol), the synthesis 
was carried out according to GP3. Column chromatography was 
accomplished with n-hexane/DCM 1:1 as mobile phase (Rf  0.7) and 
yielded 9 (3.48 g, 69 %) as yellow oil.  
 
1H NMR (400 MHz, CDCl3)  =15.17 (s, 1H, OH), 7.92  7.84 (m, 2H, Ar-H2, Ar-H6), 7.58  7.40 (m, 3H, 
Ar-H3, Ar-H4, Ar-H5), 6.93 (s, 1H, =CH-), 3.28 (t, 3JHH = 7.4 Hz, 2H, S-CH2-), 1.80  1.61 (m, 2H, 
SCH2-CH2-), 1.49 (m, 2H, SCH2CH2-CH2-), 0.98 (t, J = 7.3 Hz, 3H, -CH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3)  =216.7 (CS2), 169.5 (COH), 134.4 (Ar-C1), 131.9 (Ar-C4), 128.8 (2C, 
Ar-C3, Ar-C5), 126.7 (2C, Ar-C2, Ar-C6), 108.0 (=CH-), 33.4 (S-CH2-), 30.0 (SCH2-CH2-), 22.3 
(SCH2CH2-CH2-), 13.8 (-CH3) ppm. 
MS (EI+) m/z = 253 [M+H]+, 196 [M-Bu+H]+, 163 [M-SBu]+, 105, 85, 77. 
FTIR (ATR)  = 3062 (w), 2957 (w), 2928 (w), 2871 (w), 1588 (s), 1554 (vs), 1491 (s), 1451 (s), 1396 
(m), 1279 (w), 1233 (vs, b), 1053 (s), 947 (vs), 826 (s), 759(s) cm-1.  
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4-Bromo--hydroxydithiocinnamic acid butyl ester (13) 
Using 4-bromo-acetophenone 6 (3.98 g, 20 mmol), KOtBu (4.5 g, 
40 mmol), CS2 (1.7 mL, 1.4 mmol), and butyl iodide (2.3 mL, 
20 mmol), the synthesis was carried out according to GP3. Column 
chromatography was accomplished with n-hexane/DCM 1:1 as 
mobile phase (Rf  0.7) and yielded 13 (3.04 g, 46 %) as an orange 
solid. 
 
 
1H NMR (400 MHz, CDCl3)  =15.08 (s, 1H, OH), 7.73 (d, 3JHH = 8.7 Hz, 2H, Ar-H3, Ar-H5 ), 7.57 (d, 3JHH = 
8.7 Hz, 2H, Ar-H2, Ar-H6), 6.85 (s, 1H, =CH-), 3.27 (t, 3JHH = 7.4 Hz, 2H, S-CH2-), 1.84  1.59 (m, 2H, 
SCH2-CH2-), 1.48 (m, 2H, SCH2CH2-CH2-), 0.97 (t, 3JHH = 7.3 Hz, 3H, -CH3) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  =217.3 (CS2), 168.1 (COH), 133.4 (Ar-C1), 132.2 (2C, Ar-C3, Ar-C5), 
128.2 (2C, Ar-C2, Ar-C6), 126.6 (Ar-C4), 107.9 (=CH-), 33.6 (S-CH2-), 30.0 (SCH2-CH2-), 22.3 
(SCH2CH2-CH2-), 13.8 (-CH3) ppm. 
MS (EI+) m/z = 331/333 [M+H]+/[M+2+H]+, 274/276 [M-C4H8]+, 241/243 [M-SBu]+, 183/185, 162, 85.  
FTIR (ATR)  = 2947 (w), 2923 (w), 2864 (w), 1679 (m), 1580 (vs), 1556 (vs), 1484 (s), 1410 (s), 1376 
(m), 1303 (m), 1230 (vs), 1213 (m), 1074 (m), 1073 (s), 1045 (s), 1008 (m), 958 (s), 839 (m), 828 (m), 
816 (m), 795 (m), 765 (m) cm-1. 
3-(tert-butyldimethylsilyloxy)- -hydroxydithiocinnamic acid ethyl ester (16)  
Using 3-(tert-butyldimethylsilyl)oxy) acetophenone 3 (5.00 g, 
20 mmol), KOtBu (4.5 g, 40 mmol), CS2 (1.7 mL, 1.4 mmol), and 
ethyl iodide (1.6 mL, 20 mmol), synthesis was carried out 
according to GP3. Column chromatography, using n-
hexane/DCM 1:1 as mobile phase (Rf  0.8), yielded 16 (1.2 g, 
17 %) as orange oil. 
 
 
Analysis calcd. for C17H26O2S2Si·0.1 hexane: C 58.20; H 7.60 %; found C 58.13; H 7.74 % 
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1H NMR (200 MHz, CDCl3)  = 15.04 (s, 1H, OH), 7.43  7.33 (m, 1H, Ar-H6), 7.30  7.24 (m, 1H, Ar-
H2), 7.24  7.16 (m, 1H, Ar-H5), 6.90 (m, 1H, Ar-H4), 6.78 (s, 1H, =CH-), 3.21 (q, 3JHH = 7.4 Hz, 2H, 
S-CH2-), 1.31 (t, 3JHH  = 7.4 Hz, 3H, SCH2-CH3), 0.93 (s, 9H, SiC(CH3)3), 0.16 (s, 6H, Si(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3)  = 216.6 (CS2), 169.6 (COH), 156.2 (Ar-C3), 135.9 (Ar-C1), 129.8 (Ar-
C5), 123.8 (Ar-C6), 119.7 (Ar-C4), 118.4 (Ar-C2), 108.11 (=CH-), 28.0 (S-CH2-), 25.8 (3C, SiC(CH3)3), 18.4 
(SiCq), 13.0 (SCH2-CH3), -4.2 (2C, Si(CH3)2). 
MS (EI+) m/z = 354 [M]+, 293 [M-SEt]+, 235. 
FTIR (ATR)  = 2955 (w), 2929 (w), 2858 (w), 1587 (m), 1562 (vs), 1478 (m), 1446 (m), 1283 (s), 1253 
(s), 1230 (s), 1197 (vs), 1165 (w), 1083 (w), 1064 (w), 1038 (w), 1000 (w), 974 (s), 934 (s), 835 (vs), 
803 (m), 776 (vs) cm-1. 
3-(Tert-butyldimethylsilyloxy)--hydroxydithiocinnamic acid butyl ester (17)  
Using 3-(tert-butyldimethylsilyl)oxy) acetophenone 3 
(5.00 g, 20 mmol), KOtBu (4.5 g, 40 mmol), CS2 (1.7 mL, 
1.4 mmol), and butyl iodide (2.3 mL, 20 mmol), synthesis 
was carried out according to GP3. Column 
chromatography, using n-hexane/DCM 1:1 as mobile 
phase (Rf  0.5), yielded 17 (1.6 g, 21 %) as orange oil. 
 
 
1H NMR (400 MHz, CDCl3)  =15.12 (s, 1H, OH), 7.45 (d, J = 7.8 Hz, 1H, Ar-H6), 7.35 (s, 1H, Ar-H2), 
7.29 (t, J = 7.9 Hz, 1H, Ar-H5), 6.98 (dd, J = 8.0, 2.3 Hz, 1H, Ar-H4), 6.87 (s, 1H, =CH-), 3.27 (t, 3JHH = 7.4 
Hz, 2H, S-CH2-), 1.77  1.54 (m, 2H, SCH2-CH2-), 1.54-1.37 (m, 2H, SCH2CH2-CH2-), 1.03  0.92 (m, 12H, 
SiC(CH3)3, SCH2CH2CH2-CH3), 0.23 (s, J = 3.4 Hz, 6H, Si(CH3)2) ppm. 
13C{1H} NMR (101 MHz, CDCl3)  =216.8 (CS2), 169.4 (COH), 156.2 (Ar-C3), 135.9 (Ar-C1), 129.8 (Ar-
C5), 123.7 (Ar-C6), 119.7 (Ar-C4), 118.4 (Ar-C2), 108.2 (=CH-), 33.4 (S-CH2-), 30.1 (SCH2-CH2-), 25.8 
(SiC(CH3)3), 22.3 (SCH2CH2-CH2-), 18.4 (SiCq), 13.8 (SCH2CH2CH2-CH3), -4.3 (Si(CH3)2) ppm. 
MS (EI+) m/z = 382 [M]+, 326 [M-C4H8]+, 293 [M-SBu]+, 269, 235, 85,73,57. 
FTIR (ATR)  = 2956 (w), 2929 (w), 2858 (w), 1587 (m), 1562 (vs), 1478 (m), 1446 (m), 1283 (s), 1253 
(s), 1235 (s), 1197 (vs), 1165 (w), 1083 (w), 1057 (m), 1000 (w), 976 (s), 935 (s), 835 (vs), 804 (m), 777 
(vs) cm-1. 
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3-(Tert-butyldimethylsilyloxy)--hydroxydithiocinnamic acid hexyl ester (18)  
The synthesis of 18 was carried out according to 
GP3, using 3-(tert-butyldimethylsilyl)oxy) 
acetophenone 3 (5.00 g, 20 mmol), KOtBu (4.5 g, 
40 mmol), CS2 (1.7 mL, 1.4 mmol), and hexyl 
bromide (2.8 mL, 20 mmol). Column 
chromatography, using n-hexane as mobile phase 
(Rf  0.5), yielded 18 (3.4 g, 28 %) as orange oil. 
 
 
1H NMR (200 MHz, CDCl3)  =15.08 (s, 1H, OH), 7.48  7.38 (m, 1H, Ar-H6), 7.34-7.17 (m, 2H, Ar-H2, 
Ar-H5), 6.94 (m, 1H, Ar-H4), 6.83 (s, 1H, =CH-), 3.23 (t, 3JHH = 7.2 Hz, 2H, S-CH2-), 1.79  1.57 (m, 2H, 
SCH2-CH2-), 1.51-1.17 (m, 6H, SCH2CH2-CH2-CH2-CH2-), 1.08  0.95 (m, 9H, SiC(CH3)3), 0.95  0.79 (m, 
3H, -CH3), 0.20 (s, 6H, Si(CH3)2) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  =216.9 (CS2), 169.5 (COH), 156.2 (Ar-C3), 136.0 (Ar-C1), 129.9 (Ar-C5), 
123.8 (Ar-C6), 119.8 (Ar-C4), 118.5 (Ar-C2), 108.2 (=CH-), 33.8 (S-CH2-), 31.5 (SCH2-CH2-), 28.9 
(SCH2CH2-CH2-), 28.0 (SCH2CH2CH2-CH2-), 25.8 (SiC(CH3)3), 22.7 (SCH2CH2CH2CH2-CH2-), 18.4 (SiCq ), 
14.1 (-CH3), -4.2 (Si(CH3)2) ppm. 
MS (EI+) m/z = 410 [M]+, 326 [M-C6H12]+, 293 [M-SHex]+, 269, 235, 85,73,57. 
FTIR (ATR)  = 2955 (w), 2928 (w), 2857 (w), 1587 (m), 1563 (vs), 1489 (m), 1478 (m), 1457 (m), 1284 
(s), 1254 (s), 1232 (s), 1197 (vs), 1165 (w), 1083 (w), 1058 (m), 1000 (w), 975 (s), 934 (s), 836 (vs), 804 
(m), 777 (vs) cm-1. 
4-(tert-butyldimethylsilyloxy)- -hydroxydithiocinnamic acid ethyl ester (20) 
Using 4-(tert-butyldimethylsilyl)oxy) acetophenone 4 (5.00 g, 
20 mmol), KOtBu (4.5 g, 40 mmol), CS2 (1.7 mL, 1.4 mmol), and 
ethyl iodide (1.6 mL, 20 mmol), synthesis was carried out 
according to GP3. Column chromatography, using n-
hexane/DCM 1:1 as mobile phase (Rf  0.8), yielded 20 (1.4 g, 
19 %) as orange oil. 
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Analysis calcd. for C17H26O2S2Si·0.25 hexane: C 59.07, H 7.90 %; found C 59.06; H 7.72 % 
1H NMR (200 MHz, CDCl3)  = 15.21 (s, 1H, OH), 7.80 (d, 3JHH = 8.9 Hz, 2H, Ar-H2, Ar-H6), 6.92  6.84 
(m, 3H, Ar-H3, Ar-H5, =CH-), 3.27 (q, 3JHH = 7.4 Hz, 2H, S-CH2-), 1.38 (t, 3JHH  = 7.4 Hz, 3H, SCH2CH3), 
1.00 (s, 9H, SiC(CH3)3), 0.24 (s, 6H, Si(CH3)2). 
13C{1H} NMR (50 MHz, CDCl3)  = 215.2 (CS2), 170.1 (COH), 159.6 (Ar-C4), 128.7 (2C, Ar-C2, Ar-C6), 
127.1 (Ar-C1), 120.5 (2C, Ar-C3, Ar-C5), 107.4 (=CH-), 27.8 (S-CH2-), 25.7 (3C, SiC(CH3)3), 18.4 (SiCq), 
13.2 (SCH2CH3), -4.2 (2C, Si(CH3)2). 
MS (EI+) m/z = 354 [M]+, 293 [M-SEt]+, 235. 
FTIR (ATR)  = 2955 (w), 2929 (w), 2885 (w), 2857 (w), 1600 (m), 1582 (s), 1563 (m), 1498 (vs), 1471 
(w), 1427 (m), 1254 (s, b), 1223 (vs, b), 1169 (s), 1111 (w), 1062 (w), 1035 (w), 945 (s), 905 (vs), 834 
(vs), 801 (s), 778 (vs) cm-1. 
4-(Tert-butyldimethylsilyloxy)--hydroxydithiocinnamic acid butyl ester (21)  
Using 4-(tert-butyldimethylsilyl)oxy) acetophenone 4 
(5.00 g, 20 mmol), KOtBu (4.5 g, 40 mmol), CS2 (1.7 mL, 
1.4 mmol), and butyl iodide (1.7 mL, 15 mmol), the 
synthesis of 21 was carried out according to GP3. Column 
chromatography, using n-hexane/DCM 1:1 as mobile 
phase (Rf  0.5), yielded 21 (1.85g, 32 %) as orange oil. 
 
 
1H NMR (400 MHz, CDCl3)  =15.21 (s, 1H, OH), 7.80 (d, 3JHH = 8.8 Hz, 2H, Ar-H2, Ar-H6), 6.92  6.84 
(m, 3H, Ar-H3, Ar-H5, =CH-), 3.27 (d, 3JHH = 7.4 Hz, 1H, S-CH2-), 1.75  1.62 (m, 2H, SCH2-CH2-), 1.54  
1.36 (m, 2H, SCH2CH2-CH2-), 1.04  0.92 (m, 12H, SiC(CH3)3, SCH2CH2CH2-CH3), 0.24 (s, 6H, Si(CH3)2) 
ppm. 
13C{1H} NMR (101 MHz, CDCl3)  =215.3 (CS2), 170.0 (COH ), 159.6 (Ar-C4), 128.7 (2C, Ar-C2, Ar-C6), 
127.1 (Ar-C1), 120.5 (2C, Ar-C3, Ar-C5), 107.4 (=CH-), 33.3 (S-CH2-), 30.2 (SCH2-CH2-), 25.8 (3C, 
SiC(CH3)3), 22.4 (SCH2CH2-CH2-), 18.4 (SiCq), 13.8 (SCH2CH2CH2-CH3), -4.2 (2C, Si(CH3)2) ppm. 
MS (EI+) m/z = 382 [M]+, 326 [M-C4H8]+, 293 [M-SBu]+, 235, 85,73,57. 
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FTIR (ATR)  = 2956 (w), 2929 (w), 2858 (w), 1601 (m), 1583 (s), 1563 (m), 1499 (vs), 1463 (m), 1427 
(m), 1391 (m), 1274 (s), 1254 (s), 1232 (vs, b), 1169 (s), 1111 (w), 1052 (m), 1006 (w), 948 (s), 906 
(vs), 834 (vs), 801 (s), 779 (vs) cm-1.  
4-(Tert-butyldimethylsilyloxy)--hydroxydithiocinnamic acid hexyl ester (22)  
Synthesis was carried out following GP3 by using 4-
(tert-butyldimethylsilyl)oxy) acetophenone 4 
(5.00 g, 20 mmol), KOtBu (4.5 g, 40 mmol), CS2 
(1.7 mL, 1.4 mmol), and hexyl bromide (2.8 mL, 
20 mmol). Column chromatography was performed 
with n-hexane/DCM 1:1 as mobile phase (Rf  0.7), 
yielded 22 (2.6g, 31 %) as orange oil. 
 
 
1H NMR (200 MHz, CDCl3)  =15.20 (s, 1H, OH), 7.80 (d, 3JHH = 8.9 Hz, 2H, Ar-H2, Ar-H6), 6.96  6.81 
(m, 3H, Ar-H3, Ar-H5, =CH-), 3.26 (t, 3JHH = 7.2 Hz, 1H, S-CH2-), 1.76  1.65 (m, 2H, SCH2-CH2-), 1.65  
1.19 (m, 6H, SCH2CH2-CH2-CH2-CH2-), 1.07  0.82 (m, 12H, SiC(CH3)3, SCH2CH2CH2CH2CH2-CH3), 0.24 (s, 
6H, Si(CH3)2) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  =215.2 (CS2), 170.0 (COH), 159.6 (Ar-C4), 128.7 (2C, Ar-C2, Ar-C6), 
127.1 (Ar-C1), 120.5 (2C, Ar-C3, Ar-C5), 107.5 (=CH-), 33.6 (S-CH2-), 31.5 (SCH2-CH2-), 28.9 
(SCH2CH2-CH2-), 28.1 (SCH2CH2CH2-CH2-), 25.7 (3C, SiC(CH3)3), 22.7 (SCH2CH2CH2CH2-CH2-), 18.4 (SiCq), 
14.1 (SCH2CH2CH2CH2CH2-CH3), -4.2 (2C, Si(CH3)2) ppm. 
MS (EI+) m/z = 410 [M]+, 326 [M-C6H12]+, 293 [M-SHex]+, 235. 
FTIR (ATR)  = 2955 (w), 2928 (w), 2857 (w), 1601 (m), 1583 (s), 1563 (m), 1499 (vs), 1470 (m), 1427 
(m), 1391 (w), 1275 (s), 1254 (s), 1227 (vs, b), 1169 (s), 1111 (w), 1054 (m), 1007 (w), 946 (m), 906 
(vs), 835 (vs), 801 (s), 779 (vs) cm-1. 
  
EXPERIMENTAL 
16 Compound Syntheses and Analyses 163 
 
 
3-hydroxo--hydroxydithiocinnamic acid ethyl ester (24)  
The TBDMS group in precursor compound 16 (709 mg, 2 mmol) was 
cleaved according to GP4 by using TBAF (4 mL 1 M soln. in THF) and 
stirred for 5 days before acidification (35 mL 2 M aq. H2SO4). The crude 
material was purified by column chromatography (mobile phase: CDM . 
Rf  0.7) and pure 24 (347 mg, 72 %) obtained as orange solid.  
 
Analysis calcd. for C11H12O2S2: C 54.97, H 5.03 %; found C 54.92; H 5.06 % 
1H NMR (200 MHz, CDCl3)  = 15.09 (s, 1H, C(OH)CHCS2), 7.47  7.18 (m, 3H, Ar-H2, Ar-H5, Ar-H6), 
7.03  6.90 (m, 1H, Ar-H4), 6.82 (s, 1H, =CH-), 3.24 (d, 3JHH = 7.4 Hz, 2H, S-CH2-), 1.35 (t, 3JHH  = 7.4 Hz, 
3H, SCH2-CH3). 
13C{1H} NMR (50 MHz, CDCl3)  = 216.7 (CS2), 169.1 (C(OH)CHCS2), 155.9 (Ar-C3), 135.9 (Ar-C1), 130.1 
(Ar-C5), 119.2 (2C, Ar-C4, Ar-C6), 113.6 (Ar-C2), 108.1 (=CH-), 28.0 (S-CH2-), 12.9 (SCH2-CH3). 
MS (EI+) m/z = 240 [M]+, 179 [M-SEt]+, 121. 
FTIR (ATR)  = 3302 (w, b), 2975 (w), 2964 (w), 2924 (w), 2866 (w), 1587 (m), 1558 (vs), 1488 (m), 
1469 (m), 1404 (m, b), 1360 (w), 1310 (w), 1263 (s), 1246 (m), 1233 (s), 1176 (s), 1085 (m), 1048 (m), 
1033 (m), 998 (m), 961 (m), 900 (vs), 863 (s), 807 (m),783 (m), 758 (s) cm-1. 
3-Hydroxy--hydroxydithiocinnamic acid hexyl ester (25) 
The TBDMS group in precursor compound 18 (1.23 g, 
3mmol) was cleaved according to GP4 by using TBAF (6 mL 
1 M soln. in THF) and stirred for 6 days before acidification 
(100 mL 2 M aq. H2SO4). The crude material was flushed 
over a plug of silica gel using chloroform as solvent and 
thus 25 (795 mg, 89 %) obtained as orange oil. 
 
 
1H NMR (200 MHz, CDCl3)  =15.06 (s, 1H, C(OH)CHCS2), 7.42  7.18 (m, 3H, Ar-H2, Ar-H5, Ar-H6), 
7.04  6.88 (m, 1H, Ar-H4), 6.82 (s, 1H, =CH-), 3.22 (d, 3JHH = 7.2 Hz, 2H, S-CH2-), 1.80-1.49 (m, 2H, 
SCH2-CH2-), 1.49  1.14 (m, 6H, SCH2CH2-CH2-CH2-CH2-), 0.90-0.85 (m, 3H, SCH2CH2CH2CH2CH2-CH3) 
ppm. 
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13C{1H} NMR (50 MHz, CDCl3)  =216.9 (CS2), 169.1 (C(OH)CHCS2), 156.1 (Ar-C3), 136.0 (Ar-C1), 130.1 
(Ar-C5), 119.2, 119.1 (2C, Ar-C4, Ar-C6), 113.7 (Ar-C2), 108.2 (=CH-), 33.8 (S-CH2-), 31.4 (SCH2-CH2-), 
28.8 (SCH2CH2-CH2-), 27.9 (SCH2CH2CH2-CH2-), 22.6 (SCH2CH2CH2CH2-CH2-), 14.1 
(SCH2CH2CH2CH2CH2-CH3) ppm. 
MS (EI+) m/z = 296 [M]+, 212 [M-C6H12]+, 179 [M-SEt]+, 121. 
FTIR (ATR)  = 3377 (w, b), 2954 (w), 2927 (w), 2855 (w), 1564 (vs,b), 1490 (m), 1455 (m), 1401 (w), 
1310 (w), 1281 (m), 1231 (s), 1188 (s), 1057 (s), 997 (w), 965 (m), 905 (s), 836 (w), 802 (w),774 (vs) 
cm-1. 
4-hydroxo- -hydroxydithiocinnamic acid ethyl ester (27)  
The TBDMS group in precursor compound 20 (709 mg, 2 mmol) was 
cleaved according to GP4 by using TBAF (4 mL 1 M soln. in THF) and 
stirred for 4 days before acidification (35 mL 2 M aq. H2SO4). The crude 
material was purified by column chromatography (mobile phase: CDM . 
Rf  0.7) and pure 24 (217 mg, 45 %) obtained as orange solid.  
 
Analysis calcd. for C11H12O2S2·0.02 dichloromethane: C 54.68, H 5.01 %; found C 54.38; H 5.38 % 
1H NMR (400 MHz, CDCl3)  = 15.22 (s, 1H, C(OH)CHCS2), 7.87  7.67 (m, 2H, Ar-H2, Ar-H6), 6.96  
6.79 (m, 3H, Ar-H3, Ar-H5, CHCS2), 3.27 (d, 3JHH = 7.4 Hz, 2H, SCH2), 1.37 (t, 3JHH  = 7.4 Hz, 3H, 
SCH2CH3). 
13C{1H} NMR (101 MHz, CDCl3)  = 215.2 (CS2), 169.9 (C(OH)CHCS2), 159.3 (Ar-C4), 129.1 (2C, Ar-C2, 
Ar-C6), 126.7 (Ar-C1), 115.9 (2C, Ar-C3, Ar-C5), 107.2 (=CH-), 27.8 (SCH2), 13.2 (SCH2CH3). 
MS (EI+) m/z = 240 [M]+, 179 [M-SEt]+, 121. 
FTIR (ATR)  = 3421 (w, b), 2972 (w), 2964 (w), 2927 (w), 2852 (w), 1593 (s), 1568 (vs), 1504 (s), 1445 
(s, b), 1390 (m), 1371 (m), 1227 (vs, b), 1178 (m), 1116 (m), 1060 (m), 1043 (m), 953 (s), 838 (vs), 815 
(s), 770 (vs) cm-1. 
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4-Hydroxy--hydroxydithiocinnamic acid hexyl ester (28) 
The precursor compound 22 (1.23 g, 3mmol) was 
deprotected according to GP4 by using TBAF (6 mL 1 M 
soln. in THF) and stirred for 5 days before acidification 
(50 mL 2M H2SO4). The crude material was subjected to a 
short column chromatographic workup on silica gel using 
DCM as solvent and thus 28 (568 mg, 64 %) obtained as 
orange solid. 
 
 
1H NMR (200 MHz, CDCl3)  =15.21 (s, 1H, C(OH)CHCS2), 7.80 (d, 3JHH = 8.8 Hz, 2H, Ar-H2, Ar-H6), 6.96 
 6.79 (m, 3H, Ar-H3, Ar-H5, CHCS2), 3.27 (t, 3JHH = 7.2 Hz, 2H, S-CH2-), 1.88  1.57 (m, 2H, SCH2-CH2-), 
1.54  1.19 (m, 6H, SCH2CH2-CH2-CH2-CH2-), 0.98  0.77 (m, 3H, SCH2CH2CH2CH2CH2-CH3) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  =215.4 (CS2), 169.8 (COH), 159.3 (Ar-C4), 129.1 (2C, Ar-C2, Ar-C6), 
126.7 (Ar-C1), 115.9 (2C, Ar-C3, Ar-C5 , 107.34 (CHCS2), 33.6 (S-CH2-), 31.48 (SCH2-CH2-), 28.9 
(SCH2CH2-CH2-), 28.1 (SCH2CH2CH2-CH2-), 22.7 (SCH2CH2CH2CH2-CH2-), 14.1 (SCH2CH2CH2CH2CH2-CH3) 
ppm. 
MS (EI+) m/z = 296 [M]+, 212 [M-C6H12]+, 179 [M-SEt]+, 121. 
FTIR (ATR)  = 3538 (w), 3273 (w, b), 2955 (w), 2926 (w), 2854 (w), 1593 (s), 1562 (s, b), 15505 (s), 
1445 (s), 1391 (m), 1298 (w), 1256 (m), 1227 (vs, b), 1171 (s), 1113 (m), 1051 (m), 940 (vs), 845 (s), 
839 (s), (w), 793 (s),774 (vs) cm-1. 
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16.2  Pt(II) complexes 
Chloro-(1-(4-bromophenyl)-3-(ethylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (34) - Effect of base 
Method 1: NaH as base. The compound was prepared according to 
GP7 as described in detail in the respective pubication.118 Based on 
200 mg (0.482 mmol) K2PtCl4, the yield of 34 after repeated column 
chromatography was 89 mg (33 %). 
 
Method 2: KOtBu as base. 4-Bromo--hydroxydithiocinnamic ethyl ester 12 (118.8 mg, 0.391 mmol), 
K2PtCl4 (200 mg, 0.482 mmol), DMSO (62 µL, 0.876 mmol) and KOtBu (49.15 mg, 0.438 mmol) were 
reacted following GP6. The crude material was purified by column chromatography using a gradient 
(mobile phase: DCM/n-hexane 2 : 1 to 1 : 0, Rf  0.3) affording 34 in 25 % yield (61 mg). 
Method 3: NaOAc as base. 4-Bromo- -hydroxydithiocinnamic ethyl ester 12 (133 mg, 0.438 mmol), 
K2PtCl4 (200 mg, 0.482 mmol), DMSO (62 µL, 0.876 mmol) and NaOAc (36 mg, 0.438 mmol) were 
reacted following GP5. The crude material was purified by column chromatography using a gradient 
(mobile phase: DCM/n-hexane 2 : 1 to 1 : 0, Rf  0.3) to give 34 in 67 % yield (179 mg). 
Chloro-(1-phenyl-3-(butylthio)-3-thioxo-prop-1-en-1-olate-O,S)-(dimethylsulfoxide-S)-
platinum(II) (31) 
Following GP5, K2PtCl4 (400 mg, 0.96 mmol) was reacted with 9 
(221 mg, 0.88 mmol), using NaOAc·3H2O (119 mg, 0.88 mmol) as base 
and 125 µL (1.76 mmol) DMSO. The mixture was stirred for 2 days and 
the crude product purified via column chromatography on silica gel 
using a gradient (DCM/n-hexane 3:2 to 1:0; Rf  0.1) and crystallized 
from DCM/n-hexane to afford 31 (160 mg, 33 %) as orange powder. 
 
 
1H NMR (200 MHz, CDCl3)  !=8.13  7.81 (m, 2H, Ar-H2, Ar-H6), 7.47 (dt, J = 14.7, 7.2 Hz, 3H, Ar-H3, 
Ar-H4, Ar-H5), 7.11 (s, 1H, =CH-), 3.66 (s, 3JPtH = 23.5 Hz, 6H, CH3(DMSO)), 3.25 (t, 3JHH = 7.3 Hz, 2H, 
S-CH2-), 1.94  1.61 (m, 2H, SCH2-CH2-), 1.49 (m, 2H, SCH2CH2-CH2-), 0.96 (t, 3JHH = 7.2 Hz, 3H, -CH3) 
ppm. 
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13C{1H} NMR (50 MHz, CDCl3)  =180.6 (CS2), 174.7 (C-OPt), 137.3 (Ar-C1), 132.1 (Ar-C4), 128.9 (2C, 
Ar-C3, Ar-C5), 128.1 (2C, Ar-C2, Ar-C6), 111.7 (=CH-), 47.0 (s, 2JPtC = 59.9 Hz, CH3(DMSO)), 34.2 
(S-CH2-), 30.1 (SCH2-CH2-), 22.2 (SCH2CH2-CH2-), 13.8 (-CH3) ppm. 
MS (EI+) m/z =560 [M+H]+.  
FTIR (ATR)  = 3008 (w), 2957 (w), 2929 (w), 2874 (w), 1503 (s), 1475 (s), 1432 (m), 1287 (m), 1271 
(m), 1219 (w), 1182 (w), 1130 (m), 1033 (m), 975 (m), 944 (w), 925 (w), 834 (m), 764(s), 689 (vs) cm-1. 
Chloro-(1-(4-bromophenyl)-3-(butylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (35) 
According to GP5, the synthesis was performed by reaction of 13 
(290 mg, 0.88 mmol) and NaOAc·3H2O (128 mg, 0.94 mmol) with 
DMSO (130 µL, 1.83 mmol) overnight. The crude product was 
purified via column chromatography on silica gel (mobile phase: 
DCM/n-hexane 3:2, Rf ! 0.1). The product 35 (340 mg, 61 %) was 
obtained as yellow solid. 
 
 
1H NMR (200 MHz, CDCl3)  =7.82 (d, 3JHH = 8.7 Hz, 2H, Ar-H3, Ar-H5), 7.53 (d, 3JHH = 8.7 Hz, 2H, Ar-H2, 
Ar-H6), 7.03 (s, 1H, =CH-), 3.66 (s, 3JPtH = 23.4 Hz, CH3(DMSO)), 3.25 (t, J = 7.3 Hz, 2H, S-CH2-), 1.86  
1.68 (m, 2H, SCH2-CH2-), 1.49 (m, 2H, SCH2CH2-CH2-), 0.93 (s, 2H, -CH3) ppm. 
13C{1H} NMR (150 MHz, CDCl3)  =182.3 (CS2), 173.6 (C-OPt), 136.5 (Ar-C1), 132.5 (2C, Ar-C3, Ar-C5), 
129.8 (2C, Ar-C2, Ar-C6), 127.3 (Ar-C4), 111.5 (CHCS2), 46.8 ((CH3(DMSO)s), 34.1 (S-CH2-), 29.8 
(SCH2-CH2-), 21.8 (SCH2CH2-CH2-), 13.3 (-CH3) ppm. 
MS (EI+) m/z =638 [M]+  
FTIR (ATR)  3016 (w), 2928 (w), 2860 (w), 1583 (w), 1502, 1474 (vs), 1307 (m), 1285 (m), 1222 (m), 
1140, 1130 (m), 1086 (w), 1070 (w), 1035 (m), 1006 (s), 978 (m), 9223 (w), 852 (m), 837 (s), 783 
(m) cm-1. 
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Chlorido-(1-(3-tert-butyldimethylsilyloxy)-3-(methylthio)-3-thioxo-prop-1-en-1-olate-
O,S)-(dimethylsulfoxide-S)-platinum(II) (37) 
Compound 15 (149 mg, 0.44 mmol) was reacted with K2PtCl4 
(200 mg, 0.48 mmol), NaH (20 mg, 0.5 mmol 60 % in mineral 
oil), and DMSO (70 µL, 0.99 mmol) according to GP7. The 
mixture was stirred overnight. The crude material obtained 
after workup was subjected to column chromatography 
(mobile phase: DCM/n-hexane 2:1, Rf  0.1). Compound 37 
(124 mg, 52 %) was obtained as orange powder. 
 
 
Analysis calcd. for C18H29ClO3PtS3Si·0.25 pentane: C 34.89, H 4.84 %; found C 34.89, H 4.57 %. 
1H NMR (200 MHz, CDCl3)  = 7.65  7.36 (m, 2H, Ar-H2, Ar-H6), 7.36  7.13 (m, 1H, Ar-H5, overlaid 
by SRS), 7.08 (s, 1H, CHCS2), 7.01 (d, J = 8.1 Hz, 1H Ar-H4), 3.66 (s w/ Pt satellites, 3JPt-H = 23.3 Hz, 6H, 
CH3(DMSO)), 2.67 (s, 3H, SCH3), 0.99 (s, 9H SiC(CH3)3), 0.24 (s, 6H, Si(CH3)2). 
13C{1H} NMR (151 MHz, CDCl3)  = 180.9 (CS2), 174.5 (COPt), 156.3 (Ar-C3), 138.8 (Ar-C1), 129.8 (Ar-
C5), 124.1 (Ar-C4), 120.9 (Ar-C6), 119.6 (Ar-C2), 111.7 (CHCS2), 47.0 (2C, CH3(DMSO)), 25.9 (3C, 
SiC(CH3)3), 18.4 (SiCq), 17.7 (SCH3), -4.2 (Si(CH3)2). 
MS (EI+) m/z = 648 [M]+, 612 [M-Cl-H]+, 235. 
FTIR (ATR)  = 3013 (w), 2950 (w), 2929 (w), 2887 (w), 2856 (w), 1596 (w), 1584 (w), 1488 (vs), 1474 
(vs), 1406 (m), 1362 (w), 1312 (m), 1285 (m), 1275 (s), 1252 (m), 1222 (s), 1142 (m), 1029 (m), 1005 
(m), 976 (m), 963 (m), 938 (w), 887 (w), 849 (vs), 840 (vs), 811 (m), 789 (vs), 780 (vs) cm-1. 
Chlorido-(1-(3-tert-butyldimethylsilyloxy)-3-(ethylthio)-3-thioxo-prop-1-en-1-olate-
O,S)-(dimethylsulfoxide-S)-platinum(II) (38)  
Compound 16 (155 mg, 0.44 mmol) was brought to reaction 
with K2PtCl4 (200 mg, 0.48 mmol), NaH (20 mg, 0.5 mmol 
60 % in mineral oil), and DMSO (70 µL, 0.99 mmol) according 
to GP7. The mixture was stirred overnight. The crude material 
obtained after workup was subjected to column 
chromatography (mobile phase: DCM, Rf  0.5).  
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Compound 38 (93 mg, 32 %) was obtained as orange powder. 
Analysis calcd. for C19H31ClO3PtS3Si·0.1 pentane: C 34.98; H 4.85  %; found C 35.36, H 4.85 %. 
1H NMR (200 MHz, CDCl3)  = 7.58  7.42 (m, 2H, Ar-H2, Ar-H6), 7.34  7.19 (m, 1H overlaid by SRS, 
Ar-H5), 7.11  6.95 (m, 2H, Ar-H4, CHCS2), 3.66 (s w/ Pt satellites, 3JPt-H = 23.4 Hz, 6H, CH3(DMSO)), 
3.27 (q, 3JHH = 7.4 Hz, 2H, SCH2), 1.44 (t, 3JHH = 7.4 Hz, 3H, SCH2CH3), 0.99 (s, 9H, SiC(CH3)3), 0.23 (s, 6H, 
Si(CH3)2). 
13C{1H} NMR (50 MHz, CDCl3)  = 180.2 (CS2), 174.7 (COPt), 156.3 (Ar-C3), 138.8 (Ar-C1), 129.8 (Ar-
C5), 124.1 (Ar-C4), 120.9 (Ar-C6), 119.5 (Ar-C2), 111.8 (CHCS2), 47.0 (2C, s w/ Pt satellites, 2JPt-C = 59.3 
Hz, CH3(DMSO)), 28.9 (SCH2), 25.8 (3C, SiC(CH3)3), 18.4 (SiCq), 13.3 (SCH2CH3), -4.2 (2C, Si(CH3)2). 
MS (FAB+ in nba) m/z = 662 [M]+, 626 [M-Cl]+. 
FTIR (ATR)  = 2955 (w), 2929 (w), 2858 (w), 1590 (w), 1582 (w), 1489 (s, b), 1459 (s, b), 1416 (w), 
1283 (s), 1252 (m), 1205 (m), 1138 (m), 1091 (w), 1073 (w), 1032 (w), 999 (w), 938 (m), 883 (w), 840 
(vs), 806 (m), 782 (vs) cm-1. 
Bis-(1-(4-tert-butyldimethylsilyloxy)-3-(methylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
platinum(II) (50)  
As a side product of the synthesis of compound 38, 
compound 50 was isolated by column chromatography. 
Crystals suitable for X-Ray structure determination were 
obtained by evaporation of the solvents used for column 
chromatography (DCM/n-hexane). Due to the low quantity 
(few crystals were obtained), no further analysis was 
performed.  
 
MS (EI+): m/z = 902 [M]+, 679, 663, 221, 111, 97, 71, 57. 
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Chlorido-(1-(3-tert-butyldimethylsilyloxy)-3-(butylthio)-3-thioxo-prop-1-en-1-olate-
O,S)-(dimethylsulfoxide-S)-platinum(II) (39) 
Compound 17 (169 mg, 0.44 mmol) was reacted with 
K2PtCl4 (200 mg, 0.48 mmol), NaH (30 mg, 0.76 mmol 60 % 
in mineral oil), and DMSO (70 µL, 0.99 mmol) according to 
GP7. The mixture was stirred overnight and the crude 
material was subjected to column chromatography 
(mobile phase: DCM, Rf  0.3). Compound 39 (50 mg, 
17 %) was obtained as orange solid. 
 
 
1H NMR (600 MHz, CDCl3)  =7.52 (d, 3JHH = 8.1 Hz, 1H, Ar-H6), 7.47  7.43 (m, 1H, Ar-H2), 7.24 (m, 
1H, Ar-H5), 7.06 (s, 1H, =CH-), 7.01 (dd, 3JHH = 7.9, 2.4 Hz, 1H, Ar-H4), 3.66 (s, 6H, CH3(DMSO)), 3.25 (t, 
3JHH = 7.3 Hz, 2H, S-CH2-), 1.81  1.72 (m, 2H, SCH2-CH2-), 1.50 (m, 2H, SCH2CH2-CH2-), 1.01  0.93 (m, 
12H, SiC(CH3)3, SCH2CH2CH2-CH3), 0.23 (s, 6H, Si(CH3)2) ppm. 
13C{1H} NMR (151 MHz, CDCl3)  =180.5 (CS2), 174.5 (COPt), 156.3 (Ar-C3), 138.8 (Ar-C1), 129.9 (Ar-
C5), 124.1 (Ar-C4), 120.9 (Ar-C6), 119.5 (Ar-C2), 111.8 (CHCS2), 47.0 (2C, CH3(DMSO)), 34.3 (S-CH2-), 
30.2 (SCH2-CH2-), 25.9 (3C, SiC(CH3)3), 22.2 (SCH2CH2-CH2-), 18.4 (SiCq), 13.8 (SCH2CH2CH2-CH3), -4.2 
(2C, Si(CH3)2) ppm. 
MS (EI+) m/z = 689 [M]+. 
FTIR (ATR)  = 3013 (w), 2951 (w), 2929 (w), 2857 (w), 1599 (w), 1581 (w), 1488 (s), 1460 (s), 1418 
(w), 1361 (w), 1281 (s), 1250 (m), 1206 (m), 1147 (w), 1130 (m), 1090 (w), 1072 (w), 1035 (m), 1001 
(m), 940 (s), 840 (vs), 806 (w), 781 (vs) cm-1. 
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Chlorido-(1-(3-tert-butyldimethylsilyloxy)-3-(hexylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (40) 
The reaction was performed following GP7. K2PtCl4 
(200 mg, 0.48 mmol), DMSO (62 µL, 0.88 mmol), 18 
(180 mg, 0.44 mmol) and NaH (18 mg, 0.44 mmol 
60 % in mineral oil) were stirred for 2 d and workup 
was performed by column chromatography on 
silica gel (mobile phase: gradient DCM/n-hexane 
1:1 to 1:0, Rf  0.2), followed by repeated 
crystallization from DCM/pentane. This process 
afforded 40 (81 mg, 26 %) as orange solid. 
 
 
1H NMR (200 MHz, CDCl3)  =7.52 (d, 3JHH = 7.9 Hz, 1H, Ar-H6), 7.48  7.38 (m, 1H, Ar-H2), 7.25 (t, J = 
7.9 Hz, 1H, Ar-H5), 7.06 (s, 1H, =CH-), 7.01 (dd, 3JHH = 7.6, 2.0 Hz, 1H, Ar-H4), 3.66 (s, 3JPtH = 23.3 Hz, 
6H, CH3 (DMSO)), 3.24 (t, 3JHH = 7.3 Hz, 2H, S-CH2-), 1.92  1.60 (m, 2H, SCH2-CH2-), 1.40  1.07 (m, 6H, 
SCH2CH2-CH2-CH2-CH2-), 1.04  0.77 (m, 12H, SiC(CH3)3, -CH3), 0.24 (s, 6H, Si(CH3)2) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  =189.3 (CS2), 174.5 (COPt), 156.3 (Ar-C3), 138.9 (Ar-C1), 129.9 (Ar-C5), 
124.0 (Ar-C4), 120.9 (Ar-C6), 119.5 (Ar-C2), 111.8 (CHCS2), 47.0 (2C, CH3(DMSO)), 34.6 (S-CH2-), 31.4 
(SCH2-CH2-), 28.7 (SCH2CH2-CH2-), 28.1 (SCH2CH2CH2-CH2-), 25.9 (3C, SiC(CH3)3), 22.6 
(SCH2CH2CH2CH2-CH2-), 18.4 (SiCq ), 14.1 (SCH2CH2CH2CH2CH2-CH3), -4.2 (2C, Si(CH3)2) ppm. 
MS (FAB+ in nba) m/z = 718 [M+H]+. 
FTIR (ATR)  = 3019 (w), 2954 (w), 2928 (w), 2855 (w), 1599 (w), 1581 (w), 1488 (s), 1464 (s), 1405 
(w), 1361 (w), 1282 (s), 1252 (m), 1205 (m), 1145 (w), 1091 (w), 1072 (w), 1031 (m), 1000 (m), 984 
(w), 940 (s), 882 (w), 840 (vs), 806 (m), 781 (vs) cm-1. 
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Chlorido-(1-(4-tert-butyldimethylsilyloxy)-3-(methylthio)-3-thioxo-prop-1-en-1-olate-
O,S)-(dimethylsulfoxide-S)-platinum(II) (41)  
Following GP7, the reaction was conducted based on 200 mg 
(0.48 mmol) K2PtCl4, compound 19 (149 mg, 0.44 mmol), NaH 
(20 mg, 0.5 mmol 60 % in mineral oil), and DMSO (70 µL, 
0.99 mmol). After 2 days of stirring, workup afforded the 
crude material which was subjected to column 
chromatography using a gradient (mobile phase: 
DCM:acetone 1:0 to 1:1). Pure 41 (137 mg, 58 %) was 
obtained as orange powder.  
 
 
Analysis calcd. for C18H29ClO3PtS3Si·0.15 pentane: C 34.17, H 4.71 %; found C 34.27, H 4.60 %. 
1H NMR (200 MHz, CDCl3)  = 7.87 (d, 3JHH = 8.9 Hz, 2H, Ar-H2, Ar-H6), 7.06 (s, 1H, CHCS2), 6.80 (d, 3JHH 
= 8.8 Hz, 2H, Ar-H3, Ar-H5), 3.63 (s w/ Pt satellites, 3JPt-H = 23.4 Hz, 6H, CH3(DMSO)), 2.63 (s, 3H, 
SCH3), 0.94 (s, 9H, SiC(CH3)3), 0.19 (s, 6H, Si(CH3)2). 
13C{1H} NMR (50 MHz, CDCl3)  = 178.9 (CS2), 174.3 (COPt), 159.9 (Ar-C4), 130.3 (2C, Ar-C2, Ar-C6), 
120.5 (2C, Ar-C3, Ar-C5), 111.1 (CHCS2), 47.0 (2C, CH3(DMSO)), 25.7 (3C, SiC(CH3)2), 18.4 (SiCq), 17.63 
(SCH3), -4.2 (2C, Si(CH3)2). 
MS (FAB+ in nba) m/z = 648 [M]+. 
FTIR (ATR)   = 3007 (w), 2955 (w), 2928 (w), 2885 (w), 2856 (w), 1598 (m), 1576 (w), 1488 (s), 1467 
(vs, b), 1404 (m), 1362 (w), 1313 (m), 1249 (vs), 1168 (m), 1142 (m), 1130 (m), 1113 (m), 1037 (w), 
1008 (w), 984 (w), 960 (w), 911 (s), 900 (s), 836 (s), 802 (s), 786 (s) cm-1. 
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Chlorido-(1-(4-tert-butyldimethylsilyloxy)-3-(ethylthio)-3-thioxo-prop-1-en-1-olate-
O,S)-(dimethylsulfoxide-S)-platinum(II) (42) 
The reaction was performed following GP7. K2PtCl4 (200 mg, 
0.48 mmol), DMSO (70 µL, 0.99 mmol), 20 (155 mg, 
0.44 mmol) and NaH (23 mg, 0.58 mmol 60 % in mineral oil) 
were stirred overnight. Workup included column 
chromatography on silica gel (mobile phase: DCM, Rf  0.3), 
followed by repeated crystallization from DCM/pentane. This 
process afforded 42 (104 mg, 36 %) as orange powder. 
 
 
Analysis calcd. for C19H31ClO3PtS3Si: C 34.46; H 4.72  %; found C 34.70, H 4.63 %. 
1H NMR (200 MHz, CDCl3)  = 8.03  7.74 (m, 2H, Ar-H2, Ar-H6), 7.08 (s, 1H, CHCS2), 6.92  6.74 (m, 
2H, Ar-H3, Ar-H5), 3.65 (s w/ Pt satellites, 3JPt-H = 23.4 Hz, 6H, CH3(DMSO)), 3.26 (q, J = 7.4 Hz, 2H, 
SCH2), 1.44 (t, J = 7.4 Hz, 3H, SCH2CH3), 0.97 (s, 9H, SiC(CH3)3), 0.22 (s, 6H, Si(CH3)2). 
13C{1H} NMR (50 MHz, CDCl3)  = 182.6 (CS2), 174.6 (COPt), 159.9 (Ar-C4), 130.3 (2C, Ar-C2, Ar-C6), 
120.5 (2C, Ar-C3, Ar-C5), 111.3 (CHCS2), 47.0 (2C, CH3(DMSO)), 28.8 (SCH2), 25.7 (3C, SiC(CH3)3), 18.4 
(SiCq), 13.5 ((SCH2CH3), -4.2 (2C, Si(CH3)2). 
MS (ESI) m/z = 626 [M-Cl]+. 
FTIR (ATR)  = 3005 (w), 2953 (w), 2929 (w), 2858 (w), 1598 (m), 1491 (s), 1468 (s, b), 1404 (w), 1314 
(w), 1256 (vs), 1169 (m), 1131 (m), 1113 (w), 1037 (w), 975 (w), 909 (s), 837 (s), 803 (m), 783 (s) cm-1. 
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Chlorido-(1-(4-tert-butyldimethylsilyloxy)-3-(butylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (43) 
The reaction proceeded according to GP5. K2PtCl4 
(400 mg, 0.96 mmol), DMSO (140 µL, 1.97 mmol), 
NaOAc·3H2O (119 mg, 0.88 mmol), and 21 (335 mg, 
0.88 mmol) were stirred overnight. The crude material 
was subjected to column chromatography on silica gel 
(eluent as gradient: DCM/n-hexane 2:1 to 1:0). Evidence 
of the formed product 43 (Rf  ! 0.5)! was! found,! but! the!
compound was obtained as oil and could not be obtained 
as analytically pure material. 
 
 
1H NMR (200 MHz, CDCl3)  =7.86 (d, 3JHH = 8.7 Hz, 2H, Ar-H2, Ar-H6), 7.02 (s, 1H, CHCS2), 6.80 (d, 3JHH 
= 8.7 Hz, 2H, Ar-H3, Ar-H5), 3.62 (s, 3JPtH = 20.5 Hz, 6H, CH3(DMSO)) 3.20 (t, 3JHH = 7.3 Hz, 2H, S-CH2-), 
2.00  1.59 (m, 2H, SCH2-CH2-), 1.45 (dd, J = 15.1, 7.5 Hz, 2H, SCH2CH2-CH2-), 1.12  0.44 (m, 12H, 
SiC(CH3)3, SCH2CH2CH2-CH3), 0.19 (s, 6H, Si(CH3)2) ppm. 
Chlorido-(1-(4-tert-butyldimethylsilyloxy)-3-(hexylthio)-3-thioxo-prop-1-en-1-olate-
O,S)-(dimethylsulfoxide-S)-platinum(II) (44) 
Following GP7, the reaction was conducted based 
on 200 mg (0.48 mmol) K2PtCl4. After 4 days of 
stirring, workup included column chromatography 
on silica gel (mobile phase: DCM:THF 10:0 to 
10:0.5, Rf  0.1) but could not afford the desired 
product 44.  
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Chlorido-(1-(3-hxdroxy)-3-(methylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (45)  
Following GP7, the reaction was conducted based on 200 mg 
(0.48 mmol) K2PtCl4, compound 23 (99 mg, 0.44 mmol), NaH (20 mg, 
0.5 mmol 60 % in mineral oil), and DMSO (70 µL, 0.99 mmol). After 
overnight stirring, workup afforded the crude material which was 
subjected to column chromatography (mobile phase: DCM:acetone 
10:1, Rf  0.6). Pure 45 (132 mg, 51 %) was obtained as orange 
powder.  
 
 
Analysis calcd. for C12H15ClO3PtS3·0.4 pentane: C 29.88, H 3.55, S 17.09 %; found C 30.29, H 3,18, 
S 16,40 %. 
1H NMR (600 MHz, Acetone-d6)  = 8.82 (s, 1H, Ar-OH), 7.64  7.50 (m, 2H, Ar-H2, Ar-H6), 7.30 (m, 
1H, Ar-H5), 7.22 (s, 1H, CHCS2), 7.12  7.02 (m, 1H, Ar-H4), 3.68 (s, 3JPt-H = 24.3 Hz, 6H, CH3(DMSO)), 
2.70 (s, 3H, SCH3). 
13C{1H} NMR (151 MHz, Acetone-d6)  = 182.3 (CS2), 175.3 (COPt), 159.0 (s, Ar-C3), 139.7 (Ar-C1), 
131.0 (Ar-C5), 120.3 (Ar-C4), 120.0 (Ar-C6), 115.7 (Ar-C2), 111.8 (CHCS2), 47.0 (2C, 2JPt-C = 56.2 Hz, 
CH3(DMSO)), 17.9 (SCH3). 
MS (FAB+ in nba) m/z = 534 [M]+, 498 [M-Cl]+. 
FTIR (ATR)  = 3302 (m, b), 3024 (w), 3007 (w), 2954 (w), 2921 (m), 2853 (w), 1662 (w), 1611 (w), 
1583 (m), 1511 (s), 1491 (s), 1472 (s), 1445 (s), 1426 (s), 1402 (s), 1366 (w), 1329 (m), 1291 (s), 1248 
(m), 1210 (m), 1092 (vs), 1069 (m), 1029 (m)m, 997 (m), 973 (m), 962 (w), 933 (w), 910 (s), 865 (m), 
796 (m), 778 (s) cm-1. 
  
176 
 
16 Compound Syntheses and Analyses 
 
 
 
Chlorido-(1-(3-hxdroxy)-3-(ethylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (46) 
The reaction was performed following GP7. K2PtCl4 (200 mg, 
0.48 mmol), DMSO (70 µL, 0.99 mmol), 24 (105 mg, 0.44 mmol) and 
NaH (20 mg, 0.5 mmol 60 % in mineral oil) were stirred overnight. 
Workup included column chromatography on silica gel (mobile 
phase: DCM:acetone 10 : 1, Rf  0.5), upon which 46 (132 mg, 55 %) 
was obtained as orange powder. 
 
 
Analysis calcd. for C13H17ClO3PtS3·0.15 pentane: C 29.55; H 3.39; S 17.21 %; found C 29.48, H 3.37, 
S 17.20 %. 
1H NMR (200 MHz, THF-d8)  = 8.72 (s, 1H, Ar-OH), 7.59  7.33 (m, 2H, Ar-H2, Ar-H6), 7.33  7.03 (m, 
2H, Ar-H5, CHCS2), 7.03  6.79 (m, 1H, Ar-H4), 3.60 (s, 3JPt-H = 23.7 Hz, 6H, CH3(DMSO), overlaid by 
THF), 3.25 (q, 3JH-H = 7.4 Hz, 2H, SCH2), 1.42 (t, 3JH-H = 7.4 Hz, 3H, SCH2CH3). 
1H NMR (250 MHz, Acetone-d6)  = 8.80 (s, 1H, Ar-OH), 7.59  7.46 (m, 2H, Ar-H2, Ar-H6), 7.31 (t, 3JH-H 
= 8.1 Hz, 1H, Ar-H5), 7.21 (s, 1H, CHCS2), 7.16  7.01 (m, 1H, Ar-H4), 3.68 (s, 3JPt-H = 24.1 Hz, 6H, 
CH3(DMSO)), 3.29 (q, 3JH-H = 7.4 Hz, 2H, SCH2), 1.44 (t, 3JH-H = 7.4 Hz, 3H, SCH2CH3). 
13C{1H} NMR (50 MHz, THF-d8)  = 180.7 (CS2), 175.6 (COPt), 159.4 (Ar-C3), 139.8 (Ar-C1), 130.5 (Ar-
C5), 120.3 (Ar-C6), 119.51(Ar-C4), 115.7 (Ar-C2), 112.1 (s), 111.3 (CHCS2), 46.7 (2C, CH3(DMSO)), 29.3 
(SCH2), 13.9 (SCH2CH3). 
13C{1H} NMR (63 MHz, Acetone-d6)  = 181.15 (CS2), 175.46 (COPt), 158.86 (Ar-C3), 139.58 (Ar-C1), 
130.83 (Ar-C5), 120.26 (Ar-C6), 119.86 (Ar-C4), 115.55 (Ar-C2), 111.93 (CHCS2), 46.85 (2C, 
CH3(DMSO)), 13.63 (SCH2CH3). Signal of SCH2 overlaid by solvent signal 
MS (ESI+) m/z = 571 [M+Na]+, 512 [M-Cl-H]+. 
FTIR (ATR)  = 3335 (m, b), 3005 (w), 2981 (w), 2921 (m), 2853 (w), 1609 (w), 1581 (m), 1507 (s), 
1490 (s), 1466 (s), 1441 (s), 1429 (s), 1402 (s), 1311 (m), 1288 (m, b), 1255 (m), 1237 (m), 1198 (m), 
1138 (w), 1098 (vs), 1069 (m), 1028 (s), 997 (m), 972 (m), 931 (w), 911 (s), 884 (m), 796 (m), 779 (vs) 
cm-1. 
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Chlorido-(1-(4-hxdroxy)-3-(methylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (47) 
Following GP7, the reaction was conducted using 200 mg 
(0.48 mmol) K2PtCl4, compound 26 (99 mg, 0.44 mmol), NaH (20 mg, 
0.5 mmol 60 % in mineral oil), and DMSO (70 µL, 0.99 mmol). After 
stirring for 5 days, workup afforded the crude material which was 
subjected to column chromatography (mobile phase: DCM:acetone 
10:1, Rf  0.6). Pure 47 (136 mg, 58 %) was obtained as orange 
powder.  
 
 
Analysis calcd. for C12H15ClO3PtS3·0.35 pentane: C 29.53; H 3.46; S 17.20  %; found C 29.56, H 3.33, 
S 16.49 %. 
1H NMR (200 MHz, Acetone-d6)  = 9.28 (s, 1H, Ar-OH), 8.03 (d, 3JH-H = 8.9 Hz, 2H, Ar-H2, Ar-H6 ), 7.23 
(s, 1H, CHCS2), 6.92 (d, 3JH-H = 8.8 Hz, 2H, Ar-H3, Ar-H5), 3.66 (s, 3JPt-H = 24.3 Hz, 6H, CH3(DMSO)), 2.68 
(s, 3H, SCH3). 
13C{1H} NMR (50 MHz, Acetone-d6)  = 179.64 (CS2), 175.0 (COPt), 162.4 (Ar-C4), 131.4 (2C, Ar-C2, Ar-
C6), 129.3 (Ar-C1), 116.5 (2C, Ar-C3, Ar-C5), 110.8 (CHCS2), 46.8 (2C, CH3(DMSO)), 17.6 (SCH3). 
195Pt NMR (128 MHz, DMSO-d6)  = -3082 ppm.  
MS (FAB+ in nba) m/z = 534 [M]+, 498 [M-Cl-]+. 
FTIR (ATR)  = 3320 (m, b), 2999 (w), 2912 (w), 2854 (w), 1602 (m), 1585 (m), 1520 (w), 1490 (s), 
1454 (vs), 1416 (s), 1358 (w), 1313 (w), 1281 (m), 1265 (m), 1212 (m), 1169 (m), 1122 (vs, b), 1026 (s), 
980 (m), 952 (m), 934 (m), 925 (w), 842 (s), 794 (vs) cm-1. 
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Chlorido-(1-(4-hxdroxy)-3-(ethylthio)-3-thioxo-prop-1-en-1-olate-O,S)-
(dimethylsulfoxide-S)-platinum(II) (48) 
The reaction was performed following GP7. K2PtCl4 (200 mg, 
0.48 mmol), DMSO (70 µL, 0.99 mmol), 27 (105 mg, 0.44 mmol) and 
NaH (20 mg, 0.5 mmol 60 % in mineral oil) were stirred overnight. 
Workup included column chromatography on silica gel (mobile 
phase: DCM:THF 10 : 0.5, Rf  0.5), upon which 48 (31 mg, 13 %)was 
obtained.  
 
 
When the reaction was repeated following GP5 (base: NaOAc 58 mg, 0.71 mmol) and column 
chromatography was performed using DCM:acetone 10 : 1 as mobile phase, the compound was 
obtained in improved yield and purity (175 mg, 73 %) as orange powder. 
Analysis could not be obtained. NMR data suggest a pure compound. 
1H NMR (400 MHz, THF-d8)  = 9.10 (s, 1H, Ar-OH), 7.96 (d, 3JH-H = 8.8 Hz, 2H, Ar-H2, Ar-H6), 7.15 (s, 
1H, CHCS2), 6.78 (d, 3JH-H = 8.8 Hz, 2H, Ar-H3, Ar-H5), 3.59 (s, 6H, CH3(DMSO) overlaid by THF), 3.24 (q, 
3JH-H = 7.4 Hz, 2H, SCH2), 1.40 (t, 3JH-H = 7.4 Hz, 3H, SCH2CH3). 
1H NMR (200 MHz, Acetone-d6)  = 9.29 (s, 1H, Ar-OH), 8.02 (d, 3JH-H = 8.9 Hz, 2H, Ar-H2, Ar-H6), 7.23 
(s, 1H, CHCS2), 6.93 (d, 3JH-H = 8.9 Hz, 2H, Ar-H3, Ar-H5), 3.66 (s, 3JPt-H = 24.2 Hz, 6H, CH3(DMSO)), 3.28 
(q, 3JH-H = 7.4 Hz, 2H, SCH2), 1.41 (t, 3JH-H = 7.4 Hz, 3H, SCH2CH3). 
13C{1H} NMR (101 MHz, THF-d8)  = 178.03 (CS2), 175.37 (COPt), 162.84 (Ar-C4), 131.36 (2C, Ar-C2, Ar-
C6), 129.32 (Ar-C1), 116.39 (2C, Ar-C3, Ar-C5), 111.23 (CHCS2), 46.70 (2C, CH3(DMSO)), 29.05 (SCH2), 
13.97 (SCH2CH3). 
13C{1H} NMR (63 MHz, Acetone-d6)  = 175.41 (COPt), 162.46 (Ar-C4), 131.45 (2C, Ar-C2, Ar-C6), 
129.33 (Ar-C1), 116.54 (2C, Ar-C3, Ar-C5), 111.19 (CHCS2), 46.87 (2C, CH3(DMSO)), 13.78 (SCH2CH3). 
Signal of SCH2 overlaid by solvent signal; quartary CS2 not observed. 
MS (ESI+) m/z = 570 [M+Na]+, 512 [M-Cl-H]+, 235. 
FTIR (ATR)  = 3326 (m, b), 2999 (w), 2963 (w), 2924 (w), 2865 (w), 1602 (m), 1584 (m), 1522 (w), 
1490 (s), 1460 (vs), 1449 (vs), 1417 (s), 1360 (m), 1346 (m), 1308 (w), 1281 (m), 1260 (s), 1208 (s), 
1170 (s), 1121 (vs), 1025 (s), 971 (m), 850 (m), 842 (m), 793 (vs) cm-1.  
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16.3 Alkynyl-functionalized compounds 
Conversion of 4-hydroxy acetophenone 2 with butinyl bromide  
Following GP1, 4-hydroxy acetophenone (2 g; 14.69 mmol; 1 eq.), K2CO3 (3.05 g; 22.03 mmol; 1.5 eq.) 
and butinyl bromide (1.65 mL; 17.63 mmol; 1.2 eq.) were stirred for 24 h or 7 d.  
The same reaction was repeated using 4-hydroxy acetophenone (2 g; 14.69 mmol; 1 eq.), Cs2CO3 
(7.18 g; 22.03 mmol; 1.5 eq.) and butinyl bromide (1.65 mL; 17.63 mmol; 1.2 eq.). The mixture was 
stirred for 44 h at r.t.  
Furthermore, the reaction was carried out by following GP2, using 4-hydroxy acetophenone (1 g, 
7.34 mmol, 1 eq.), Cs2CO3 (3.57 g, 11.02 mmol, 1.5 eq.), butinyl bromide (1.11 mL, 8.08 mmol, 
1.1 eq.) and KI (0.15 g, 0.734mmol, 0.1 eq.).  
In all cases, the strating material 4-hydroxy acetophenone was recovered in almost quantitative 
yields, thus indicating that no conversion had occurred due to decomposition of butinyl bromide. 
4-(Pent-4-in-1-yloxy)acetophenone (53) 
4-Hydroxy acetophenone (1 g, 7.39 mmol), was convereted with pentynyl 
chloride (856 µL, 8.08 mmol) according to GP2, using Cs2CO3 (3.59 g, 
11.02 mmol), and KI (0.12 g, 0.7 mmol). The product 53 was obtained as white 
crystals (1.37 g; 91.9 %). 
 
Analysis calcd. for C13H14O2 (M = 202,25 g/mol): C, 77.20; H, 6.98; found: C, 76.82; H, 6.92. 
m.p.: 60,4 - 61,2 °C  
1H NMR (400 MHz, CDCl3):  = 7.92 (d, 3JHH = 8.9 Hz, 2H, Ar-H2, Ar-H6), 6.93 (d, 3JHH = 8.9 Hz, 2H, Ar-
H3, Ar-H5), 4.13 (t, 3JHH = 6.11 Hz, 2H, O-CH2), 2.55 (s, 3H, CH3), 2.41 (td, 3JHH = 6.93 Hz, 4JHH = 2.63 Hz, 
2H, CH2 ), 2.02 (m, 2H, CH2!), 1.98 (t, 4JHH = 2.7 Hz, 1H, CH) ppm. 
13C{1H} NMR (100 MHz, CDCl3): " = 197.7 (Ar-C1), 163.5 (Ar-C4), 131.1 (Ar-C2, Ar-C6), 130.8 (C=O), 
114.50 (Ar-C3, Ar-C5), 82.3 (C-), 69.2 (CH), 66.4 (O-CH2), 27. 8 (CH2!), 26.2 (S-CH3), 14.9 
(CH2 ) ppm. 
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MS(EI+) m/z = 202 [M]+, 187 [M-Me]+, 121 [M-Me-pentynyl+H]+. 
FTIR (ATR)  = 3234 (m), 2998 (w), 2957 (w), 2938, 2880 (w), 1665 (s), 1597 (vs), 1511 (s), 1465 (m), 
1422 (m), 1359 (s), 1306 (m), 1254 (vs), 1171 (vs), 1120 (m), 1041 (s), 959 (m), 931 (m), 827 (vs), 704 
(s,b), 588 (vs) cm-1. 
4-(Prop-2-inyloxy)--hydroxydithiocinnamic acid methyl ester (54) 
Compound 51 (494.9 mg, 2.87 mmol), KOtBu (651.2 mg, 
5.74 mmol), CS2 (0.23 mL, 4.018 mmol) and methyl iodide (0.18 mL, 
2.87 mmol) were reacted according to GP3. Column 
chromatography was performed using dichloromethane as mobile 
phase (Rf  0.9). 54 was obtained as yellow solid (108 mg, 14.2 %).  
 
Compound 51 (1.0 g, 5.74 mmol) was furthermore converted using 2.5 eq. (1.61 g, 14.35 mmol) or 
3 eq. of KOtBu (1.93 g; 17.22 mmol), CS2 (0.48 mL, 8.036 mmol) and methyl iodide (0.36 mL; 
5.74 mmol). Column chromatography using dichloromethane/n-hexane (2 : 1, Rf  0.7; or 3 : 2, 
Rf  0.6) yielded 54 as yellow solid. When 3 eq. of KOtBu were used, the yield was significantly 
enhanced (550 mg, 36.2 % / 3 eq. vs. 237 mg, 15.6 % / 2.5 eq.). 
Analysis calcd. for C13H12O2S2 (M = 264.36 g/mol): C, 59.06; H, 4.58; S, 24.26; found: C, 59.36; H, 4.56; 
S, 24.80. 
m.p.: 109.7-113.1 °C 
1H NMR (400 MHz, CDCl3)  = 15.16 (s, 1H, OH), 7.77 (d, 3JHH = 9.0 Hz, 2H, Ar-H2, Ar-H6), 7.03 (d, 3JHH = 
9.0 Hz, 2H, Ar-H3, Ar-H6), 6.93 (s, 1H, =CH-), 4.76 (d, 4JHH = 2.4 Hz, 2H, O-CH2), 2.65 (s, 3H, S-CH3), 
2.56 (t, 4JHH = 2.4 Hz, 1H, CH) ppm. 
13C{1H} NMR (100 MHz, CDCl3)   = 216.2 (CS2), 169.4 (C-OH), 160.7 (Ar-C4), 128.8 (Ar-C2, Ar-C6), 
127.1 (Ar-C1), 115.2 (Ar-C3, Ar-C5), 107.4 (=CH-), 77.9 (C-), 76.3 (CH), 65.0 (O-CH2), 17.2 (S-CH3) 
ppm. 
MS (EI+) m/z = 264 [M]+, 217 [M-SMe]+, 178 [M-SMe-Propargyl]+ 
FTIR (ATR)  = 3273 (m), 2912 (w), 2859 (w), 1603 (m), 1580, 1551 (m), 1501(m), 1427(m), 1374 (m), 
1295 (w), 1230 (vs), 1183 (s), 1120 (m), 1020 (m), 937 (vs), 841 (m), 808 (m), 788 (m) cm-1. 
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4-(Pent-4-in-1-yloxy)--hydroxydithiocinnamic acid ethylester (55) 
53 (1 g, 4.94 mmol), CS2 (0.41 mL, 6.914 mmol), ethyl 
iodide (0.4 mL, 4.94 mmol) and KOtBu (1.39 g, 
12.35 mmol, 2.5 eq) were converted following GP3 in 
slightly altered reactant ratios. Column chromatography 
with dichloromethane/n-hexane (2 : 1; Rf  0.7) as mobile 
phase yielded 55 (638 mg; 42.3 %) as yellow solid.  
 
Analysis calcd. for C16H18O2S2 (M = 306.44 g/mol): C, 62.71; H, 5.92, S, 20.93; found: C, 63.09; H, 6.08; 
S, 20.98. 
m.p.: 64.0 °C  
1H NMR (400 MHz, CDCl3)  = 15.23 (s, 1H, OH), 7.85 (d, 3JHH = 9.1 Hz, 2H, Ar-H2, Ar-H6), 6.95 (d, 3JHH = 
9.1 Hz, 2H, Ar-H3, Ar-H6), 6.88 (s, 1H, =CH-), 4.14 (t, 3JHH = 6.1 Hz, 2H, O-CH2 ), 3.27 (q, 3JHH = 7.4 Hz, 
2H, S-CH2), 2.42 (td, 3JHH = 6.9 Hz, 4JHH = 2,7 Hz, 2H, CH2!), 2.03 (p, 3JHH = 6.5 Hz, 2H, CH2"), 1,98 (t, 1H, 
4JH1-H3 = 2.7 Hz, !CH ), 1,38 (t, 3JHH = 7.4 Hz, 3H, CH3) ppm. 
13C{1H}-NMR (100 MHz, CDCl3)  = 215.9 (CS2), 170.7 (C-OH), 162.9 (Ar-C4), 129.1 (Ar-C2, Ar-C6), 
126.8 (Ar-C1), 115.0 (Ar-C3, Ar-C5), 107.5 (=CH-), 83.35 (!C-), 69.2 (!CH), 66.4 (O-CH2  ), 27.8 (CH2"), 
27.5 (S-CH2), 14.9 (CH2!), 12.8 (CH3) ppm. 
MS (EI+) m/z = 306 [M]+, 245 [M-SEt]+, 187 [M-SEt-(CH2=C=S)]+, 121. 
FTIR (ATR)  = 3261 (m), 2971 (w), 2954 (w), 2925 (w), 2869 (w), 1605 (m), 1581 (vs), 1545 (s), 1502 
(vs), 1461 (m), 1430 (s), 1400 (m), 1385 (m), 1368 (m), 1298 (w), 1228 (vs), 1176 (s), 1118 (m), 1046 
(s), 950 (s), 932 (s), 837 (s), 806 (w), 778 (vs), 643 (m), 607 (m), 529 (m) cm-1. 
Synthesis of 4-Bromo--hydroxydithiocinnamic acid propargylic ester (57)103 
4-Brom--hydroxydithiocinnamic acid 56 was prepared according to 
literature procedures and could be obtained in 56 % yield after 
recrystallization from n-hexane/ethyl acetate (4:1). Further following 
the literature procedure, 57 (43 %) was then isolated after 
crystallization from ethanol and isopropanol as yellow-orange solid.  
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The overall yield of this reaction was 24 % over two steps. 
1H NMR (400 MHz, CDCl3)  = 14.93 (s, 1H,OH), 7.74 (d, 3JHH = 8.8 Hz, 2H, Ar-H3, Ar-H5), 7.59 (d, 
3JHH = 8.8 Hz, 2H, Ar-H2, Ar-H6), 6.87 (s, 1H, =CH-), 4.02 (d, 4JHH = 2.7 Hz, 2H, S-CH2), 2.25 (t, 4JHH = 
2.7 Hz, 1H, CH) ppm. 
13C{1H} NMR (100 MHz, CDCl3)   = 213.8 (CS2), 169.3 (C-OH), 133.0 (Ar-C1), 132.3 (2C, Ar-C2, Ar-C6), 
128.3 (2C, Ar-C3, Ar-C5), 127.1 (Ar-C4), 107.4 (=CH-), 77.3 (C-), 72.1 (CH), 22.3 (S-CH2!) ppm. 
MS (EI+) m/z = 312/314 [M/M+2]+, 274/276 [M-C3H2]+, 241 [M-Spropargyl]+, 183, 162, 155, 85. 
FTIR (ATR)  = 3294 (m), 2961 (w), 2873 (w), 1582, 1559 (m), 1478 (m), 1415 (m), 1238 (m), 1218 (m), 
1069, 1052 (m), 1007 (m), 961 (m), 831 (m), 785 (m), 761 (m), 667 (m), 639 (m), 459 (m) cm-1. 
Conversion of 4-bromo-acetophenone with CS2 and propargyl bromide (58) 
Furthermore, preparation of 57 was attempted by following GP3. 4-
bromo acetophenone (0.99 g, 5 mmol), KOtBu (1.12 g, 10 mmol), CS2 
(0.42 mL, 7 mmol) and propargyl bromide (0.54 mL, 5 mmol, 80 % in 
toluene) were used. When the alkinyl halogenide was added at room 
temperature, an immediate brown discoloration appeared. Column 
chromatography with a gradient of dichloromethane/hexanes (1:3 to 
1:0, Rf  0,5) afforded a yellow solid (785.2 mg) which was identified as 
rearrangement product.  
 
 
1H NMR (600 MHz, CDCl3)  = 7.82 (dd, JHH = 8.5, 2.6 Hz, 2H, Ar-H3, Ar-H5), 7.57 (dd, JHH = 8.5, 1.9 Hz, 
2H, Ar-H2, Ar-H6), 7.34/7.33 (d, JHH = 1.1 Hz / s, 1H, C(O)=CH-CS2 ), 6.46/6.39 (m / d, JHH = 1.1 Hz, 1H, 
S-CH=C(CH3)), 2.31 (d, 4JHH = 0.9 Hz, 3H, CH3). 
13C{1H} NMR (151 MHz, CDCl3)  = 182.7/182.4 (CS2), 168.8/168.4 (Ar-C(-O-)=), 137.39/137.36 (Ar-
C1), 136.8/131.6 (=C(CH3)-), 131.9 (2C, Ar-C2, Ar-C6), 129.3/129.2 (2C, Ar-C3, Ar-C5), 126.46/126.45 
(Ar-C4), 118.8/112.2 (=CH-CS2), 103.4/102.6 (=CH-S), 16.1/15.8 (CH3). 
MS (EI+) m/z = 312/314 [M/M+2]+; 284/286 [M-CHCH3]+, 279/281 [M-SH]+; 183/185; 157, 155. 
FTIR (ATR)  =3083, 3054 (w), 2913 (w), 1584, 1557 (m), 1489 (m), ca. 1450 (vs), 1388 (m), 1231 (s), 
1179 (m), 1067 (s), 1052 (s), 1006 (m), 977 (m), 848 (m), 815 (m), 769 (m), 641 (m) cm-1. 
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In a second attempt to circumvent the brown discoloration assumed to indicate the cyclization 
reaction, 4-bromo acetophenone (1.99 g, 10 mmol), KOtBu (2.24 g, 20 mmol) and CS2 (1.08 mL, 
14 mmol) were reacted. After 3.5 h of stirring at -78 °C, propargyl bromide (1.08 mL, 10 mmol, 80 % 
in toluene) was added. TLC control immediately after addition of the alkinyl halogenide indicated the 
formation of two new products (Rf10.3 und Rf20.7 in DCM). After 1.5 h of no visible conversion, the 
suspension was slowly allowed to warm to room temperature, which quickly lead to the occurence of 
a dark-brown discoloration, barely indicated in TLC controls. Thus, the suspension was quickly cooled 
again and stirred for another hour upon which sulfuric acid (35 mL, 0.5 M aqueous solution) was 
added. The phases were separated, extracted with DCM (3 ´ 5 mL), washed with water (2 ´ 5 mL) 
and dried over sodium sulfate. After evaporation of the solvents, an oily residue was obtained. NMR 
analysis indicated the presence of the desired product 57, but purification by crystallization methods 
was not possible.  
4-Bromo--hydroxydithiocinnamic acid butinyl ester (59) 
Preparation of 59 was achieved by slightly modifying the reactant 
ratios in GP3. By using 4-Bromo acetophenone (3.98 g, 20 mmol), 
CS2 (1.7 mL, 28 mmol), butinyl bromide (1.7 mL, 18 mmol, 0.9 eq.) 
and KOtBu (4.51 g, 40 mmol), crude 59 was obtained which was 
purified by column chromatography with 
dichloromethane/n-hexane (3 : 2, Rf  0,6) as mobile phase. 59 
(1.46 g, 22.3 %) was obtained as yellow solid. 
 
 
m.p.: 66,4 °C  
Analysis calcd. for C12H11BrOS2 (M = 327,24 g/mol): C, 47.71; H, 3.39; S, 19.60; found C, 48.19; H, 
3.50; S, 19.41. 
1H NMR (600 MHz, CDCl3):  = 15.00 (s, 1H, OH); 7.74 (d, 3JHH = 8.8 Hz, 2H, Ar-H3, Ar-H5); 7.59 (d, 3JHH 
= 8.8 Hz, 2H, Ar-H2, Ar-H6); 6.88 (s, 1H, =CH-); 3.46 (t, 3JHH = 7.1 Hz, 2H, S-CH2 ); 2.65 (td, 3JHH = 7.1, 
4JHH = 2.7 Hz, 2H, CH2!); 2.07 (1H, t, 4JHH = 2,6 Hz, !CH) ppm. 
13C{1H} NMR (150 MHz, CDCl3):  = 216.6 (CS2); 169.5 (C-OH); 133.5 (Ar-C1); 132.6 (2C, Ar-C2, Ar-C6); 
128.6 (2C, Ar-C3, Ar-C5); 127.2 (Ar-C4); 108.2 (=CH-); 81.97 (!C-); 70.0 (!CH); 32.0 (S-CH2"); 17.9 (CH2 
!) ppm. 
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MS (EI+) m/z = 326/328 [M/M+2]+, 274/276 [M-C4H4]+, 241/243 [M-Sbutinyl]+, 183/185, 162, 
155/157, 85. 
FTIR (ATR)  = 3283 (m), 2961, 2927 (w), 2851 (w), 1578 (s), 1553 (m), 1481 (s), 1414 (s), 1379 (m), 
1232 (vs), 1206 (s), 1074 (m), 1052 (m), 1007 (m), 953 (vs), 830 (vs), 797 (vs), 750 (vs), 666 (vs), 641 
(vs), 544 (s) cm-1. 
Conversion of 54 with one equivalent of K2PtCl4 and DMSO 
54 (108 mg; 0,409 mmol), K2PtCl4 (200 mg; 0,482 mmol), DMSO (0,06 mL; 0,876 mmol) and 
NaOAc·3H2O (56 mg; 0,409 mmol) converted following GP5. Repeated crystallization from DCM/n-
hexane did not yield the desired complex 60. 
Preparation of 60 was further attempted by using 54 (62,6mg; 0,237mmol), K2PtCl4 (108,2 mg; 0,261 
mmol), DMSO (0,03 mL; 0,474 mmol) and KOtBu (26,6 mg; 0,237 mmol) according to GP6. Repeated 
crystallization from DCM/n-hexane did not yield the desired complex. 
The same base/reactant combination was also used in an approach using inert conditions (GP6), 
again without success. 
Bis(4-( Prop-2-inyloxy)--hydroxydithiocinnamic acid ethyl ester-O,S)-platinum(II) 
(61) 
Following GP8, 54 (127.4 mg; 0.482 mmol), K2PtCl4 (100 mg; 
0.241 mmol) und NaOAc·3H2O (66 mg, 0.482 mmol) were 
converted to give a dark-red crude material. This was 
precipitated from DCM/hexane, followed by flushing through 
a short plug of silica gel using DCM and traces of hexane 
when crystallization did not afford a pure compound. The 
target complex was isolated as dark-red solid (18.5 mg, 
10.6 %)  
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Analysis calcd. for C26H22O4PtS4: C, 43.26; H, 3.03; S, 17.77; found C, 43.19; H, 2.84; S, 17.36. 
1H NMR (400 MHz, CDCl3)  = 8.02 (d, 3JHH = 9.0 Hz, 4H, Ar-H2, Ar-H6), 7.09 (s, 2H, =CH-), 7.02 (d, 3JHH 
= 9.0 Hz, 4H, Ar-H3, Ar-H5), 4.77 (d, 4JHH = 2.4 Hz, 4H, O-CH2), 2.63 (s, 6H, S-CH3), 2.56 (t, 4JHH = 2.4 Hz, 
2H, CH) ppm. 
13C{1H} NMR (100 MHz, CDCl3)  = 177.3 (CS2), 174.2 (C-OPt), 160.7 (Ar-C4), 132.7 (Ar-C1), 129.7 (2C, 
Ar-C2, Ar-C6), 115.4 (2C, Ar-C3, Ar-C5), 112.4 (=CH-), 78.1 (C-), 76.2 (CH), 55.9 (O-CH2), 17.3 
(S-CH3) ppm. 
MS (ESI+) m/z = 744.8 [M+Na]+. 
FTIR (ATR)  = 3278 (m), 2918 (w), 2851 (w), 1602 (s), 1582 (m), 1495 (m), 1449 (vs), 1405 (m), 1308 
(s), 1290 (s), 1259 (s), 1242 (s), 1219 (s), 1177 (m), 1020 (w), 1030 (m), 979 (m), 954 (m), 836 (m), 808 
(m), 784 (m) cm-1. 
Bis(4-(Pent-4-in-1-yloxy)--hydroxydithiocinnamic acid ethyl ester-O,S)-platinum(II) 
(62) 
55 (147.7 mg; 0.482 mmol), K2PtCl4 (100 mg; 
0.241 mmol) und NaOAc·3H2O (65.6 mg, 
0.482 mmol) were reacted following GP8 and 
stirred for 4 days. For purification, the crude solid 
was first precipitated from DCM/n-hexane, the 
precipitate filtered and then flushed through a plug 
of silica gel using DCM as solvent. The pure product 
(54 mg; 28 %) was obtained as red solid.  
 
Analysis calcd. for C32H34O4PtS4 (M = 805,95 g/mol): C, 47.69; H, 4.25; S, 15.91; C, 47.38; H, 4.21; S, 
15.41. 
1H NMR (400 MHz, CDCl3)  = 8.00 (d, 3JHH = 9.0 Hz, 2H, Ar-H2, Ar-H6); 7.08 (s, 1H, =CH-); 6.94 (d, 3JHH 
= 9.0 Hz, 2H, Ar-H3, Ar-H6); 4.15 (t, 3JHH = 6.1 Hz, 2H, O-CH2 ); 3.22 (q, 3JHH = 7.4 Hz, 2H, S-CH2); 2.43 
(td, 3JHH = 7.0 Hz, 4JHH = 2.7 Hz, 2H, CH2!); 2.04 (m, 2H, CH2"); 1.99 (t, 4JHH = 2.6 Hz, 1H, !CH); 1.44 (t, 
3JHH = 7.4 Hz; 3H, CH3) ppm. 
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13C{1H} NMR (100 MHz. CDCl3)  = 175.9 (CS2), 174.6 (C-OPt), 162.3 (Ar-C4), 131.9 (Ar-C1), 129.8 (Ar-
C2, Ar-C6), 114.9 (Ar-C3, Ar-C5), 112.6 (=CH-), 83.4 (C-), 69.2 (CH), 66.4 (O-CH2 ), 28.3 (CH2!), 27.9 
(S-CH2), 14.9 (CH2"), 13.4 (CH3) ppm. 
MS (DEI+) m/z = 805 [M]+. 
MS(ESI+) m/z = 828 [M+Na]+, 685 [M-2SEt+2H]+. 
FTIR (ATR)  = 3270 (w), 3254 (w), 2956 (w), 2924 (w), 2873 (w), 1601 (w), 1578 (m), 1493 (m), 1447 
(vs), 1405 (m), 1311 (m), 1290 (m), 1244 (vs), 1223 (s), 1175 (s), 1044 (m), 960 (m), 837 (m), 808 (m), 
785 (s), 655 (m), 533 (m) cm-1. 
Conversion of 55 with one equivalent of K2PtCl4 and DMSO (63) 
55 (119 mg, 0.388 mmol) K2PtCl4 (200 mg, 0.482 mmol), 
DMSO (62 µL, 0.876 mmol) and NaOAc (36 mg, 
0.438 mmol) were converted according to GP5. After 4 
days of stirring, the crude product was purified by 
column chromatography on silica gel using a gradient 
(mobile phase DCM/acetone 100 : 2.5 to 100 : 10, 
Rf  0.4), upon which an orange crystalline solid was 
isolated. This was characterized as the triple-bond 
hydrated compound (48 mg, 19 % based on amount of 
55 used). 
 
 
Analysis calcd for C18H25ClO4PtS3 · 0.2 CH2Cl2: C, 34.20; H, 3.99; S, 15.22; found C, 33.51, H 3.90, S, 
14.76. 
1H NMR (200 MHz, CDCl3)  = 7.95 (d, 3JHH = 8.9 Hz, 2H, Ar-H2, Ar-H6), 7.09 (s, 1H, =CH-), 6.87 (d, 3JHH 
= 8.9 Hz, 2H, Ar-H3, Ar-H6), 4.02 (t, 3JHH = 6,0 Hz, 2H, O-CH2 ), 3.65 (s,3JPtH = 23.4 Hz, 6H, CH3 (DMSO)), 
3.26 (q, 3JHH = 7.5 Hz, 2H, S-CH2), 2.66 (t, 3JHH = 7.5 Hz, 3H, CH2!), 2.18 (s,3H, COCH3), 2.13-2.00 (m, 2H, 
CH2"), 1.44 (t, 3JHH = 7.4 Hz, 3H, CH3) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  = 208.9 (C=O), 178.6 (CS2), 174.8 (C-OPt), 162.9 (Ar-C4), 130.7/130.4 
(Ar-C2, Ar-C6), 129.8 (Ar-C1), 114.8 (2C, Ar-C3, Ar-C5), 111.2 (=CH-), 67.08 (O-CH2 ), 46.7 (CH3 
(DMSO)), 39.6 (CH2!), 29.9 (C(O)-CH3), 28.4 (S-CH2), 22.9 (CH2"), 13.0 (CH3) ppm. 
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FTIR (ATR)  = 3013 (w), 2963 (w), 2928 (w), 2917 (w), 2870 (w), 1705 (s), 1600 (s), 1573 (m), 1493 
(s), 1453 (vs), 1405 (s), 1352 (m), 1309 (m), 1247 (vs), 1220 (m), 1175 (s), 1047 (m), 1020 (s), 966 (m), 
845 (m), 796 (m) cm-1. 
MS (ESI+) m/z = 652.8 [M+Na]+. 
Conversion of 57 with one equivalent of K2PtCl4 and DMSO 
Following GP5, 57 (137.2 mg, 0.438 mmol), K2PtCl4 (200 mg, 0.482 mmol), DMSO (60 µL; 0.876 mmol) 
and NaOAcк3H2O (59.6 mg, 438 mmol) converted. Purification was attempted through crystallization 
from DCM/n-hexane. Despite evidence of the formation of the desired product in NMR spectra, it 
was not possible to isolate pure 64.  
Further attempts to isolate desired complex 64 by using KOtBu (49.15 mg, 0.438 mmol) as a base 
according to GP6 were also not successful. 
Conversion of two equivalents 57 with K2PtCl4  
57 (156.8 mg; 0.501mmol) was reacted with K2PtCl4 (103.9 mg; 0.250 mmol) following GP8, using 
NaAcк3H2O (68.1 mg; 0.501 mmol) as a base. Precipitation from n-hexane yielded a brown solid 
which could not be identified as the target compound 65.  
Bis(4-Brom--hydroxydithiocinnamic butinylester-O,S)-platin(II) (66) 
59 (157.7 mg; 0.482 mmol) was brought to reaction with 
K2PtCl4 (100 mg; 0.241 mmol) and NaOAc·3H2O (65.59 mg, 
0.482 mmol) according to GP8. The crude material was 
flushed through a short plug of silica using DCM as solvent, 
upon which the pure compound 66 (25.2 mg; 12 % yield) 
was isolated as red solid.  
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Smp.: 175.8 °C (decomp.)  
Analysis calcd. for C26H20Br2O2PtS4 (M = 847,59 g/mol): C, 36.84; H, 2.38; S, 15.13; found: C, 36.82; H, 
2.74; S, 12.28. 
1H NMR (400 MHz, CDCl3)  = 7.85 (d, 3JHH = 8.8 Hz, 2H, Ar-H2, Ar-H5), 7.58 (d, 3JHH = 8.8 Hz, 2H, Ar-
H2, Ar-H6), 7.06 (s, 1H, =CH-), 3.40 (t, 3JHH = 7.1 Hz, 2H, S-CH2), 2.74 (td, 3JHH = 7.1, 4JHH = 2.7 Hz, 2H, 
CH2  ), 2.11 (t, 4JHH = 2,6 Hz, 1H, CH) ppm. 
13C{1H} NMR (100 MHz. CDCl3): ! = 177.0 (CS2), 174.1 (C-OPt), 138.1 (Ar-C1), 132.6 (Ar-C2, Ar-C6), 
129.2 (Ar-C3, Ar-C5), 126.8 (Ar-C4), 113.2 (=CH-), 81.7 (C-), 70.6 (CH), 32.7 (S-CH2! ), 18.6 (CH2 ) 
ppm. 
FTIR (ATR)  = 3282 (w), 3269 (w), 2953, 2918 (s), 2850 (s), 1584 (m), 1506 (m), 1491 (m), 1453 (vs), 
1384 (m), 1306 (m), 1288 (m), 1258 (m), 1216 (m), 1178 (m), 1072 (m), 1009 (s), 972 (m), 829 (m) 
,777(s), 643 (m) cm-1. 
MS data could not be obtained in EI, FAB or ESI-based measurements. 
Conversion of 59 with one equivalent of K2PtCl4 and DMSO (67) 
59 (143.33 mg; 0.438 mmol), K2PtCl4 (200 mg; 0.482 mmol.), 
DMSO (62 µL; 0.876 mmol) and NaOAc·3H2O (59.60 mg, 
0.438 mmol) were converted according to GP5. Column 
chromatography on silica gel using a gradient (mobile phase 
DCM/ethyl acetate 100 : 0 to 100 : 5) afforded a brown solid 
(Rf  0,3), which could not be identified as the target compound. 
Instead, one isolated fraction was identified as the hydrated 
homolog 67.  
 
 
1H NMR (600 MHz, CDCl3)  = 7.80 (d, 3JHH = 8.7 Hz, 2H, Ar-H2, Ar-H5), 7.52 (d, 3JHH = 8.7 Hz, 2H, Ar-
H2, Ar-H6), 7.02 (s, 1H, =CH-), 3.65 (s, 6H, CH3(DMSO)), 3.44 (t, 3JHH = 6.6 Hz, 2H, S-CH2 ), 3.00 (t, 3JHH 
= 6.6 Hz, 2H, CH2!), 2.19 (s, 3H, C(O)-CH3) ppm. 
13C{1H} NMR (150 MHz, CDCl3)  = 206.4 (C=O), 180.9 (CS2), 174.2 (C-OPt), 136.4 (Ar-C1), 132.6 (2C, 
Ar-C2, Ar-C6), 129.9 (2C, Ar-C3, Ar-C5), 127.5 (Ar-C4), 111.8 (=CH-), 46.8 (CH3 (DMSO)), 42.1 (CH2!), 
29.5 (C(O)-CH3), 27.6 (S-CH2 ) ppm.   
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16.4 Azide-functionalized compounds 
p-(Azidomethyl) acetophenone (70) 
p-(azidomethyl) acetophenone was prepared in two steps,395,396 starting 
with the literature-reported synthesis of p-bromomethyl acetophenone 69 
from p-methyl acetophenone (5 g, 37.5 mmol). The crude material obtained 
after extraction from Et2O/water, which still contained ca. 10 mol-% methyl 
acetophenone 68 (6.95 g, ca. 28 mmol), was then dissolved in 
dimethylformamide (DMF, 30 mL) and cooled to 0 °C. 
 
A suspension of NaN3 (1.84 g, 28.3 mmol) in DMF (40 mL) was added and the mixture stirred at 0 °C 
for 4 h, upon which no conversion was visible by tlc control. The mixture was thus heated up to 90 °C 
for 1.5 h, allowed to cool down and stirred overnight. To the resulting yellow solution, water and 
ethyl acetate (50/50 mL) were added and the evolving two-phased system separated. The aqueous 
phase was extracted with ethyl acetate (3 ´ 20 mL), the combined organic phases washed with brine 
(2 ´ 10 mL) and dried over sodium sulfate. The crude material was purified by column 
chromatography (mobile phase: ethyl acetate/n-hexane 1:2, Rf  0,3) and 70 obtained as pale yellow 
oil in 97 % yield (4.77 g, overall yield 73 %) 
 
1H NMR (400 MHz, CDCl3)  = 7.94 (d, 3JHH = 8.0 Hz, 2H, Ar-H3, Ar-H5), 7.39 (d, 3JHH = 8.0 Hz, 2H, Ar-
H2, Ar-H6), 4.39 (s, 2H, Ph-CH2-), 2.57 (s, 3H, CO-CH3). 
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p-(Azidomethyl) -hydroxydithiocinnamic acid ethyl ester (71) 
Compound 71 was prepared following GP3, using 70 (1.75 g; 
10 mmol), KOtBu (2.23 g; 20 mmol), CS2 (850 µL; 14 mmol), and ethyl 
iodide (800 µL; 10 mmol). For purification, the crude material was 
subjected to column chromatography using a gradient (mobile phase: 
DCM/hexanes 1:2 to 1:1; Rf  0.5).   
 
Analysis calcd. for C12H13N3OS2 (M = 279.38 g/mol): C, 51.59; H, 4.69; N, 15.04; S, 22.95; found: C, 
51.61, H, 4.84, N, 14.72, S, 22.87. 
1H NMR (200 MHz, CDCl3)  = 15.12 (s, 1H, OH), 7.89 (d, 3JHH = 8.3 Hz, 2H, Ar-H2, Ar-H6), 7.40 (d, 3JHH = 
8.2 Hz, 2H, Ar-H3, Ar-H5), 6.89 (s, 1H, =CH-), 4.40 (s, 2H, Ph-CH2-), 3.28 (q, 3JHH = 7.4 Hz, 2H, S-CH2), 
1.38 (t, J = 7.4 Hz, 3H, CH3) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  = 217.8 (CS2), 169.4 (C-OH), 139.8 (Ar-C4), 134.7 (Ar-C1), 128.8 (2C, 
Ar-C3, Ar-C5), 127.6 (2C, Ar-C2, Ar-C6), 108.2 (=CH-), 54.3 (Ph-CH2-), 27.7 (S-CH2-), 12.6 (-CH3) ppm. 
MS (EI+) m/z = 280 [M+H]+, 237 [M-N3]+; 218 [M-SEt]+. 
FTIR (ATR)  = 2974, 2925 (w), 2870 (w), 2098 (s), 1583 (vs), 1556 (vs), 1501 (s), 1416 (s), 1228 (s), 
1118 (w), 1062 (m), 1037 (m), 949 (s), 774 (s) cm-1. 
  
EXPERIMENTAL 
16 Compound Syntheses and Analyses 191 
 
 
Chloro-(4-(azidomethyl)--hydroxydithiocinnamic acid ethyl ester-O,S)-
(dimethylsulfoxide-S)- platinum(II) (72) 
Compound 72 was prepared from 71 following GP5, using 71 
(122.3 mg; 0,438 mmol), K2PtCl4 (200 mg; 0.482 mmol.), DMSO 
(62 µL; 0,876 mmol) and NaOAc (36 mg, 0,438 mmol). In a first 
attempt, column chromatography on silica gel using a gradient 
(mobile phase: DCM/hexanes 2 : 1 to DCM to DCM/acetone 
10 : 1) yielded 53 % semi-pure product. 
 
Attempts to further purify the complex by crystallization from DCM/hexane and subsequent column 
chromatography (gradient: DCM/acetone 10 : 0 to 10 : 1) lead to partial decomposition and resulted 
in a final yield of 83.7 mg (33 %) pure product 72. 
In a second attempt, column chromatography on silica gel (mobile phase: DCM/acetone 50 : 1 to 10 : 
1) was performed and lead to 82 % (211 mg) yellow crystalline 72 after partial evaporation of the 
mobile phase and allowing for the left-over acetone to slowly evaporate from the solution. 
 
Analysis calcd. for C14H18ClN3O2PtS3 (M = 587.04 g/mol): C, 28.64; H, 3.09; N, 7.16; S, 16.39; calcd. for 
C14H18ClN3O2PtS3·0.5 acetone C, 30.22; H, 3.44; N, 6.82; S, 15.61; found C, 30.29, H, 3.22, N, 6.77, S, 
15.79. 
1H NMR (200 MHz, CDCl3)  = 7.97 (d, 3JHH = 8.3 Hz, 2H, Ar-H2, Ar-H6), 7.35 (d, 3JHH = 8.3 Hz, 2H, Ar-
H3, Ar-H5), 7.08 (s, 1H, =CH-), 4.37 (s, 2H, Ph-CH2-), 3.66 (s w/ Pt satellites, 3JPtH = 23.5 Hz, 6H, CH3 
(DMSO)), 3.27 (q, 3JHH = 7.4 Hz, 2H, S-CH2), 1.45 (t, J = 7.4 Hz, 3H, CH3) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  = 180.9 (CS2), 173.9 (C-OPt), 139.5 (Ar-C4), 137.2 (Ar-C1), 128.6 (2C, 
Ar-C2, Ar-C6), 128.5 (2C, Ar-C3, Ar-C5), 111.6 (=CH-), 54.5 (Ph-CH2-), 47.0 (2C, CH3 (DMSO)), 28.92 
(S-CH2), 13.3 (CH3) ppm. 
MS data could not be obtained in ESI measuremetns. 
FTIR (ATR)  = 2962 (w), 2926 (m), 2853 (w), 2095 (s), 1517 (w), 1461 (vs), 1406 (w), 1288 (s), 1256 
(s), 1146 (s), 1029 (s), 978 (m), 841 (m), 810 (s), 689 (m) cm-1. 
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Bis(4-(azidomethyl)--hydroxydithiocinnamic acid ethyl ester-O,S)-platinum(II) (73) 
Following GP8, 71 (268.3 mg; 0.964 mmol), K2PtCl4 (200 mg; 
0.482 mmol.), and NaOAc (79 mg, 0,964 mmol) were used to 
prepare compound 73 in 12 % final yield (45.8 mg) after 
repeated column chromatographic purification on silica gel 
using DCM/hexanes 2 : 1 and 1 : 1 as mobile phase.  
 
71 (67.3 mg; 0.241 mmol) was further converted with K2PtCl4 (50 mg; 0.120 mmol.), DMSO (17 µL, 
0.241 mmol) and NaOAc (20 mg, 0,241 mmol) according to GP5. Column chromatography using a 
gradient (mobile phase: DCM/hexanes 1:1 to 1:0) yielded 73 (63 mg, 70 % yield) as red crystalline 
material. 
Analysis calcd. for C24H24N6O2PtS4 (M = 751,83 g/mol): C, 38.34; H, 3.22; N, 11.18; S, 17.06; calcd. for 
C24H24N6O2PtS4·0.1 acetone: C, 38.52; H, 3.27; N, 11.09; S, 16.93; found C, 38.34, H, 3.27, N, 10.73, S, 
16.98. 
1H NMR (400 MHz, CDCl3) ! 8.02 (d, J = 8.1 Hz, 2H, Ar-H2, Ar-H6), 7.39 (d, J = 8.1 Hz, 2H, Ar-H3, Ar-
H5), 7.07 (s, 1H, =CH-), 4.39 (s, 2H, Ph-CH2-), 3.24 (q, 3JHH = 7.4 Hz, 2H, S-CH2), 1.45 (t, 3JHH = 7.4 Hz, 
3H, CH3) ppm. 
13C{1H} NMR (50 MHz, CDCl3)  178.3 (CS2), 174.2 (C-OPt), 139.5 (Ar-C4), 139.1 (Ar-C1), 128.9 (2C, Ar-
C3, Ar-C5), 128.2 (2C, Ar-C2, Ar-C6), 113.0 (=CH-), 54.5 (Ph-CH2-), 28.4 (S-CH2), 13.2 (CH3) ppm. 
MS (ESI+) m/z = 774 [M+Na]+ 
FTIR (ATR)  = 2959 (vs), 2921(vs), 2850 (s), 2094 (s), 1510 (w), 1461 (vs), 1374 (w), 1285 (s), 1257 (s), 
1176 (s), 1096 (m), 1018 (m), 966 (w), 780 (s) cm-1.  
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16.5 Peptide derivatizations 
Leu5-Enkephalin bound to Rink Amide AM Resin (74) 
 
Leu5-Enkephalin bound to Rink Amide AM Resin 74 was prepared by automated SPPS (GP12) in a 
250 µmol scale according to the described procedure, using Rink resin with 0.59 or 0.71 mmol/g 
loading. Fmoc-protected amino acids (Fmoc-Leu-OH, Fmoc-Phe-OH, 2 ´ Fmoc-Gly-OH, Fmoc-Tyr(tBu)-
OH) were used in 4-fold excess (1 mmol). After drying of the peptidized resin, it was split into two 
equal portions equivalent to 125 mmol peptide and treated separately for further reactions. 
Free Leu5-Enkephalin amide (75) 
 
One 125 µmol equivalent of 74 was cleaved (90 min/r.t.) and precipitated from Et2O/n-hexane. 
Repeated washing and lyophilization according to the described protocol for SPPS (GP12) yielded 
Leu5-Enk 75 as C-terminal amide (58 mg; 84 %) in >90 % purity.  
 
rp-HPLC (gradient1): tR = 13.7 min (>90 %) 
MS (ESI+): m/z = 555.0 [M+H]+ (calcd. for C28H39N6O6: 555.3). 
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1H NMR (400 MHz, THF-d8)  = 10.82 (s, 1H, Y1: Ar-OH), 8.64 (m, 1H, -NH-), 8.32 (m, 1H, -NH-), 8.14 
(m, 1H, -NH-), 7.76 (d, 3JHH = 8.1 Hz, -NH-), 7.51 (d, 3JHH = 8.1 Hz, -NH-), 7.24 (m, 5H, F4: Ar-H2,3,5,6, 
-NH-), 7.14 (m, 1H, F4: Ar-H4), 7.07 (d, 3JHH = 8.2 Hz, 2H, Y1: Ar-H2,6), 6.70 (d, 3JHH = 8.3 Hz, 2H, Y1: Ar-
H3,5), 6.50 (d, 2JHH = 104.4 Hz, 2H, L5: -NH2), 4.59 (m, 1H, F4: CH), 4.36 (m, 1H, L5: CH), 4.14 (m, 1H, 
Y1: CH), 4.06-3.84 (m, 2H, G2/G3: -CH2 -; additional signals obscured by SRS), 3.20-2.88 (m, 4H, Y1/F4: 
-CH2-Ar +SRS), 1.58 (m, L5: -CH2-CH Me2 + SRS), 0.89-0.85 (m, L5:2 ´ -CH3 + SRS) ppm. Parts of the 
signal sets are obscured by solvent residual signals (SRS) 
1H NMR (400 MHz, DMSO-d6)  != 9.32 (s, 1H, Y1: Ar-OH), 8.69 (t, 3JHH = 5.5 Hz,1H, G2: -NH-), 8.11 (t, 
3JHH = 5.7 Hz, 1H, G3: -NH-), 8.07 (d, 3JHH = 8.2 Hz, 1H, F4: -NH-), 8.01 (m, 3H, Y1: -NH2, L5: -NH-), 7.25 
(m, 4H, F4: Ar-H2,3,5,6), 7.18 (m, 1H, F4: Ar-H4), 7.06 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-H2,6), 7.03 (d, 2JHH = 
66.5 Hz, 2H, L5: -NH2), 6.70 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-H3,5), 4.54 (dt, 3JHH = 9.0, 4.5 Hz, 1H, F4: CH), 
4.21 (dt, 3JHH = 15.4, 7.7 Hz, 1H, L5: CH),3.98 (m, 1H, Y1: CH), 3.87-3.62 (m, 4H, G2/G3: -CH2-), 3.05-
2.98, 2.84-2.27 (2 m, 4H, Y1/F4: -CH2-Ar), 1.61-1.52 (m, 1H, L5:-CH Me2), 1.46 (m, 2H, L5:-CH22-), 0.89-
0.83 (m, 6H, L5:2 ´ -CH3) ppm. 
13C NMR (100 MHz, DMSO-d6)  != 173.7 (L5: C=O), 171.0 (F4: C=O), 168.7 (Y1: C=O), 168.5 (G2: C=O), 
168.3 (G3: C=O), 156.5 (Y1: Ar-C4), 137.7 (F4: Ar-C1), 130.3 (2C, Y1: Ar2,6), 130.2 (Y1: Ar-C1), 129.0, 
127.8 (4C, F4: Ar), 126.2 (F4: Ar-C4), 115.2 (2C, Y1: Ar-C3,5), 53.5 (Y1: CH), 53.6 (F4: CH), 50.7 (L5: 
CH), 41.6 (G: CH), 41.4. (G: CH), 40.8 (L5: CH2), 37.3 (F4: CH2-Ar), 35.3 (Y1: CH2-Ar), 24.0 (L5: CH ), 
22.90 (L5: CH3), 21.6 (L5: CH3) ppm. Data of 13C NMR obtained indirectly from HSQC and HMBC 
experiments.  
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Alkyne-functionalized Leu5-Enkephalin (76) 
 
 
Peptide-loaded rink resin 74, equivalent to 125 µmol, was coupled with pentynoic acid (PA, 49 mg, 
0.5 mmol) under addition of HOBt/TBTU (4/3.8 eq) and DiPEA (8 eq.) at room temperature for 2 h by 
SPPS (following GP13). After cleavage and precipitation, a white powder of 76 (50 mg; 63 % yield) 
was obtained which was > 85 % purity according to analyt. HPLC and thus used without further 
purification. 
rp-HPLC (C8, gradient 1): tR = 16.05 min (82 %). 
rp-HPLC (C18, gradient 1): tR = 16.35 min (>85 %). 
MS (ESI+): m/z = 635.0 [M+H]+ (calcd for C33H43N6O7: 635.3). 
1H NMR (400 MHz, DMSO-d6)  = 9.11 (s, 1H, Y1: Ar-OH), 8.18 (t, 3JHH = 5.6 Hz,1H, G2: -NH-), 8.09 (d, 
3JHH = 8.1 Hz, 1H, Y1: -NH-),8.04 (d, 3JHH = 8.1 Hz, 1H, F4: -NH-), 7.94 (m, 2H, G3: -NH-, L5: -NH-), 7.24 (m, 
4H, F4: Ar-H2,3,5,6), 7.18 (m, 1H, F4: Ar-H4), 7.00 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-H2,6), 7.00 (d, 2JHH = 
47.3 Hz, 2H, L5: -NH2), 6.63 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-H3,5), 4.51 (dt, 3JHH = 8.9, 4.6 Hz, 1H, F4: CH), 
4.41 (dt, 3JHH = 9.0, 4.8 Hz,1H, Y1: CH) 4.21 (dt, 3JHH = 15.2, 7.9 Hz, 1H, L5: CH), 3.80-3.52 (m, 4H, 
G2/G3: -CH2-), 3.04/2.79 (2m, 2H, F4: -CH2-Ar), 2.91/2.65 (2 m, 2H, Y1: -CH2-Ar), 2.70 (t, 3JHH = 2.1 Hz, 
PA0: !CH), 2.31-2.23 (m, 4H, PA0: CH2,), 1.61-1.52 (m, 1H, L5:-CH"Me2), 1.47 (m, 2H, L5:-CH2-), 0.89-
0.82 (m, 6H, L5:2 ´ -CH3) ppm. 
13C NMR (100 MHz, DMSO-d6)  != 173.9 (L5: C=O), 171.7 (Y1: C=O), 170.6 (F4: C=O), 170.3 (PA0: C=O), 
169.0 (G2: C=O), 168.6 (G3: C=O), 155.7 (Y1: Ar-C4), 137.7 (F4: Ar-C1), 130.0 (2C, Y1: Ar-C2,6), 129.2 
(2C, F4: Ar-C3,5), 128.0 (2C, F4: Ar-C2,6), 127.9 (Y1: Ar-C1), 126.2 (F4: Ar-C4), 114.8 (2C, Y1: Ar-C3,5), 
83.7 (PA0: -C"!), 71.2 (PA0: !CH !=), 54.4 (Y1: CH), 54.0 (F4: CH), 51.0 (L5: CH), 42.0 (G: CH), 41.9 (G: 
CH), 40.8 (L5: CH2), 37.3 (F4: CH2-Ar), 36.6 (Y1: CH2-Ar), 34.0 (PA0: -CH-), 24.2 (L5: CH"), 23.0 (L5: 
CH3), 21.6 (L5: CH3), 14.0 (PA0: -CH2-) ppm. 
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Azide-functionalized Leu5-Enkephalin (77) 
 
 
Peptide-loaded rink resin 74, equivalent to 125 µmol, was coupled with azidoacetic acid (AA, 
50.5 mg, 0.5 mmol) under addition of HOBt/TBTU (4/3.8 eq) and DiPEA (8 eq.) at room temperature 
for 2 h by SPPS, following GP12. After cleavage and precipitation, a white powder of 77 (47 mg, 59 %) 
was obtained which was of 90 % purity according to analyt. HPLC and thus used without further 
purification. 
rp-HPLC (C18, gradient1): tR = 16.3 min (90 %). 
MS (ESI+): m/z = 638.0 [M+H]+ (calcd. for C30H40N9O7: 638.3). 
1H NMR (400 MHz, DMSO-d6)  = 9.14 (s, 1H, Y1: Ar-OH), 8.35 (t, 3JHH = 5.7 Hz,1H, G2: -NH-), 8.26 (d, 
3JHH = 8.2 Hz, 1H, Y1: -NH-),8.04 (d, 3JHH = 8.1 Hz, 1H, F4: -NH-), 7.98 (t, 3JHH = 5.7 Hz,1H, G3: -NH-),7.94 
(d, 3JHH = 8.3 Hz, 1H, L5: -NH-), 7.24 (m, 4H, F4: Ar-H2,3,5,6), 7.18 (m, 1H, F4: Ar-H4), 7.01 (d, 3JHH = 
8.5 Hz, 2H, Y1: Ar-H2,6), 7.00 (d, 2JHH = 50 Hz, 2H, L5: -NH2), 6.63 (d, 3JHH = 8.5 Hz, 2H, Y1: Ar-H3,5), 
4.61-4.40 (m, 2H, Y1/F4: CH), 4.20 (dt, 3JHH = 15.1, 8.0 Hz, 1H, L5: CH), 3.84-3.58 (m, 6H, AA0/G2/G3: 
-CH2-), 3.03/2.79 (2m, 2H, F4: -CH2!-Ar), 2.93/2.65 (2 m, 2H, Y1: -CH2!-Ar), 1.62-1.52 (m, 1H, 
L5:-CH Me2), 1.47 (m, 2H, L5:-CH2!-), 0.89-0.82 (m, 6H, L5:2 ´ -CH3) ppm. 
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13C NMR (100 MHz, DMSO-d6)  = 173.8 (L5: C=O), 171.3 (Y1: C=O), 170.6 (F4: C=O), 168.9 (G2: C=O), 
168.6 (G3: C=O), 167.2 (AA0: C=O), 155.8 (Y1: Ar-C4), 137.7 (F4: Ar-C1), 130.0 (2C, Y1: Ar-C2,6), 129.2 
(2C, F4: Ar-C3,5), 128.0 (2C, F4: Ar-C2,6), 127.6 (Y1: Ar-C1), 126.2 (F4: Ar-C4), 114.9 (2C, Y1: Ar-C3,5), 
54.3 (Y1: CH), 54.0 (F4: CH), 51.0 (L5: CH), 50.5 (AA0: CH), 42.1 (G: CH), 41.9 (G: CH), 40.8 (L5: 
CH2!), 37.3 (F4: CH2!-Ar), 36.7 (Y1: CH2!-Ar), 24.2 (L5: CH ), 23.0 (L5: CH3), 21.6 (L5: CH3) ppm.  
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16.6 Bioconjugates via CuAAC 
Enkephalin-modified bischelate of azide-(O,S)2Pt (78) 
 
 
 
Method 1: The reaction was carried out according to GP9, using 76 (10 mg, 15.7 µmol) and 73 
(5.92 mg, 7.88 mmol). CuSO4·5 H2O (31 µL 0.1 M soln.) and sodium ascorbate (63 µL 0.1 M soln) was 
used to enable the conversion. After 3 days of stirring, THF was removed in vacuo, water decanted. 
The residue was re-dissolved in THF/water, precipitation achieved with cold Et2O. After 
centrifugation, the water phase was removed and the precipitate repeatedly washed with Et2O. After 
lyophilization, 22 mg of crude material were obtained which were purified in several fractions by 
semiprep. rp-HPLC using gradient3. Pure (> 95 %) 78 was obtained in 31 % yield (5 mg).  
Method 2: In a second approach, the reaction was carried out using 76 (5 mg, 7.9 µmol) and 73 
(2.9 mg, 3.9 mmol). DiPEA (1.4 µL) as well as CuI·(2 mg) was used to enable the conversion. After 5 
days of stirring, the solution was liberated of THF and precipitation enforced through addition of ice-
cold Et2O. The mixture was centrifuged, the solvents removed, the red solid repeatedly washed with 
Et2O and lyophilized. After prep. HPLC (gradient1), the desired complex was obtained, but a 
significantly increased abundance of several side products showed that this method is less effective 
than the usage of CuSO4/Na-acsorbate. 
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rp-HPLC (C18, gradient1): tR = 23.6 min (> 95 %). 
MS (ESI+): m/z = 2020.8 [M]+ (calcd. for [C90H108N18O16PtS4]+: 2020.7 / highest peak), 1010.9 [M+H]2+ 
(calcd. for [C90H109N18O16PtS4]+: 1010.8 / highest peak). 
1H NMR (400 MHz, DMSO-d6)  = 9.13 (s, 1H, Y1: Ar-OH), 8.25 (t, 3JHH = 5.5 Hz,1H, G2: -NH-), 8.12 (d, 
3JHH = 8.0 Hz, 1H, Y1: -NH-), 8.08-7.92 (m, 2H, F4: -NH-, G3: -NH-, L5: -NH-, (O,S): Ar-H2,6), 7.81 (s, 1H, 
PA0: ta-CH=), 7.41 (d, 3JHH = 8.4 Hz, (O,S): Ar-H3,5), 7.23-7.22 (m, 4H, F4: Ar-H2,3,5,6) 7.21 (s, 1H, (O,S): 
=CH-), 7.17-7.14 (m, 1H, F4: Ar-H4), 7.00 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-H2,6), 7.00 (d, 2JHH = 47.7 Hz, 2H, 
L5: -NH2), 6.62 (d, 3JHH = 8.3 Hz, 2H, Y1: Ar-H3,5), 5.58 (s, 2H, (O,S): Ph-CH2-Nta), 4.51 (dt, 3JHH = 8.8, 
4.7 Hz, 1H, F4: CH), 4.45-4.40 (m, 1H, Y1: CH), 4.19 (dt, 3JHH = 15.3, 7.8 Hz, 1H, L5: CH), 3.77-3.58 (m, 
4H, G2/G3: -CH2-), 3.25 (m, 2H, (O,S): S-CH2-, obscured by SRS), 3.03/2.79 (2m, 2H, F4: -CH2!-Ar), 
2.92/2.65 (2 m, 2H, Y1: -CH2!-Ar), 2.77 (m, 2H, PA0: -CH2!-), 2.44-2.37 (m, 4H, PA0: -CH2-), 1.59-1.51 
(m, 1H, L5:-CH Me2), 1.46 (m, 2H, L5:-CH2!-), 1.35 (t, 3JHH = 7.3 Hz, 3H, (O,S): -CH3), 0.87-0.80 (m, 6H, 
L5:2 ´ -CH3) ppm. Some signals are partially obscured by solvent residual signals (SRS).  
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Enkephalin-modified bischelate of alkyne-(O,S)2Pt (79) 
 
The reaction was carried out according to GP9, using 77 (10 mg, 7.8 µmol) and 66 (3.2 mg, 3.9 µmol). 
CuSO4·5 H2O (16 µL 0.1 M soln.) and sodium ascorbate (31 µL 0.1 M soln.) was used to enable the 
conversion. The mixture was stirred for 5 days, upon which the THF was removed in vacuo, water 
decanted, the solid re-dissolved in THF/water, precipitated from ice-cold Et2O and washed. 
Preparative rp-HPLC (gradient4) yielded 79 (2 mg, 24 % yield). 
rp-HPLC (C18, gradient1): tR = 25.9 min (>90%). 
MS (ESI+): m/z = 2080.3 [M]+ (calcd. for [C92H112N18O18PtS4]+: 2080.7 / highest peak). 
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Conversion of azide-(O,S)Pt(DMSO)Cl 72 with alkyne-Enk 76 
Following GP9, 76 (5 mg, 7.9 µmol) and 72 (4.63 mg, 7.9 µmol) were brought to reaction under 
addition of sodium ascorbate (4 µL 1 M soln.) and CuSO4·5 H2O (16 µL 0.1 M soln.) and stirred for 
4 days. The solvent was reduced in vacuo, the red solid re-dissolved in THF/water, precipitated from 
Et2O and washed.  
Analytical HPLC indicated consumption of the starting material to multiple products. ESI mass 
spectrometry of the most abundant peaks gave no indication of the desired product, but the isotopic 
pattern of the obtained signal sets indicated possible formation of a copper-containing compound. 
The nature of the actually obtained compound could be identified. 
Enkephalin-modified triazol-(O,S) ligand (80) 
 
The reaction was carried out with 76 (10 mg, 15.8 µmol), 71 (4.4 mg, 15.8 µmol), sodium ascorbate 
(38 µL 1 M soln) and CuSO4·5 H2O (35 µL 0.5 M soln) according to GP10. After stirring for 24 h, 
Na2EDTA (435 µL 0.1 M soln.) was added and the mixture stirred overnight. THF was removed in 
vacuo upon which a brownish oil was formed. Cu-EDTA containing water was decanted, the residue 
washed with water and Et2O. The oil was dissolved in acetonitrile/water and lyophilized to give ca. 
13 mg of crude material. This was purified by prep. rp-HPLC (gradient 3) to give pure 80 (6 mg, 42 %; 
>95 %purity) as yellow amorphous solid after lyophilization.  
rp-HPLC (C18, gradient1): tR = 20.4 min (> 95 %). 
MS (ESI+): m/z = 914.1 [M+H]+ (calcd. for [C45H56N9O8S2]+: 914.4). 
1H NMR (400 MHz, DMSO-d6)  = 15.15 (s, 1H, (O,S): C-OH), 9.13 (s, 1H, Y1: Ar-OH), 8.24 (t, 3JHH = 5.6 
Hz,1H, G2: -NH-), 8.12 (d, 3JHH = 8.1 Hz, 1H, Y1: -NH-), 8.04 (d, 3JHH = 8.1 Hz, 1H, F4: -NH-), 7.99-7.95 (m, 
3H, G3: -NH-, (O,S): Ar-H2,6), 7.93 (d, 3JHH = 8.4 Hz, 1H, L5: -NH-), 7.79 (s, 1H, PA0: ta-CH=), 7.38 (d, 
3JHH = 8.4 Hz, (O,S): Ar-H3,5), 7.23 (m, 4H, F4: Ar-H2,3,5,6), 7.18 (m, 2H, F4: Ar-H4, (O,S): =CH-), 7.00 (d, 
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3JHH = 8.4 Hz, 2H, Y1: Ar-H2,6), 7.00 (d, 2JHH = 48.3 Hz, 2H, L5: -NH2), 6.62 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-
H3,5), 5.60 (s, 2H, (O,S): Ph-CH2-Nta), 4.51 (dt, 3JHH = 8.9, 4.6 Hz, 1H, F4: CH), 4.42 (dt, 3JHH = 9.5, 
4.7 Hz,1H, Y1: CH), 4.19 (dt, 3JHH = 15.2, 7.9 Hz, 1H, L5: CH), 3.82-3.54 (m, 4H, G2/G3: -CH2-), 3.27 (m, 
2H, (O,S): S-CH2-, obscured by SRS), 3.03/2.81 (2m, 2H, F4: -CH2-Ar), 2.92/2.63 (2 m, 2H, Y1: -CH2-Ar), 
2.78 (t, 3JHH = 8.2 Hz, PA0: -CH2-), 2.46-2.35 (m, 2H, PA0: -CH2-), 1.63-1.50 (m, 1H, L5:-CH Me2), 1.46 
(m, 2H, L5:-CH2-), 1.32 (t, 3JHH = 7.4 Hz, 3H, (O,S): -CH3), 0.89-0.82 (m, 6H, L5:2 ´ -CH3) ppm. Some 
signals are partially obscured by solvent residual signals (SRS). 
13C NMR (100 MHz, DMSO-d6)  != 174.4 (L5: C=O), 171.7 (Y1: C=O), 170.6 (F4: C=O), 171.4 (PA0: C=O), 
168.8 (G3: C=O), 168.7 (G2: C=O), 168.5 ((O,S): C-OH), 155.7 (Y1: Ar-C4), 146.4 (PA0: ta-Cq),140.6 ((O,S): 
Ar-C4), 137.7 (F4: Ar-C1), 129.8 (2C, Y1: Ar-C2,6), 129.0 (PA0: Cq !=), 128.8 (2C, F4: Ar-C3,5), 128.2 (Y1: 
Ar-C1), 128.0 (2C, (O,S): Ar-C3,5), 127.7 (2C, F4: Ar-C2,6), 127.1 (2C, (O,S): Ar-C2,6), 125.9 (F4: Ar-C4), 
122.3 (PA0: N-CH=), 121.9 (PA0: ta-CH=), 114.6 (2C, Y1: Ar-C3,5), 107.4 ((O,S): =CH-), 54.1 (Y1: CH), 
53.8 (F4: CH), 52.1 ((O,S): Ph-CH2-Nta), 50.7 (L5: CH), 42.1 (G2: CH), 41.7 (G3: CH), 40.7 (L5: CH2), 
37.1 (F4: CH2-Ar), 36.3 (Y1: CH2-Ar), 34.3 (PA0: -CH-), 27.1 ((O,S): S-CH2-), 23.9 (L5: CH ), 22.9 (L5: 
CH3), 21.4 (L5: CH3), 21.0 (PA0: -CH2-),12.6 ((O,S): -CH3) ppm. Data of 13C NMR obtained indirectly 
from HSQC and HMBC experiments. Expected signal of (O,S)-CS2 (above 200 ppm) not within spectral 
range. 
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Enk-(O,S)Pt(DMSO)Cl from 80 (81) 
 
80 (1.3 mg, 1.4 µmol) was reacted with K2PtCl4 (28 µL 0.1 M soln.) in presence of DMSO (50 µL) and 
NaOAc (14 µL 0.1 M soln.) according to GP11. The desired compound was obtained as yellow-orange 
solid (1.8 mg, 100 %). 
MS (ESI+): m/z = 1259.8 [M+K]+ (calcd. for [C47H60ClKN9O9PtS3]+: 1260.3 / highest peak), 1243.9 
[M+Na]+ (calcd. for [C47H60ClNaN9O9PtS3]+: 1244.3 / highest peak), 1222.0 [M+H]+ (calcd. for 
[C47H61ClN9O9PtS3]+: 1222.3 / highest peak). 
1H NMR (400 MHz, DMSO-d6)  = 9.13 (s, 1H, Y1: Ar-OH), 8.24 (t, 3JHH = 5.5 Hz,1H, G2: -NH-), 8.12 (d, 
3JHH = 8.1 Hz, 1H, Y1: -NH-), 8.05 (d, 3JHH = 8.1 Hz, 1H, F4: -NH-), 8.00-7.95 (m, 4H, G3: -NH-, L5: -NH-, 
(O,S): Ar-H2,6), 7.78 (s, 1H, PA0: ta-CH=), 7.35 (d, 3JHH = 8.3 Hz, (O,S): Ar-H3,5), 7.24-7.23 (m, 5H, F4: 
Ar-H2,3,5,6, (O,S): =CH-), 7.17 (m, 1H, F4: Ar-H4), 7.00 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-H2,6), 7.00 (d, 2JHH = 
48.0 Hz, 2H, L5: -NH2), 6.62 (d, 3JHH = 8.3 Hz, 2H, Y1: Ar-H3,5), 5.56 (s, 2H, (O,S): Ph-CH2-Nta), 4.51 (dt, 
3JHH = 8.9, 4.7 Hz, 1H, F4: CH), 4.42 (dt, 3JHH = 9.3, 4.6 Hz,1H, Y1: CH), 4.19 (dt, 3JHH = 15.2, 7.8 Hz, 1H, 
L5: CH), 3.77-3.49 (m, 4H, G2/G3: -CH2-), 3.26 (m, 2H, (O,S): S-CH2-, obscured by SRS), 3.03/2.79 (2m, 
2H, F4: -CH2-Ar), 2.92/2.65 (2 m, 2H, Y1: -CH2-Ar), 2.76 (m, 2H, PA0: -CH2-), 2.46-2.35 (m, 4H, PA0: 
-CH2-), 1.60-1.50 (m, 1H, L5:-CH Me2), 1.46 (m, 2H, L5:-CH2-), 1.32 (t, 3JHH = 7.3 Hz, 3H, (O,S): -CH3), 
0.87-0.81 (m, 6H, L5:2 ´ -CH3) ppm. Some signals are partially obscured by solvent residual signals 
(SRS). DMSO signal not detected due to substitution by DMSO-d6. 
13C NMR (100 MHz, DMSO-d6)  != 180.0 ((O,S): CS2), 173.5 (L5: C=O), 173.2 ((O,S): C-OPt),171.9 (Y1: 
C=O), 170.7 (F4: C=O), 171.5 (PA0: C=O), 168.9 (G2: C=O), 168.4 (G3: C=O), 155.6 (Y1: Ar-C4), 146.4 
(PA0: ta-Cq), 140.9 ((O,S): Ar-C4), 137.7 (F4: Ar-C1), 129.8 (2C, Y1: Ar-C2,6), 129.1 (PA0: Cq !=), 128.8 
(2C, F4: Ar-C3,5), 128.0 (2C, (O,S): Ar-C3,5), 128.0 (Y1: Ar-C1), 127.7 (2C, F4: Ar-C2,6), 127.1 ((O,S): Ar-
C2,6), 126.1 (F4: Ar-C4), 122.3 (PA0: N-CH=), 121.8 (PA0: ta-CH=), 114.6 (2C, Y1: Ar-C3,5), 110.7 ((O,S): 
=CH-), 54.1 (Y1: CH), 53.7 (F4: CH), 52.1 ((O,S): Ph-CH2-Nta), 50.7 (L5: CH), 41.7 (G2: CH), 41.6 (G3: 
CH), 40.7 (L5: CH2), 37.1 (F4: CH2-Ar), 36.3 (Y1: CH2-Ar), 34.4 (PA0: -CH-), 27.9 ((O,S): S-CH2-), 23.9 
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(L5: CH), 22.0 (L5: CH3), 21.4 (L5: CH3), 21.0 (PA0: -CH2-), 13.0 ((O,S): -CH3) ppm. Data of 13C NMR 
obtained indirectly from HSQC and HMBC experiments. 
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16.7 Bioconjugates via amide bonds 
4-Bromo--hydroxydithiocinnamic acid -carboxyethane (82) 
The reaction was carried out by following GP3 and using 4-Bromo 
acetophenone 6 (1.99g; 10 mmol), CS2 (844 µL; 14 mmol), KOtBu 
(2.24 g; 20 mmol), and bromoacetic acid (1.25 g, 9 mmol). After 
phase separation of the reaction mixture, extraction with 
dichloromethane and drying over NaSO4, the crude product was 
recrystallized from chloroform and 82 (1.6 g, 53 %) obtained as 
yellow crystalline material.  
 
 
Crystals suitable for X-ray characterization were obtained by slow evaporation of acetone from the 
NMR sample. 
Analysis calcd. for C11H9BrO3S2: C, 39.65; H, 2.72; S, 19.25; found C, 39.57; H, 2.72; S 19.19 %. 
1H NMR (200 MHz, Acetone-d6)  = 15.02 (s, 1H, OH), 7.98 (d, 3JHH = 8.9 Hz, 2H, Ar-H3, Ar-H3), 7.73 (d, 
3JHH = 8.9 Hz, 2H, Ar-H2, Ar-H6), 7.26 (s, 1H, =CH-), 4.22 (s, 2H, S-CH2-) ppm. 
13C NMR (63 MHz, Acetone-d6)  = 217.10 (CS2), 169.82 (COH), 168.68 (COOH), 133.87 (Ar-C1), 133.10 
(2C, Ar-C3, Ar-C5), 129.57 (2C, Ar-C2, Ar-C4), 127.40 (Ar-C4), 108.35 (=CH-), 36.44 (S-CH2-) ppm. 
MS (DEI): m/z = 332/334 [M/M+2]+, 241/243 [M-SCH2COOH]+, 183/185.  
IR (ATR):  = 2916 (w), 1715 (m), 1578 (m), 1553 (m), 1515 (w), 1481 (m), 1415 (m), 1353 (w), 1275 
(m), 1234 (s), 1160 (s), 1110 (w), 1073 (m), 1056 (m), 1007 (m), 948 (vs), 867 (m), 824 (vs), 762 (vs) 
cm-1. 
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Chloro-(4-(bromo)--hydroxydithiocinnamic acid -carboxyethane-O,S)-
(dimethylsulfoxide-S)- platinum(II) (83) 
K2PtCl4 (130 mg, 0.31 mmol) was dissolved in water (2 mL) stirred 
for 30 min in presence of DMSO (60 µL, 0.84 mmol). 82 (80 mg, 
0.24 mmol), dissolved in THF (40 mL), was added slowly and the 
mixture stirred at r.t. for 2 days. THF was removed and an orange 
precipitate formed. Extraction from DCM was not completely able 
to dissolve all precipitate.  
 
Solids were filtered, dissolved in acetone and the combined organic solutions concentrated in vacuo. 
The residue was carefully dissolved in a minimum amount of acetone/water and lyophilized to give 
an orange powder alongside with a dark residue. This was removed manually and the desired 
complex (109 mg, 70 %) isolated. 
 
1H NMR (200 MHz, Acetone-d6)  = 8.05 (d, 3JHH = 8.9 Hz, 2H, Ar-H3, Ar-H3), 7.71 (d, 3JHH = 8.9 Hz, 2H, 
Ar-H2, Ar-H6), 7.38 (s, 1H, =CH-), 4.20 (s, 2H, SCH2), 3.68 (s, 3JHH = 24.6 Hz, 6H, CH3 (DMSO)) ppm. 
1H NMR (400 MHz, THF-d8)  = 7.99 (d, 3JHH = 8.7 Hz, 2H, Ar-H3, Ar-H3), 7.60 (d, 3JHH = 8.7 Hz, 2H, Ar-
H3, Ar-H3), 7.28 (s, 1H, =CH-), 4.08 (s, 2H, SCH2), 3.61 (s, 6H, CH3 (DMSO)) ppm. 
13C NMR (101 MHz, THF)  = 180.53 (CS2), 174.35 (COPt), 168.81 (COOH), 137.40 (Ar-C1), 132.89 (2C. 
Ar-C2, Ar-C6), 130.65 (2C, Ar-C3, Ar-C5), 127.50 (Ar-C4), 111.86 (=CH-), 46.70 (2C, CH3(DMSO)), 37.19 
(S-CH2-) ppm. 
MS (ESI+): could not be obtained.  
IR (ATR):  = 3013 (w), 2965 (w) 2927 (w), 1725 (m), 1680 (m), 1583 (m), 1507 (s), 1481 (s), 1458 (s), 
1407 (m), 1385 (m), 1280 (m), 1258 (m), 1246 (m), 1168 (s), 1142 (s), 1113 (s), 1071 (s), 1010 (vs), 
978 (s), 892 (m), 832 (s), 784 (vs) cm-1. 
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Coupling of 82 with Enk 75 in solution (84) 
 
 
By LPSS following GP13, compound 82 (6.6 mg, 19.8 µmol) and Enk 75 (10 mg, 18.0 µmol) were 
coupled using TBTU (6.3 mg, 19.8 µmol) and DiPEA (6.7 µL, 41 µmol) in DMF (600 µL). The reaction 
mixture was diluted with CH3CN/water and directly subjected to semiprep. HPLC (gradient 1) in 
several portions. Pure 84 was obtained as yellow powder (6 mg, 38 %). 
rp-HPLC (C8, gradient1): tR = 18.9 min (>95 %). 
rp-HPLC (C18, gradient1): tR = 20.5 min (> 95%). 
MS (ESI+): m/z = 906.7/908.7 [M+K]+, 890.8/892.8 [M+Na]+, 868.8/870.8 [M+H]+ (calcd. for 
[C39H46BrN6O8PtS2]+: 869.2), 851.8/853.8 [M-NH2]. 
1H NMR (400 MHz, THF-d8)  = 14.97 (s, 1H, (O,S): C-OH), 10.74 (s, 1H, Y1: Ar-OH), 8.20 (d, 3JHH = 
6.9 Hz, Y1: -NH-), 8.09 (t, 3JHH = 5.5 Hz, G2: -NH-), 7.91 (d, 3JHH = 8.7 Hz, 2H, (O,S): Ar-H2,6), 7.65 (d, 
3JHH = 8.7 Hz, 2H, (S,O): Ar-H3,5), 7.54 (m, 2H, G3/F4: -NH-), 7.42 (d, 3JHH = 7.3 Hz, L5: -NH-), 7.23 (m, 
4H, F4: Ar-H1,2,4,5), 7.17 (s, 1H, (O,S): =CH-), 7.13 (m, 1H, F4: Ar-H3), 7.01 (d, 3JHH = 8.4 Hz, 2H, Y1: Ar-
H2,6), 6.64 (d+s, 3JHH = 8.4 Hz, 3H, Y1: Ar-H3,5, L5: -NH2), 6.33 (s, 1H, L5: -NH2 ), 4.63 (dd, 3JHH = 13.5, 
7.9 Hz, 1H, F4: CH), 4.43 (m, 2H, Y1/L5: CH); 4.11 (dd, 2H, 1JHH = 34.0 Hz, 3JHH = 15.2 Hz, (O,S): S-CH2-), 
3.88-3.62 (m, 4H, G2/G3: -CH2-), 3.17, 3.00, 2.89 (m, 4 H, Y1/F4: -CH2-Ar), 1.59 (m, 3H, L5: -CH2-CHMe2), 
0.88 (m, 6H, L5:2 ´ -CH3) ppm. 
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Enk-(O,S)Pt(DMSO)Cl from 84 (85) 
 
 
CM159 (2 mg, 2.3 µmol) was reacted with K2PtCl4 (46 µL 0.1 M soln.) in presence of DMSO (50 µL) 
and NaOAc (23 µL 0.1 M soln.) according to GP11. The desired compound was obtained as orange 
solid (1.4 mg, 52 %). 
rp-HPLC (C18, gradient1): rt = 18.9 min (under solvolysis of Cl/DMSO ligands). 
MS (ESI+): m/z = 1214.9 [M+K]+ (calcd. for [C41H50BrClKN6O9PtS3]+: 1215.1 / first high peak), 1198.8 
[M+Na]+ (calcd. for [C41H50BrClNaN6O9PtS3]+: 1199.1 / first high peak). 
1H NMR (400 MHz, THF-d8)  = 10.80 (s, 1H, Y1: Ar-OH), 8.32 (d, 1H, 3JHH =6.9 Hz, Y1: -NH-), 8.02 (d, 
3JHH = 8.6 Hz, 2H, (O,S): Ar-H2,6), 7.93 (t, 3JHH = 5.6 Hz, G2: -NH-), 7.60 (d, 3JHH = 8.6 Hz, 2H, (O,S): Ar-
H3,5), 7.50 (m, 2H, G3/F4: -NH-), 7.39 (d, 3JHH = 7.3 Hz, L5: -NH-), 7.34 (s, 1H, (O,S): =CH-), 7.24 (m, 4H, 
F4: Ar-H1,2,4,5), 7.14 (m, 1H, F4: Ar-H3), 7.02 (d, 3JHH = 8.3 Hz, 2H, Y1: Ar-H2,6), 6.65 (d+s, 3JHH = 8.4 Hz, 
3H, Y1: Ar-H3,5, L5: -NH2), 6.29 (s, 1H, L5: -NH2), 4.63 (dd, 3JHH = 13.4, 7.9 Hz, 1H, F4: CH), 4.43 (m, 2H, 
Y1/L5: CH); 4.06 (dd, 2H, 1JHH = 28.0 Hz, 3JHH = 16.0 Hz, (O,S): S-CH2-), 3.83 (m, 4H, G2/G3: -CH2-), 3.76, 
3.62 (CH3 (DMSO),obscured by SRS but observed through HSQC) 3.17, 3.12-2.87 (m, 4 H, Y1/F4: 
-CH2-Ar), 1.62 (L5: -CH2-CHMe2, obscured by SRS), 0.89 (m, 6H, L5:2 ´ -CH3) ppm. 
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Coupling of 83 with Enk 75 in solution (86) 
 
83 (12.7 mg, 19.8 µmol) and Enk 75 (10 mg, 18 µmol) were coupled using TBTU (6.3 mg, 19.8 µmol) 
and DiPEA (6.7 µL, 41 µmol) in DMF (600 µL) by LPSS, following GP13. Precipitation from Et2O/n-
hexane merely gave a turbid solution and an orange slurry, therefore the volatile solvents were 
removed in vacuo, precipitation achieved by addition of 4 mL water. After centrifugation, repeated 
washing and lyophilization, an oily residue was obtained which could, as such, not be analyzed 
through ESI mass spectrometry. It was therefore subjected to repeated semiprep. HPLC (gradient 3, 
gradient 4) and the resulting fractions lyophilized. Due to partial solvolysis during HPLC runs, no pure 
fractions were obtained. The components of the two main fractions were identified by their ESI mass 
spectral profile and were found to contain the Enk-bound (O,S) unit coordinated towards Pt(II) with 
varying combinations of the monodentate ligands DMSO, Cl, CH3CN and HOBt. 
rp-HPLC (C8, gradient1): tR = 19.0 min: 
MS (ESI+): (19.0 min) m/z = 1197.6 [(O,S)Pt(HOBt)]+, 1140.9 [(O,S)Pt(DMSO)]+, 1103.7 
[(O,S)Pt(CH3CN)]+, 1063.0 [(O,S)Pt]+. Selected simulations below. 
rp-HPLC (C8, gradient1): rt = 19.8 min:  
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MS (ESI+): (19.8 min) m/z = 1275 [(O,S)Pt(DMSO)(HOBt)]+, 1238 [(O,S)Pt(CH3CN)(HOBt)]+, 1197 
[(O,S)Pt(HOBt)]+, 1140[(O,S)Pt(DMSO)]+, 1103[(O,S)Pt(CH3CN)]+, 1063[(O,S)Pt]+. Selected simulations 
below. 
 
  
  
Figure 54 representative ESI+ MS spectra of fractions of compound 86. 
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Conversion of 34 with HOBt: (O,S)Pt(HOBt)2 (87) 
Compound 34 (20 mg, 32.7 µmol) was stirred in DMF (2 mL) 
in presence of HOBt (8.9 mg, 65.5 µmol) at r.t. for 3 days. 
The solvent was removed in vacuo, and the crude material 
purified via column chromatography on silica gel using a 
gradient (mobile phase: DCM  acetone  EtOH). The 
fraction collected in pure ethanol was crystallized from 
DCM/n-hexane to obtain a yellow precipitate.   
 
MS (ESI-pos): m/z = 766.6 [M+H]+ (calcd. for [C23H20BrN6O3PtS2]-: 767.0 / highest peak), 631.6 
[M-HOBt]+ (calcd. for [C17H15BrN3O2PtS2]-: 631.9 / highest peak). 
MS (ESI-neg): m/z = 764.6 [M-H]- (calcd. for [C23H18BrN6O3PtS2]-: 764.9 / highest peak). 
1H NMR (200 MHz, MeOD)  = 8.03  7.79 (m, 1H, Ar-H), 7.79  7.38 (m, 8H, Ar-H), 7.36  7.09 (m, 
4H, Ar-H, =CH-), 3.20 (q, 3JHH = 7.4 Hz, 2H, S-CH2-), 1.39 (t, 3JHH = 7.4 Hz, 3H, -CH3) ppm. 
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16.8 NMR-based test of stability under cleaving conditions (TFA) 
For peptide cleavage from resin, 95 % TFA is frequently used as reagent. It is not possible to collect 
well-resolved 1H NMR spectra under these conditions, thus a lower concentration of TFA was chosen 
for overview spectra. 34 (10 mg), as a representative compound, was dissolved in CD2Cl2 (450 µL) and 
the 1H NMR spectrum (200 MHz, NS = 128) recorded at room temperature. TFA (500 µL) was added 
and after short mixing, the 1H NMR spectrum was recorded again. In a series of measurements, 1H 
NMR spectra were then recorded at r.t. over the course of 20 h in 10 min intervals, starting from 
40 min after TFA addition (instrumental problems prevented an earlier start of data recording).  
Decomposition set in after a short period, visible e.g. by loss of the Pt-DMSO signal, shift of the S-CH3 
signal and loss of Ar-H and =CH- signals. A half-life of max. 2 h in presence of ca. 50 % TFA can be 
assumed. 
 
Figure 55 Time development of the 1H NMR spectrum of 34 in the presence of 50 % TFA. First spectrum (red), no TFA 
added; second spectrum (dark orange), recorded after addition of TFA and short shaking, t = 10 min. third (light orange) and 
following spectra, time series started 40 min after addition of TFA. Every 10th recorded spectrum is given up to a final 
recording time of 20 h. Cut-out: intrinsic signal of CD2Cl2 was cut out for better visibility (range: 4.5  6.5 ppm). 
  
 
 
17 BEHAVIOR OF THE COMPOUNDS IN SOLUTION 
17.1 UV-visible spectroscopy of compound 30 
Stability studies 
Buffered solutions used were: phosphate buffer (PB, 10 mM or 50 mM, pH 7.4), tetramethyl 
ammonium acetate (TMAA, 25 mM, pH 7.4), or sodium acetate (AmAc, 20 mM, pH 6.8) 
Long-term solubility 
Compound 30, selected as a reference compound, was subjected to UV-visible spectrophotometry in 
different solvent combinations. The stock solution was prepared at 10 mM in DMSO. 100 µL aliquots 
were added to different solvent combinations to give a final drug concentration of 1 mM in pure 
DMSO, DMSO/water (10/90 % v/v and 50/50 % v/v) and DMSO/PB (10/90 % v/v and 50/50 % v/v). 
The samples were kept at room temperature and UV-vis spectra periodically recorded at the 
indicated times (i.e., 0 h, 24 h, 48 h, 72 h, 96 h). For this, 100 µL aliquots were diluted to 100 µM in 
DMSO in 10 mm quartz cuvettes. Data acquisition was performed in the range of 200-800 nm. 
Hydrolysis studies 
A stock solution of 30 (10 mM in DMSO) was diluted to 1 mM in DMSO or DMSO/water 50/50 % v/v. 
A 100-fold excess of AgNO3 (1 M in DMSO) was added, the mixture diluted to 100 µM in the 
respective solvent combination and UV-vis spectra recorded in the range of 200-800 nm before 
AgNO3 addition and immediately afterwards. 
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Hydrolysis studies over 24 h 
A Stock solution of 30 (10 mM in DMSO) was diluted to 100 µM in DMSO or DMSO/PB (50/50 resp. 
10/90 % v/v). UV-visible spectra were recorded over a period of 24 h at r.t. in 10 mm quartz cuvettes 
in the range of 200-800 nm, using 1 min intervals during the first 10 min, 10 min intervals up to 1 h 
and hourly intervals afterwards.  
17.2 Determination of LogPo/w values through the shake-flask method 
For determination of LogP values by the shake-flask method, mQ water and n-octanol (ACS reagent 
grade, Acros) were presaturated through vigorous stirring for a minimum time of 48 h and the phases 
allowed to separate for at least 24 h to ensure complete phase separation.  
Stock solutions of the compounds under investigation were prepared at 500 µM in presaturated 
n-octanol and diluted to a final concentration of 50 µM in the same solvent. The solutions were then 
combined with presaturated water in 1500 µL micro reaction tubes. Three mixtures for each 
compound were prepared with n-octanol/water ratios of 2:1, 1:1 and 1:2 (v/v) at a final volume of 
1200 µL (i.e., 800/400, 600/600 and 400/800 µL n-octanol/water volumes). The mixtures were 
rigorously mixed (vortexed, 10 s) and then vigorously shaken on a laboratory shaker for 60 min to 
enable saturation of both phases with substance, and subsequently centrifugated (10 min at 
10.300 g) to separate the phases. Of each sample, both phases were then sampled carefully to avoid 
cross-contamination and triplicate 100 µL aliquots of each phase transferred onto a 96-well plate. In 
addition, blanks of water and n-octanol were always included. 
Samples were generally transferred using manual pipettes and 200 µL tips. n-Octanol presents 
enhanced adhesion towards standard tips and therefore, uptake and release of sample was 
performed slowly and the sample volume was released several times into the respective new 
container. For each sample and phase, a new tip was used to avoid cross-contamination of the 
phases or compounds. 
UV-visible spectra were recorded between 230 and 600 nm using a plate reader. Spectra were 
recorded three times and averaged. Spectral data of the triplicate aliquots was then averaged and 
baseline corrected. Po/w values were then calculated from the three individual volume ratio 
experiments, using the average absorbance values of the n-octanol and water phases from 300-
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500 nm. The overall logPo/w value was then calculated from the average out of three individual Po/w 
values using equation 3.  
logPo/w value 
 /!= "# $ % &'%!(')*+= "# $, &'-..01..23,!(')*-..01..23+ 
Po/w octanol-water partition coefficient 
(3) 
cx concentration resp. phase ,4-..01..23 average of abs. values between  300-500 nm in resp. phase  
17.3 Determination of extinction coefficients  
For all compounds, the stock solution, prepared in pre-saturated n-octanol with c = 500 µM, was 
subjected to serial dilution to give solutions of 500, 200, 100, 50, 20, 10, and 5 µM concentrations. 
100 µL of each solution were transferred in duplicates onto a UV-star 96-well plate, including blanks 
(pre-saturated n-octanol). Absorption was read in the range of 230-600 nm using a plate reader. 
After executing a baseline correction using the blank absorbance values, band maxima were 
determined and  calculated for each maximum at all concentrations from the Lambert-Beer law 
(equations 4/5):  
Lambert-Beer law 
, = "5# 66. = 78 9 % 9 : A absorbance [a.u.] (4)  molar extinction coefficient [Lmol-1cm-1]  =  !" # $ c concentration [mol L-1] (5) d pathlength [cm] 
 
After plotting the data, average  values were calculated for each maximum in the linear range of 
results, typically using 20-500 µM data; in some cases 50-500 µM. The defined concentrations and 
separately determined pathlength of d(100µL) = 0.218 cm were used for calculation (vide infra). 
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Pathlength determination 
Pathlength determination of the octanol solutions in micro wells was performed by adapting the 
established method for water.419 Solutions of 26 and 47 as representative compounds were used at 
c = 125 µM in n-octanol. Sample volumes of 225, 200, 175, 150, 125, 100, 75, and 50 µL were 
pipetted in triplicates into 96 well plates and their UV-vis spectra recorded in the range of 230-
1000 nm. Parallel, spectra of the same solutions were measured in a 1 cm quartz cuvette on the 
same plate reader, using an inset for cuvettes. All spectra were recorded 3 times. 
Wavelengths of maximum absorption (350 and 430 nm for 47, 344 and 404 nm for 26) were chosen 
for extrapolation, the absorbance at 600 nm served as reference value (no specific absorption of the 
investigational compounds at this wavelength). 
Pathlengths were calculated for individual filling values using equation 6: 
Pathlength   =  !"#$% & !'((%)!"#$*+" & !'((*+",-./* 
!"#$%  abs. at maximum of absorption band for respective volume V in well 
(6) !'((%  abs. at 600 nm for respective volume V in well !"#$*+"  abs. at maximum of absorption band in 1 cm cuvette !'((*+" abs at at 600nm in 1 cm cuvette 
 
Plotting of d vs. V and linear regression afforded the pathlength equation 7)  
pathlength equation  = 0 1 2 3 ( d pathlength [cm] (7) a slope [cm µL-1] V volume [µL] ( intrinsic pathlength  
The regression equation was nearly identical in all determined maxima (Figure 56). For 100 µL filling 
volume, as was used in all subsequent experiments, the pathlength of n-octanol solutions was found 
to be 0.218 cm.  
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Figure 56 Regressions for pathlength determinations of n-octanol solutions using two representative compounds. 
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18 BIOLOGICAL STUDIES 
18.1 General information 
Cell lines 
Cell lines were kindly provided by Prof. Dr. Stephan Hahn (Molecular gastrointestinal oncology, 
Medical Faculty, Ruhr University Bochum) and frequently STR analyzed.xxviii The following adherent 
human epithelial cell lines were used in this study (information on characteristics obtained from the 
ATCC421 and DSMZ422 databases):  
Table 13 Main characteristics of the used cell lines.  
 MCF-7 HeLa HT-29 HEK 293T 
Tissue mammary gland/breast; 
derived from metastatic 
site: pleural effusion 
cervix colon human embryonal 
kidney 
Disease adenocarcinoma cervix adeno-
carcinoma 
colorectal adeno-
carcinoma 
 
Age 69 years  31 years 44 years fetus 
Gender female female female n/ka 
Ethnicity Caucasian black Caucasian n/ka 
a n/k  not known 
  
                                                          
xxviii STR (short tandem repeat) analysis is a frequently applied method to establish the cell lines identity and 
exclude possible cross contaminations.420 
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Equipment 
Cell culture and testing was performed using various standard laboratory equipment listed below. 
Device Type Manufacturer 
Laminar flow benches Msc-Advantage 1.2 Thermo Scientific 
Incubators HeraCell 150 / HeraCell 150i Thermo Scientific  
Cell counter TC10TM Automated cell counter BIO-RAD 
Centrifuges Universal 320R Hettich Zentrifugen 
 5417R Eppendorf 
Microplate reader Saphire2 Tecan 
Optical microscope  Hund Wetzlar 
Fluorescence microscope IX-81 Olympus 
Autoclave VX-96 Systec 
plate shaker TIMIX Edmund Bühler GmbH 
Consumables 
Type and manufacturer of the containers and transfer devices used for cell culture were kept 
constant during the investigations and are listed below. 
Item  Type Supplier 
Cell culture dishes 10 cm Ø  Sarstedt Ref. 83.3902 
Multiwell plates  
(96-well) 
Nunclon DeltaSurface, flat bottom Nunc / ThermoScientific  
cat. 167008 
 UV Star, flat bottom plates Greiner Bio-One, ref. 655081 
Microscopic slides 8-well µ-slide ibiTreat IBIDI GmbH 
FalconTM tubes 15 and 50 mL, sterile Sarstedt 
Microreactor 
tubes 
1.5, 2 mL Sarstedt 
5 mL Eppendorf 
Pipettes 2, 5, 10, 25 mL Sarstedt serological pipettes, 
sterile 
Sarstedt 
Pipette filter tips 10/20, 200, 1000 µL, graduated, sterile tipOne / Star lab 
Ritips 0.5, 2.5 mL Ritter 
Counting slides dual chamber counting slides BIO-RAD 
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Chemicals 
The following media, additives and reagents were used for biological applications: 
chemical description supplier  
Dulbeccos Modified Eagles 
Medium (DMEM)* 
high glucose (4.5 g), GlutaMAX 
supplement, phenol red 
Gibco®  61965-026 
 high glucose (4.5 g), no phenol red Gibco® 31053-028 
Sodium Pyruvate 100 mM Solution; 11 g/L  
(100 ´ concentrated) 
Gibco®  11360-039 
L-glutamine GlutaMAX 200 mM  
(100 ´ concentrated) 
Gibco®  25030-038 
Penicillin-Streptomycin PenStrep 5000 u/mL penicillin; 
5000 µg/mL streptomycin (100 ´ 
concentrated) 
Gibco®  15070-063 
Dulbecco's Phosphate-
Buffered Saline (DPBS)* 
without calcium, magnesium, 
phenol red 
Gibco®  14190-086 
Trypsin-EDTA* 0.05% EDTA, phenol red Gibco®  25300-054 
Fetal Bovine Serum (FBS) FBS Superior, standardized,  
heat inactivated 
Biochrom AG® S0615 
PrestoBlue® Cell Viability 
Reagent 
10 ´ concentrated resazurin-based 
fluorescence dye 
Molecular 
Probes 
A-13261 
Propidium Iodide (PI)  Molecular 
Probes 
P1304MP 
DAPI 4',6-Diamidino-2-phenylindole, 
dihydrochloride 
Molecular 
Probes 
D1306 
Dimethyl sulfoxide (DMSO) analytical reagent grade VWR 23500.297 
MTT reagent thiazolyl blue tetrazolium bromide Sigma M5655 
Cisplatin (CDDP) cis-diammineplatinum(II) dichloride Sigma P4394  
*Formulation of DMEM, DPBS, trypsin-EDTA is given in the appendix. 
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18.2 Cell culture conditions 
General conditions 
Cells were generally handled under sterile conditions in a laminar airflow cabinet. Sterile conditions 
were ensured by using sterilized consumables (purchased sterile or autoclaved) and applying 70 % 
ethanol as superficial disinfectant towards surfaces prior to usage. 
The cells were maintained in 10 cm Ø cell culture dishes at 37 °C in a humidified incubator under an 
atmosphere containing 10 % CO2.  
Cells were cultured in Dulbeccos Modified Eagles Medium (DMEM, high glucose, with phenol red), 
which was supplemented with 10 % (v/v) fetal bovine serum (FCS), 1 % sodium pyruvate, 1 % 
L-glutamine, and 100 units·mL-1 PenStrep. For microscopy applications, an equally supplemented 
DMEM without phenol red was used. 
Cell passaging was usually performed at 80-90 % cell confluence by standard procedures and until 
the 50th passage at most. 
Cell passage 
For cell passaging, the medium was removed and cells washed with 5 mL of PBS. Cells were 
harvested by adding Trypsin-EDTA (3 mL) and incubation for ca. 3 min, until they detached from the 
culture dish surface as witnessed by microscopic inspection. Subsequently, DMEM (7 mL) was added 
and the cell suspension transferred into a 50 mL Falcon tube. After centrifugation (300 g, 2 min, r.t.), 
the supernatant was removed and the cell sediment suspended in 10 mL fresh DMEM. Cells were 
counted using an automated system.  
For all assays, an aliquot of cell suspension with the defined number of cells was diluted to 100.000 
cells/mL or 60.000 cells/mL in DMEM. 100 µL aliquots were transferred into 96-well nunclon plates, 
yielding 10.000 or 6.000 cells/well, respectively, depending on cell line and experiment. Blank wells 
were filled with medium without cells. The plates were incubated for one day prior to drug 
treatment to allow cell attachement.  
For fluorescence microscopy, HeLa and MCF7 cell sediments obtained by centrifugation were 
carefully washed with 1´ PBS once to remove remaining medium with phenol red, and resuspended 
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in 5 mL DMEM without phenol red. After counting, cells were seeded onto 8-well microscopy slides 
at a final concentration of 25.000 cells/well in 250 µL DMEM (without phenol red) and incubated for 
one day prior to drug treatment. 
For cell line maintenance, an adequate aliquot of cell suspension (cell line dependent) was 
transferred to a new cell culture dish containing DMEM to give a total volume of 10 mL. 
Drug treatment  
Stock solutions of all samples were prepared at the highest possible concentration in DMSO 
(typically 10-50 mM) to keep the amount of DMSO in final samples as low as possible. Stock solutions 
of Cisplatin were prepared at 3.33 mM in PBS. For each independent experiment, fresh stock 
solutions of all compounds were prepared from powder. All samples were diluted to the desired 
concentration in DMEM immediately prior to their application to treat cells in a concentration range 
between 500 and 1 µM. By microscopic inspection of the plates after the desired incubation time, it 
was ensured that no precipitate had formed during incubation. In cases where precipitates were 
formed (in some cases at approx. 500 µM), either the drug concentration surely lead to 0 % viability 
or the concentration was deleted from the evaluation range.  
In separate control experiments, the effect of DMSO present in the different sample concentrations 
was tested by adding DMSO in representative quantities (0-5 % v/v). No significant effect on cell 
growth at drug concentrations close to respective IC50 values was witnessed (typically with max. 
0.5 % DMSO). Therefore, the effect of DMSO was generally neglected.  
PrestoBlue® Assay 
Medium was removed from the preincubated wells and 90 µL fresh drug-containing medium or pure 
medium (for controls and blanks) was added in triplicates or quadruplicates for each concentration. 
After an incubation time of 22, 46, or 70 h, 10 µL PrestoBlue® cell viability agent176 was added and 
the plate quickly shaken on a laboratory shaker to ensure homogenous distribution of reagent 
throughout the well (ca. 10 sec). The cells were then further incubated up to 24, 48 or 72 h, after 
which the fluorescence intensities were read on a Tecan Saphire2 plate reader with the following 
read-out settings: excitation Ex = 560 nm (bandwidth 10 nm); emission Em = 590 nm (bandwidth 
10 nm); 3 reads/well at 40 µs integration time, room temperature.  
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Figure 57 Representative 96-well layout for PrestoBlue® assay. The exact dilution scheme was adjusted to the compounds 
requirements in the individual experiments. In wells reserved for reference samples, CDDP, DMSO or ligand compounds 
were plated. For investigational drugs, one sample at maximum possible concentration was plated to determine 0 % 
viability and to check solubility behavior.   
MTT Assay 
For comparative MTT assays, sample dilution was performed with double concentrations. 100 µL 
drug-containing medium or pure medium (for controls) was added to the pre-incubated cells (in 
100 µL DMEM), giving a final volume of 200 µL at the desired drug concentrations. After 48 h of 
incubation at 37 °C, 50 µL of MTT solution (prepared from 2.5 mg/mL thiazolyl blue tetrazolium 
bromide in 1´ PBS or mQ water and filter sterilized) was added and the samples incubated for 2 h. 
Then, the medium was carefully removed and the formed formazan crystals dissolved in DMSO 
(200 µL/well). The resulting solution was homogenized by repeated up-and-down pipetting of the 
solutions, after which the absorbance intensities were read on a Tecan Saphire2 plate reader with the 
following settings: measurement !meas = 550 nm, reference !ref = 620 nm, 3 reads/well, room 
temperature. 
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18.3 Data handling 
Data obtained from the in vitro assays were evaluated with Microsoft Office Excel 2007 and OriginPro 
8. Fluorescence intensity was determined in arbitrary units (a.u.) and corrected by blanks without 
cells as determined separately for each plate. Quadruple values for each drug concentration were 
averaged, standard deviations (SD, equation 8) determined and possible outliers elucidated by 
Grubbs test at a significance level of   = 0.05 using equation 9: 
standard deviation  =  ! ("# $ "%)&'#*+, $ 1  SD standard deviation (8) n number of samples "# value of individual sample "% mean of n samples 
 
Grubbs outlier test - = . |"% $ "#|  N Critical Z ( = 0.05) (9) 3 1.15 4 1.48 
 
Dose-response curves were plotted using the semi-logarithmic scale, i.e. fluorescence intensity [a.u.] 
(resp. absorbance value for MTT) vs.decadic logarithm of final drug concentration [µM].  
For IC50 value determination, the original, uncorrected data were applied. Single fluorescence 
intensities (outlier depleted) were used for dose-response curve plotting instead of their mean 
values. Fluorescence values of positive and negative controls were included for a better definition of 
A1 and A2 at a virtual drug concentration of 10-6 resp. 106 µM. IC50 values were then calculated from 
the inflection point of the sigmoidal curve fit function of OriginPro 8. The regression was based on 
the following equation 10: 
sigmoidal curve fit ( ) = !" + !# $ !"1 + %   &'* A1 lower asymptote (10) A2 upper asymptote p power / slope x0 inflection point / IC50 value [µM] 
 
The dose-response curves were obtained from at least two, typically three, independent experiments 
and the singular IC50 values averaged. Results are given as average IC50 values ± biological SD out of 
the independent experiments.  
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18.4 Fluorescence microscopy 
Sample solutions of compound 46 were prepared from DMSO stock solutions as stated above for the 
PrestoBlue® assay, using DMEM without phenol red. Medium from the preincubated microscopy 
slides was replaced by 250 µL drug-containing medium at concentrations above the determined IC50 
(50 µM), around the IC50 (20 µM for HeLa and 30 µM for MCF7), and below the IC50 value (10 µM). 
Slides were then incubated for 72 h to achieve the desired cellular reactions.  
4,6-Diamidin-2-phenylindol (DAPI) and propidium iodide (PI) were stored as separate stock solutions 
in 1´ PBS. Immediately prior to the experiment, a 10´ concentrated DAPI/PI staining solution was 
prepared and 27.8 µL directly added to the incubated cells to give final concentrations of 50 µg/mL 
DAPI and 20 µg/mL PI. The medium was not substituted in order to retain all, living and dead, cells in 
the microscopy wells. Stained cells were preincubated for 1 h before microscopy.  
Fluorescence micrographs were collected on an Olympus IX-81 fluorescence microscope. The device 
is equipped with an XM10 monochrome CCD camera and various filter sets. Filter cubes with 
 Ex = 330-385 nm,  Em = 420+ nm (for DAPI-stained cells) and with  Ex = 530-550 nm,  Em = 590+ nm 
(for PI-stained cells) were used to record the micrographs at 200-fold magnification. Fluorescence 
micrographs of the individual records were colorized with symbolic colors after data collection and 
overlays generated using the integrated CellM software. 
 
  
 
 
19 BIOMOLECULE INTERACTION STUDIES 
19.1 Materials 
All proteins used for these studies were purchased from commercial suppliers. Stock solutions of 
proteins, i.e. horse heart cytochrome c (Sigma C7752), chicken egg white lysozyme (Sigma L7651), 
and bovine pancreas RNAse A (Sigma R5500), were prepared in Millipore water at 1 mM and stored 
at -20 °C until usage.  
9-Methylguanine (9-mg) was kindly provided by Markus Galanski (University of Vienna). 
Oligonucleotides (ODNs) were prepared by Domenica Musumenci (University of Naples). The 
sequences were synthesized in solid phase with the standard phosphoramidite method by using an 
automatic synthesizer. Detachment from the solid support was enabled with ammonia solution.289  
Stock solutions (10 mM) of each of the individual Pt(II) compounds were prepared by dissolving the 
complex under investigation in DMSO. 
19.2 Devices 
UV-Vis absorption spectra were recorded on a Varian Cary 50 UV-Vis spectrophotometer in the range 
of 200-800 nm.  
ESI mass spectra were recorded on a ThermoFinnigan LTQ Orbitrap high-resolution mass 
spectrometer (Thermo, San Jose, CA, USA), equipped with a conventional ESI source by direct 
introduction of the sample. The instrumental settings were adapted according to the experimental 
requirements as listed in the individual sections. 
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Data was acquired and processed with a nominal resolution of 100 000 (at m/z 400), using Xcalibur 
2.0 software (Thermo). For spectra in positive mode, monoisotopic and average deconvoluted 
masses were obtained with the integrated Xtract tool. 
19.3 Metal complex - protein interaction studies 
UV-vis spectroscopic experiments on protein interaction 
UV-vis measurements with proteins were carried out by diluting the compounds stock solutions to 
30 µM in TMAA. After recording the initial spectrum without protein, the desired model protein was 
added at 10 µM to yield a final metal:protein ratio of 3:1. Spectra were recorded over 72 h at r.t., 
operating in 10 min intervals during the first hour, in 1 h intervals up to 24 h and finally in 3 h 
intervals up to 72 h. 
ESI MS on Pt-protein adducts 
DMSO stock solutions (10 mM) of the investigational complexes were prepared and introduced into 
tetramethylammonium acetate buffer (TMAA, 25 mM, pH 7.4) at 300 µM, containing 100 µM protein 
to give a final metal:protein molecular ratio of 3:1. Samples were incubated at 37 °C for 24 h or 72 h. 
ESI mass spectra of the metal-protein mixtures were recorded from samples generated through 
20-fold dilution with water. The following standardized working conditions were applied: Direct 
introduction, flow rate 5 !L/min; spray voltage 3.1 kV, tube lens voltage 230V, capillary voltage 45 V 
and capillary temperature 220 °C. Sheath and auxiliary gases were set at 17 a.u. and 1 a.u., 
respectively.  
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19.4 Reactions with 9-methylguanine 
Stock solutions of 9-mg and the complexes were prepared at 10 mM in DMSO. 
ESI MS of adducts with 9-mg 
For adduct formation, samples were diluted in LC-MS grade water or in ammonium acetate buffer 
(AmAc 20mM, pH = 6.8) to give a final metal:9-mg ratio of 3:1, c(9-mg) = 100 µM. Samples were then 
incubated at 37 °C for 24 h, ESI mass spectra recorded, and re-incubated further to a final incubation 
time of 90 h.  
To record the positive ESI mass spectra, the incubated samples were diluted 20-fold in water before 
injection into the instrument. For recording of free 9-mg, the stock solution was diluted 100-fold in 
water. Spectra were recorded on an LTQ-Orbitrap high-resolution mass spectrometer (Thermo, San 
Jose, CA, USA), equipped with a conventional ESI source (direct introduction, 7 µL/min) in the range 
of 100-1000 m/z values. The following standardized working conditions were applied: spray voltage 
3.1 kV, tube lens voltage 230V, capillary voltage 45 V and capillary temperature 220 °C. Sheath and 
auxiliary gases were set at 17 a.u. and 1 a.u., respectively.  
UV-vis spectroscopy of adducts with 9-mg 
All dilutions were performed from 10 mM stock solutions in DMSO. After recording the baseline, a 
UV-vis spectrum the Pt(II) complex of interest was collected. Then, 9-mg was added in a 1:1 ratio 
where appropriate and UV-vis spectra collected over a defined period of time. For long-term 
reactivity, spectra were recorded at a concentration of 100 µM for both compounds in 10 min 
intervals during the first hour and hourly up to 72 h. Data was collected in the range of 200-800 nm. 
For short-term reactivity, spectra were recorded at 50 mM final concentration, scanning the range of 
200-600 nm to reduce scanning time. 
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19.5 Incubation with oligonucleotides 
Sample preparation 
Stock solutions of the platinum compounds were prepared at 10 mM concentration in DMSO. Stock 
solutions of oligonucleotides were prepared at 100 µM in LC-MS grade water. 
For adduct formation of the Pt complexes with oligonucleotides, the substances were combined in a 
1:1 or 3:1 metal:oligonucleotide ratio in LC-MS grade water to give a final c(ODN) of 20 µM. The 
samples were kept at 37 °C for 24 or 72 h before measurement. 
ODN data recording: ESI MS in negative mode 
For recording of the ESI mass spectra, the incubated samples or free oligonucleotides were diluted to 
10 µM in LC-MS grade water. Unplatinated ODN3 was diluted in MeOH/water to give a 50/50 vol-% 
mixture of both solvents immediately prior to data recording. 
Spectra were recorded in negative mode (direct introduction, 7 µL/min) in the range of -300 to -2000 
m/z values. The following standardized working conditions were applied: spray voltage 2.7 kV, tube 
lens voltage -113 V, capillary voltage -20 V and capillary temperature 280 °C. Sheath and auxiliary 
gases were set at 23 a.u. and 4 a.u., respectively.  
For MS2 experiments, selected isolated multicharge peaks were subjected to collision induced 
dissociation (CID); usually those at m/z = -5 or -6 were selected. The normalized collision energy 
(NCE) was adjusted manually; usually an intensity of 17-19 a.u. was chosen.  
Data simulation of fragment peaks was performed using the Mongo Oligo mass calculator tool292 and 
the isotope simulation tool of Xcalibur software.  
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20 SUMMARY 
In the herein presented work, a series of platinum(II) complexes as potential cytotoxic agents is 
described. They all share a common pharmacophore of an (O,S) bidentate ligand based on the 
structural motif of -hydroxydithiocinnamic esters. Numerous modifications are possible at this 
ligand, some of which have been explored within this thesis.  
First, a panel of -hydroxydithiocinnamic esters 7-28 (Scheme 26) was prepared with varying 
substituents at the aromatic moiety (H, p-Br, m- and p-OX where X = H or TBDMS) and different alkyl 
chain lengths at the dithioester unit (to give dithio-methyl, -ethyl, -butyl, or hexyl esters, 
respectively,). Subsequently, they were coordinated towards a platinum(II) center to afford neutral 
(O,S) bidentate complexes 29-48 where the ligand sphere is completed by a chlorido ligand and 
DMSO which coordinates via its sulfur atom (Scheme 26). In addition, two representative (O,S)2Pt 
bischelate complexes 49 and 50 are reported as reference compounds for this substance class which 
is very stable and preferentially formed during the synthesis of the monofunctional compounds 29-
48. The overall aim of synthesizing such a panel of compounds was to achieve different polarities and 
hence degrees of aqueous solubility of the compounds and to see what effects the different 
substituents might have on the biological activity of Pt(II) compounds with this particular 
pharmacophore (chapter 3). 
All compounds were analyzed by means of standard analytical methods. The metal complexes 
behavior in aqueous solution was assessed by carrying out UV-visible spectroscopic experiments 
aimed at elucidating the solubility of these compounds and hydrolysis processes occurring when the 
compounds are placed in buffered medium. These studies presented the prerequisite for further 
studies on the compounds interaction with biomolecules. It was found that as a first aquation step, 
the chlorido ligand is released, whilst the DMSO ligand may be retained within the system 
(chapter 4).  
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X \ R Me Et Bu Hex 
H 7 8 9 10 
p-Br 11 12 13 14 
m-O-TBDMS 15 16 17 18 
p-O-TBDMS 19 20 21 22 
m-OH 23 24  25 
p-OH 26 27  28 
 
X \ R Me Et Bu Hex 
H 29 30 31 32 
p-Br 33 34 35 36 
m-O-TBDMS 37 38 39 40 
p-O-TBDMS 41 42 43 44 
m-OH 45 46   
p-OH 47 48   
   
Scheme 26 Compounds discussed in the first part of this work. 
In an attempt to quantify the compounds aqueous solubility, the LogPo/w value of the corresponding 
ligands was determined by the shake-flask method. This allowed for an indirect assessment of the 
Pt(II) compounds relative hydro- or lipophilicity and proved that the incorporation of a hydroxy 
group at the phenyl ring in meta position results in the lowest LogPo/w values and hence in the 
highest polarity. Overall, the compounds are rather unpolar, as shown by generally positive LogPo/w 
values, which means that more compound is found in the octanol- than in the aqueous phase 
(chapter 4). 
Furthermore, the biological activity of compounds 29-36 of the H- and p-Br substituted series as well 
as of compounds 45-46 of the hydroxy-substituted series was assayed against four representative 
cancer cell lines (HeLa, HT29, MCF7, 293T HEK) by means of the resazurin-based PrestoBlue® assay. 
Albeit the compounds generally seem to be less cytotoxic than the reference compound, Cisplatin, 
they manifest an interesting activity pattern: There seems to be a two-sided activity profile 
depending on the compounds lipophilicity: on the one hand, the most polar compounds, i.e. those 
with a methyl- or ethyl group at the dithioester subsite, are the most active in compound series with 
a Ph-H or Ph-OH group (29, 30, 43-46). On the other hand, in the series with p-Br-Ph, the opposite 
trend seems to appear, with an increasing cytotoxicity upon elongation of the alkyl chain. This finding 
could be an indicator for a different cellular accumulation or processing of more polar vs. very 
lipophilic compounds.  
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Notably, varying the position of the Ph-OH group to give meta- or para-OH compounds (45/46 and 
47/48, respectively) brings forth a significant difference in antiproliferative activity. The origin of this 
functional difference might lay in different polarities or, maybe additionaly, in differences in cellular 
processing. Future experiments might be able to shed light on this interesting finding.  
In general, the compounds seem to exert their highest activity against most model cell lines when 
incubated for 48 h, as was assessed by a time-line of three different incubation times, 24, 48, and 
72 h. Fluorescence microscopy on HeLa and MCF7 cell lines incubated with 46 furthermore gave a 
first visual impression of the cellular response to drug treatment: the compounds induce cellular 
death, very probably by apoptosis in favor of necrosis (chapter 5).  
Selected compounds of the series presented in this thesis have furthermore been challenged against 
a panel of three model proteins (cytochrome c, lysozyme, ribonuclease A) and adduct formation 
monitored by ESI mass spectrometry and UV-vis spectroscopy. One model protein, albumin, was 
used to quantify the compounds interaction with a serum protein by means of ICP-OES. It was 
shown that the compounds are able to form stable covalent bonds with specific amino acid side 
chains. As potential binding sites, especially His and to some extent also Met side chains are 
considered, an assumption based on a comparison with similar experiments on Cisplatin and analogs 
and the finding of a His15-bound Pt(II) complex fragment in the crystal structure of HEWL-46 and 
HEWL-48 adducts (chapter 7).  
Furthermore, the binding ability of three selected representatives, 30, 46, and 48, towards DNA was 
probed by making use of two model systems, namely 9-methylguanine (9-mg) and single-strand 
oligonucleotides ODNs with a defined sequence containing adjacent guanines as potential binding 
sites (ODN1, ODN2) or not containing any guanine binding sites (ODN3). Binding of the compounds 
to 9-mg was found to occur within minutes, as observed in UV-vis spectra, and several adduct 
compositions were found in the ESI MS spectra. The (O,S)Pt unit can bind 9-mg either under 
retention or release of DMSO, in the latter case probably a bidentate binding of Pt to N7 and O6 of 9-
mg occurs. Furthermore, adducts of the (O,S)Pt unit with two 9-mg molecules were witnessed 
(chapter 8).  
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In adduct spectra of the compounds with the oligonucleotide models, a multifaceted adduct 
formation behavior was found. MS2 experiments of adducts formed with ODN1 suggest a 
preferential binding of the (O,S)Pt unit to guanine, as expected. But in addition to this stable binding, 
additional binding sites must exist that allow for multiple metal centers to bind to the 
oligonucleotide single strands. This becomes especially apparent from the observation that multiple 
(O,S)Pt units can bind to ODN3, which basically consists of a C-A tandem sequence without any 
guanine. Phosphate backbone binding is highly unprobable, so that alternate nucleobase binding 
sites must exist. In this case, adenine, and possibly even cytosine, present probable targets 
(chapter 8).  
Overall, it was shown that the panel of investigated compounds is able to bind various biomolecules 
in a defined manner. Together with the biological and biophysical data acquired within this thesis, it 
becomes clear that many factors contribute to the final antiproliferative activity of these complexes. 
Compounds 29/30 and 45/46, bearing a methyl/ethyl substituent at the dithioester and no 
substituent resp. a m-OH group at the phenyl ring were identified as the most potential drug 
candidates worthy of further, detailed investigation.  
It is by far not yet clear how these compounds could possibly work in vivo, yet some important 
contributions to a first understanding of the compounds mode of action have been made. Future 
investigations might elucidate the cellular response in detail, so that the compound class could be 
further optimized and a lead structure may be identified.  
In efforts to enable an enhanced drug targeting towards cancer cells, synthetic pathways towards the 
formation of bioconjugates have furthermore been reported. Two general methods to link the 
(O,S)Pt pharmacophore to a model peptide, Leu5-enkephalin, have been applied, namely the most 
prominent click reaction, CuAAC, and the linking via amide bonds. To make CuAAC possible, the 
-hydroxydithiocinnamic ester motif was derivatized with alkyne- and azide- functional groups 
(compounds 54-59 and 71, respectively, Scheme 27). The first approach, introducing aklyne groups 
into the structure, resulted in numerous synthetic obstacles such as uncontrolled rearrangement 
processes or hydration of the triple bonds during ligand and complex syntheses, thus making the 
isolation of monofunctional compounds with the desired (O,S)PtCl(DMSO) coordination environment 
impossible. Merely (O,S)2Pt bischelate structures (61, 62, 66, Scheme 27) were obtained with a 
preserved alkyne group. On the contrary, synthesis of azidomethyl-dedrived complexes 72 and 73 
proceeded readily and in good yields (Scheme 27, chapter 11). 
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Scheme 27 Derivatives of -hydroxydithiocinnamic esters with alkyne and azide functional groups; accessability of the 
respective Pt(II) complexes. 
After deriving Leu5-Enkephalin (Leu5-Enk) with carboxylic acids bearing either a terminal alkyne (76) 
or azide (77), the linking of the two units was pursued. It was possible to obtain bioconjugates of 
bischelates with both functional groups (78 and 79). The synthesis of 78, based on the azide-(O,S) 
compound 73, proceeded better and gave less side products as well as an increased yield of pure 
compound. The isolation of the respective monofunctional complex 81 was then possible by first 
linking the ligand 71 with alkyne-functionalized Enk 76 by CuAAC, followed by coordination to the 
Pt(II) center (chapter 11). The three relevant bioconjugates are summarized in Chart 10. 
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Chart 10 Metal-peptide bioconjugates isolated by CuAAC. 
As an alternative route towards bioconjugates with the two desired units, the coupling through an 
amide bond was also feasible. After preparing compound 82 with a carboxymethyl group bound to 
the dithiocarbonyl unit, the coupling to Leu5-Enk 75 in solution was successfully performed (84). It 
was then possible to generate the monofunctional compound 85 with DMSO and Cl- as monodentate 
ligands (Chart 11). All described compounds were identified by their mass spectrometric profile and 
NMR spectroscopic data (chapter 12).  
 
 
Chart 11 Metal-peptide bioconjugate obtained from amide bond formation 
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Overall, it could be shown that the basic structural motif of the compounds presented in this thesis 
offers multiple possibilities to derivatize and optimize the biological relevant properties of the (O,S)Pt 
pharmacophore. Several synthetic approaches have been demonstrated and diverse methods to 
explore the functional consequences of such variations applied. This work may thus present a first 
step into the direction of new, promising drug candidates with an optimized biological profile. 
 
 

  
 
 
21 ZUSAMMENFASSUNG 
In der hier vorgestellten Arbeit wird eine Serie von Platin(II) Komplexen beschrieben, welche 
potentiell als zytotoxische Substanzen dienen können. Sie alle besitzen (O,S) bidentate Liganden als 
gemeinsames Pharmakophor welches auf -Hydroxydithiozimtsäureestern basiert. Diese 
Grundstruktur erlaubt verschiedene Modifizierungen, von denen einige in dieser Arbeit untersucht 
wurden.  
Zuerst wurde eine Reihe von -Hydroxydithiozimtsäureestern (7-28, Scheme 26) hergestellt, welche 
verschiedene Substituenten am Phenylring tragen (H, p-Br, m- und p-OX, mit X = H oder TBDMS) und 
außerdem verschieden lange Alkylketten an der Dithioestereinheit gebunden sind, um die 
entsprechende Dithio-methyl, -ethyl, -butyl, oder hexylester zu erhalten. Durch Koordination an das 
Platin(II) Zentrum entstanden neutrale Komplexe 29-48 mit den -Hydroxydithiozimtsäureester-
Derivaten als (O,S)-chelatisierende Einheit (Scheme 26). Die Koordinationssphäre wird abgesättigt 
durch einen Chloridoliganden und durch DMSO, welches als S-Donor fungiert. Des Weiteren wurden 
zwei repräsentative Bischelatkomplexe, 49 und 50, hergestellt welche als Vertreter der sehr stabilen 
(O,S)2Pt Komplexe dienen. Das übergeordnete Ziel der Herstellung dieser Substanzreihe bestand 
darin, verschieden polare und damit unterschiedlich stark wasserlösliche Komplexe zu erhalten. 
Darüber hinaus sollte ermittelt werden, wie die unterschiedlichen Substituenten am Pharmakophor 
die biologische Aktivität der Pt(II) Komplexe beeinflussen (Kapitel 3). 
Alle Substanzen wurden vollständig mittels Standard-Analysemethoden untersucht. Unter 
Anwendung von UV-Vis Spektroskopie wurde das Verhalten der Metallkomplexe im wässrigen 
Medium untersucht, um Informationen über die Löslichkeit und das Hydrolyseverhalten dieser 
Verbindungen in Pufferlösungen zu erhalten. Diese Untersuchungen bildeten eine Grundlage für 
weitere Untersuchungen zur Interaktion der Verbindungen mit Biomolekülen. Es konnte gezeigt 
werden, dass als erster Hydrolyseschritt der Chloridoligand abgespalten wird, während der DMSO-
Lingand unter bestimmten Messbedingungen in der Koordinationssphäre erhalten bleiben kann 
(Kapitel 4).  
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X \ R Me Et Bu Hex 
H 7 8 9 10 
p-Br 11 12 13 14 
m-O-TBDMS 15 16 17 18 
p-O-TBDMS 19 20 21 22 
m-OH 23 24  25 
p-OH 26 27  28 
 
X \ R Me Et Bu Hex 
H 29 30 31 32 
p-Br 33 34 35 36 
m-O-TBDMS 37 38 39 40 
p-O-TBDMS 41 42 43 44 
m-OH 45 46   
p-OH 47 48   
   
Scheme 26 Verbindungen, die im ersten Teil der Arbeit hergestellt und untersucht wurden. 
Um die Löslichkeit der Komplexe in Wasser zu quantifizieren, wurden die LogPo/w Werte der 
entsprechenden Liganden mithilfe der Shake-Flask-Methode ermittelt. Dies ermöglichte eine 
indirekte Messung der relativen Hydro- oder Lipophilie für die Komplexe 29-48. Es konnte gezeigt 
werden, dass das Einbringen einer Hydroxygruppe in meta-Position zu den niedrigsten LogPo/w- 
Werten, und damit zur größten Polarität, in dieser Serie führt. Im Allgemeinen sind die Verbindungen 
wenig polar, was sich in positiven LogPo/w Werten äußert, welche wiederum auf eine bevorzugte 
Anreicherung der Substanzen in der Oktanol- und nicht in der Wasserphase hindeuten (Kapitel 4).  
Des Weiteren wurde die biologische Aktivität der Verbindungen 29-36 mit H- und p-Br Substituenten 
und von Verbindungen 45-46 mit hydroxy-Substituenten gegenüber vier repräsentativen Zelllinien 
(HeLa, HT29, MCF7, 293T HEK) untersucht. Als Assaymethode wurde der auf Resazurin basierende 
PrestoBlue® Assay verwendet. Obwohl die Substanzen generell weniger toxisch auf die Zelllinien 
wirken als die Referenzsubstanz Cisplatin, zeigen sie dennoch ein sehr interessantes 
Aktivitätsspektrum, welches von der Lipophilie der Verbindungen abzuhängen scheint: Auf der einen 
Seite sind die polarsten Verbindungen (solche mit Methyl- bzw. Ethylgruppen an der 
Dithioesterfunktion und einem unsubstituierten oder m-OH-Phenylring, 29, 30, und 43-46) am 
zytotoxisch aktivsten gegenüber den Zelllinien: In dieser Reihe nimmt die Aktivität bei zunehmender 
Kettenlänge (C4- oder C6-Ketten) ab. Auf der anderen Seite aber zeigt sich bei den Verbindungen mit 
einem p-Br Substituenten (33-36)ein entgegengesetzter Trend: Hier erhöht sich die Zytotoxizität mit 
länger werdender Alkylkette. Diese Beobachtungen könnten ein Hinweis darauf sein, dass eher 
polare bzw. sehr unpolare Verbindungen unterschiedlichen Akkumulations- und 
Verarbeitungsmechanismen in der Zelle ausgesetzt sind. Wenn die Position der OH-Gruppe am 
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Phenylring verändert wird (m-OH in 45/46 vs. p-OH in 47/48), ergeben sich interessanter Weise 
signifikante Unterschiede in der zytotoxischen Wirkung der Substanzen. Die Ursache für diese 
Unterschiede kann einerseits in der abweichenden Polarität der Verbindungen liegen, und/oder in 
Unterschieden in der zellulären Verarbeitung beider Substanzgruppen. Zukünftige, weiterführende 
Untersuchungen könnten hier Aufschluss geben (Kapitel 5). 
Generell scheinen die Substanzen ihre größte Aktivität gegenüber der Modellzelllinien bei einer 
Inkubationszeit von 48 h zu zeigen. Dies wurde in einer Serie zeitabhängiger Experimente gefunden, 
in denen die IC50 Werte nach 24, 48, und 72 h bestimmt wurden. Fluoreszenzmikroskopische 
Aufnahmen von HeLa und MCF7-Zellen nach Inkubation mit Verbindung 46 gaben außerdem 
Aufschluss über die Zellantwort auf Behandlung mit dieser Substanz: Der Zelltod, sehr wahrscheinlich 
durch Apoptose, tritt ein.  
Ausgewählte Vertreter der hier vorgestellten Substanzklasse wurden außerdem auf ihre Reaktivität 
gegenüber Modellproteinen (Cytochrom c, Lysozym, Ribonuklease A) mittels ESI-
Massenspektrometrie untersucht. Ein weiteres Modellprotein, Albumin, wurde verwendet um die 
Serumprotein-Interaktion der Substanzen mithilfe von ICP-OES zu charakterisieren. Es konnte 
generell gezeigt werden, dass die Verbindungen stabile kovalente Bindungen mit spezifischen 
Aminosäure-Seitenketten eingehen können. Als potentielle Bindungsstellen gelten vor allem 
Histidine, auch Methionine könnten eine Rolle bei der Anbindung von (O,S)Pt-Einheiten spielen. 
Diese Mutmaßung basiert im Wesentlichen auf Erkenntnissen aus ähnlichen Untersuchungen mit 
Cisplatin und dessen Analoga sowie den Strukturdaten aus Lysozym-Addukten mit den Verbindungen 
46 und 48, in denen beide Male das ND1-Atom von His15 als Bindungsstelle identifiziert wurde 
(Kapitel 7). 
Des Weiteren wurde die Fähigkeit der Substanzen, DNA zu binden, mithilfe von drei 
Modellkomplexen (30, 46, und 48) untersucht. Dabei wurden zwei Modellsysteme verwendet: 
9-Methylguanin (9-mg) und einzelsträngige Oligonukleotide (ODNs) mit definierten Sequenzen, 
welche einerseits benachbarte Guanine (ODN1, ODN2), oder gar keine Guanine (ODN3) enthalten. 
Wie aus den UV-Vis spektroskopischen Untersuchungen hervor geht, reagieren die Komplexe in 
Minutenschnelle mit der Modellnukleobase 9-mg. Außerdem konnten verschiedene Addukte in den 
dazugehörigen ESI massenpektrometrischen Daten gefunden werden. Die (O,S)Pt Einheit kann 9-mg 
entweder unter Verlust oder Erhalt des DMSO-Liganden binden; im ersteren Fall wird wahrscheinlich 
eine bidentate Bindungsweise an N7 und O6 des 9-mg ermöglicht. Zusätzlich wurden auch Bisaddukte 
von einer (O,S)Pt-Einheit mit zwei 9-mg Molekülen gefunden (Kapitel 8). 
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In den Adduktspektren der Substanzen mit den ODN-Sequenzen wurde ein vielschichtiges 
Bindungsverhalten der Platinverbindungen beobachtet. Anhand von MS2-Experimenten mit 
Addukten der Verbindungen mit ODN1 konnte wie erwartet die bevorzugte Bindung der (O,S)Pt-
Einheit an Guanin nachgewiesen werden. Zusätzlich zu dieser stabilen Bindung müssen jedoch auch 
andere Bindungsstellen existieren, welche das Anbinden mehrerer Metallzentren an die 
Oligonukleotid-Einzelstränge ermöglichen. Dies wird besonders deutlich anhand der Adduktspektren 
mit ODN3, welches im Wesentlichen aus einer C-A Tandemsequenz besteht. In diesen wurden trotz 
Abwesenheit von Guanin mehrere an ODN3 koordinierte (O,S)Pt-Einheiten gefunden. Eine Bindung 
über das Phosphodiester-Grundgerüst ist sehr unwahrscheinlich, so dass neben Guanin auch noch 
andere potentielle Bindungsstellen, wie Adenin oder auch Cytosin, für die (O,S)Pt-Einheit vorhanden 
sein sollten (Kapitel 8).  
Generell konnte anhand der Biomolekül-Interaktionsstudien gezeigt werden, dass die untersuchten 
Substanzen ein definiertes Reaktivitätsspektrum gegenüber verschiedenen Biomolekülen aufweisen. 
Zusammen mit den biologischen und biophysikalischen Daten die im Rahmen dieser Arbeit erhoben 
wurden, konnte gezeigt werden dass viele verschiedene Faktoren zur finalen 
zellwachstumshemmenden Wirkung der Verbindungen beitragen. Verbindungen 29/30 und 45/46 
mit Methyl-/Ethylgruppen am Dithioester-Schwefel und Phenyl- bzw. meta-Hydroxyphenylgruppen 
als aromatische Einheit konnten als viel versprechende Kandidaten für weitere detaillierte 
Untersuchungen identifiziert werden.  
Es ist bei Weitem noch nicht geklärt wie diese Verbindungen in vivo agieren könnten. Die Ergebnisse 
dieser Arbeit leisten einen wichtigen Beitrag zu einem ersten Verständnis der Wirkungsweise dieser 
Substanzklasse. Zukünftige Untersuchungen könnten die Zellantwort auf eine Behandlung mit den 
potentiellen Cytostatika detaillierter erkunden, so dass eine Leitstruktur für die weitere Entwicklung 
identifiziert werden kann. 
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Scheme 27 Organische Precursorverbindungen zur Herstellung von Biokonjugaten mittels CuAAC und Zugänglichkeit der 
entsprechenden Platinkomplexe. 
Um eine verbesserte Selektivität der Substanzen gegenüber Krebszellen zu ermöglichen, wurden 
Synthesewege zur Anbindung von Biomolekülen erkundet, welche dann als Targeting-Einheit 
fungieren können. Zwei generelle, bekannte Methoden wurden zu diesem Zweck angewendet: Der 
prominenteste Vertreter der Click-Chemie, die Kupfer(Cu)-katalysierte Azid-Alkin-Cycloaddition 
(CuAAC) und das Verbinden mittels Amidbindungen. Um eine CuAAC zu ermöglichen wurde das 
Grundgerüst der -Hydroxydithiozimtsäureester mit terminalen Aklin- und Azidgruppen 
funktionalisiert (Verbindungen 54-59 und 71, Scheme 27). Das Einbringen von terminalen Alkinen in 
das Grundgerüst erwies sich als äußerst umständlich und ging mit vielen unkontrollierten 
Umlagerungsreaktionen sowie Hydratationsreaktionen an der Dreifachbindung während der 
Komplex- und Ligandensynthesen einher. Aufgrund dessen war es nicht möglich, monofunktionale 
Komplexe mit der gewünschten (O,S)PtCl(DMSO) Koordinationsumgebung zu isolieren; lediglich 
Bischelate (61, 62, 66, Scheme 27) wurden erhalten in denen die terminale Alkingruppe bewahrt 
blieb. Im Gegensatz dazu verlief die Synthese der Benzylazid-funktionalisierten Verbindungen 
reibungslos und mit guten Ausbeuten (Kapitel 11). 
Nachdem Leu5-Enkephalin mittels Carbonsäuren die entweder eine Alkin- (76) oder eine Azidgruppe 
(77) tragen derivatisiert wurde, sollte die Verlinkung durch CuAAC durchgeführt werden. Es war 
möglich, Bischelate mit beiden funktionellen Gruppen, einem terminalen Alkin (62) oder Azid (73), an 
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das entsprechend komplementäre Enkephalin-Derivat zu koppeln (78 und 79). Dabei verlief aber die 
Synthese von 78 wesentlich effektiver; es wurden weniger Nebenprodukte erhalten und die 
Ausbeute an reinem Metall-Peptid-Konjugat war dadurch höher. Es war weiterhin möglich, den 
monofunktionalen Komplex 81 zu erhalten indem zuerst CuAAC am Liganden 71 durchgeführt wurde 
und anschließend das Pt(II) Zentrum eingeführt wurde (Kapitel 11). Die drei relevanten Metall-
Biokonjugate sind in Chart 10 abgebildet. 
 
Chart 10 Isolierte Metall-Biokonjugate nach CuAAC. 
Als alternative Zugangsmöglichkeit zu Biokonjugaten mit den gewünschten Einheiten (O,S)Pt und Enk 
wurde die Ausbildung von Peptidbindungen untersucht. Nachdem in Verbindung 82 eine 
Carboxymethyl-Gruppe am Dithioester-Schwefel eingebracht wurde konnte sie erfolgreich in Lösung 
an Leu5-Enk 75 gekoppelt werden. Anschließend wurde der Platin-Komplex generiert der wie 
gewünscht die monodentaten Chlorido- und DMSO-Liganden trug (Chart 11). Alle isolierten 
Verbindungen wurden mithilfe ihrer massenspektrometrischen Isotopenprofile und anhand von 
NMR-Spektren identifiziert (Kapitel 12).  
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Chart 11 Metall-Biokonjugat nach Verknüpfung durch eine Peptidbindung. 
Im Rahmen dieser Arbeit konnte gezeigt werden, dass das grundlegende Strukturmotiv der hier 
vorgestellten Verbindungen eine Vielzahl von Modifizierungsmöglichkeiten bietet, welche den 
Zugang zu Verbindungen mit optimierten biologisch-relevanten Eigenschaften des (O,S)Pt 
Pharmakophors ermöglichen. Mehrere synthetische Ansätze hierzu wurden in dieser Arbeit 
vorgestellt und verschiedene Methoden zur Untersuchung der funktionellen Konsequenzen 
angewendet. Diese Arbeit leistet somit einen ersten Beitrag zur Entwicklung neuer, 
vielversprechender Medikamente mit optimiertem biologischen Profil. 
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Table S 1 Crystallographic data of compounds 50 and 82. 
 
 
 
Compound 50 82 
Empirical formula  C34H50O4PtS4 Si2 C11H9BrO3S2 
Formula weight [g∙ŵol–1] 902.25 333.22 
collection T [K] 133(2) 170.0 
λ (Mo K) [Å] 0.71073 Å 0.71073 
Crystal system  monoclinic orthorhombic 
Space group P21/c P212121 
Cell constants   
a [Å] 16.9053(8) 6.2614(2) 
b [Å] 11.9274(8) 7.1327(3) 
c [Å] 20.3286(12) 27.5023(8) 
α [°] 90 90.00 
β [°] 106.746(4) 90.00 
γ [°] 90 90.00 
V [Å3] 3925.1(4) 1228.27(7) 
Z 4 4 
ρcalcd [g∙cŵ–3] 1.527 1.802 
µ [mm–1] 3.883 3.678 
F(000) 1824 664.0 
crystal dimensions [mm] 0.04  0.04  0.03 0.21 × 0.18 × 0.11 
2 Θ range [°] 2.52 to 27.46 5.9 to 73.48 
index ranges -21 ≤ h ≤ 19 -ϵ ≤ h ≤ ϵ 
 -15 ≤ k ≤ 12 -ϴ ≤ k ≤ ϭϭ 
 -21 ≤ l ≤ 26 -ϰϮ ≤ l ≤ ϰϮ 
measured reflections 23843 22844 
unique reflections 8605 4878 
Rint 0.0703 0.0477 
data with I > 2σ(I) / restraints / 
parameters 8605 / 0 / 418 4878/0/156 
Goodness-of-fit on F2 / S* 1.050 1.093 
R1 [I > 2σ(I)]** 0.0441 0.0359 
wR2 [I > 2σ;IͿ]*** 0.0825 0.0692 
R1all** 0.0830 0.0545 
wR2 [all data, on F2]*** 0.0971 0.0841 
max./min. residual electron 
deŶsity [e∙Å–3] 1.839/-1.453 0.58/-0.47 
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Table S 2 Crystallographic data of compounds 72 and 73. 
 
  
Compound 72 73 
Empirical formula  C14H18ClN3O2PtS3 C24H24N6O2PtS4 
Formula weight [g∙ŵol–1] 587,04 751,82 
collection T [K] 293 293 
λ (Mo K) [Å] 0.71075 0.71075 
Crystal system  monoclinic triclinic 
Space group P21/n P-1 
Cell constants   
a [Å] 24.68(3) 11.436(8) 
b [Å] 7.408(6) 13.558(10) 
c [Å] 24.75(2) 26.982(18) 
α [°] 90.00 91.835(9) 
β [°] 118.097(12) 94.275(10) 
γ [°] 90.00 105.974(9) 
V [Å3] 3992(7) 4005(5) 
Z 4 2 
ρcalcd [g∙cŵ–3] 1.925 3.802 
µ [mm–1] 7.488 27.023 
F(000) 2188.0 3990.0 
crystal dimensions [mm] 0.2 × 0.2 × 0.2 0.2 × 0.2 × 0.2 
2 Θ range [°] 3.2 to 55.14 3.04 to 55.04 
index ranges -ϯϭ ≤ h ≤ ϯϮ -ϭϰ ≤ h ≤ ϭϰ 
 -ϵ ≤ k ≤ ϵ -ϭϳ ≤ k ≤ ϭϳ 
 -ϯϮ ≤ l ≤ ϯϮ -ϯϱ ≤ l ≤ ϯϱ 
measured reflections 38244 34466 
unique reflections 9144 17736 
Rint 0.1067 0.0716 
data with I > 2σ(I) / restraints/ 
parameters 9144/36/441 17736/0/429 
Goodness-of-fit on F2 / S* 1.081 1.393 
R1 [I > 2σ(I)]** 0.0659 0.1040 
wR2 [I > 2σ;IͿ]*** 0.1687 0.2496 
R1all** 0.0788 0.1284 
wR2 [all data, on F2]*** 0.1801 0.275 
max./min. residual electron 
deŶsity [e∙Å–3] 4.23/-4.61 6.68/-9.24 
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Table S 3 Bond lengths [Å] for compound 50. 
Atoms Bond  lengths [Å]  
Atoms  
(continued) 
Bond  
lengths [Å]  
Atoms  
(continued) 
Bond  
lengths [Å] 
Pt(1) O(1) 2.022(4)  Si(2) C(27) 1.841(7)  C(12) C(14) 1.535(11) 
Pt(1) O(3) 2.020(3)  Si(2) C(29) 1.884(6)  C(12) C(13) 1.536(10) 
Pt(1) S(1) 2.2275(14)  O(1) C(3) 1.283(7)  C(16) C(17) 1.512(9) 
Pt(1) S(3) 2.2303(15)  O(2) C(8) 1.374(6)  C(18) C(19) 1.388(8) 
S(1) C(1) 1.687(6)  O(3) C(20) 1.276(7)  C(19) C(20) 1.395(8) 
S(2) C(1) 1.758(5)  O(4) C(25) 1.368(7)  C(20) C(21) 1.507(7) 
S(2) C(16) 1.816(6)  C(1) C(2) 1.405(8)  C(21) C(26) 1.385(8) 
S(3) C(18) 1.690(6)  C(2) C(3) 1.387(8)  C(21) C(22) 1.393(8) 
S(4) C(18) 1.757(6)  C(3) C(4) 1.511(8)  C(22) C(23) 1.389(8) 
S(4) C(33) 1.803(6)  C(4) C(5) 1.378(8)  C(23) C(24) 1.374(8) 
Si(1) O(2) 1.662(4)  C(4) C(9) 1.402(7)  C(24) C(25) 1.393(8) 
Si(1) C(10) 1.843(6)  C(5) C(6) 1.385(8)  C(25) C(26) 1.388(7) 
Si(1) C(12) 1.864(7)  C(6) C(7) 1.381(8)  C(29) C(31) 1.507(10) 
Si(1) C(11) 1.868(7)  C(7) C(8) 1.380(8)  C(29) C(30) 1.533(9) 
Si(2) O(4) 1.672(4)  C(8) C(9) 1.381(8)  C(29) C(32) 1.532(10) 
Si(2) C(28) 1.843(7)  C(12) C(15) 1.526(9)  C(33) C(34) 1.529(8) 
 
  
SUPPLEMENT 
Supplement A: Crystallographic Data 275 
 
 
Table S 4 Bond angles [°] for compound 50. 
Atoms Bond  angles [°]  
Atoms  
(continued) 
Bond  
angles [°] 
O(1)-Pt(1)-O(3) 80.62(14)  C(7)-C(6)-C(5) 120.2(5) 
O(1)-Pt(1)-S(1) 96.81(11)  C(6)-C(7)-C(8) 120.0(6) 
O(3)-Pt(1)-S(1) 176.78(11)  O(2)-C(8)-C(7) 118.1(5) 
O(1)-Pt(1)-S(3) 177.55(10)  O(2)-C(8)-C(9) 121.3(5) 
O(3)-Pt(1)-S(3) 96.93(11)  C(7)-C(8)-C(9) 120.6(5) 
S(1)-Pt(1)-S(3) 85.63(5)  C(8)-C(9)-C(4) 119.1(5) 
C(1)-S(1)-Pt(1) 108.8(2)  C(15)-C(12)-C(14) 108.1(7) 
C(1)-S(2)-C(16) 105.6(3)  C(15)-C(12)-C(13) 109.8(6) 
C(18)-S(3)-Pt(1) 108.6(2)  C(14)-C(12)-C(13) 109.0(6) 
C(18)-S(4)-C(33) 105.4(3)  C(15)-C(12)-Si(1) 110.2(5) 
O(2)-Si(1)-C(10) 111.5(2)  C(14)-C(12)-Si(1) 109.0(5) 
O(2)-Si(1)-C(12) 104.5(3)  C(13)-C(12)-Si(1) 110.7(5) 
C(10)-Si(1)-C(12) 110.9(3)  C(17)-C(16)-S(2) 114.7(5) 
O(2)-Si(1)-C(11) 107.9(3)  C(19)-C(18)-S(3) 128.7(4) 
C(10)-Si(1)-C(11) 110.5(3)  C(19)-C(18)-S(4) 114.3(4) 
C(12)-Si(1)-C(11) 111.4(3)  S(3)-C(18)-S(4) 117.1(3) 
O(4)-Si(2)-C(28) 109.8(3)  C(20)-C(19)-C(18) 129.3(5) 
O(4)-Si(2)-C(27) 111.2(3)  O(3)-C(20)-C(19) 126.9(5) 
C(28)-Si(2)-C(27) 110.4(4)  O(3)-C(20)-C(21) 114.2(5) 
O(4)-Si(2)-C(29) 103.1(2)  C(19)-C(20)-C(21) 118.9(5) 
C(28)-Si(2)-C(29) 111.7(4)  C(26)-C(21)-C(22) 119.8(5) 
C(27)-Si(2)-C(29) 110.5(3)  C(26)-C(21)-C(20) 118.8(5) 
C(3)-O(1)-Pt(1) 129.5(3)  C(22)-C(21)-C(20) 121.4(5) 
C(8)-O(2)-Si(1) 131.6(4)  C(23)-C(22)-C(21) 119.5(5) 
C(20)-O(3)-Pt(1) 129.5(4)  C(24)-C(23)-C(22) 120.6(5) 
C(25)-O(4)-Si(2) 132.0(4)  C(23)-C(24)-C(25) 120.0(5) 
C(2)-C(1)-S(1) 129.1(4)  O(4)-C(25)-C(26) 122.7(5) 
C(2)-C(1)-S(2) 112.2(4)  O(4)-C(25)-C(24) 117.6(5) 
S(1)-C(1)-S(2) 118.8(3)  C(26)-C(25)-C(24) 119.6(5) 
C(3)-C(2)-C(1) 128.3(5)  C(21)-C(26)-C(25) 120.3(5) 
O(1)-C(3)-C(2) 127.5(5)  C(31)-C(29)-C(30) 109.3(6) 
O(1)-C(3)-C(4) 113.8(5)  C(31)-C(29)-C(32) 109.6(6) 
C(2)-C(3)-C(4) 118.7(5)  C(30)-C(29)-C(32) 109.3(6) 
C(5)-C(4)-C(9) 120.3(5)  C(31)-C(29)-Si(2) 110.7(5) 
C(5)-C(4)-C(3) 121.9(5)  C(30)-C(29)-Si(2) 108.9(4) 
C(9)-C(4)-C(3) 117.8(5)  C(32)-C(29)-Si(2) 108.9(5) 
C(4)-C(5)-C(6) 119.8(5)  C(34)-C(33)-S(4) 108.1(4) 
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Table S 5 Bond lengths [Å] for compound 72. 
Atoms Bond  lengths [Å]  
Atoms  
(continued) 
Bond  
lengths [Å] 
Pt1 S9 2.196(5)   C25 C8 1.519(16) 
Pt1 S10 2.262(5)   C27 C15 1.51(3) 
Pt1 Cl12 2.336(5)   C44 C11 1.476(18) 
Pt1 O35 2.010(11)   C44 C14 1.39(2) 
Pt2 S6 2.193(5)   C44 O0AA 1.343(17) 
Pt2 S11 2.239(5)   C8 C13 1.44(2) 
Pt2 Cl13 2.343(5)   C8 C2 1.448(17) 
Pt2 O0AA 2.002(11)   C11 C17 1.457(18) 
S6 C31 1.785(13)   C11 C3 1.369(18) 
S6 C46 1.791(14)   C13 C5 1.47(2) 
S6 O1 1.467(13)   C2 C6 1.434(17) 
S7 C18 1.857(16)   C5 C12 1.427(19) 
S7 C20 1.827(17)   C6 C12 1.362(17) 
S8 C19 1.699(16)   C7 C9 1.442(19) 
S8 C27 1.741(19)   C7 C10 1.375(19) 
S9 C4 1.780(14)   C7 C0AA 1.50(2) 
S9 C1 1.778(14)   C12 C1A 1.501(18) 
S9 O2 1.479(13)   C9 C3 1.391(19) 
S10 C20 1.674(17)   C10 C17 1.36(2) 
S11 C19 1.715(16)   C1A N5 1.55(3) 
C18 C34 1.52(2)   N1 N5 1.15(2) 
C19 C14 1.40(2)   N1 N3 1.21(3) 
C20 C45 1.35(2)   C0AA N0AA 1.51(2) 
C25 O35 1.271(16)   N0AA N4 1.14(2) 
C25 C45 1.375(17)   N2 N4 1.22(3) 
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Table S 6 Bond angles [°] for compound 72. 
Atoms Bond  angles [°]  
Atoms  
(continued) 
Bond  
angles [°] 
S9 Pt1 S10 89.46(17)   O35 C25 C8 113.9(11) 
S9 Pt1 Cl12 90.11(17)   C45 C25 C8 118.0(10) 
S10 Pt1 Cl12 176.37(14)   C15 C27 S8 109.8(16) 
O35 Pt1 S9 173.5(3)   C25 O35 Pt1 128.8(9) 
O35 Pt1 S10 95.8(4)   C14 C44 C11 123.1(12) 
O35 Pt1 Cl12 84.9(4)   O0AA C44 C11 112.0(12) 
S6 Pt2 S11 89.88(18)   O0AA C44 C14 124.6(12) 
S6 Pt2 Cl13 89.70(18)   C20 C45 C25 126.1(13) 
S11 Pt2 Cl13 178.15(15)   C13 C8 C25 120.5(11) 
O0AA Pt2 S6 173.5(4)   C13 C8 C2 124.0(12) 
O0AA Pt2 S11 95.5(4)   C2 C8 C25 115.4(11) 
O0AA Pt2 Cl13 85.0(4)   C17 C11 C44 119.1(12) 
C31 S6 Pt2 110.3(5)   C3 C11 C44 123.2(12) 
C31 S6 C46 101.7(8)   C3 C11 C17 117.6(13) 
C46 S6 Pt2 109.0(6)   C44 C14 C19 130.5(14) 
O1 S6 Pt2 116.9(6)   C8 C13 C5 113.3(14) 
O1 S6 C31 109.2(6)   C6 C2 C8 117.8(11) 
O1 S6 C46 108.7(7)   C13 C5 C12 122.7(12) 
C20 S7 C18 106.1(8)   C12 C6 C2 121.0(12) 
C19 S8 C27 107.3(8)   C9 C7 C0AA 120.8(13) 
C4 S9 Pt1 111.3(5)   C10 C7 C9 118.0(15) 
C4 S9 C1 103.0(9)   C10 C7 C0AA 121.2(13) 
C1 S9 Pt1 110.0(5)   C5 C12 C1A 118.3(12) 
O2 S9 Pt1 117.6(5)   C6 C12 C5 121.0(13) 
O2 S9 C4 108.1(7)   C6 C12 C1A 120.7(14) 
O2 S9 C1 105.7(7)   C3 C9 C7 119.4(15) 
C20 S10 Pt1 105.9(6)   C17 C10 C7 122.7(14) 
C19 S11 Pt2 110.9(5)   C10 C17 C11 119.9(14) 
C34 C18 S7 106.4(14)   C12 C1A N5 115.7(14) 
S11 C19 S8 119.5(8)   C11 C3 C9 122.4(14) 
C14 C19 S8 114.4(12)   N5 N1 N3 167(2) 
C14 C19 S11 125.5(12)   N1 N5 C1A 108.9(17) 
S10 C20 S7 115.0(9)   N0AA C0AA C7 112.2(14) 
C45 C20 S7 111.6(12)   N4 N0AA C0AA 110.1(19) 
C45 C20 S10 133.4(13)   N0AA N4 N2 160(3) 
O35 C25 C45 128.1(11)   C44 O0AA Pt2 129.2(10) 
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Table S 7 Bond lengths [Å] for compound 73. 
Atoms Bond  lengths [Å]  
Atoms  
(continued) 
Bond  
lengths [Å] 
Pt1 S8 2.229(3)   C59 C7AA 1.56(2) 
Pt1 S15 2.244(4)   C64 C94 1.40(2) 
Pt1 O2 2.018(9)   C94 C3BA 1.40(2) 
Pt1 O3 2.016(9)   C94 C4BA 1.57(3) 
Pt2 S9 2.240(4)   C102 C110 1.41(2) 
Pt2 S16 2.227(4)   C7BA C8BA 1.402(17) 
Pt2 O1 1.997(10)   C7BA C8AA 1.493(19) 
Pt2 O1AA 1.992(8)   C8BA C2AA 1.418(17) 
Pt3 S10 2.233(4)   C15 C42 1.403(18) 
Pt3 S12 2.245(4)   C8AA C9AA 1.45(2) 
Pt3 O0AA 2.035(10)   C8AA C2BA 1.422(19) 
Pt3 O5 2.019(9)   C3AA C36 1.39(2) 
C7 C46 1.392(17)   C3AA C40 1.54(2) 
C7 C3BA 1.31(2)   C3AA C45 1.36(2) 
S8 C5AA 1.714(14)   C9AA C36 1.39(2) 
S9 C5BA 1.684(14)   C2BA C45 1.38(2) 
S10 C2AA 1.680(14)   C40 N35 1.48(2) 
S11 C4 1.744(14)   C57 N15 1.64(5) 
S11 C6 1.811(13)   O1 C19 1.306(17) 
S12 C42 1.693(14)   O2 C32 1.300(15) 
S13 C42 1.731(15)   O3 C28 1.252(15) 
S13 C29 1.811(13)   C4 C20 1.386(16) 
S14 C5AA 1.751(13)   C5 C8 1.388(17) 
S14 C10 1.836(14)   C6 C14 1.59(2) 
S15 C4 1.726(13)   C5AA C11 1.384(17) 
S16 C5 1.721(14)   C8 C19 1.440(18) 
S17 C2AA 1.749(13)   C9 C13 1.52(2) 
S17 C18 1.837(14)   C10 C9BA 1.52(2) 
S18 C9 1.823(14)   C11 C28 1.453(16) 
S18 C5BA 1.764(14)   C12 C30 1.57(2) 
S19 C5 1.742(12)   C5BA C24 1.376(18) 
S19 C12 1.858(15)   C16 C23 1.38(2) 
O0AA C6AA 1.241(16)   C16 C38 1.55(2) 
O5 C7BA 1.311(15)   C16 C44 1.40(2) 
C4AA C0BA 1.430(18)   C17 C29 1.55(2) 
C4AA C6BA 1.36(2)   C18 C26 1.565(19) 
C0AA C1AA 1.36(2)   C20 C32 1.397(17) 
C0AA C102 1.42(2)   C21 C33 1.44(2) 
C0AA C57 1.57(3)   C21 C41 1.42(2) 
C6AA C49 1.513(19)   C21 C61 1.63(3) 
C6AA C15 1.455(19)   C22 C25 1.41(2) 
C1BA C0BA 1.38(2)   C22 C32 1.512(17) 
C1BA C86 1.38(2)   C22 C34 1.42(2) 
C1AA C81 1.41(2)   C23 C37 1.46(2) 
C0BA C19 1.501(18)   C24 C38 1.37(2) 
C27 C46 1.390(19)   C25 C41 1.41(2) 
C27 C64 1.39(2)   C7AA N0AA 1.49(3) 
C6BA C59 1.38(2)   N31 N35 1.24(2) 
C46 C28 1.497(17)   N31 N50 1.18(3) 
C49 C81 1.43(2)   C33 C34 1.38(2) 
C49 C110 1.37(2)   C37 C0CA 1.41(3) 
C59 C86 1.42(2)   C38 O1AA 1.282(17) 
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Atoms  
(continued) 
Bond  
lengths [Å]  
Atoms  
(continued) 
Bond  
lengths [Å] 
C39 C0CA 1.39(3)   N0AA N1AA 1.14(5) 
C39 C44 1.39(2)   N8 N9 1.21(3) 
C0CA C68 1.54(3)   N8 N13 1.10(4) 
C4BA N7 1.77(4)   N18 N6 1.39(4) 
C61 N18 1.23(4)   N2AA N1AA 1.27(5) 
C68 N9 1.51(3)   N6 N10 1.35(5) 
 
Table S 8 Bond angles [°] for compound 73. 
Atoms Bond  angles [°]  
Atoms  
(continued) 
Bond  
angles [°] 
S8 Pt1 S15 88.52(13)   C45 C2BA C8AA 115.5(14) 
O2 Pt1 S8 174.7(3)   C9AA C36 C3AA 119.0(16) 
O2 Pt1 S15 96.7(3)   N35 C40 C3AA 110.3(16) 
O3 Pt1 S8 96.0(3)   S12 C42 S13 118.2(8) 
O3 Pt1 S15 175.5(3)   C15 C42 S12 129.7(12) 
O3 Pt1 O2 78.7(4)   C15 C42 S13 112.1(11) 
S16 Pt2 S9 87.59(13)   C3AA C45 C2BA 124.0(16) 
O1 Pt2 S9 175.7(3)   C0AA C57 N15 112(2) 
O1 Pt2 S16 96.7(3)   C19 O1 Pt2 131.8(8) 
O1AA Pt2 S9 96.2(3)   C32 O2 Pt1 127.8(8) 
O1AA Pt2 S16 176.2(3)   C28 O3 Pt1 132.0(8) 
O1AA Pt2 O1 79.5(4)   S15 C4 S11 116.8(7) 
S10 Pt3 S12 88.17(13)   C20 C4 S11 112.5(10) 
O0AA Pt3 S10 174.9(3)   C20 C4 S15 130.6(11) 
O0AA Pt3 S12 96.9(3)   S16 C5 S19 117.0(7) 
O5 Pt3 S10 96.6(3)   C8 C5 S16 130.2(10) 
O5 Pt3 S12 175.2(3)   C8 C5 S19 112.8(10) 
O5 Pt3 O0AA 78.3(4)   C14 C6 S11 103.9(9) 
C3BA C7 C46 128.9(14)   S8 C5AA S14 117.1(7) 
C5AA S8 Pt1 108.6(4)   C11 C5AA S8 130.8(11) 
C5BA S9 Pt2 108.1(5)   C11 C5AA S14 112.1(11) 
C2AA S10 Pt3 109.0(4)   C5 C8 C19 126.9(12) 
C4 S11 C6 106.4(6)   C13 C9 S18 108.0(10) 
C42 S12 Pt3 108.7(5)   C9BA C10 S14 109.9(10) 
C42 S13 C29 105.8(7)   C5AA C11 C28 125.2(12) 
C5AA S14 C10 106.2(6)   C30 C12 S19 111.3(10) 
C4 S15 Pt1 107.8(4)   S9 C5BA S18 117.4(7) 
C5 S16 Pt2 108.6(4)   C24 C5BA S9 130.6(12) 
C2AA S17 C18 104.8(7)   C24 C5BA S18 112.0(10) 
C5BA S18 C9 106.2(7)   C23 C16 C38 119.4(14) 
C5 S19 C12 105.9(6)   C23 C16 C44 121.4(15) 
C6AA O0AA Pt3 130.0(9)   C44 C16 C38 119.1(14) 
C7BA O5 Pt3 130.5(8)   C26 C18 S17 104.2(10) 
C6BA C4AA C0BA 118.2(14)   O1 C19 C0BA 115.7(11) 
C1AA C0AA C102 122.2(16)   O1 C19 C8 125.5(12) 
C1AA C0AA C57 119.0(17)   C8 C19 C0BA 118.8(12) 
C102 C0AA C57 118.5(16)   C4 C20 C32 125.5(12) 
O0AA C6AA C49 114.6(12)   C33 C21 C61 118.7(16) 
O0AA C6AA C15 128.0(12)   C41 C21 C33 121.2(15) 
C15 C6AA C49 117.3(12)   C41 C21 C61 120.0(16) 
C86 C1BA C0BA 120.1(14)   C25 C22 C32 116.9(12) 
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Atoms  
(continued) 
Bond  
angles [°]  
Atoms  
(continued) 
Bond  
angles [°] 
C0AA C1AA C81 122.5(18)   C25 C22 C34 121.3(13) 
C4AA C0BA C19 114.9(12)   C34 C22 C32 121.8(13) 
C1BA C0BA C4AA 120.6(12)   C16 C23 C37 117.5(16) 
C1BA C0BA C19 124.3(12)   C38 C24 C5BA 125.9(14) 
C46 C27 C64 119.4(13)   C22 C25 C41 120.4(15) 
C4AA C6BA C59 121.9(14)   N0AA C7AA C59 102.8(17) 
C7 C46 C28 120.6(12)   O3 C28 C46 114.7(11) 
C27 C46 C7 114.8(12)   O3 C28 C11 127.1(11) 
C27 C46 C28 124.6(12)   C11 C28 C46 118.1(11) 
C81 C49 C6AA 121.9(13)   C17 C29 S13 106.5(9) 
C110 C49 C6AA 117.5(14)   N50 N31 N35 176(2) 
C110 C49 C81 120.6(14)   O2 C32 C20 130.0(11) 
C6BA C59 C86 119.1(14)   O2 C32 C22 111.3(11) 
C6BA C59 C7AA 124.7(14)   C20 C32 C22 118.7(11) 
C86 C59 C7AA 116.1(15)   C34 C33 C21 119.3(16) 
C27 C64 C94 121.7(17)   C33 C34 C22 119.7(15) 
C1AA C81 C49 115.9(15)   N31 N35 C40 114.4(19) 
C1BA C86 C59 119.8(15)   C7 C3BA C94 116.2(15) 
C64 C94 C3BA 118.9(16)   C0CA C37 C23 119.1(19) 
C64 C94 C4BA 120.8(18)   C24 C38 C16 118.8(13) 
C3BA C94 C4BA 120.2(17)   O1AA C38 C16 111.2(12) 
C110 C102 C0AA 115.1(16)   O1AA C38 C24 129.7(13) 
C49 C110 C102 123.5(16)   C44 C39 C0CA 117.3(19) 
O5 C7BA C8BA 125.9(12)   C37 C0CA C68 119(2) 
O5 C7BA C8AA 111.9(11)   C39 C0CA C37 122(2) 
C8BA C7BA C8AA 122.3(13)   C39 C0CA C68 119(2) 
C7BA C8BA C2AA 128.0(13)   C25 C41 C21 118.0(15) 
C42 C15 C6AA 126.7(13)   C94 C4BA N7 107(2) 
C9AA C8AA C7BA 120.5(12)   C39 C44 C16 122.4(17) 
C2BA C8AA C7BA 118.3(13)   N18 C61 C21 110(3) 
C2BA C8AA C9AA 121.3(13)   N9 C68 C0CA 108(2) 
S10 C2AA S17 119.4(7)   N1AA N0AA C7AA 108(4) 
C8BA C2AA S10 129.7(10)   N13 N8 N9 171(4) 
C8BA C2AA S17 110.8(10)   N8 N9 C68 109(3) 
C36 C3AA C40 117.0(15)   C61 N18 N6 126(4) 
C45 C3AA C36 121.1(15)   C38 O1AA Pt2 128.8(8) 
C45 C3AA C40 121.7(15)   N0AA N1AA N2AA 160(6) 
C36 C9AA C8AA 118.9(13)   N10 N6 N18 162(4) 
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Table S 9 Bond lengths [Å] for compound 82. 
Atoms Bond  
lengths [Å] 
 Atoms  
(continued) 
Bond  
lengths [Å] 
Br1 C9 1.895(2)   C7 C6 1.398(3) 
S1 C3 1.744(2)   C7 C8 1.386(4) 
S1 C2 1.791(2)   C11 C6 1.398(3) 
S2 C3 1.671(2)   C11 C10 1.374(3) 
O3 C5 1.323(3)   C8 C9 1.395(4) 
C3 C4 1.432(3)   C9 C10 1.379(3) 
C5 C4 1.375(3)   C1 O1 1.310(3) 
C5 C6 1.465(3)   C1 O2 1.217(3) 
C2 C1 1.513(3)         
 
Table S 10 Bond angles[°] for compound 82. 
Atoms Bond  
angles [°] 
 Atoms  
(continued) 
Bond  
angles [°] 
C3 S1 C2 103.28(11)   C7 C6 C5 119.4(2) 
S2 C3 S1 122.62(13)   C11 C6 C5 121.9(2) 
C4 C3 S1 111.32(16)   C11 C6 C7 118.7(2) 
C4 C3 S2 126.05(17)   C7 C8 C9 118.3(2) 
O3 C5 C4 122.5(2)   C8 C9 Br1 119.86(18) 
O3 C5 C6 113.5(2)   C10 C9 Br1 118.79(19) 
C4 C5 C6 124.0(2)   C10 C9 C8 121.3(2) 
C5 C4 C3 126.2(2)   C11 C10 C9 119.8(2) 
C1 C2 S1 114.44(15)   O1 C1 C2 111.73(19) 
C8 C7 C6 121.2(2)   O2 C1 C2 124.5(2) 
C10 C11 C6 120.6(2)   O2 C1 O1 123.7(2) 
 

  
 
SUPPLEMENT B: PROTEIN INTERACTION - ESI MS 
SPECTRAL DATA 
Interaction with horse heart cytochrome c 
  
  
  
Figure S 1 Deconvoluted ESI MS spectra of cytochrome c incubated with representative H- and p-Br- substituted complexes 
29, 30, 32, (left) 33, 34, 36 (right).118  
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Figure S 2 Deconvoluted ESI MS spectra of cytochrome c incubated with the O-silyl protected compounds 37 (red), 38 
(orange), 41 (green), and 42 (blue) for 24 and 72 h. 
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Figure S 3 Deconvoluted ESI MS spectra of cytochrome c incubated with the OH-substituted compounds 45 (red), 46 
(orange), 47 (green), and 48 (blue) for 24 and 72 h.  
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Interaction with hen egg white lysozyme 
  
  
  
Figure S 4 Deconvoluted ESI mass spectra of H- and p-Br derived compounds 29, 30, 32 (left), 33, 34, 36 (right) after 
incubation with HEWL in a 3:1 Pt:protein ratio for 72 h. 
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Figure S 5 Deconvoluted ESI MS spectra of HEWL incubated with m- and p-OH substituted compounds 45-48 for 24h in a 3:1 
metal:HEWL ratio at 37 °C using TMAA buffer. 
 
  
14200 14400 14600 14800 15000 15200Da
0
25
50
75
100
R
el
at
ive
 
Ab
u
n
da
n
ce
14303.81
14723.77
14802.79 15142.74
HEWL
HEWL
+ HEWL
+
+ DMSO
HEWL
+ 2
Da14200 14400 14600 14800 15000 15200
0
25
50
75
100
R
el
at
ive
 
Ab
u
n
da
n
ce
14303.81
14723.77
14801.78 15142.72
HEWL
HEWL
+
HEWL
+
+ DMSO
HEWL
+ 2
14200 14300 14400 14500 14600 14700 14800 14900 15000 15100
m/z
0
25
50
75
100
R
el
at
ive
 
Ab
u
n
da
n
ce
14304.82
14737.79
15170.76
HEWL
+
HEWL
+ 2
HEWL
14200 14400 14600 14800 15000 15200Da
0
10
20
30
40
50
60
70
80
90
100
R
el
at
ive
 
Ab
u
n
da
n
ce
14303.81
14737.78
15171.76
HEWL
+
HEWL
+ 2
HEWL
288 
 
Supplement B: Protein Interaction - ESI MS Spectral Data 
 
 
 
Interaction with ribonuclease A 
 
Figure S 6 Deconvoluted ESI MS spectra of RNase A incubated with compounds 45 (left) and 47 (right) for 72h (top) and 24h 
(bottom) in a 3:1 metal:RNAse A ratio at 37 °C using TMAA buffer. Presence of sulfate in the RNase A spectra is intrinsic to 
the protein and has been observed in other, independent experiments. It does not originate from the actual incubation 
experiment and was thus neglected. 
 
 
Figure S 7 Multicharged ESI MS spectrum of the monoadduct of cyt c with 46 after 24h incubation (37 °C, TMAA buffer) in a 
3:1 Pt:cyt c ratio . Top, theoretical isotopic pattern for ([cytc]++[(O,S)Pt]++5H+) at charge state +7. Bottom, experimental 
isotopic pattern of the monoadductt at charge state +7. The calculated sum formula is [C571H890N148O158S6Fe1Pt1]7+. 
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SUPPLEMENT C: DNA INTERACTION 
Positive ESI MS and UV-vis experiments with 9-methyl guanine 
 
 
Figure S 8 Positive ESI MS spectrum of free 9-mg for comparison with the adduct spectra. Spectrum was recorded in  
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Figure S 9 UV Vis Spectra of the adduct formation between 46 and 9-mg (c = 50µM, LC-MS H2O), recorded without 9-mg 
(black line), and after different time intervals up to 72 h (left) and over 30 min in short intervals (right). Inset: free 9-mg. 
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Negative ESI MS experiments of free ODNs 
  
Figure S 10 Comparison of theoretical vs. experimental multicharge isotopic patterns at charge state -6 (ODN2, left) resp. -9 
(ODN3, right).  
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Figure S 11 Multicharged ESI MS spectra of ODN1 (top left) and ODN2 (top right) recorded in LC-MS grade water and 
ammonium acetate. S/N ratio is greatly improved in LC-MS grade water. Below, multicharged ESI MS spectra of ODN3 
recorded in LC-grade water/ 50% MeOH and ammonium acetate. 50 % MeOH had to be added directly prior to the 
experiment in order to acquire reasonable spectra. All Z values are negative. 
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Negative ESI MS of ODN adducts 
  
  
  
 
Figure S 12 Adduct spectra of ODN2 (left) and ODN3 (right) with compound 30 (top), 46 (middle) and 48 (bottom), recorded 
after incubation in LC-MS grade water for 24 h at 37 °C in a 3:1 metal:ODN ratio. c(ODN) was 10 µM. All Z are negative 
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Table S 11 found mass data in samples of free ODN1 and respective metal adducts. Signals of free ODN1 within the adduct 
spectra are summarized as free ODN1 under the respective sections; adduct peaks are listed separately for both 
incubation ratios. The reported mass values represent those of the signal with the highest intensity within each 
experimental isotopic pattern. The number of found Na adducts is reported. Isolated signals for MS2 experiments are 
highlighted in red. 
ODN1 free value Z  Na  ODN1 /30 value Z x (O,S)Pt+ Na 
 505,94 7  0  free ODN1 505,79 7 0 0 
 590,26 6  0   590,26 6 0 0 
 708,51 5  0   708,51 5 0 0 
       885,89 4 0 0 
      1:1  659,92 6 1 0 
       791,91 5 1 0 
       990,64 4 1 0 
      1:3  659,92 6 1 0 
       729,42 6 2 0 
       791,91 5 1 0 
       875,51 5 2 0 
       958,7 5 3 0 
       990,14 4 1 0 
       1094,38 4 2 0 
       1199,13 4 3 0 
           
ODN1 /46 value Z x (O,S)Pt+ Na  ODN1 /48 value Z x (O,S)Pt+ Na 
free ODN1 505,94 7 0 0  free ODN1 505,86 7 0 0 
 590,26 6 0 0   590,26 6 0 0 
 708,52 5 0 0   708,51 5 0 0 
 886,15 4 0 0   886,84 4 0 0 
1:1  662,59 6 1 0  1:1  662,42 6 1 0 
 795,11 5 1 0   795,11 5 1 0 
 993,27 4 1 0   881,90 5 2 0 
1:3  662,59 6 1 0   1005,97 4 1 2 
 795,11 5 1 0  1:3  567,79 7 1 0 
 882,11 5 2 0   662,42 6 1 0 
 994,14 4 1 0   734,58 6 2 0 
 1102,63 4 2 0   795,11 5 1 0 
       806,91 6 3 0 
       881,70 5 2 0 
       968,30 5 3 0 
       993,20 4 1 0 
       1102,92 4 2 0 
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Table S 12 Found mass data in samples of free ODN2 and respective metal adducts. Signals of free ODN2 within the adduct 
spectra are summarized as free ODN2 under the respective sections; adduct peaks are listed. The reported mass values 
represent those of the signal with the highest intensity within each experimental isotopic pattern. The number of found Na 
adducts is reported. 
ODN2 free value z  Na  ODN2 / 30 value z x (O,S)Pt+ Na 
 533,80 7  0  Free ODN2 622,94 6 0 0 
 623,11 6  0  3:1  593,51 7 1 0 
 747,73 5  0   653,23 7 2 0 
 934,66 4  0   692,77 6 1 0 
       712,51 7 3 0 
       762,26 6 2 0 
       772,36 7 4 0 
       831,59 6 3 0 
       901,42 6 4 0 
       914,52 5 2 0 
       970,42 6 5 0 
       998,31 5 3 0 
       1081,71 5 4 0 
       1143,40 4 2 0 
       1165,51 5 5 0 
       1247,64 4 3 0 
       1352,14 4 4 0 
       1456,63 4 5 0 
           
ODN2 / 46 value z x (O,S)Pt+ Na  ODN2 / 48 value z x (O,S)Pt+ Na 
Free ODN2 533,80 7 0 0  Free ODN2 533,80 7 0 0 
 622,94 6 0 0   622,94 6 0 0 
 747,73 5 0 0   747,73 5 0 0 
 934,66 4 0 0   934,91 4 0 0 
 940,41 4 0 1  3:1  595,80 7 1 0 
3:1  595,66 7 1 0   657,65 7 2 0 
 657,51 7 2 0   695,10 6 1 0 
 695,10 6 1 0   767,60 6 2 0 
 767,26 6 2 0   834,32 5 1 0 
 834,32 5 1 0   839,26 6 3 0 
 838,71 5 1 1   921,32 5 2 0 
 839,76 6 3 0   1007,51 5 3 0 
 920,92 5 2 0   1043,40 4 1 0 
 925,31 5 2 1   1094,71 5 4 0 
 1007,71 5 3 0   1151,65 4 2 0 
 1043,40 4 1 0   1259,89 4 3 0 
 1093,91 5 4 0   1265,39 4 3 1 
 1151,65 4 2 0   1368,63 4 4 0 
 1156,89 4 2 1  Adenine loss 600,76 6 0 -A* 
 1259,89 4 3 0   672,93 6 1 -A* 
 1368,13 4 4 0   721,12 5 0 -A* 
* -A: signals detected of ODN2 after loss of adenine    
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Table S 13 observed m/z values in multicharged spectra of ODN3 incubated with compound 30.  
ODN3 free  ODN3 / 30 adducts  ODN3 / 30 adducts (continued) 
value z Na *  value z x (O,S)Pt+ Na *  value z x (O,S)Pt+ Na * 
650,02 11 0   757,22 10 1 0   1141,74 7 2 0  
652,20 11 1 *  759,11 10 1 1 *  1144,88 7 2 1  
654,19 11 2   761,41 10 1 2   1148,02 7 2 2  
656,19 11 3   763,41 10 1 3   1151,16 7 2 3  
658,19 11 4   765,61 10 1 4   1154,30 7 2 4 * 
715,32 10 0   768,01 10 1 5   1157,01 7 2 5  
717,51 10 1   841,24 9 1 0   1160,29 7 2 6  
719,81 10 2   843,57 9 1 1   1163,29 7 2 7  
722,01 10 3 *  846,35 9 1 2   1167,00 7 2 8  
724,11 10 4   848,57 9 1 3 *  1213,01 7 3 4  
726,41 10 5   851,23 9 1 4   1262,19 6 1 0  
728,41 10 6   853,34 9 1 5   1265,86 6 1 1 * 
730,90 10 7   855,78 9 1 6   1273,14 6 1 3  
794,91 9 0   858,56 9 1 7   1284,34 6 1 6  
797,35 9 1   890,01 9 2 1   1292,17 6 1 8  
799,90 9 2   946,65 8 1 0   1346,85 6 2 4  
802,12 9 3 *  949,27 8 1 1        
804,68 9 4   952,14 8 1 2    
807,01 9 5   954,64 8 1 3 *       
809,67 9 6   957,51 8 1 4        
812,00 9 7   960,38 8 1 5        
814,56 9 8   963,13 8 1 6        
894,52 8 0   965,76 8 1 7        
897,02 8 1   968,25 8 1 8        
899,89 8 2   971,13 8 1 9        
902,52 8 3 *  998,77 8 2 0        
905,39 8 4   1001,39 8 2 1        
908,14 8 5   1004,14 8 2 2 *       
910,76 8 6   1006,76 8 2 3        
913,76 8 7   1009,76 8 2 4        
916,50 8 8   1012,38 8 2 5        
919,13 8 9   1015,38 8 2 6        
921,88 8 10   1018,00 8 2 7        
1022,31 7 0   1020,63 8 2 8        
1025,00 7 1   1082,17 7 1 0        
1028,59 7 2   1085,31 7 1 1        
1031,73 7 3 *  1088,16 7 1 2 *       
1034,87 7 4   1091,45 7 1 3        
1038,01 7 5   1094,44 7 1 4        
1041,01 7 6   1097,44 7 1 5        
1044,29 7 7   1100,72 7 1 6        
1047,29 7 8   1103,89 7 1 7        
1050,29 7 9   1107,43 7 1 8        
1053,57 7 10   1110,29 7 1 9        
1192,00 6 0              
1196,36 6 1 *             
1200,00 6 2              
1203,69 6 3          
1225,34 6 8              
1431,44 5 0         * most abundant peak of series 
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Table S 14 observed m/z values in muslticharged spectra of ODN3 incubated with compound 46. Left, signals belonging to 
free ODN3, right; signals belonging to Pt adducts.  
ODN3 free  ODN3 / 46 adducts 
value z Na *  value z x (O,S)Pt+ Na * 
596,01 12 0 *  689,65 11 1 0 * 
597,68 12 1   691,46 11 1 1  
599,51 12 2   693,65 11 1 2  
650,02 11 0 *  758,61 10 1 0 * 
652,19 11 1   760,81 10 1 1 * 
654,10 11 2   763,01 10 1 2  
656,10 11 3   765,01 10 1 3  
658,19 11 4   767,41 10 1 4  
715,32 10 0 *  769,30 10 1 5  
717,62 10 1   843,06 9 1 0 * 
719,71 10 2   845,35 9 1 1  
722,01 10 3   847,90 9 1 2  
724,31 10 4   850,34 9 1 3  
726,21 10 5   852,45 9 1 4  
794,80 9 0 *  891,24 9 2 0  
797,46 9 1   948,52 8 1 0 * 
799,79 9 2   951,39 8 1 1  
802,12 9 3   954,01 8 1 2  
804,57 9 4   956,76 8 1 3  
807,12 9 5   959,14 8 1 4  
894,52 8 0   1002,77 8 2 0  
897,15 8 1 *  1005,51 8 2 1 * 
899,89 8 2   1008,01 8 2 2  
902,64 8 3   1010,13 8 2 3  
905,39 8 4   1013,63 8 2 4  
908,01 8 5   1057,52 8 3 0  
1022,17 7 0   1059,64 8 3 1  
1025,45 7 1 *  1062,88 8 3 2  
1028,31 7 2   1065,01 8 3 3  
1031,73 7 3   1068,14 8 3 4  
1034,73 7 4   1084,31 7 1 0  
1037,87 7 5   1087,31 7 1 1 * 
1041,15 7 6   1090,59 7 1 2  
1192,70 6 0 *  1093,45 7 1 3  
1196,36 6 1   1096,01 7 1 4  
1200,19 6 2   1099,87 7 1 5  
1203,69 6 3   1146,16 7 2 0 * 
1431,44 5 0 *  1148,88 7 2 1  
     1152,30 7 2 2  
     1155,44 7 2 3  
     1158,73 7 2 4  
     1207,87 7 3 0 * 
     1210,87 7 3 1  
     1214,30 7 3 2  
     1264,69 6 1 0 * 
     1268,69 6 1 1  
* most abundant peak of series  1273,13 6 1 2  
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Table S 15 observed m/z values in muslticharged spectra of ODN3 incubated with compound 48. Left, signals belonging to 
free ODN3, right; signals belonging to Pt adducts.  
ODN3 free  ODN3 / 48 adducts  ODN3 / 48 adducts (continued) 
value z Na *  value z x (O,S)Pt+ Na *  value z x (O,S)Pt+ Na * 
595,76 12 0   689,65 11 1 0 *  1111,01 8 4 0 * 
650,20 11 0 *  758,81 10 1 0 *  1114,01 8 4 1  
652,00 11 1   761,01 10 1 1   1116,50 8 4 2  
654,00 11 2   762,81 10 1 2   1119,38 8 4 3  
656,00 11 3   764,90 10 1 3   1146,16 7 2 0 * 
658,00 11 4   767,21 10 1 4   1149,30 7 2 1  
715,32 10 0 *  769,10 10 1 5   1152,44 7 2 2  
717,31 10 1   843,02 9 1 0 *  1155,58 7 2 3  
719,81 10 2   845,68 9 1 1   1158,72 7 2 4  
721,81 10 3   848,01 9 1 2   1162,01 7 2 5  
723,61 10 4   850,34 9 1 3   1165,01 7 2 6  
795,02 9 0   852,67 9 1 4   1208,30 7 3 0 * 
797,24 9 1 *  891,24 9 2 0   1211,44 7 3 1  
799,79 9 2   948,77 8 1 0   1214,44 7 3 2  
802,01 9 3   951,14 8 1 1 *  1217,44 7 3 3  
804,45 9 4   954,14 8 1 2   1220,58 7 3 4  
807,01 9 5   956,64 8 1 3   1265,20 6 1 0 * 
894,27 8 0   959,76 8 1 4   1268,52 6 1 1  
897,14 8 1 *  1002,89 8 2 0 *  1269,87 7 4 0  
899,77 8 2   1005,64 8 2 1   1273,12 6 1 2  
902,52 8 3   1008,14 8 2 2   1275,72 6 1 3  
905,26 8 4   1011,01 8 2 3   1279,29 6 1 4  
908,01 8 5   1056,89 8 3 0 *  1337,36 6 2 0 * 
1022,31 7 0   1059,64 8 3 1   1394,01 7 6 0  
1025,60 7 1 *  1062,38 8 3 2        
1028,74 7 2   1065,13 8 3 3        
1031,73 7 3   1084,17 7 1 0 *       
1035,02 7 4   1087,59 7 1 1        
1192,70 6 0   1090,30 7 1 2        
1196,36 6 1 *  1093,30 7 1 3        
1200,19 6 2   1096,87 7 1 4        
1203,02 6 3   1100,01 7 1 5        
1431,64 5 0     * most abundant peak of series 
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MS2 of free ODN1 
Table S 16 MS2 fragmentation data for free ODN1. Found: first peak of signal sets found (at instruments nominal 
resolution; 100 000 at m/z 400). Calcd: calculated monoisotopic m/z value as obtained from Mongo Oligo Mass 
calculator.*292 
found  
(m/z) 
calcd  
(m/z) 
error  
(ppm) fragment z 
 found  
(m/z) 
calcd  
(m/z) 
error  
(ppm) fragment z 
297,04330 297,043 -1,01 w1 -2  (continued) 
306,04852 306,048 -1,70 w1 -1  675,12018 675,120 -0,27 a3-B3 -1 
386,07386 386,074 0,36 a2-B2 -1  683,10339 683,105 2,36 M-TH -5 
395,38959 395,390 1,04 w4 -3  683,30409 683,306 2,80 M-T -5 
449,06549 449,066 1,14 w3 -2  685,10010 685,101 1,31 w9 -4 
489,07885 489,079 0,32 a4-B4 -2  686,10394 686,104 0,09 M-CH -5 
490,06927 490,070 1,49 w8 -5  686,30438 686,306 2,36 M-C -5 
496,73792 496,738 0,16 w5 -3  689,45032 689,451 0,99 y7 -3 
547,87836 547,879 1,17 w9 -5  705,10626 705,107 1,05 a10-B10 -4 
553,60504 553,606 1,73 y4 -2  705,62817 705,628 -0,24 y5 -2 
555,24536 555,246 1,15 w11 -6  741,11909 741,120 1,22 y10 -4 
571,58478 571,586 2,13 M-CH -4  742,77967 742,782 3,13 a8-B8 -3 
571,75262 571,754 2,41 M-C -4  745,61060 745,611 0,54 w5 -2 
579,76636 579,767 1,10 y6 -3  761,11139 761,112 0,80 w10 -4 
593,58850 593,589 0,85 w4 -2  785,62433 785,624 -0,42 a6-B6 -2 
595,09393 595,094 0,12 w1 -1  790,79846 790,80 1,95 y8 -3 
600,41833 600,419 1,12 d6-H2O -3  813,38104 813,382 1,18 y11 -4 
606,42206 606,422 -0,10 w6 -3  817,45337 817,455 1,99 w8 -3 
608,68719 608,688 1,33 w10 -5  819,17368 819,173 -0,83 y3 -1 
612,83862 612,839 0,62 w8 -4  844,12954 844,130 0,54 a9-B9 -3 
624,69287 624,693 0,21 a11-B11 -5  870,15372 870,154 0,32 y6 -2 
632,84509 632,846 1,44 a9-B9 -4  899,13937 899,139 -0,41 w3 -1 
633,60181 633,602 0,30 a5-B5 -2  950,15021 950,151 0,83 a7-B7 -2 
665,10809 665,109 1,37 y9 -4  979,16504 979,166 0,98 a4-B4 -1 
666,49628 666,497 1,08 w11 -5       
* Mongo Oligo Mass Calculator gives vaues with 10-3 m/z accuracy; the high-resoluton spectrometer allows data to be given 
in 10-5 m/z accuracy.  
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MS2 of ODN1-46 monoadduct 
Table S 17. Peak assignment for MS2 data of the ODN1-46 monoadduct. For fragments without Pt, the found first peak and 
calculated monoisotopic mass (Mongo Oligo calculator),292 are listed. For fragments with Pt, the found peak of highest 
intensity and matching signal of calculated isotopic pattern (Xcalibur software) is listed. 
found  
(m/z) 
calcd  
(m/z) 
error  
(ppm) assignment z 
449,06520 449,066 1,78 w3 -2 
489,07811 489,079 1,82 a4-B4 -2 
496,73756 496,738 0,89 w5 -3 
582,01421 582,01701 4,81 [G- + (O,S)Pt+ H+]- -1 
595,09280 595,094 2,02 w2 -1 
606,42143 606,422 0,94 w6 -3 
633,09664 633,098 2,15 a7-B7 -3 
745,61051 745,611 0,66 w5 -2 
772,90004 772,90225 2,86 [ODN1 - C + (O,S)Pt+ -6H+]5- -5 
785,62387 785,624 0,17 a6-B6 -2 
847,87952 847,88328 4,43 ODN1-GH -4 
870,15378 870,154 0,25 y6 -2 
899,13919 899,139 -0,21 w3 -1 
910,13626 910,137 0,81 w6 -2 
950,14898 950,151 2,13 a7-B7 -2 
979,16491 979,166 1,11 a4-B4 -1 
1002,11127 1002,11538 4,01 [(a6-B6) + (O,S)Pt+ -2H+]2- -2 
1166,63925 1166,64164 2,05 [(a7-B7) + (O,S)Pt+ -3H+]2- -2 
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Figure S 13 Experimental vs. theoretical isotopic patterns of diagnostic fragments of the ODN1-46 monoadduct after CID.  
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MS2 of ODN1-30 monoadduct 
Table S 18. Peak assignment for MS2 data of the ODN1-30 monoadduct. For fragments without Pt, the found first peak and 
calculated monoisotopic mass (Mongo Oligo calculator),292 are listed. For fragments with Pt, the found peak of highest 
intensity and matching signal of calculated isotopic pattern (Xcalibur software) is listed. 
found 
(m/z) 
calcd 
(m/z) 
error 
(ppm) assignment z 
392,30934 392,308 -3,42 a6-B6 -4 
449,06517 449,066 1,85 w3 -2 
496,73746 496,738 1,08 w5 -3 
566,01989 566,02209 3,89 [G- + (O,S)Pt+  H+]- -1 
606,42082 606,422 1,95 w6 -3 
612,83783 612,839 1,91 w8 -4 
633,09702 633,098 1,55 a7-B7 -3 
745,61053 745,611 0,63 w5 -2 
769,50044 769,50291 3,21 [ODN1  C + (O,S)Pt+  6H+]5- -5 
779,50487 779,50932 5,71 [ODN1 + {(O,S)Pt-SEt}+  6H+]5- -5 
847,87996 847,88328 3,92 [ODN1  G  4H+]4- -4 
870,15479 870,154 -0,91 y6 -2 
899,13796 899,139 1,15 w3 -1 
910,13624 910,137 0,83 w6 -2 
950,14911 950,151 1,99 a7-B7 -2 
979,16632 979,166 -0,33 a4-B4 -1 
994,11421 994,11792 3,73 [(a6-B6) + (O,S)Pt+  2H+]2- -2 
1158,64034 1158,64419 3,32 [(a7-B7) + (O,S)Pt+  3H+]2- -2 
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Figure S 14 Experimental vs. theoretical isotopic patterns of diagnostic fragments of the ODN1-30 monoadduct after CID. 
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MS2of ODN1-30 bisadduct 
 
 
Figure S 15 Multicharged MS2 spectrum of the ODN1-30 bisadduct. Only few fragments could beassigned, no Pt-containing 
peaks could be identified with certainity. 
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Figure S 16 Overlay of 1H NMR spectra of Leu5-Enk 75 (top/violet), ligand 84 (second, petrol), complex 85 (third, green) and 
small-molecule complex 83 (bottom, red). All spectra were recorded in THF-d8. Due to low sample quantity resp. low 
solubility, signals in the aliphatic region are partially obscured by the solvent residual signals. 
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Figure S 17 1H and 13C NMR spectra of the rearranged product 58 of the one-pot ligand synthesis attempt of 57. The 
proposed structure and signal assignment are given in the figure. Spectra were recorded at 298 K in CDCl3 on a 600 MHz 
spectrometer. * marks solvent residual signals. 
 
  
 
SUPPLEMENT E: MEDIA COMPOSITION 
DPBS  
Dulbecco's Phosphate-Buffered Saline (DPBS), without calcium, magnesium, phenol red 
Supplier: Gibco®, Catalog number 14190-086 
 
Components M [g/mol] x [mg/L] mM 
Potassium Chloride (KCl) 75.0 200.0 2.6666667 
Potassium Phosphate monobasic (KH2PO4) 136.0 200.0 1.4705882 
Sodium Chloride (NaCl) 58.0 8000.0 137.93103 
Sodium Phosphate dibasic (Na2HPO4·7H2O) 268.0 2160.0 8.059702 
Trypsin-EDTA  
Trypsin-EDTA (0.05%), with phenol red  
Supplier: Gibco®, Catalog number 25300-054 
 
Components M [g/mol] c [mg/L] mM 
Inorganic Salts 
Potassium Chloride (KCl) 75.0 400.0 5.3333335 
Potassium Phosphate monobasic (KH2PO4) 136.0 60.0 0.44117647 
Sodium Bicarbonate (NaHCO3) 84.0 350.0 4.1666665 
Sodium Chloride (NaCl) 58.0 8000.0 137.93103 
Sodium Phosphate dibasic (Na2HPO4·7H2O) 268.0 90.0 0.33582088 
Other Components 
D-Glucose (Dextrose) 180.0 1000.0 5.5555553 
EDTA  4Na  2H2O 416.2 200.0 0.4805382 
Phenol Red 398.0 10.0 0.025125628 
Trypsin 23800.0 500.0 0.021008404 
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DMEM  
DMEM (Dulbecco's Modified Eagle Medium), high glucose (4.5 g), GlutaMAX Supplement 
Supplier: Gibco®; Catalog number 61965-026 
Components M [g/mol] x [mg/L] mM 
Amino Acids 
Glycine 75.0 30.0 0.4 
L-Alanyl-Glutamine 217.0 862.0 3.9723501 
L-Arginine hydrochloride 211.0 84.0 0.39810428 
L-Cysteine 313.0 48.0 0.15335463 
L-Histidine hydrochloride-H2O 210.0 42.0 0.2 
L-Isoleucine 131.0 105.0 0.8015267 
L-Leucine 131.0 105.0 0.8015267 
L-Lysine hydrochloride 183.0 146.0 0.7978142 
L-Methionine 149.0 30.0 0.20134228 
L-Phenylalanine 165.0 66.0 0.4 
L-Serine 105.0 42.0 0.4 
L-Threonine 119.0 95.0 0.79831934 
L-Tryptophan 204.0 16.0 0.078431375 
L-Tyrosine disodium salt dihydrate 261.0 104.0 0.39846742 
L-Valine 117.0 94.0 0.8034188 
Vitamins 
Choline chloride 140.0 4.0 0.028571429 
D-Calcium pantothenate 477.0 4.0 0.008385744 
Folic Acid 441.0 4.0 0.009070295 
Niacinamide 122.0 4.0 0.032786883 
Pyridoxal hydrochloride 204.0 4.0 0.019607844 
Riboflavin 376.0 0.4 0.0010638298 
Thiamine hydrochloride 337.0 4.0 0.011869436 
i-Inositol 180.0 7.2 0.04 
Inorganic Salts 
Calcium Chloride (CaCl2) (anhyd.) 111.0 200.0 1.8018018 
Ferric Nitrate (Fe(NO3)3·9H2O) 404.0 0.1 2.4752476E-4 
Magnesium Sulfate (MgSO4) (anhyd.) 120.0 97.67 0.8139166 
Potassium Chloride (KCl) 75.0 400.0 5.3333335 
Sodium Bicarbonate (NaHCO3) 84.0 3700.0 44.04762 
Sodium Chloride (NaCl) 58.0 6400.0 110.344826 
Sodium Phosphate monobasic (NaH2PO4·H2O) 138.0 125.0 0.9057971 
Other Components 
D-Glucose (Dextrose) 180.0 4500.0 25.0 
Phenol Red 376.4 15.0 0.039851222 
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SUPPLEMENT F: ABBREVIATIONS 
The following abbreviations were used in this monograph: 
 
(O,S) -hydroxo dithiocinnamic ester 
unit   wave number [cm-1] (in IR) 
µW microwave 
9-mg 9-methyl guanine 
Å Angström 
aa amino acid 
AA azidoacetic acid 
abs. absorbance [a.u.] 
AIBN azobisisobutylnitril 
Apaf apoptotic protease activating 
factor 
approx. approximately 
arom aromatic 
ATR attenuated total reflection 
b broad (in IR and NMR) 
Bcl-2 B-cell lymphoma 2 
bf bright field 
bp  base pair 
BSA bovine serum albumin 
Bu butyl 
calcd. calculated 
CD circular dichroism 
CDDP cis-diammine dichlorido 
platinum(II) 
CID collision-induced dissociation 
COSY  Correlation Spectroscopy 
Cp cyclopentadiene; 
cyclopentadienyl 
ctDNA calf thymus desoxyribonucleic 
acid 
CuAAC copper-catalyzed 1,3-dipolar 
azide-alkyne cycloaddition 
cyt c cytochrome c 
d  doublet 
DACH diaminocyclohexane 
DAPI 4,6-diamidino-2-phenylindole 
DCM dichloromethane 
dd doublet of a doublet (in NMR) 
decomp. decomposition 
DEI direct electron ionization (in MS) 
DiPEA diisopropyl ethylamine 
DMEM Dulbeccos Modified Eagles 
Medium 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA desoxyribonucleic acid 
DPBS Dulbecco's Phosphate-Buffered 
Saline 
dt doublet of a triplet (in NMR) 
e.g. exempli gratia  
(latin: for example) 
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EA ethyl acetate 
EDTA ethylenediamine tetraacetate 
EI MS electron impact mass 
spectrometry 
Enk enkephalin 
EPR  Enhanced Permeability and 
Retention 
eq. equivalent 
ER endoplasmatic reticulum 
ESI  electrospray ionization 
Et ethyl 
Et2O diethyl ether 
FAB fast atom bombardment (in MS) 
FAB fast atom bombardment 
FCS fetal calf serum 
FGP functional group pair 
Fmoc Fluorenylmethoxycarbonyl 
FTICR fourier transform ion cyclotron 
resonance 
FTIR fourier transformation infrared 
spectroscopy 
GP general procedure 
GSH glutathione (L--glutamyl-L-
cysteinyl-glycine) 
h hours 
HEWL hen egg white lysozyme 
Hex hexyl 
HMBC  Heteronuclear Multiple Bond 
Correlation Spectroscopy 
HMG  High Mobility Group 
HOBt 1-Hydroxybenzotriazol 
HPLC high pressure liquid 
chromatpgraphy 
HSAB hard and soft acids and bases 
HSQC  Heteronuclear Single Quantum 
Coherence Spectroscopy 
i.e. id est (latin: that is) 
ICP-OES inductively coupled plasma 
optical emission spectrometry 
IP3 inositol trisphosphate 
IR  infrared 
IRMPD infrared-multiphoton dissociation 
J coupling constant [Hz] 
KOtBu potassium-tert-butoxylate 
LC liquid chromatography 
LPPS liquid phase peptide synthesis 
m medium (in IR) 
multiplet (in NMR) 
m- meta- (stereodescriptor) 
m/z ratio of mass to charge 
MALDI matrix-assisted laser desorption 
ionization 
Mav molar mass - average mass 
Me methyl 
MeOH methanol 
Mmono monoisotopic mass 
mp. melting point 
mQ Millipore 
MS mass spectrometry 
MT metallothionein 
MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium 
bromide 
NaH sodium hydride 
NBS N-bromo succinimide 
nBu4NOH tetrabutylammonium hydroxide 
NCE normalized collision energy 
NER  nucleotide excision repair 
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NH4OAc ammonium acetate 
NMR nuclear magnetic resonance 
NSCLC non-small cell lung cancer 
NTA nitrogen atom of triazol unit 
OAc acetate 
ODN oligodesoxinucleotide 
ODN oligodeoxynucleotide 
p- para- (stereodescriptor) 
PA pentinoic acid 
PB Phosphate buffer 
PBS Phosphate-Buffered Saline 
Ph phenyl 
PI Propidium Iodide 
Po/w octanol-water partition 
coefficient 
ppm parts per million 
r.t. room temperature 
resp. respectively 
Rf  retention faktor 
RNA  ribonucleic acid 
RNase Ribonuclease 
rp-HPLC reversed phase high pressure 
liquid chromatpgraphy 
rpm rotations per minute 
s strong (in IR)  
singlet (in NMR) 
SAR structure-activity-relationships 
SCLC small cell lung cancer 
SD  standard deviation 
SPPS solid phase peptide synthesis 
SRS solvent residual signal (in NMR) 
t triplet (in NMR) 
T temperature [°C or K] 
TBAF tetrabutyl ammonium fluoride 
TBDMS tert-butyl dimethylsilyl 
TBTU N,N,N,N-Tetramethyl-O-
(benzotriazol-1-yl)uronium 
tetrafluoroborate 
tBu tert-butyl 
TES triethylsilane 
TFA trifluoro acetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMAA tetramethyl ammonium acetate 
UV  ultraviolet 
UV-vis UV-visible 
vs very strong (in IR) 
w weak (in IR) 
w/ with 
w/o without 
  chemical shift [ppm] 
  wave length 
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Amino acids were abbreviated using either the three- or one-letter code; nucleobases were 
abbreviated using the one-letter code: 
 
amino acid three-letter  code 
one-letter  
code 
tyrosine Tyr Y 
phenylalanine Phe F 
methionine Met M 
leucine Leu L 
histidine His H 
glycine Gly G 
glutamic acid Glu E 
cysteine Cys C 
aspartic acid Asp D 
 
nucleobase one-letter code 
adenine  A 
cytosine  C 
guanine  G 
thymine  T 
uracil U 
 
 
 
  
 
SUPPLEMENT G: DIGITAL MEDIA 
On the provided CD, the following media are made available: 
 
Crystallographic data of compounds 50, 72, 73, and 80 (res-files) 
Manuscripts that have been prepared during the PhD project (PDF format) 
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